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ABSTRACT 
Introduction: Several observational studies support an association between periodontal 
disease and Alzheimer‘s disease (AD). Poorly managed oral hygiene together with the 
immunosuppressed status of demented patients appears central to this hypothesis as 
together they contribute not only to an increased incidence of oral infections but also to 
recurrent bacteraemia that can seed oral bacteria into systemic circulation. The aim of 
this study was to establish a link between periodontal disease and AD with a view to 
identifying the red complex periodontal disease bacteria (Treponema denticola, 
Tannerella forsythia and Porphyromonas gingivalis) and/or bacterial components in 
human AD and non-AD brain tissue and explore the proof of concept of the red 
complex bacteria accessing the brain of ApoE
null
 mice during experimental 
periodontitis, and assess how they may contribute to the development of AD pathology.  
Methods: Molecular techniques (PCR, cloning and sequencing) were employed for 
investigating the presence of bacterial DNA within the specimens (human or mouse) 
using two different approaches (universal and species specific primers). The presence of 
specific virulence factors were determined using anti-bacterial antibodies. The innate 
immune responses were detected using antibodies against complement activation, 
alongside inflammatory assessment using specific antibodies for activated microglia and 
astrocytes. Further, histology staining was used to assess tissue preservation and the 
presence of pathological hallmarks of AD. 
Results: Human AD and non-AD controls failed to demonstrate the presence of red 
complex pathogens when analysed using molecular methodologies. However, 
immunofluorescence labelling of a virulence factor (LPS) was positive for P. gingivalis 
in 4 out of 10 AD cases. Immunoblotting demonstrated bands corresponding to P. 
ginigivalis LPS in the same AD brain specimens (p = 0.029). Analysis of brain tissue 
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from ApoE
null 
mice induced with periodontal disease using molecular methods 
demonstrated 6 out of 12 ApoE
null
 mice brains contained P. gingivalis genomic DNA at 
12 weeks (P = 0.006), and increased to 9 out of 12 at 24 weeks (P = 0.0001). In 
addition, tissue sections of infected mice demonstrated periodic acid-Schiff (PAS)-
positive, argyrophilic inclusions in the hippocampus at both time points, which also 
labelled positive with the bacterial-specific anti-peptidoglycan antibody. Also, it was 
noted that microglia in both infected and control groups demonstrated strong 
intracellular labelling with C3 and C9, presumed on-going biosynthesis, however, the 
pyramidal neurons of the hippocampus in 4 out of 12 P. gingivalis infected mice brains 
were clearly opsonised with C3 activation fragments (P =  0.032) suggesting they were 
under attack from complement mediated lysis. 
Conclusion: These results show P. gingivalis was able to access the brain of humans 
and ApoE
null
 mice, supporting the concept of the focal infection theory. Together these 
results suggest a potential link with AD via the periodontal pathogen translocating from 
its original oral niche to the brain. ApoE
null
 mice induced with periodontal disease 
demonstrated the intracerebaral innate immune responses were initiated by local CNS 
cells, which not only contributed to a higher inflammatory burden but also bystander 
damage of functional neurons in the hippocampus area of the brain which is associated 
with memory. Although further research is needed to establish clinical measures that 
demonstrate a cause and effect relationship between oral infections and AD, this study 
does provide initial support to the role of periodontal pathogens in the development of 
dementia. Early treatment of periodontal disease in addition to greater awareness of the 
importance of maintaining good oral health may halt or slow down the progression of 
this debilitating disease. 
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1. INTRODUCTION 
There is growing support for the longstanding ―focal infection‖ theory of Miller and 
Hunter (Miller 1891; Hunter 1900) which suggests that the main oral diseases (caries, 
pulpal necrosis/root canal and periodontal diseases) can negatively affect the health of 
distant body organs. There are a number of risk factors which are common to both oral 
diseases and other organ specific, inflammatory pathologies at remote body sites. These 
include aging, infection, immunosenescence, genetic predisposition and socio-economic 
factors (Joshipura et al., 2000). In order to understand how one common, clinical 
condition such as chronic periodontitis becomes a potential risk factor for the 
development of, in this case, Alzheimer‘s disease (AD), this chapter will introduce each 
of these conditions in two parts, before reviewing the evidence available from current 
literature. 
 
1.1.Part I 
1.1.1. The oral cavity 
The mouth comprises of the oral cavity, which is important for both nutritional and 
communication functions required for a healthy existence and social values (Scheid, 
2012). The cavity is comprised of a variety of structures ranging in specialist functions 
that include teeth (deciduous and permanent), keratinised and non-keratinised mucosa, 
gingiva, periodontal structures (periodontal ligament, cementum and alveolar bone), 
salivary glands and specialist linings for taste e.g. the dorsal surface of the tongue 
(Scheid, 2012). The cavity stretches from the lips to the oropharynx at the anterior pillar 
of the fauces (Berkovitz and Holland, 2009).  
Bacteria can gain direct access to the oral cavity and colonise its tissue and 
mineralised anatomical structures, which results in the build-up of a biofilm (Marsh, 
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2004). In order to retain healthy levels of biofilm-forming bacteria the oral cavity has its 
own protective barriers. These include the buccal, gingival, and tongue mucosal 
surfaces (Marsh, 2004). These surfaces work together with the internal secretions such 
as saliva, mucous and the gingival crevicular fluid to aid the physical act of mastication 
and protect the oral cavity (Loesche and Lopatin, 1998). The saliva contains a range of 
both innate and adaptive agents designed to minimise the attachment and survival of 
organisms that may be established within the oral cavity (Fábián et al., 2012). Chemical 
factors such as antimicrobial peptides (AMPs) (Gorr and Abdolhosseini, 2011) and β-
defensins (Lu et al., 2004) are innate immune mechanisms involved in controlling 
pathogenic bacterial colonisation. The adaptive immune control measures include 
immunoglobulins (IgA) specific for the mucosal surfaces (Kinane et al., 1999; Cole et 
al., 1995), and various enzymes (for example defensins, lactoferrin and lysozyme) 
designed to prevent the microbial metabolic processes (Bu et al., 2006) essential for 
their colonisation or lyse bacterial cells.  
In addition, the oral mucosa has developed an immune protection based upon the 
activity of cell mediated immunity in the periodontal structures in direct response to 
bacterial antigenic challenges (Arenzana-Seisdedos, 1985; Taubman and Kawai, 2001) 
and antigen presentation. This results in the subsequent infiltration of T and B cells, a 
hallmark of the host‘s response to the presence of these non-host organisms (Arenzana-
Seisdedos, 1985; Taubman and Kawai, 2001; Medzhitov, 2007; Kumagai et al., 2008). 
It is recognised that if the balance between natural protective barriers is 
disrupted, the bacterial load will initiate disease states such as dental caries (Fejerskov, 
1997), periodontal disease (Socransky and Haffajee, 1992; Holt and Ebersole, 2005), 
ulcerative lesions (Leão et al., 2007) and a predisposition to opportunistic infections 
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from other microbial species such as viruses (Slots et al., 2006) and fungi (Moyes and 
Naglic, 2011).  
1.1.2. Complement a pivotal pathway in bacterial infections 
The complement system is a vital part of the innate immune response to bacterial 
infections and is implicated in numerous inflammatory conditions including periodontal 
disease. In brief, the complement system can be activated via three different pathways 
(classical, alternative and the mannose binding lectin (MBL) pathways as shown in Fig. 
1.1). The classical pathway is activated through C1q binding to the Fc portion of IgM or 
IgG which initially binds to neurotoxic proteins from pathogens and damaged cells. C1q 
binds to other proteins eventually forming a complex known as C1qrs. Next the C4 is 
cleaved to C4b and becomes attached to C2. Resulting in the formation of C4b2a that 
further along the pathway binds to C3 generating a C3 convertase enzyme C4b2a3b. 
This can catalyse the cleavage of C5 into C5b and the anaphylotoxin C5a is also 
released The C5b activation fragment interacts with proteins of the terminal 
complement pathways C6, C7, C8 and C9 to form the membrane attack complex 
(MAC) (Fig. 1.1).  
In the MBL pathway MBL binds to carbohydrates on the bacterial cell surfaces, 
forming mannose-associated serine protease-2. This molecule has the ability to interact 
with complement proteins, C4 and C2 to ultimately cleave C3 and from here the process 
is as described for the classical pathway (Fig. 1.1). The alternative pathway is activated 
by bacterial polysaccharides (zymosan, LPS etc.) through factor P (properdin) to cleave 
C3 to C3a and C3b. This is the dominant pathway of activation in periodontal disease. 
Then C3b and factors B and D convert C5 into C5a and C5b before the cascade 
continues to completion i.e. MAC formation (Fig. 1.1).  
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Figure 1.1: Schematic overview of the complement system. Demonstrating the three 
pathways (classical, alternative and the mannose binding lectin; MBL) and how they aid 
the removal of pathogens via anaphylatoxins, opsonin enhanced phagocytosis or 
formation of the MAC on the surface membrane of pathogens. Regulatory proteins both 
plasma soluble proteins (C1 inhibitor, C4bp or C4 binding protein, Factors H and I, 
ckusterin) and membrane bound proteins (CD53, CD46, CD55 and CD59) acting at 
various stages of the complement pathway. 
 
The anaphylotoxins (C4a, C3a and C5a) produced following complement 
activation act by promoting vasodilation and stimulating cellular immune responses via 
monocyte/macrophage cells contributing to local acute inflammation (Perry, 1998). 
Whereas, the final MAC is formed on the surface of the pathogen, inserting C8 and C9 
into the bacterial membrane, forming pores to disrupt the membrane. These pores 
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disrupt the phospholipid bilayer of target cells, leading to cell lysis and ultimately death. 
All three pathways of complement activation merge to facilitate opsonisation and 
recognition of labelled bacteria by phagocytic cells (Gasque, 2004; Hajishengallis, 
2010; Hanisch, 2002; Janeway, et al., 2005; Jack et al., 2001). 
1.1.3. Periodontal disease(s) 
Periodontal diseases are polymicrobial, chronic inflammatory disease processes with an 
established subgingival bacterial aetiology that can ultimately lead to loss of tooth 
attachment (Grenier and Mayrand, 1995; Socransky et al., 1998; 2005). Environmental 
factors such as level of oral hygiene, smoking, stress and systemic factors appear to play 
a role in their development (Stabholz et al., 2010). More than one-third of the adult 
population suffers from periodontitis resulting in tooth loss. In addition, periodontal 
diseases have been associated with many systemic conditions such as cardiovascular 
disease (Mattila et al., 1989; Destefano et al., 1993; Sanz et al., 2010), cerebrovascular 
diseases (Wu et al., 2000; Sfyroeras et al., 2012), rheumatoid arthritis (Tolo and 
Jorkjend, 1990; Gleissner et al., 1998), AD (Riviere et al., 2002; Stein et al., 2007; 
Kamer et al., 2009), and even cancer (Meyer et al., 2008).  It is the chronic form of 
periodontal disease that is of interest here due to its suggested associations with AD, 
although, the strength and relevance of the link is currently under investigation.  
 
1.1.4. Host’s inflammatory response 
The junctional epithelium (JE) plays a key role in protecting the host from periodontal 
disease. The JE links the gingiva to the tooth enamel, thereby creating a seal to prevent 
bacteria from entering the gingival tissue (Larjava et al., 2011). However, in periodontal 
disease the portion of the attached JE is reduced to less than 100 µm at the bottom of the 
pocket hence the JE transforms into pocket epithelium (PE), in healthy individuals 
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portion of the attached JE length is up to 10 times longer. In deep pockets the PE length 
can reach 10 mm or more. In established periodontal disease lesions, bacterial biofilms 
flourish in the pockets between the teeth and PE which separates the biofilm from the 
connective tissue and inflammatory infiltrate. The role of PE, therefore, is thought to be 
crucial in pathogenesis of periodontal disease. It is not clear how PE participates in 
regulation of periodontal inflammation and little is currently known about how 
molecular pathways in the host PE/JE cells could regulate their inflammatory response 
to complex polybacterial biofilms. In the inflammatory infiltrate, the outcome of the 
cytokine response is regulated by production of pro-inflammatory cytokines that are 
encountered by anti-inflammatory cytokines.  
The inflammatory response taking place in periodontal disease begins with a 
complex bacterial challenge where molecules such as lipopolysaccharide (LPS), 
capsular proteins, flagellin, fimbrillin, peptidoglycan, bacterial DNA, proteases, and 
enzymes (for example gingipains, dentisilin, and trypsin like proteases) (Kawai and 
Akira, 2005) stimulate the hosts‘ innate immune responses (Ohlrich et al., 2009). This 
causes hosts pattern recognition receptors (PRRs) on the PE to produce a range of 
cytokines to recruit appropriate immune cells to the site of infection (Kawai and Akira, 
2005). In addition, the metabolic products of the bacteria cause the PE to secrete 
neuropeptides (such as neuropeptides substance P, calcitonin gene-related peptide, 
vasoactive intestinal polypeptide, and neuropeptide Y), promote vasodilation of local 
blood vessels and permit an influx of neutrophils in response to signals from 
chemokines (Ohlrich et al., 2009). At this point there are no clinical signs of 
inflammation and if the plaque is removed then the tissue will return to homeostasis; the 
reversible stage of gingivitis (Darveau et al., 1997; Darveau, 2010). 
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If the microbial burden continues then the vascular leakage and activation of 
serum proteins amplifies the local inflammatory response leading to the initiation of the 
hosts‘ adaptive immune responses with clinical signs progressing to bleeding and 
gingival inflammation. If adequate treatment is not sought, the disease will progress 
further with increased gingival bleeding, and changes in colour and contour of the 
gingivae as macrophages, plasma cells and T and B lymphocytes infiltrate the soft 
tissues (Ohlrich et al., 2009). The innate and adaptive immune responses involved in the 
inflammatory process result in tissue destruction (Darveau et al., 1997, Darveau, 2010) 
(Fig. 1.2).  
 
Figure 1.2: Severe periodontal disease. Image shows the effect of chronic periodontitis, 
the inflammed, receding gums and pus are clearly visible alongside the irreversible 
alveolar bone loss. 
 
When the diseased state progresses to periodontal disease irreversible 
attachment loss and alveolar bone loss becomes apparent (both histologically and 
clinically), as the inflammatory lesion extends deeper affecting the alveolar bone (Di 
Benedetto et al., 2013). It is now accepted that the majority of the destruction of bone as 
a result of chronic periodontal disease is due to the disruption of the balance between 
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osteoblast and osteoclast activity (in favour of osteoclasts) caused by the bacterial 
products and inflammatory cytokines (organ specific inflammation) (Di Benedetto et 
al., 2013). In susceptible individuals, acute phase inflammation fails to resolve and this 
gives rise to chronic inflammation which results in periodontal disease specific 
pathology. 
Diagnosis of periodontal disease is generally made by a thorough examination 
carried out by the individuals‘ dental practitioner. Clinical diagnosis involves measuring 
the depth of the gingival pocket using a calibrated periodontal probe. Measurements are 
taken from four different sites around the circumference of each tooth. The greater the 
depth of gingival pocket indicates a greater loss of supporting tissue. The probe can also 
feel for the calculus deposition (calcified dental plaque), sweep for plaque and highlight 
where the pocket is bleeding as an indicator of active inflammation and tissue 
destruction. Periodontal disease is controlled by improving the patients‘ self-care along 
with regular professional treatment to remove any newly formed deposits and calculus.  
 
1.1.5. Oral Microbes 
Periodontal disease occurs as a result of microbial burden within the oral cavity 
initiating the hosts‘ immune response. Analysis of normal human microbiota revealed 
>700 bacterial species or phylotypes, of which 60% have not been cultivated.  
Similarly, by using culture-independent molecular methods, Paster (2001) detected 
>500 species or phylotypes in subgingival plaque of healthy and periodontal disease 
individuals.  Due to
 
the vast complexity of the microbial oral flora, it is likely
 
that all of 
the organisms involved
 
in the development of periodontitis have not yet been identified.  
Further, viruses (herpes simplex virus, cytomegalovirus, EBV-1) have been detected in 
crevicular samples from individuals with periodontitis (Slots, 2002).   
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Socransky et al., (1998) published seminal data showing the presence and levels 
of 40 subgingival taxa in 13,261 human subgingival plaque samples from 185 subjects 
using DNA-DNA checkerboard hybridization. These authors suggested the existence of 
five major complexes of bacteria (Fig.1.3). Several microbial species belonging to the 
red and orange complexes (Porphyromonas gingivalis, Treponema denticola, 
Tannerella forsythia, Actinobacillus actinomycetemcomitans, Fusobacterium 
nucleatum, Prevotella intermedia, Prevotella nigrescens, Peptostreptococcus micros, 
Campylobacter rectus, Selenomonas noxia, Streptococcus intermedius, and Eikenella 
corrodens), are associated with deep periodontal pockets and periodontal progression 
(Fig. 1.3).  Other species in green and yellow complexes have no relation to periodontal 
progression. In addition, the bacterial species belonging to the red complex (P. 
gingivalis, T. denticola and T. forsythia) are seldom detected in the absence of members 
of the orange complex. F. nucleatum (a member of the orange complex) represents a 
bridging species (Kolenbrander et al., 2000; 2002) in the progression of the subgingival 
biofilm maturation and microbial succession (Fig. 1.4).  Although F.  nucleatum is not 
considered
 
a primary periodontal pathogen the bacterium has attracted interest because
 
of its important role in mediating the attachment of several
 
bacterial species into the 
plaque biofilm (Kolenbrander et al., 2000; 2002; Nishihara and Koseki, 2004). This was 
further demonstrated by Nishihara and Koseki (2004) who reviewed the microbiology 
in periodontal disease and their succession from early, secondary, and late colonizers 
(Fig 1.4) which indicated that the bridging species (F. nucleatum) is implicated in both 
subgingival biofilm development and periodontitis progression.   
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Figure 1.3: Microbial complexes in subgingival biofilm. (Modified from Socransky et 
al., (1998) Microbial complexes in subgingival plaque. J Clin Periodontol 25:134-144).  
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Figure 1.4: Microbial ecology of subgingival plaque as a pathogenic biofilm.  
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1.1.6. Periodontal pathogens  
Periodontal disease is a polymicrobial mixed infection and is a major chronic 
immunoinflammatory disease of humans with no single bacterial species triggering the 
destructive host responses (Darveau, 2010). As mentioned previously, the red complex 
bacteria (P. gingivalis, T. forsythia and T. denticola) are considered as key players in 
chronic periodontal disease pathogenesis and in driving inflammation and tissue 
damage (Socransky et al., 1998; Holt and Ebersole, 2005). These three bacteria are 
found in high numbers in adult periodontal lesions and in deeper pockets (Farias et al., 
2012). A strong relationship between P. gingivalis and T. forsythia has been 
demonstrated in samples taken from sub-gingival plaques of various pocket depths 
(Gmür et al., 1989). P. gingivalis, T. forsythia and T. denticola are major bacteria 
investigated in this thesis; hence, their relevant characteristics are described in detail. In 
addition, F. nucleatum is discussed in light of its bridging role in mediating the 
attachment of several bacterial species into the plaque biofilm. 
 
i) Porphyromonas gingivalis  
P. gingivalis was initially isolated by Oliver and Wherry (1921) and was classed as 
belonging to the Bacteroides genus of anaerobic Gram negative bacteria. Over time, the 
nomenclature has changed on the basis of these organisms ability to hydrolyse sugars 
and if they are pigmented or not. Thus, the Porphyromonas species are asaccharolytic 
and display black pigment (Mayrand and Holt, 1988; Shah and Collins, 1990; Paster et 
al., 1994).  
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Figure 1.5: TEM images of P. gingivalis. A) lower magnification image, bar represents 
500 nm. B) Higher magnification of single P. gingivalis cell, note the outer membrane 
vesicles (OMVs) being released, bar represents 100 nm. Cells were prepared for TEM 
as stated in section 4.2.11. 
 
P. gingivalis is the most studied example of the periodontal pathogens (Fig. 1.5). 
It is a non-motile, non-spore forming, rod shaped, Gram negative, anaerobic bacteria 
and can exist with/without fimbriae (Mayrand and Holt, 1988). P. gingivalis has been 
shown to play a significant role in the initiation, and chronic progression of 
periodontitis (Slots and Listgarten, 1988; Hajishengallis, 2011; 2012). This bacterium is 
highly pathogenic due to the virulence factors it possesses which aid its invasion and 
survival within host tissues (Holt et al., 1999). The presence of fimbriae on the surface 
of the bacteria aids its adhesion, colonisation, invasion and survival within host tissues 
(Holt et al., 1999). In addition, P. gingivalis produces a large number of hydrolytic, 
proteolytic and lipolytic enzymes, many of which are exposed on the surface of the 
bacterium so that it can come into direct contact with the host cells (Mayrand et al., 
1980, Slots, 1981). Collagenases, aminopeptidases and trypsin-like proteases are critical 
to the pathogenesis of periodontal disease. Aminopeptidases and trypsin-like proteases 
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are known as gingipains (Holt and Ebersole, 2005). Gingipains cleave polypeptides 
after the arginine and lysine residues and have been shown to play a key role in the 
adherence of P. gingivalis to host cells and other bacteria (Imamura, 2003). In addition, 
a major component of the outer membrane of P. gingivalis (and all Gram negative 
bacteria) is LPS (discussed further in section 1.1.7), which acts as a pathogen associated 
molecular pattern (PAMP) stimulating the hosts‘ immune response and ultimately 
leading to destruction of the host tissue. The outermost part of the LPS molecule 
consists of a series of repeating units of monosaccharides, which form the O-
polysaccharides that are structurally and antigenically diverse. This is responsible for 
the O serotype of Gram negative bacteria. The core oligosaccharides (R polysaccharide) 
are structurally similar in most Gram negative bacteria. These oligosaccharides are 
attached to lipid A, which is responsible for the majority of the toxicity of this 
endotoxin. 
Further, Gram negative bacteria produce outer membrane vesicles (OMVs) 
when undergoing surface membrane modifications (Grenier and Mayrand, 1987; 
Duncan et al., 2004). During bacterial growth a small portion of the cells outer 
membrane bulges away from the cell where it will pinch off and ultimately be released, 
hence, why membrane blebbing is often observed. OMVs contain outer membrane 
components (LPS), cell wall components (peptidoglycan) along with gingipains and 
other biologically active components which will initiate the hosts immune responses 
(Manning and Kuehn, 2011), contribute to the biofilm formation or enter extracellular 
milieu due to their small size (20-200 nm) (Schooling and Beveridge, 2006). P. 
gingivalis has been shown to selectively sort virulence factors into OMVs (Haurat et al., 
2011) therefore playing an essential role in the pathogenesis of the bacteria.  
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In addition to OMVs, Short chain fatty acids (butyric and propionic acids) are 
also released by P. gingivalis as by-products of metabolism. These inhibit fibroblast 
proliferation in addition to contributing to the noxious smell of the bacteria (Singer and 
Buckner, 1981; Grenier and Mayrand, 1995). These by-products are also shared as 
nutritional pro-growth supplements between P. gingivalis and T. denticola (Grenier, 
1995). 
P. gingivalis has recently been described as a ―keystone pathogen‖ meaning that 
this bacterium can influence the populations of bacterial species taking up residency 
following its initial colonisation in the host (Hajishengallis et al., 2011; 2012).  
 
ii) Treponema denticola 
 Figure 1.6: TEM images of T. denticola. A) Lower magnification image, bar represents 
500 nm. B) Higher magnification of T. denticola cell, bar represents 100 nm. Cells were 
prepared for TEM as stated in section 4.2.11. 
 
T. denticola along with P. gingivalis is implicated in chronic periodontal disease and 
together they demonstrate a synergistic relationship. Simonson et al., (1992), reported 
that T. denticola was not detected in the absence of P. gingivalis in a total of 221 
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specimens taken from a multinational population. Also, T. denticola is found located 
within the surface layers of the sub-gingival plaque, with P. gingivalis being deeper 
within the plaque, beneath the surface layer (Kigure et al., 1995). In addition, Grenier 
(1992) demonstrated that a symbiotic nutrient relationship exists between these two 
bacteria. The growth stimulating factors produced by P. gingivalis (ATCC 33277) and 
T. denticola (ATCC 35405) for their symbiosis are their metabolic by-products 
isobutyric acid and succinic acid respectively (Grenier, 1995).  
T. denticola (Fig. 1.6) is motile and is capable of chemotaxis which allows the 
bacteria to respond to environmental stimuli (Sim et al., 2005). The motility of T. 
denticola is facilitated by the presence of periplasmic flagella. These aid the 
translocation in environments which would generally slow/immobilise externally 
located flagella and their internal location means that the bacteria is protected from 
flagella specific antibodies produced by the host (Charon and Goldstein, 2002). Unlike 
P. gingivalis, T. denticola outer sheath does not contain typical LPS but instead it 
contains lipo-oligosaccharides (LOS), however, LOS can also stimulate an immune 
response within the host and can activate fibroblast activity (Schultz et al., 1998; 
Schröder et al., 2000). The outer sheath proteins of T. denticola also function as OMVs 
targeting the adaptive immune response of the host (Weinberg and Holt, 1991; Kuehn 
and Kesty, 2005). In addition, the transposases of T. denticola function to ‗cut and 
paste‘ mobile genetic elements within the genome, hence, T. denticola has a high 
potential for genetic variability when growing as part of a biofilm (Mitchell et al., 
2010). Another enzyme possessed by the bacterium is dentisilin which is a protease 
enzyme located on the cell surface that aids the bacteria by disrupting host signalling 
pathways via degradation of the hosts‘ cellular matrix proteins (Uitto et al., 1988; 
Grenier et al., 1990; Makinen et al., 1995; Ishihara et al., 1996; Beausejour et al., 
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1997). As for P. gingivalis, it has been reported that T. denticola also possesses trypsin-
like enzyme activity (Ohta et al., 1986; Fenno et al., 2001). Finally, to aid the 
colonisation of the bacteria T. denticola has a β-barrel, integrated outer sheath protein 
which acts as a porin and has surface exposed loops which are able to bind a variety of 
host proteins.  
 
iii) Tannerella forsythia 
 
Figure 1.7: TEM images of T. forsythia. A) Lower magnification image, bar represents 
500 nm. B) Higher magnification of T. forsythia cell, bar represents 500 nm. Cells were 
prepared for TEM as stated in section 4.2.11. 
 
T. forsythia (Fig. 1.7) is one of the least studied significant periodontal pathogens as it 
has fastidious growth characteristics and can be difficult to manipulate genetically 
(Onishi et al., 2008). So far only a few putative virulence factors have been identified 
for T. forsythia and these include trypsin-like and PrtH proteases which may play a role 
in degradation of host proteins, cleaving components involved in the innate (cytokines, 
chemokine, complement proteins) or the adaptive (IgGs) immune system, whilst aiding 
the growth of the bacteria through supplying essential amino acids and heme (Sharma, 
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2010). T. forsythia also possesses two sialidases, known as SiaHI and NanH, these 
enzymes have the ability to cleave sialic acids on host glycoproteins. This results in the 
destruction of the host glycoproteins and/or the unmasking of hidden epitopes on host 
surfaces thereby aiding the pathogenesis of the bacterium. 
In addition, T. forsythia has also been shown to express a number of surface 
components such as the surface layer (S-layer), which promotes adherence to, and 
invasion of epithelial cells (Sabet et al., 2003; Lee et al., 2006). Another surface 
component is the leucine-rich repeat BspA protein which is thought to contribute to 
alveolar bone loss in mice (Sharma et al., 2005) in addition to its role in protein 
interactions vital for the interaction of T. forsythia with the host and other bacteria 
(Sharma et al., 1998; Loimaranta et al., 2009). Inagaki et al., (2006) investigated the 
epithelial cell adherence and invasion abilities of T. forsythia and found that these are 
dependent on BspA. They also reported that P. gingivalis FDC 381 or its OMVs 
enhance the attachment and invasion of T. forsythia ATCC 43037 to epithelial cells 
(Inagaki et al., 2006). Finally, surface lipoproteins are present which can induce an 
inflammatory response within the host leading to cell/tissue destruction (Hasebe et al., 
2007), and T. forsythia presents with trypsin like protease activity as outlined for the 
other bacteria (Grenier, 1995). 
 
iv) Fusobacterium nucleatum 
F. nucleatum is a predominant species of the subgingival biofilm and is commonly 
located in the oral cavity of both healthy individuals and those with periodontal disease 
(Dzink et al., 1988).  It is a Gram negative anaerobic bacterium and, as mentioned 
previously, F. nucleatum has the ability to co-aggregate with both early and late 
colonizers of the oral cavity. Hence, it is suggested to promote plaque development via 
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functioning as a bridge bacterium (Bolstad et al., 1996; Kolenbrander, 2000; Rickard et 
al., 2003; Weiss et al., 2000). In addition, F. nucleatum is viewed as an opportunistic 
pathogen in polymicrobial infections and has been shown to contribute to various 
conditions, including bacterial vaginosis (Citron, 2002), acute appendicitis (Swidsinski 
et al., 2011), and preterm birth (Barak et al., 2007; Han et al., 2004). 
Several potential virulence mechanisms have been proposed for F. nucleatum and 
these include the binding to leukocytes (Mangan et al., 1989; Ozaki et al., 1990) and 
immunoglobulin G (Grenier and Michaud, 1994), binding to and lysing of erythrocytes 
(Ozaki et al., 1990), plus adhering to and invading epithelial cells (Han et al., 2000). In 
addition, F. nucleatum has the ability to produce a serine protease which degrades 
extracellular matrix proteins (Bachrach et al., 2004), activate leukocytes (Sheikhi et al., 
2000) and lymphocytes (Tuttle et al., 1992), and produce OMVs containing probable 
virulence factors (Skår et al., 2003). 
Settem et al., (2012) demonstrated that a more potent immune response and 
increased alveolar bone loss was induced in a periodontal mouse model treated with 
mixed T. forsythia and F. nucleatum infections than infection with either species alone. 
In contrast, Kesavalu et al., (2007) demonstrated that F. nucleatum did not further affect 
the alveolar bone loss due to polymicrobial infection comprising P. gingivalis, T. 
denticola, and T. forsythia. Therefore, as this study is using a mixed infection 
containing all three red complex bacteria (P. gingivalis, T. denticola, and T. forsythia), 
and in the presence of all three pathogens it was shown not to be responsible for 
destructive periodontal disease (resulting in tooth loss) its presence will not be 
investigated and F. nucleatum will be viewed initially as bridging bacteria in the 
formation of a polymicrobial infection. 
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1.1.7. Virulence factors that damage the host 
There are three ways in which bacteria can damage the host tissue. The first mechanism 
is via direct damage due to the pathogens ability to adhere, grow and evade the hosts‘ 
defences (Peterson, 1996), although, this method of tissue destruction is believed to be 
the least prevalent mode of pathogen induced damage. The second mechanism is the 
pathogens ability to produce an autoimmune response which is excessive and beyond 
the threshold of the hosts‘ immune response and as a result there is tissue damage 
(Birkedal-Hansen, 1993; Kornman et al., 1997). The final mode of pathogen induced 
tissue damage is via toxins that are ‗poisonous‘ to the host (Peterson, 1996).  
A toxin can be any substance which contributes to illness and there are two main 
forms of toxin produced by periodontal bacteria: endotoxins and exotoxins (Peterson, 
1996).  
 
i) Endotoxin – LPS 
LPS is an integral component of Gram negative bacteria and is found in the outer 
membrane layer. It protects the bacteria by restricting the entry of noxious substances 
such as bile salts, digestive enzymes and some antibiotics and enables the bacterium to 
evade many host defence factors including complement, lysozyme and cationic proteins. 
LPS may also be found in a cell-free form occurring after bacterial autolysis as a result 
of exposure to antibiotics during rapid growth or when essential nutrients are depleted 
from the environment. Such conditions may arise during bacteraemia. In a cell-free 
form, LPS forms complexes with molecular weights >10
6
. It is a stable molecule, which 
can withstand heating to 100 °C for several hours. LPS synthesis is controlled by 
chromosomal genes and not by plasmid DNA. 
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Figure 1.8: The structure of the bacterial endotoxin LPS.  
 
Rough type LPS does not contain the O polysaccharide, whereas smooth LPS contains 
two or more repetitive units forming the O chain. LPS of P. gingivalis is generally of 
smooth type although this can vary amongst strains (Kabanov et al., 2010). Smooth type 
LPS consists of three regions: lipid A, R polysaccharide and O polysaccharide (Ratez 
and Whitfield, 2002) (Fig. 1.8). The lipid A region contains the hydrophobic membrane 
anchoring region of LPS and is made up of a phosphorylated N-acetylglucosamine 
(NAG) dimer with six or seven fatty acids attached, this structure being highly 
conserved amongst Gram negative bacteria (Ratez and Whitfield, 2002). The R 
polysaccharide (also known as the core R antigen) region is attached to the sixth 
position of a NAG and is made up of a short chain of sugars. Two unusual sugars are 
incorporated into the LPS of Gram negative bacteria these are heptose and 2-keto-3-
deoxyoctonate (KDO) and are often used for the identification of Gram negative LPS 
(Ratez and Whitfield, 2002). The third region, the O polysaccharide (also known as the 
somatic O antigen), is attached to the core polysaccharide and consists of repeating 
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oligosaccharide subunits made up of three to five sugars (chains can reach up to 40 
repeated units), this region of LPS is a major antibody binding site (Ratez and 
Whitfield, 2002). The lipid A region of LPS is a powerful biological response modifier 
which can stimulate the mammalian immune system. Lipid A binds to pathogen 
recognition receptors (PRRs) in many cell types which promotes cell activation and 
secretion of pro-inflammatory cytokines and nitric oxide (Beutler, 2003). This can result 
in the stimulation of prostaglandin and leukotriene production, and activation of the 
complement cascade and the coagulation cascade (Taubman et al., 2005). Hence, high 
levels of LPS within the host can result in an elevated immune response which, once 
above the hosts‘ threshold level, will result in damage to the tissue (Taubman et al., 
2005). 
P. gingivalis has been shown to contain two LPS macromolecules, an O-LPS 
containing the O polysaccharide attached to the lipid A core and an A-LPS where the 
phosphorylated branched mannan repeating unit is attached to the lipid A core 
(Rangarajan et al., 2008). In addition P. gingivalis LPS possesses significant amount of 
lipid A heterogeneity containing tetra- (LPS1435/1449) and penta-acylated (LPS1690) 
structures.  The heterogeneity of LPS includes differences in the number of phosphate 
groups alongside both the amount of lipid A fatty acids and their specific position. The 
presence of multiple lipid A structures makes it more difficult for the innate host 
responses to recognise the molecule therefore aiding the virulence of P. gingivalis 
(Reife et al., 2006).  
 Another important factor regarding the LPS of P. gingivalis is its ability to 
modify certain surface proteins; Veith et al., 2002 demonstrated that gingipain complex 
from different strains of P. gingivalis have an intimate association between LPS and the 
glycosylation of the protein - resulting in the cross-reactivity between monoclonal 
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antibodies against LPS and to the carbohydrate moieties on gingipains. O'Brien-
Simpson et al., 2001 suggested that the modification recognised by the P. gingivalis 
monoclonal antibody (clone 1B5) is located in the C-terminal segment of RgpB, overall 
suggesting that gingipains can be modified by LPS attachment to the conserved C-
terminal segment. This could have larger implications in the virulence of the pathogen 
as it displays a mechanism by which the gingipains attach to the outer membrane (Veith 
et al., 2002). 
LPS also activates the immune response through receptors on the membrane of 
host cells or PRRs with both the tetra- and penta-acylated lipid A structures of P. 
gingivalis differentially activating the TLR-mediated NF-κB signalling pathway. P. 
gingivalis LPS has been shown to use both toll like receptors 2 and 4 (TLR2 and 
TLR4), depending on the cell type (Kocgozlu et al., 2009). The resulting bone loss 
following infection with P. gingivalis is dependent on the hosts‘ immune response. In 
support of this view Baker et al., (1994; 1999; 2000) demonstrated that both CD4+ T 
cell deficient mice and SCID (severe-combined-immunodeficiency) mice were resistant 
to alveolar bone loss due to P. gingivalis (Baker, 1994; 1999; 2000). 
T. forsythia cell membrane contains rough type LPS (Posch et al., 2013). This is 
the same structure as smooth type LPS although it lacks the O polysaccharide region 
(Fig. 1.8). T. forsythia LPS produces a typical innate immune response resulting in the 
release of pro-inflammatory mediators (Posch et al., 2013) as described for P. gingivalis 
LPS. In addition to LPS T. forsythia also has an S-layer; the S-layer is the outermost 
cell envelope component of a number of bacteria providing an additional protective 
barrier to the bacteria alongside playing a role in cell adhesion and surface recognition. 
The S-layer of T. forsythia is made up of two glycoproteins, TfsA and TfsB, both of 
which are specifically recognised in the sera of patients with periodontitis. Also, TfsA 
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and TfsB may mediate adhesion to, and/or invasion of, human gingival epithelial cells 
and epidermal carcinoma cells of the mouth. Sekot et al., (2011) demonstrated that the 
mutant strain of T. forsythia which lacks the S-layer induced a significantly higher level 
of proinflammatory cytokines than wild type T. forsythia, thereby suggesting that the S-
layer attenuates the host immune response by evading innate immune recognition 
(Shimotahira et al., 2013). 
On the other hand T. denticola has LOS (as mentioned previously)(Schultz et 
al., 1998) whose structure differs to LPS as its O polysaccharide region is limited to 
only 10 saccharide units (Preston et al., 1996). LOS has a similar lipid A structure to 
LPS with an identical array of functions. Hence, T. denticola LOS has been shown to 
stimulate osteoclastogenesis and MMP (matrix metalloproteinase) expression (Choi et 
al., 2003) and can induce inflammatory mediator production by macrophages (Tanabe 
et al., 2008) alongside production of IL (interleukin) -8 from fibroblasts (Preston et al., 
1996). The continuous high secretion of cytokines (IL-6, IL-8, PGE2, MMPs) by the 
host cells following stimulation by factors such as LPS modulates the tissue destruction 
in periodontal disease (Ishikawa, 2007). 
 
ii) Exotoxins – Proteases 
Although the primary cause for connective tissue destruction is the result of proteolytic 
activity of host cells, bacteria also secrete products which can damage the extracellular 
matrix proteins and these represent the exotoxins. Exotoxins are proteins (often 
enzymes and metabolic by-products) which exert damage on the host following release 
from the bacterial cell. These include proteases, coagulases and fibrinolysins which act 
on their specific substrates (Daly, 1980; Sandholm, 1986). For example, P. gingivalis 
has the ability to secrete a large variety of enzymes such as collagenases, which break 
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the peptide bonds in collagen (the main structural protein of connective tissue) (Travis 
et al., 1997). P. gingivalis is also armed with gingipains. There are two types of 
gingipains expressed and these are lysine specific (Kgp) and arginine specific (Rgps) as 
determined by the specificity for their cleaving sites (Holt and Ebersole, 2005; 
Imamura, 2003). Gingipains are known to play a major role in the progression of 
periodontal disease, inducing inflammation and tissue destruction in the periodontium, 
which includes alveolar bone loss (Miyachi et al., 2007). In addition, gingipains are also 
shown to degrade CD14 on the surface membrane of macrophages (Imamura, 2003). 
T. denticola expresses a number of different proteolytic enzymes which promote 
the invasion and destruction of oral tissues (Kesavalu et al., 1997; Potempa et al., 
2000). Dentilisin is a protease secreted by T. denticola and is bound in the outer sheath 
cleaving specific proteins at a phenylalanine residue site (Uitto et al., 1988; Rosen et 
al., 1999). Dentilisin hydrolyses a range of proteins including transferrin, fibrinogen and 
immunoglobulins. In addition, T. denticola has been shown to possess trypsin like 
activity (Makinen et al., 1995; Gazi et al., 1997) which has been identified as a result of 
the protein encoded for by the OpdB (oligopeptidaseB) gene (Fenno et al., 2001). 
T. forsythia also possesses trypsin like activity. This was initially reported by 
Grenier (1995), who identified a protein which cleaves at arginine or lysine bonds, but 
this is believed to degrade only small peptides. An additional protease (PrtH) secreted 
by T. forsythia, with the ability to cleave larger proteins, has since been identified by 
Saito et al., (1997) and functions as a cysteine protease. Studies have suggested that 
PrtH may be involved in the disintegration of the gingival epithelium and induction of 
chemokine IL-8 from detached cells (Sharma, 2010). In addition, T. forsythia induces 
alveolar bone loss in mice dependant on the BspA protein (Sharma et al., 2005) by 
activating antigen presenting cells via TLR2 dependant signalling (Myneni et al., 2011). 
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Although not directly secreted by bacteria, another form of proteases (secreted 
by the host) that plays a role in the tissue destruction by periodontal pathogens are 
MMPs. MMPs play a role in tissue remodelling and cell migration. If synthesis of these 
proteases is increased these may be involved in the pathogenesis of periodontal disease 
as they have the ability to degrade proteins such as collagen, fibronectin, elastin and 
proteoglycan (Sapna et al., 2013). Exposure to bacterial components such as LPS can 
induce MMP secretion in gingival epithelial cells (Birkedal-Hansen, 1993). In addition, 
P. gingivalis proteases can up-regulate MMP secretion in epithelial cells and 
subsequently this leads to further tissue destruction.  
 
1.1.8. Bacterial peptidoglycan 
Peptidoglycan is the only cell wall component common to all bacteria. It is the essential 
scaffold of all cell walls that provides rigidity. Peptidoglycan, as the name implies, is 
formed of glycan (sugar) strands cross-linked via short peptides (proteins) (Fig. 1.9). 
The glycan segment comprises of two alternating amino-hexose sugars; N-
acetylglucosamine and N-acetyl muramic acid cross-linked by short chains of amino 
acids. Usually, L-alanine is bound to muramic acid (L.L-DAP), in Gram positive 
bacteria, or L.D mesodipemellic acid (L.D- (meso)-DAP) in Gram negative bacteria 
(Ghuysen et al., 1963; Ghuysen 1968). The cell walls of Gram positive bacteria contain 
90-95 % peptidoglycan whereas Gram negative bacterial cell walls contain only 5-10 % 
peptidoglycan. The greater amount of peptidoglycan present in Gram positive bacteria 
protects them from complement mediated lysis as the MAC is unable to penetrate the 
cell wall. Thus, peptidoglycan can act as an immune evasion strategy for some bacteria.  
In addition, peptidoglycan can act as a PAMP, initiating immune responses 
within the host. Both bacterial peptidoglycan and its products (muramylpeptides) have 
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been shown to act as inflammatory mediators by activating host innate PRR (TLRs and 
intracellular receptors nucleotide-binding oligomerization domain receptors (NOD) 1 
and 2) (Sorbara and Philpott, 2011). The binding of peptidoglycan to a PRR (such as 
TLR2) results in an inflammatory response within the host ultimately leading to 
destruction of the host tissue (as described for LPS). Peptidoglycan preferentially binds 
to TLR2 on immune cells within the host unlike LPS (Iwaki et al., 2002). 
 
Figure 1.9: Assembly of Gram negative peptidoglycan. NAM = N-acetylmuramic acid 
and NAG = N-acetylglucosamine. 
As for the three periodontal (red complex) pathogens, P. gingivalis 
peptidoglycan has been shown to be highly toxic (Ishii et al., 2010), and it differs 
slightly from other forms of Gram negative peptidoglycan as it contains L.L-DAP 
instead of L.D- (meso)-DAP (Barnard and Holt, 1985). T. denticola cell wall also 
contains peptidoglycan and has the ability to mount an immune response in the host 
(Tanabe et al., 2009), and was shown to be highly toxic in a time- and concentration-
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dependent manner (Grenier and Uitto, 1993). Tanabe et al., (2009) demonstrated that T. 
denticola peptidoglycan can activate intracellular signalling pathways, leading to an 
increased production of inflammatory mediators by macrophage-like cells.  
T. forsythia cell membrane also contains peptidoglycan, however, these bacteria 
lack the metabolic pathway to synthesize their own N-acetyl muramic acid. Hence for 
the growth of T. forsythia an exogenous source of N-acetyl muramic acid is needed. 
Therefore, it has been speculated that by scavenging the N-acetyl muramic 
acid/peptidoglycan from within the periodontal pocket T. forsythia may be dampening 
the hosts‘ immune response, and actually reducing the level of inflammation (Sharma, 
2010).  
1.1.9. Immune evasion strategies of P. gingivalis, T. denticola and T. forsythia 
Extensive amount of data supports the idea that P. gingivalis, T. denticola and T. 
forsythia are master evaders of the host‘s immune system (Schenkein, 1989; Lamont 
and Jenkinson, 1998; Potempa et al., 2008; Mahtout et al., 2009; Magalhães et al., 
2008; Potempa and Pike, 2009; Belstrøm et al., 2011; Slaney et al., 2006) (Table 1.1). 
All of the red complex bacteria exhibit passive immune evasion mechanisms which aid 
their survival within the host, such as, cell aggregation and biofilm formation. The 
structural nature of a biofilm provides a physical barrier against immune cells of the 
host. Their passive defence mechanisms, allow the bacteria to evade the immune 
response of the host (Socransky and Haffajee, 2002). In addition, a number of active 
mechanisms are employed by bacteria which are based on three main processes 
including degradation of complement fragments (avoiding opsonisation by protease 
digestion of complement fragments), recruitment of hosts regulatory proteins (Factor H, 
C4 binding protein) and the protection by the bacterial cell wall. In the latter either the 
MAC is unable to form or their cell wall component (polysaccharides) mediated 
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complement activation is supressed (Thompson, 2002; Walport, 2001; Ngampasutadol 
et al., 2008; Potempa et al., 2008; McDowell et al., 2011; Shimotahira et al., 2013).  
In the case of P. gingivalis, it is very resistant to killing by complement due to 
the ability of the gingipains to degrade C3 and C5 and, thereby, preventing the 
deposition of C3b on the surface of the bacterial cell (Popadiak et al., 2007; Slaney et 
al., 2006). The finding that gingipains are modified by and reactive with an LPS 
recognising monoclonal antibody (MAb 1B5) suggests a mechanism for the attachment 
of the RgpA and Kgp complexes to the outer membrane (Veith et al., 2002), this 
potentially increases the virulence of the bacterium as gingipains present on the surface 
of the bacterial cell will be readily available to degrade complement proteins amongst 
others therefore avoiding the hosts immune response. Gingipains can also attach to C4b 
binding protein and avoid being killed by complement mediated lysis (Potempa et al., 
2008). Gingipains have also been shown to degrade the CD14 receptor, cytokines (IL-
12, IL-1β, IL-6, and Interferon gamma IFN-γ) and AMPs (Hajishengallis, 2011; Gutner 
et al., 2009). Another immune evasion mechanism which has been demonstrated for P. 
gingivalis is its adherence to erythrocytes via CR (complement receptor)-1. This allows 
the bacteria to go undetected by circulating phagocytes in addition to providing a 
potential transport mechanism for the movement of P. gingivalis via systemic 
circulation (Belstrøm et al., 2011). In addition, the ability to alter the lipid A structure of 
LPS could be one of the strategies utilised by P. gingivalis to evade innate host defence 
in gingival tissues potentially contributing to the pathogenesis of periodontal disease 
(Herath et al., 2013). 
T. denticola on the other hand exploits the hosts own regulatory proteins to 
avoid immune recognition as it has the ability to bind complement factor H to its 
surface (McDowell et al., 2005; 2009; 2011) where subsequently the bound factor H is 
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rapidly cleaved by the protease dentilisin (McDowell et al., 2011, Fenno et al., 1998, 
Yamazaki et al., 2006, Miller et al., 2012). Dentilisin also has the ability to degrade 
other proteins (C3) within the complement system via its protease activity (Yamazaki et 
al., 2006).  
Little is known about T. forsythia and its associated immune evasion 
mechanisms. Although, recently Shimotahira et al., (2013) suggested that the immune 
evasion strategies‘ of T. forsythia are similar to those employed by P. gingivalis. Jusko 
et al., (2012) demonstrated that T. forsythia is highly resistant to killing by human 
complement. This has been attributed to a recently identified metalloproteinase of T. 
forsythia known as karilysin which has the ability to inhibit complement at several 
stages. Jusko et al., (2012) demonstrated that karilysin had the ability to inhibit both the 
classical and lectin complement pathways via the degradation of mannose-binding 
lectin, ficolin-2, ficolin-3, and C4 thereby aiding the evasion of the hosts immune 
response. Recent findings from the same group (Jusko et al., 2013) also demonstrated 
that mirolysin, a novel metalloproteinase of T. forsythia, had the ability to inhibit the 
pathways of the complement system.  
In addition, the trypsin-like and PrtH proteases play a role in the immune 
evasion of T. forsythia via the degradation of host proteins involved in the immune 
response. Also, sialidases belonging to T. forsythia (SiaHI and NanH), as mentioned 
previously, have the ability to cleave sialic acids on host glycoproteins. This allows 
them to destroy the host glycoproteins and/or unmask the hidden epitopes on host 
surfaces thereby aiding the pathogenesis of the bacterium.  
A key factor of T. forsythia which aids the evasion of the hosts‘ immune 
response is the S-layer of the bacterium. As mentioned previously the S-layer is present 
in the outermost cell envelope of a broad range of bacteria. However, T. forsythia is 
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unique in that it is currently the only known Gram-negative bacterium which has a 
glycosylated S-layer. The S-layer of T. forsythia is composed of two high molecular 
weight glycoproteins encoded by the tfsA and tfsB genes which are 220 and 210 kDa 
size, respectively (Higuchi et al., 2000). The key function of the S-layer, with regards to 
evading the hosts‘ immune response, is providing an additional protective barrier to the 
bacteria. In addition, the mutant strain of T. forsythia which lacks the S-layer has been 
shown to induce a greater immune response from the host when compared with the wild 
type strain (Sekot et al., 2011). Therefore, the S-layer of T. forsythia has the ability to 
impair the hosts‘ immune response by evading innate immune recognition (Shimotahira 
et al., 2013). Together, the S-layer of T. forsythia and its enzymes (for example 
karilysin, PrtH proteases and sialidases) play a significant role in evading this 
bacterium‘s recognition by the innate immune system. 
 The immune invasion strategies of periodontal bacteria are of great importance 
not only in periodontal disease, but also in relation to systemic disease as not only can 
the bacteria and their virulence factors access the systemic system but they can also 
cause an increase in serum derived markers. All of these properties have the potential to 
reach remote body organs and elicit consequences on the hosts‘ general health. One 
simple pathway is that periodontal bacteria can gain access to systemic circulation 
through everyday activities such as chewing food or brushing teeth during episodes of 
bleeding (Forner et al., 2006) in the form of transient bacteraemia. These bacteraemic 
episodes can also occur when undergoing invasive dental procedures (Savarrio et al., 
2005; Daly et al., 2001; Tomas et al., 2007), and fitting with the theory of ‗focal 
infection‘ once present in systemic circulation periodontal bacteria have the potential to 
go undetected by the immune system (due to the immune evasion mechanisms) and 
ultimately to contribute to systemic disease. 
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Table 1.1: Tactics employed by periodontal pathogens to avoid eradication from the 
host. 
Mechanism Effector proteins 
& organism 
Supporting references 
Hijacking of C4b-bp & shedding and 
proteolysis of CD46 C‘ment 
regulators 
HrgpA & Kgp (P. 
gingivalis) 
Potempa et al., 2008; Mahtout et 
al., 2009 
Exploitation of CR1 receptor on 
erythrocytes 
Unknown (P. 
gingivalis) 
Belstrøm et al., 2011 
Degradation of  CD14 Gingipains (P. 
gingivalis) 
Potempa & Pike, 2009  
Degradation of complement proteins 
and inflammatory mediators 
Gingipains (P. 
gingivalis), 
Dentisilin (T. 
denticola) 
Hajishengallis, 2011; Gutner et 
al., 2009; Popadiak et al., 2007; 
Slaney et al., 2006; Yamazaki et 
al., 2006 
Inhibit phagocyte mediated killing 
via cross talk between CXCR4-
TLR2 
FimA (P. 
gingivalis) 
Hajishengallis et al., 2008 
Suppression of  the neutrophil 
oxidative burst (TLR-dependent) 
Unknown (T. 
denticola) 
Sabroe et al., 2005 
Hijacking of Factor H C‘ment 
regulator 
11.4 kDa factor H- 
binding lipoprotein 
(T. denticola) 
Magalhães et al., 2008 
Survives phagocytosis  Dentilisin (T. 
denticola) 
Lamont & Jenkinson, 1998; 
Yanagisawa et al., 2006 
Avoids recognition by innate 
immune response  
S-layer (T. 
forsythia) 
Sabet et al., 2003; Sekot et al., 
2011 
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1.1.10. Risk factors, genetics, diagnosis and treatment 
There are a number of factors associated with an increased risk for periodontal disease 
the majority of which are modifiable such as smoking (Bergstrom, 1989; Albandar et 
al., 2000; Tomar and Asma, 2000) and uncontrolled diabetes (considered modifiable as 
it can be controlled) (Kinane and Chestnutt, 1997). Non-modifiable factors include the 
hosts‘ immune response, as it is widely accepted that the destruction occurring in 
periodontal disease is not only due to the presence of harmful bacteria but also the 
specific response of the host (Van Dyke and Serhan, 2003). Another non-modifiable 
risk factor is osteoporosis. Studies have shown that alveolar bone density is altered in 
individuals with osteoporosis (Van Dyke et al., 2005). Furthermore, ageing is 
potentially considered as a risk factor for periodontal disease, although, this may a result 
of cumulative destruction rather than an increased rate of destruction occurring with age 
(Grossi et al., 1994; 1995; Genco, 1996).  
There is also a proposed genetic susceptibility associated with periodontal 
disease as studies have demonstrated that 10-15% of the population are at a higher risk 
of gingivitis developing into periodontal disease (reviewed by Kinane and Hart, 2003). 
Individuals respond to different antigens in ways predicted by their genetic make-up. 
The hosts‘ immune response is, to an extent, determined by previous exposure to a 
foreign substance (adaptive immunity), but it is predominantly influenced by the 
individuals‘ genes. A number of familial studies have been performed which suggest a 
genetic predisposition to chronic periodontal disease (Hassel and Harris, 1995), 
although it has to be noted that familial patterns may simply reflect common 
environmental factors within families. Twin studies have also been carried out which 
generally support a significant heritable component of periodontal disease. Corey et al., 
(1993) analysed 4908 pairs of twins, although their analysis failed to control for 
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external factors such as smoking status and environmental factors. Michalowicz (1991) 
assessed probing depth and clinical attachment loss, followed by alveolar bone height 
and found that there was significant genetic component (whilst controlling for smoking 
status and oral hygiene practices). In 2000, Michalowicz examined genetic and 
environmental variances and heritability for gingivitis and periodontal disease. They 
found that adult periodontal disease estimated to have approximately 50% heritability, 
with no evidence of heritability for gingivitis. Despite this evidence for genetic 
susceptibility in periodontal disease there currently lacks a successful genetic 
target/model and to date clinical evidence examining inflammatory genes has been 
inconclusive. 
 
1.1.11. Animal models of periodontal disease 
Animal models for experimentally induced periodontal disease are vital to 
understanding disease pathogenesis, co-morbidities and for subsequent therapeutic 
regimens. A variety of animals have been used as potential candidates for true 
periodontal disease induction, including rats, mice (germfree and wild type) and beagle 
dogs (Yamasaki et al., 1979; Schou et al., 1993; Eggert et al., 1980; Kesavalu et al., 
2007;   Polak, 2009; Do et al., 2013). These models have been tested using both mono 
infections, mixed infection and polymicrobial infections. The earliest model of 
Yamasaki et al., (1979) used germfree mice to establish if the JE around the molar teeth 
was different from that seen in mice reared in normal conditions and found no 
differences. Eggert et al., (1980) examined the epithelia surrounding molar teeth with 
limited eruption in the rat, mouse and hamsters. They reported that there are two types 
of epithelial arrangements namely the gingivae and the JE with shorter gingival crevice 
depths than previously thought. Subsequent models introduced P. gingivalis at the 
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gingival margins of maxillary molar teeth in a hamster model and murine model, and 
measured bone resorption (Pathirana et al., 2007; Hojo et al., 2008). A rat model of 
periodontal disease induced with the dominant polymicrobial periodontal pathogens was 
first demonstrated by Kesavalu et al., (2007). It was clearly shown that repeated 
polymicrobial infections induced periodontal disease with the associated alveolar bone 
resorption and soft tissue damage. In addition, a murine model of experimental 
periodontitis has been developed by Polak et al., (2009) in which P. gingivalis and F. 
nucleatum infection was initiated to assess bone loss and host responses. These 
researchers found mixed infections were superior to mono infection driven experimental 
models of periodontitis. Subsequent studies from the Kesavalu laboratory explored the 
possibility of P. gingivalis and T. denticola mono and mixed infections in induction of 
periodontal disease processes and once again demonstrated alveolar bone resorption 
(Verma et al., 2010). In addition to investigating co-morbidities, the ApoE
null
 mouse 
model has been used with mono and polymicrobial periodontal pathogen infections, 
confirming the presence of both periodontal disease and atherosclerosis (Rivera et al., 
2013; Chukkapalli et al., 2014; Velsko et al., in press).  ApoE in this context was a key 
factor due to its proven association with the metabolic regulation of cholesterol, and 
subsequently cardiovascular disease. However, this specific animal model may also 
prove useful for investigating other disorders due to the association of ApoE with the 
development of dementia, specifically AD. By using an ApoE
null 
animal model, the 
pathological changes occurring in the brain could be viewed prior to any repair as ApoE 
is essential for neuronal repair after infection. In addition, ApoE has been demonstrated 
to play a vital role in the formation of insoluble β amyloid (Aβ) fibrils (Wisniewski and 
Frangione, 1992) therefore providing an opportunity to assess changes occurring in the 
CNS in the absence of the classical hallmarks of AD (Aβ plaques). 
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The rat and mouse models of experimentally induced periodontal disease clearly 
demonstrate the role of pathogens in the initiation of the disease as well as providing 
proof of concept that they infiltrate to remote body regions to initiate organ specific 
pathology (Rivera et al., 2013; Chukkapalli et al., 2014; Velsko et al., in press). They 
have already been found in the walls of human coronary arterial tissues (Chiu, 1999; 
Haraszthy et al., 2000) and in atheromatous plaques (Cavrini et al., 2005; Kozarov et 
al., 2005). These models are extremely useful for exploring the ―focal infection‖ theory 
(Miller, 1891; Hunter, 1900) in relation to other inflammatory diseases.  
Currently periodontal disease has been linked directly with cardiovascular 
disease (Mattila et al., 1989; Destefano et al., 1993; Sanz et al., 2010), diabetes mellitus 
(Martinez et al., 2011), respiratory infections (Scannapieco et al., 1998; 1999), 
rheumatoid arthritis (Tolo and Jorkjend, 1990; Gleissner et al., 1998), stroke (Sfyroeras 
et al., 2012) Osteoporosis (Jeffcoat, 1998), obesity (Suvan et al., 2011) and pregnancy 
complications (Offenbacher et al., 1998) such as low birth weight (Offenbacher et al., 
1996) and preterm birth (Jeffcoat et al., 2011). More conditions are being added to this 
list all the time. In an attempt to explain the mechanisms underlying the link shown 
between periodontal disease and systemic disease, a number of hypotheses have been 
suggested. These include the direct invasion of distant organs by oral bacteria and/or 
their products, or the effect of increased systemic inflammation due to their presence 
within systemic circulation (Cullinan et al., 2009). Most recently periodontal disease 
has been linked with the aetiology of AD (Riviere et al., 2002; Stein et al., 2007; Kamer 
et al., 2009) and this forms the subject of part II of this thesis. 
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1.2.Part II 
The brain is a very complex organ, and overlapping neurodegenerative diseases add 
further complications when researchers are investigating the mechanisms of disease 
processes. A characteristic feature of human neurodegenerative diseases is the selective 
loss of neurons in a disease specific distribution. Prior understanding of the anatomy 
and the cellular neurobiology of the central nervous system (CNS) is necessary for the 
investigator.  
 
1.2.1. The Human Brain 
The CNS encompasses the brain and the spinal cord which are constantly submerged in 
cerebrospinal fluid (CSF). The CSF provides the brain with protection, support and 
nutrition alongside removal of metabolites. The brain and the spinal cord are surrounded 
by limiting membranes known as the meninges which in turn are surrounded by the 
bones of the vertebrae and cranium (Tamraz et al., 2006).  
The brain consists of both grey and white matter. The grey matter is made up of 
cell bodies of neurons whereas the white matter contains the dendrites and axons of cell 
bodies forming the network that connects neurons from one anatomical region of the 
brain to another. The largest part of the brain is the cerebrum which has a heavily folded 
(sulci) surface of grey matter known as the cerebral cortex (Tamraz et al., 2006). The 
brain is made up of two halves, called hemispheres, which are connected to each other 
by the corpus callosum. Each hemisphere comprises of a frontal, parietal, temporal and 
occipital lobe (Tamraz et al., 2006) (Fig. 1.11). The frontal lobe is located at the anterior 
of each cerebral hemisphere (Fig. 1.10) and this part of the brain is associated with an 
individual‘s personality, behaviour and emotions along with storing of long-term 
memories (Simons and Spiers, 2003).  
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Figure 1.10: Schematic image of the brain from a lateral view, indicating the position of 
the different lobes present in each hemisphere.  
 
The parietal lobe is situated posterior to the frontal lobe and superior to the 
occipital lobe (Fig. 1.10) and is responsible for receiving and processing information 
regarding temperature, taste, touch and movement from the rest of the body. Reading 
and arithmetic are also processed within the parietal lobe region of the cerebral cortex 
(Menon et al., 2000). The two occipital lobes are the smallest of the four lobes which 
make up the cerebral cortex and are found in the rear most portion of the hemispheres 
(Fig. 1.10) and function to process visual information as this is the location of the 
primary visual cortex. The temporal lobe is situated on the lower side of each cerebral 
hemisphere (Fig. 1.10) and is involved in processing hearing, memory and language 
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functions. The temporal lobe also contains the structures of the limbic system (Shepard, 
1994). 
The limbic system (Figure 1.11) is made up of a number of interconnected 
structures including the thalamus, cingulate gyrus, fornix, amygdala, hippocampus and 
parahippocampal gyrus which mediate emotions, learning and memory. Each structure 
plays its individual role in the functioning of the limbic system. For example, the 
thalamus relays signals between the spinal cord and the cerebrum, whereas the cingulate 
gyrus is involved with sensory input concerning emotions and regulation of aggressive 
behaviour. The fornix is an arching fibrous band of nerve fibres which connects the 
hippocampus to the hypothalamus, the parahippocampus also being an important 
connecting pathway of the limbic system. On the other hand the amygdala is involved in 
emotional responses, hormonal secretions and memory, and finally the hippocampus 
functions to form memories and send them to the appropriate location within the 
cerebral hemisphere for storage, along with retrieving memories when necessary 
(Tamraz et al., 2006).  
 
Figure 1.11: Basic diagram of the limbic system showing the location of the 
thalamus, hypothalamus, amygdala and hippocampus. 
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Situated below the cerebral hemispheres is the cerebellum which plays a vital 
role in motor control. The posterior section of the brain is the brain stem; this adjoins 
and structurally continues with the spinal cord. The brain stem is responsible for 
regulating many of the bodies life support mechanisms including blood pressure, heart 
rate and breathing along with coordinating motor control signals sent from the brain to 
the body. The three sections of the brain stem are the mid brain, medulla oblongata and 
pons (Tamraz et al., 2006).  
 
1.2.2. Memory 
As mentioned previously, one anatomical area of the brain associated with memory is 
the hippocampus, a structure located on the medial surface of the temporal lobe. In 
addition, the prefrontal cortex also participates in learning and memory (Wickelgren, 
1979; Damasio, 1989; Squire, 1992). Exactly how the two areas connect and the 
processes involved with learning and memory formation is complex, but anatomically, 
the hippocampus is joined to rest of the cortex by the subiculum.  
Memory is a functional entity, attempts to describe its unit of biological measure 
began with electroencephalogram (EEG) recordings; these demonstrated a difference in 
brain activity between the young and old (Obrist et al., 1962). Surprisingly, the change 
in the EEG recordings from active and healthy elderly subjects was minimal compared 
with younger control subjects (Obrist et al., 1962). Taken together, these findings 
suggested slowing down of the dominant alpha rhythm was related to an individual‘s 
health status, intellect and longevity (Obrist et al., 1962).  
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An electrophysical correlate of a form of simple memory was first described by 
Bliss and Lomo (1973) and this represents ―long term potentiation‖ (LTP). These 
scientists first described the process in the hippocampus where neurons ―learned‖ 
following repetitive electrical stimulations via the perforant pathway of dentate gyrus 
granular cells (Bliss and Lomo, 1973). Following high frequency electrical stimulation, 
an increase in the excitatory post-synaptic potential amplitude of the dentate granule cell 
population was observed. This increase in the efficacy of synaptic signalling has been 
related to memory as it can vary in duration (Abraham et al., 2002). Studies have also 
demonstrated a significant link between hippocampal volume and single measures of 
memory such as immediate recall (Petersen et al., 2000), delayed recall (Hackert et al., 
2002), or delayed recognition (Kopelman et al., 2001). 
 
1.2.3. Cellular neurobiology 
The CNS is made up of nerve cells and their processes in addition to specialised non-
neuronal support cells collectively called glia (Fig. 1.12). These cell types include 
ependymal cells, oligodendrocytes, astrocytes, and microglial cells. Of these, astrocytes 
and microglia are of interest to neuro-biologists/scientists as they play a significant role 
in driving inflammation in neurodegenerative diseases.  
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Figure 1.12: Glial cells of the CNS. Image shows the basic structure of astrocytes, 
microglia and oligodendrocytes.  
 
i) Neurons: biology and function  
The brain contains around one hundred billion nerve cells known as neurons (Johnson 
and Erner, 1972). These represent some of the functional building blocks of the brain 
and they originate from the ectoderm during embryogenesis (Allen and Barres, 2009). 
Following silver impregnation techniques, Camillo Golgi (1873) first visualised these 
cells, and their structural complexities were investigated by Ramon y Cajal between 
1888-1891 demonstrating that a neuron is made up of a cell body (stroma), dendrites 
(processes) and an axon (Fig. 1.13).  
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Figure 1.13: The basic structure of a neuron and its synaptic connections; the electrical 
signal refers to the action potential which is generated in the cell body, travelling along 
the axon to pass via the synapse to the dendrites of another neuron in excitatory 
synapses and allowing communication throughout the CNS. 
 
Neurons form the basic information processing unit of the CNS, communicating 
via the release and capture of neurotransmitter and neuromodulator chemicals, some of 
which work in the synapses going between release sites and receptors. Signals are 
transmitted via the generation of an action potential which travels rapidly along the 
axon to its terminal which is connected to the dendrite of another neuron via a synapse 
(Stewart et al., 1997) (Fig. 1.13). A synapse consists of a pre- and post- synaptic 
terminal, when the action potential reaches the pre-synaptic terminal the membrane is 
depolarised and neurotransmitters are released. These are detected by receptors on the 
post-synaptic membrane of another neuron. The signal is then processed by the neuron 
into meaningful information (Stewart et al., 1997). Each neuron has the ability to 
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contact thousands of other neurons via synapses, with new connections constantly being 
formed. It is through these connections that memories are stored, personalities are 
formed and habits are made (Edelman and Changeux, 2001). In order to perform their 
functional role, the neurons depend upon the glial cells. 
 
ii) Oligodendrocytes  
Oligodendrocytes are cells of the ectodermal origin, named originally by del Rio-
Hortega in 1928. Oligodendroglial cells provide support and insulation to the axons of 
neurons within the CNS. They form the myelin sheath, which consists of 80% lipid and 
20% protein (Morell and Quarles, 1999) and wraps around the axon of a neuron. Myelin 
sheaths not only reduce any ion leakage from the neuron and decrease the capacitance 
of the cell membrane but they also increase the speed of the action potentials (Susuki, 
2010). Oligodendrocytes can be easily demonstrated in tissue sections by 
immunolabelling with antibodies raised to galactocerebroside c and myelin basic 
protein (Ranscht et al., 1982) (Fig. 1.14). Since oligodendrocytes play little role in 
neurodegenerative diseases, these cells will not be discussed further. 
 
iii) Ependymal cells 
Ependymal cells are a single layer of epithelial cells, situated at the boundary between 
the CSF and the brain (Del Bigio, 1995). Ependymal cells can be easily identified by 
morphology stains such as haematoxylin and eosin (H/E). They are cuboidal in shape 
and are ciliated (Bleier, 1971; Millhouse, 1971). The adult ependymal cells are derived 
from radial glia during embryogenesis (Spassky et al., 2005). The ependymal cells aid 
the movement of CSF through the ventricles (Worthington and Cathcart, 1963; Cathcart 
and Worthington, 1964), form tight junctions and control fluid release across the 
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epithelial layer (Bruni, 1998) to protect the brain from potentially harmful substances in 
the CSF (Kuchler et al., 1994). In addition, they express phagocytic receptors to allow 
the detection and clearance of bacteria (Stahl and Ezekowitz, 1998; Laflamme and 
Rivest, 2001) together with expression of membrane bound complement regulatory 
proteins which are up-regulated following bacterial infection (Canova et al., 2006).  
 
iv) Microglial cells: Biology and function  
Microglia comprise a distinct population of glial cells within the CNS as originally 
discovered by del Rio-Hortega (1932), who expanded the idea of a cellular ―third 
element‖ (besides the neurons and astrocytes) in the CNS as formerly described by 
Cajal (1913
a, b
). By using silver impregnation methods, del Rio-Hortega identified 
microglia which differed from other cells in their external morphology as well as their 
embryonic origins. According to del Rio-Hortega (1932), microglia had a mesodermal 
origin and as new technologies have developed over the years, it has become clear that 
microglia are derived from mesodermal precursor cells of haematopoietic stem cell 
lineage. These cells migrate and colonise the CNS during embryogenesis (Rezaie and 
Male, 2002).   
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Figure 1.14: Microglia labelling using the anti 1ba1 antibody taken from mouse brain 
tissue. Blue indicates DAPI nuclear label, Red indicates TRITC label for positive 
microglia. 
 
Microglial cells are the resident immune cells of the CNS acting as primary cells 
responding to the presence of noxious agents or injury within the brain. Microglia differ 
from other populations of macrophages in that they have scattered branches that emerge 
from the cell body allowing them to communicate with surrounding neurons and other 
glial cells (Fig. 1.14). It is these processes which allow microglia to survey the local 
environment for pathological changes or inflammatory stimuli (Nimmerjahn et al., 
2005). Resting microglia are present throughout the CNS allowing for constant 
surveillance for any infection or injury. 
Following the detection of an infection or injury, microglial cells adopt an ―activated 
state‖ (Nimmerjahn et al., 2005; Davalos et al., 2005) in which they produce many pro-
inflammatory mediators (cytokines, chemokines, reactive oxygen species (ROS) and 
nitric oxide). The release of inflammatory mediators aids the clearance of the pathogen 
and the resolution of the inflammatory response. The rapid response of microglia to a 
variety of stimuli is attributed to their expression of a large array of surface receptors 
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which are able to trigger or amplify an immune response. Receptors present on host 
microglial cells include PRRs (recognition of PAMPs), complement receptors, cytokine 
receptors, and receptors that enhance macrophage effector functions following 
interaction with the adaptive immune system (T cells/Ig) (Aloisi, 2001). PRRs include 
TLRs and the binding of a PAMP to TLRs leads to the activation of NF-κB (nuclear 
factor kappa-light-chain-enhancer of activated B cells) and MAPK (Mitogen-activated 
protein kinase) pathways, which eventually induce the transcription of pro-
inflammatory mediators.  
Microglial cells also express receptors for a number of cytokines that are 
produced exclusively in the brain during CNS inflammation. These include receptors 
for pro- and anti- inflammatory cytokines, the balance of which plays a key role in 
inducing and regulating the immune functions of microglia (Chao et al., 1995; Smith et 
al., 1998). Another common feature associated with microglial cell activation is up-
regulation of complement receptors, which mediate or enhance phagocytosis through 
recognition of serum components deposited on microbes. These include complement 
receptors CR1, CR3, and CR4 that bind the complement component C3bi (Barnum, 
1999) and C1qRp that binds C1q (Gasque et al., 1998).   
Protein antigens are normally processed by macrophages (microglia) and other 
antigen presenting cells (astrocytes) into small fragments which are then expressed on 
the surface of these cells in association with major histocompatibility complex (MHC) 
class II molecules. Therefore, only the cells with receptors which recognise the antigen 
together with the MHC molecule will participate in the immune reaction. The activation 
of microglial cells by infection/injury stimulates the up-regulation of MHC class II 
molecules (Perry, 1998). Hence microglia can influence the adaptive immune response 
acting as antigen presenting cells.  
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In addition to the immune functions of the cell, microglia have been shown to 
support and monitor synaptic functions (Wake et al., 2009), induce apoptosis of 
developmental Purkinje cells (Marin-Teva et al., 2004) and control synaptogenesis 
(Roumier et al., 2004). Hence, microglial cells play an important role during the 
development and maintenance of the CNS and have been shown to exert both protective 
and pathogenic functions. 
v) Astrocytes: biology and function  
Astrocytes, the most abundant glial cell population, are of neuroectodermal origin and 
are essential for brain homeostasis and neuronal function (Dong and Benveniste, 2001). 
Astrocytes are made up of oval or irregular nuclei with an open chromatin pattern and 
stellate morphology with numerous fine processes radiating in all directions (Fig.1.15). 
The two main types of astrocytes found in the brain, fibrillary and protoplasmic, can be 
distinguished based upon their cellular morphologies and anatomical locations (Cajal, 
1909).  
 
Figure 1.15: GFAP positive labelled astrocytes (green), cell nucleus shown in red (PI); 
images taken from mouse brain tissue using anti-GFAP antibody. 
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Fibrillary astrocytes are most evident in the white matter which links various 
areas of the brain. The processes of fibrillary astrocytes contain a specific form of 
cytoskeletal intermediate filament called glial fibrillary acidic protein (GFAP). An 
antibody directed against GFAP can be used to identify this cell type. However, it does 
not fully label the finer processes of the fibrillary astrocyte (Eng, 1985) (Fig. 1.15). 
GFAP is essential for reactive astrogliosis and glial scar formation (Pekny and Pekna, 
2004; Herrmann et al., 2008) and is the second main cell subtype contributing to 
neurodegenerative disease pathology.  
Protoplasmic astrocytes are found in the grey matter that consists mainly of 
groups of cell bodies. These astrocytes have long thin processes that contain few 
bundles of GFAP. Both astrocyte subtypes form part of the blood-brain barrier and the 
gap junctions between distal processes of neighbouring astrocytes (Peters et al., 1991). 
Astrocytes perform multiple functions throughout the brain and spinal cord such as 
providing biochemical support to the endothelial cells of the blood-brain barrier, 
ensuring nutrients are provided to the nervous tissue, maintaining extracellular ion 
balance, and they have a vital role in the repair and scarring process of the CNS 
following injury (Chen et al., 2003; Sofroniew, 2009).  
Astrocytes, alongside microglia, are also antigen presenting cells in the brain 
and thus demonstrate their capacity to express MHC class II antigens and co-
stimulatory molecules (B7 and CD40) critical for antigen presentation and T-cell 
activation. Astrocytes also express PRRs including TLR2 (Bsibsi et al., 2002; Bowman 
et al., 2003), TLR3, (Park et al., 2006), TLR4 (Carpentier et al., 2005; Bowman et al., 
2003), TLR5 (Carpentier et al., 2005; Bowman et al., 2003) and TLR9 (Carpentier et 
al., 2005; Bowman et al., 2003). In addition, a range of complement receptors and 
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complement factors are expressed by astrocytes (as seen in microglia) (Gasque et al., 
2000).  
Further, astrocytes produce a wide array of immunologically relevant cytokines 
and chemokines, hence, play a key role in the type and extent of CNS immune and 
inflammatory responses. The release of cytokines, chemokines and neurotrophic factors 
can activate neighbouring cells and amplify the local, initial innate immune response 
further or modify blood-brain barrier permeability and attract immune cells from the 
blood circulation into the neural tissue, thus supporting an adaptive immune response. 
The balance between inflammatory and immunosuppressive pathways is fundamental 
for controlled reactions to CNS infection or injury.  
 
1.2.4. The blood-brain barrier and immune privileged status of the brain  
The CNS maintains an immune privilege status as a consequence of a blood-brain 
barrier composed of capillaries with tight junctions between individual endothelial cells 
augmented by astrocytic foot processes providing an additional protective layer (Huber 
et al., 2001; Abbott et al., 2006) (Fig. 1.16). Along with being a physical barrier, the 
blood-brain barrier is also a system of cellular transport mechanisms. It maintains 
homeostasis by allowing access of essential nutrients and restricting the entrance of 
potentially harmful cells such as neutrophils, naive T cells (adaptive immune system), 
plasma proteins and neurotoxic proteins from the blood. Lipid soluble molecules are 
able to penetrate the barrier relatively easily through the plasma membrane of cells, 
whereas water soluble ions such as sodium and potassium require the specialised carrier 
mediated transport mechanisms (Shepard, 1994). The intact blood-brain barrier also 
52 
 
 
prevents microglial cell activation as the result of systemic antigens, gaining 
unrestricted access to the brain parenchyma.   
 
Figure 1.16: The blood-brain barrier, showing the basic structure from a transverse 
section composed of epithelial cells, pericytes and astrocytes. Magnified image 
demonstrates the specific structure of the endothelial cell layer forming tight junctions.  
 
1.2.5. The CNS immune responses to infection  
Efficient immune responses are essential in order to maintain a healthy CNS. Due to its 
immune privileged status, the CNS requires an innate protective mechanism with the 
ability to neutralise and subsequently remove pathogens, without recruiting the 
peripheral adaptive immune surveillance cells. Therefore the cells of the CNS are 
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adequately equipped to recognise and respond to the presence of pathogens. Although 
the innate immune response within the CNS is not as specific as adaptive immune 
components, it can distinguish self from non-self via PRRs which recognise PAMP‘s on 
the surface of microorganisms (Janeway et al., 2005). In addition all nucleated 
eukaryotic cells are protected, to some extent, by having complement regulatory 
proteins on their surface membranes and this limits complement deposition and lysis of 
host‘s peripheral (Morgan and Gasque, 1996; Markiewski and Lambris, 2007) and CNS 
cells (Singhrao et al., 1999; 2000). Despite astrocytes and neurons having the capacity 
to deal with infection, it is microglial cells that are considered as the primary protective 
cells in the CNS. In vitro studies demonstrate both resting and activated microglia 
express a broad spectrum of defence molecules of the innate immune system, as 
mentioned previously.  
During an infection, the cells at the site of inflammation display PRRs such as 
TLRs to recognise the type of PAMP‘s displayed by the invading bacteria (Laflamme 
and Rivest, 2001). The PAMP‘s also induce cytokine synthesis (Qin et al., 2005) 
bringing about microglial cell differentiation and antigen-presenting functions of this 
cell type. Consequently, microglia up regulate MHC class I and II antigens and induce 
anti-bacterial activity (Qin et al., 2005; Olson and Miller, 2004). MHC class II 
expression is required for activation of naive T cells, and the production of numerous 
pro-inflammatory cytokines, including cytokines which induce the differentiation of 
effector T cells (O‘Keefe et al., 2002). In addition activated microglia express 
complement receptors (CR1, CR3, CR4), complement derived anapylatoxins (C4a, C3a, 
C5a) and pro-inflammatory cytokines including interleukins that aid in the removal of 
bacteria and their associated LPS from the brain (Banati et al., 1997; 2002; Laflamme 
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and Rivest, 2001; Hanisch, 2002; Olson and Miller, 2004; Gasque, 2004; Qin et al., 
2005; Perry et al., 2010).   
LPS specifically binds to CD14 (Kitchens, 2000) and is used routinely to 
activate microglia both in vitro and in vivo. Evidence indicates that LPS-induced signal 
transduction begins with CD14-mediated activation of TLR4 (Kaisho and Akira, 2002). 
It has been demonstrated that CD14 is up-regulated on microglia in vivo following 
treatment with LPS (Nadeau and Rivest, 2000). Interestingly, the microglial cell TLR4 
signalling pathway is activated not only during pathogen infection in the CNS but also 
in the presence of systemic infection. When LPS was injected into the peritoneal 
cavities of mice, TLR4‑induced transcription was observed in the brain (Bauman et al., 
2009; Bhaskar et al., 2010). 
Microglia are more effective at clearing the bacterial surface membrane 
component LPS. However, the TLR2 receptor present on astrocytes is able to bind 
another surface membrane component of bacteria, peptidoglycan, resulting in the 
production of proinflammatory cytokines and chemokines (Esen et al., 2004; Lin et al., 
2011).  
The meninges and the choroid plexus regions of the brain are also equipped to 
deal with bacterial infection. The meninges are phylogenetically younger than the 
blood-brain barrier and have a well-developed population of cells that communicate 
through lymphatic vessels with the adaptive immune system located in the systemic 
lymph nodes. Antigen presenting cells, similar to dendritic cells are present in the 
meninges that express OX62 and the MHC class II antigens on their surface 
membranes. Similar cells are also found lying within blood vessels of the choroid 
plexus but not in the normal brain parenchyma (McMenamin, 1999). Following an 
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injection of dendritic cells into the subarachnoid space, dura mater and choroid plexus 
they migrate to the local cervical lymph nodes where they activate T cells facilitating 
the clearance of pathogens from these anatomical compartments (Cserr et al., 1992). 
The meninges also contain macrophage-like cells expressing the mannose receptor, 
CD14 and the highly conserved TLRs 2 and 4. These receptors aid the cells to recognise 
and bind Gram negative bacteria and their associated PAMPs (Laflamme and Rivest, 
2001; Stahl and Ezekowitz, 1998) and mediate intracellular signalling thereby aiding 
the protection of the brain. 
Another key part of the innate immune response within the CNS is the 
complement system (see section 1.1.2). Microglia, astrocytes and neurons are all able to 
express the components of complement, as mentioned previously (Morgan and Gasque, 
1996; Gasque, 2004; Markiewski and Lambris, 2007; Hajishengallis, 2010).  
 
1.2.6. Implication of the immune response in neurodegeneration 
The CNS demonstrates a complex and well adapted localised immune system which 
generally functions to protect the brain from any infection or injury. However, it is 
important to note that any dysregulation of these pathways might lead to pathogenic, 
chronic neuroinflammation and neurodegeneration. Neurodegeneration is the slow and 
progressive dysfunction and loss of neurons and axons within the CNS. The resident 
cells of the CNS have poor regenerative potential and, therefore, a major inflammatory 
response can induce irreversible damage to neurons and oligodendrocytes. Neuronal 
loss is the common feature of neurodegenerative diseases and studies have shown that 
inflammation is a constant element.  
Microglia can participate in neuroprotective roles as well as contribute to disease 
processes including neurodegeneration. Microglia have been shown to readily up-
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regulate MHC class II expression in the vast majority of inflammatory and 
neurodegenerative conditions (Kreutzberg, 1996). In addition prolonged microglial cell 
activation may result in pathological forms of inflammation that contribute to the 
progression of chronic inflammatory neurodegenerative diseases (Glass et al., 2010; 
Perry et al., 2010).  
For some neurodegenerative conditions it has been shown that the activation of 
microglia can be triggered by misfolded proteins for example; Aβ or 
hyperphosphorylated tau protein in AD, (Rogers et al., 1992; Shen et al., 2001) and 
truncated α-synuclein in Parkinson‘s disease (Klegeris and McGeer, 2007) as well as 
genetic mutations (superoxide dismutase 1 mutation in amyotrophic lateral sclerosis) 
(Lobsiger et al., 2007). These triggers in turn lead to an activation dependent release of 
ROS and proinflammatory cytokines accompanied by a loss of neuronal support (Amor 
et al., 2010). 
Dysregulation of astrocytic responses may also play a key role in 
neuroinflammation. Under normal conditions the interaction with astrocytes leads to a 
block of the microglial inflammatory response, however, if this function is impaired it 
may result in a down-regulation of the astrocyte suppressive function, hence, causing 
microglial hyper-activation and a subsequent release of pro-inflammatory cytokines.  
It has also been suggested that communication between activated microglia and 
astrocytes can result in the amplification of inflammatory responses, and this 
contributes to the production of neurotoxic factors (Liu et al., 2011). For example, LPS-
induced secretion of factors such as IL‑1β and TNF-α (tumour necrosis factor α) by 
microglia can result in potent induction of pro-inflammatory gene expression and 
colony stimulating factor 1 (CSF1) production by astrocytes. These astrocyte-derived 
pro-inflammatory factors can in turn feedback on microglia to promote further 
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microglial cell activation and microgliosis, thereby establishing a positive feedback loop 
(Saijo and Glass 2011). Saijo et al., (2009) demonstrated that co-cultures of microglia 
and astrocytes stimulated with LPS produce significantly more neurotoxic factors than 
either cell type alone. However, the functional significance of microglial cell–astrocyte 
communication in the amplification of inflammatory responses and neurodegeneration 
in vivo remains to be defined.  
 
1.2.7. The ageing brain  
Ageing in the brain is a complex process which generally begins around middle age, 
continues throughout adulthood and is associated with a decline in cognitive 
performance (Whalley, 2003). A feature of the ageing brain is generalised shrinkage 
(Hartmann et al., 1994), although, the ageing process appears to affect specific areas of 
the brain hence resulting in a decline in function associated with that specific region. 
The frontal lobe and pre-frontal cortex are documented as the area‘s most vulnerable to 
the ageing process (Kemper, 1984). Other changes observed in the ageing brain are a 
decrease in the volume of the pre-frontal regions (Raz and Rodrigue, 2006), thinning of 
the cortical ribbon and increase in the sulcus width (Salat et al., 2004), along with a 
general increase in ventricular volume (Chou et al., 2008). Another important 
component of normal ageing is inflammation with the characteristic functional declines 
being largely influenced by changes in redox status and oxidative stress induced 
inflammation. These changes in inflammation throughout ageing are a common 
precursor to disease such as dementia, cancer, osteoporosis and vascular disease (Chung 
et al., 2011). 
The normal ageing brain presents with a number of pathological features, that 
include argyrophillic grains (proteinaceous intracellular protein aggregates in neuronal 
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and glial cells), neuromelanin (found in double membrane granular structures), corpora 
amylacea (round cytoplasmic glycoproteinacous inclusions) and lipofuscin (membrane-
bound cellular waste) (Keller, 2006). These pathologies affect various types of cells 
within the CNS -including astrocytes, microglia, neurons and oligodendrocytes, hence 
may present as precursors to neurological conditions associated with ageing (dementia). 
The interplay of these features associated with the ageing brain may be responsible for 
the loss in the functional integrity of the brain during advancing age.  
One specific area of the brain shown to deteriorate with advancing age is the 
blood-brain barrier (Fig. 1.17). A general increase in blood-brain barrier permeability is 
observed with ageing in healthy individuals (Farrall and Wardlaw, 2009) with 
physiological changes such as the loosening of tight junctions, changes in the astrocytic 
endfeet, stiffening of the vessel wall (Bell and Zlokovic, 2009) and a significant 
decrease in microvessel density (Brown and Thore, 2011). During normal ageing and in 
several diseases of the CNS (such as AD) alterations in the blood composition, levels of 
brain inflammation and the entrance of immune cells via blood-brain barrier can result 
in neuronal damage and cognitive dysfunction (Man et al., 2007; Liu et al.,. 2010; 
Villeda et al., 2011). It has been suggested that peripheral inflammatory conditions may 
have an affect the blood-brain barrier and modulate their response in ageing and in CNS 
diseases. In a healthy person, immune cell migration through the brain barriers is low, 
however, in some neuroinflammatory diseases, an increased number of immune cells 
reach the CNS (Sardi et al., 2011; Pellicano et al., 2012). 
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Figure 1.17: The effect of ageing and neurodegenerative disease (AD) on the blood-
brain barrier.  
1.2.8. Neurodegenerative diseases  
Dementia comprises a group of neurodegenerative diseases in which the symptoms 
include a decline in cognitive and intellectual function, together with loss of memory, 
attention and problem-solving skills. Due to its association with neurodegeneration 
leading to loss of function the specific area of brain affected by each form of dementia 
largely governs the symptoms experienced in each case. For example dementia with 
Lewy bodies, affects the cerebral cortex, brain stem and parts of the basal forebrain 
cholinergic system producing cognitive fluctuation and mild yet spontaneous 
Parkinsonism (McKeith et al., 1996).  
On the other hand fronto-temporal dementia affects the frontal lobe and can 
extend to the temporal lobe. Examples include Pick‘s disease, frontal lobe degeneration 
and dementia associated with motor neuron disease (Gibbs and Gajdusek, 1972; 
Mitsuyama and Takamiya, 1979; Brun, 1987). Hence, the symptoms are generally 
behavioural and/or related to executive function (Lund and Manchester Group, 1994; 
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Mitsuyama and Inoue, 2009). Another type of dementia is AD (Alzheimer, 1907), and is 
the most common form of dementia affecting the human population world-wide. The 
clinical features are associated with cognitive decline and irreversible memory loss. 
This functional loss is attributed to a large proportion of the specific neuronal damage in 
the hippocampal region (Cummings, 2004).  
 
1.2.9. Alzheimer’s disease 
AD was identified over 100 years ago by Alois Alzheimer. In 1906 he presented his 
work on ‗a characteristic disease of the cerebral cortex‘ whereby he described a 51 year 
old woman who exhibited progressive cognitive impairment, focal symptoms, 
hallucinations, delusions and psychiatric incompetence. His notes on this interesting 
case began in February 1902 and continued beyond her death in April 1906. Post-
mortem examination showed arteriosclerotic changes and using the Bielschowsky‘s 
silver stain Alzheimer was able to demonstrate extracellular senile plaques and intra 
neuronal neurofibrillary tangles (NFTs). These findings led to the eponym, Alzheimer‘s 
disease, first used by Emil Kraepelin in his 1910 textbook of psychiatry (Zilka and 
Novak, 2006; Jucker et al., 2006; Kraepelin, 1910).  
AD is characterised by impaired neurocognition. Individuals generally present 
with a decline and ultimately loss of multiple cognitive functions consisting of memory 
impairment and at least one of aphasia (partial or total loss of the ability to 
communicate verbally or using written words), apraxia (inability to perform particular 
purposive actions) or agnosia (inability to interpret sensations and hence to recognise 
things) (Castellani et al., 2010).  
AD can be divided into two forms, familial and sporadic. Familial AD 
represents only 5-10% of AD cases which are associated with early-onset (before age 
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65) and are the result of rare genetic mutations (Selkoe, 2000; Larner and Doran, 2006; 
Bird et al., 1988; Van Broeckhoven, 1995). The majority of AD cases do not exhibit an 
obvious genetic component and are termed sporadic or late-onset AD, in which both 
environmental and genetic differences may act as risk factors. Late-onset/sporadic AD 
accounts for the vast majority of AD cases, generally occurring after the age of 65. The 
apolipoprotein E (ApoE) gene is a known genetic risk factor associated with late-onset 
AD, and more recent investigations suggest further risk associated with genes encoding 
innate immune molecules and inflammatory traits exist (van Exel et al., 2009; Lambert 
et al., 2009; Harold et al., 2009). In particular, cytokine-related genes appear to be 
involved in the susceptibility to inflammation in sporadic form of AD. This study is 
focused on the late-onset form of AD. 
Although symptoms are largely present while the individual is alive and a 
clinical diagnosis can be made using specific criteria (Dubois et al., 2007). AD, at 
present, can only be definitively diagnosed at post-mortem based upon 
neuropathological findings using a standard protocol, outlined by the Consortium to 
Establish a Registry for AD (CERAD), to assess the pathological hallmarks of AD 
(Braak and Braak, 1991). 
The neuropathological changes occurring in the AD brain include both classical 
lesions such as Aβ plaques and NFTs (Terry et al., 1994; Mandelkow and Mandelkow, 
1998; Trojanowski and Lee, 2000; Iqbal and Grundke-Iqbal, 2002; Crews and Masliah 
2010) accompanied by inflammation (Fig. 1.18).  
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Figure 1.18: The neuropathological changes occurring in AD. A) Aβ plaques, 
arrow pointing to large plaque, B) Tau positive labelled NFTs as indicated by arrow C) 
inflammation depicted here by activated microglia seen associating with Aβ plaque 
(arrow). 
 
The insoluble Aβ protein is the main constituent of Aβ plaques and is formed 
when the amyloid precursor protein (APP) is cleaved by α, β or γ secretase enzymes 
(Yan et al., 1999; Sinha et al., 1999; Vassar et al., 1999; Hussain et al., 1999) releasing 
the Aβ peptide with either 1-40 or 40-42 residues. Of these, the 40-42 amino-acid 
peptide is considered to be neurotoxic and aggregates into Aβ plaques within the 
extracellular spaces in the cerebrum. The CERAD criterion for definite diagnosis of AD 
involves the quantification of neurotoxic or neurotic plaques in multiple neocortical 
regions as they define disease progression. Aβ plaques are also observed in the brains of 
cognitively intact individuals, but they tend to be in fewer numbers and are generally of 
the diffuse (Aβ40) plaque types, which so far appear to have little pathological 
significance. 
The NFTs, on the other hand, accumulate in the cytoplasm of the neuron where 
hyper phosphorylated tau, a microtubule-associated protein, is the major constituent 
(Hanger et al., 1998). The presence of NFTs correlates with the severity of the cognitive 
decline and, hence, a specific staging criterion of NFTs (Braak and Braak, 1991; 1995) 
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is used in the pathological diagnosis of AD. In addition to the classical hallmarks of AD 
a number of other neuropathlogies have been associated with the disease, such as 
cerebral amyloid angiopathy, neuronal loss, synapse loss, granuovacuolar degeneration 
and hirano bodies (Serrano-Pozo et al., 2011), although these are not involved in the 
post-mortem diagnostic criteria. 
Inflammation is now a recognised element of AD neuropathology (Akiyama et 
al., 2000) with AD brains demonstrating astrogliosis (Beach et al., 1989; Itagaki et al., 
1989), microgliosis (Rogers et al., 1988; Itagaki et al., 1989; Masliah et al., 1991; 
Imamura et al., 2001), cytokines (Hanisch, 2002) and complement activation fragments 
(Eikelenboom and Stam, 1982; McGeer et al., 1989; Rogers et al., 1992) associated 
with both Aβ plaques and NFTs (Shen et al., 2001). 
Although the pathological characteristics of AD are useful diagnostic markers, 
the cognitive decline suffered by AD individuals is associated with the progressive 
degeneration of the limbic system (Arnold et al., 1991; Klucken et al., 2003), 
neocortical regions (Terry et al., 1981), and the basal forebrain (Tipel et al., 2005). 
Hence the question remains; what causes the initial neurodegenerative process in AD 
individuals? 
 
1.2.10. Research into the causes of late-onset Alzheimer’s disease 
As mentioned previously apart from the classical hallmarks, inflammation is another 
key element of AD pathology. In AD a hyper inflammatory response can take place if 
microglia are already in their ―primed state‖ due to a previous challenge (Ye and 
Johnson, 2001; Godbout et al., 2005), and this can increase the severity of 
neurodegeneration. The exact cause of inflammation in AD individuals remains under 
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investigation – initially and largely still attributed to the pathological hallmarks of the 
disease, specifically the Aβ plaques. 
Hardy and Selkoe (2002) defined the amyloid cascade hypothesis which led to 
extensive research to find mechanistic basis of neurodegeneration and the development 
of AD (Masters and Beyreuther, 2006). The amyloid hypothesis proposes that a fault 
with the processing of the APP by endogenous secretase enzymes in the brain is the 
cause of Aβ deposition (Yan et al., 1999; Sinha et al., 1999; Vassar et al., 1999; 
Hussain et al., 1999). The subsequent accumulation of Aβ due to an imbalance between 
production and clearance from the brain in AD and is believed to trigger neuronal death 
due to the toxic effects of excess Aβ (Hardy and Higgins, 1992; Hardy and Selkoe, 
2002). This hypothesis is strengthened by AD individuals presenting with genetic 
mutations in the APP and presenillins which are responsible for γ-secretase enzymes 
such conditions not only determine the length of the Aβ fragment being generated but 
also their aggregating properties and their toxicity (Hardy, 1997).  
Pros and cons of the amyloid cascade theory remain as individuals with the 
absence of any clinical symptoms have been shown to present with Aβ plaques and 
NFT at post-mortem examination in quantities that would be sufficient enough for an 
AD diagnosis. These individuals only demonstrate modest elevations of inflammatory 
markers and this is dramatically less than observed in clinical AD individuals (Lue et 
al., 1996). Therefore, inflammation may be another key factor in the cognitive decline 
presented in AD. Also, direct evidence of inflammatory toxicity (complement mediated 
cell lysis) can be observed in the AD brain although this originally also centred on the 
amyloid hypothesis (Webster et al., 1997). In addition, a number of clinical studies have 
strongly suggested that conventional anti-inflammatory drugs (nonsteroidal anti-
inflammatory drugs and asprin) may delay the onset or slow the progression of AD 
65 
 
 
(Stewart et al., 1997; Anthony et al., 2000; Broe et al., 2000). However, this was not the 
case in all individuals. 
As mentioned earlier, the initial inflammatory hypothesis suggested that the 
neuroinflammation was a downstream consequence of the Aβ hypothesis with the added 
assumption that the activation of microglia may lead to the phosphorylation of tau 
contributing to the formation of NFTs via overexpression of IL-1 (Sheng et al., 1997). 
However, like the amyloid hypothesis this inflammatory hypothesis is incomplete in 
explaining the aetiology of AD, and despite the initial results the trials using anti-
inflammatory drug treatment provided conflicting results. In addition, the inflammatory 
hypothesis lacked consideration for microbial aetiology. It cannot be ignored that 
inflammatory cascades are initiated by infectious agents. 
There are two different inflammatory aspects to consider when exploring a 
microbial aetiology of AD. These are the effect of microbes in systemic circulation and 
the effect of microbial invasion of the CNS, both of which will be discussed in more 
detail due to direct implications in the present study. 
 
i) Systemic infections and AD 
 Infections are common in elderly individuals and are the main cause of death in a 
majority of neurodegenerative conditions. Advancing age is the greatest risk factor for 
all forms of AD. Some consequences of advancing age are a compromised immune 
system (Pawelec, 1999; Targonski et al., 2007) and a potential neglect of personal 
hygiene (Stein et al., 2007; De Oliveira, 2010; Paganini-Hill et al., 2012) which can 
lead to conditions associated with repeated chronic infections. Recurrent exposure to 
bacteraemia from common infections in the elderly, due to conditions such as chronic 
periodontitis (Forner et al., 2006; Lockhart et al., 2008), intra-abdominal (Norman and 
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Yoshikawa, 1983), and urinary tract infections (De Vecchi et al., 2013), will contribute 
to inflammation within the systemic circulation.  
Holmes et al., (2009) suggests that cytokines from peripheral circulation, as a 
result of systemic inflammation, have the potential to reach the brain parenchyma, 
initiate a local immune response, and impair memory. This is supported by Dunn et al., 
(2005) as they demonstrated that the multiple episodes of recurrent peripheral infections 
in the elderly can result in clinical symptoms similar to that of late-onset AD. Also, the 
innate immune responses suggest extrinsic inflammatory cytokines are involved in 
exacerbating neurocognition (Holmes et al., 2009). Cytokine-related genes have been 
implicated in the susceptibility to inflammation in late-onset AD (van Exel et al., 2009; 
Eikelenboom et al., 2011) and high levels of TNF-α cytokine in the blood plasma is 
considered a risk factor for cognitive deficit (Holmes et al., 2009).  
Interestingly, patients with AD who also have an acute peripheral infection 
(such as chest or urine infections) present signs of a sudden decline in cognitive state, 
and rarely return to their previous cognitive performance levels, despite full recovery 
from the infectious agents (Holmes et al., 2003; Dunn et al., 2005; Perry et al., 2007; 
Holmes et al., 2009). Animal models have also demonstrated that LPS from Gram 
negative bacteria administered systemically, directly to the peritoneum, or directly in 
the brain all induced neuroinflammation in the form of glial cell activation 
(Cunningham et al., 2005; Godbout et al., 2005; Chen et al., 2008; Henry et al., 2009). 
In addition to Aβ formation in the brain (Sheng et al., 2003) and, where measured, 
learning and memory impairment was recorded (Tanaka et al., 2006; Chen et al., 2008). 
As mentioned previously, chronic periodontal disease represents a common but 
chronic infection in the elderly with several studies supporting a deterioration in oral 
health with increasing age and in clinically demented patients (Aida et al., 2011, Arai et 
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al., 2003, Griffin et al., 2012, Philip et al., 2012) with implications on systemic 
inflammation via the induction of recurrent transient bacteraemia. Possible explanations 
for the decline in oral health within the elderly include; side effect of medications 
causing xerostomia (dry mouth) (Friedlander et al., 2006), physical impairments 
(difficulty accessing the dentist or maintaining own personal care) and dependence on 
care of others (Griffin et al., 2012). Further evidence in support of the hypothesis of 
Holmes et al., (2009) and a potential link between periodontal disease, as a source of 
systemic inflammation, and AD comes from Kamer et al., (2009). They detected high 
levels of the TNF-α cytokine and a high titre of antibodies to periodontal pathogens 
circulating in the blood taken from AD patients (Kamer et al., 2009). Although their 
findings need to be interpreted with caution as they used a relatively modest sample size 
(16 controls and 18 AD patients) and found circulating IgG to periodontal pathogens in 
72% AD individuals (p = 0.042) but also in 38% of the control individuals, and due to 
the case control methodology they cannot determine if the antibodies were present prior 
to or following the onset of AD. Further studies have shown that TNF-α, and several 
immune response plasma proteins could predict the development of AD (Ray et al., 
2006; 2007). Also, a study by Sparks Stein et al., (2012) suggested the involvement of 
periodontal disease in the risk of AD onset/progression, they analysed 158 patients, who 
were cognitively intact at baseline, with 77 individuals remaining cognitively intact for 
the duration. They demonstrated that AD individuals had significant elevations in 
antibodies to periodontal pathogens at baseline, prior to diagnosis of the neurological 
changes. It has been proposed that the host‘s immune responses to tissue destruction 
from periodontal disease results in systemic mediator release and potentially contributes 
to the pathogenesis of AD (Kamer et al., 2009). 
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ii) CNS infections and Alzheimer’s disease  
In 1913 microbial infections were considered as possible causative agents in AD 
(Noguchi and Moore, 1913) and, with the progression of technology, research into a 
microbial link with AD has resurfaced (Lerner et al., 1997; Schmidt et al., 2002; 
Riviere et al., 2002; Holmes et al., 2003; 2009; Dunn et al., 2005; Kamer et al., 2008; 
Balin et al., 2008, Itzhaki and Wozniak 2008; Miklossy 2008; Urosevic and Martins, 
2008) suggesting a direct involvement of pathogens in the aetiology of AD.  
The aetiological hypothesis suggests that viruses, bacteria and/or their virulence 
factors can access the brain and thereby contribute to AD pathogenesis. A review by 
Holmes and Cotterell (2009) outlines a range of infective agents consistently being 
linked to AD. These include herpes simplex virus type I (Itzhaki and Wozniak, 2008), 
Chlamydophilia pneumonia (Balin et al., 2008), Treponema spp., (Riviere et al., 2002) 
and Borrelia burgdorferi (Miklossy, 2011). More recent findings have led to the ―dental 
aetiological‖ hypothesis, which involves periodontal disease elements (Kondo et al., 
1994; Stein et al., 2007; 2010; Riviere et al., 2002; Foschi et al., 2006; Kamer et al., 
2008; Watts et al., 2008; Sparks Stein, 2012). The ‗dental aetiological‘ hypothesis not 
only involves systemic response to oral pathogens (Kamer et al., 2009; Singhrao and 
Crean, 2010) but also the possibility that oral pathogens, and/or their products, can 
invade the brain resulting in tissue specific pathology.  
 
1.2.11. Invasion of the CNS by oral pathogens 
There are three main routes via which oral bacteria can spread from their initial site of 
colonisation to other tissues, including the brain. These include nerve pathways, the 
lymphatic system and the vascular system.  
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i) Peripheral nerves route 
The olfactory and the trigeminal nerves pathways can be exploited by periodontal 
pathogens especially those that are invasive (motile). These can burrow their way into 
nerves to reach nerve ganglia as a means of bypassing the blood-brain barrier for direct 
entry into the CNS (Riviere et al., 2002; Danielyan et al., 2009; Johnson et al., 2010). 
This observation is supported by studies in immunosuppressed animal models using T. 
denticola (Foschi et al., 2006). In addition, oral Treponema species (Riviere et al., 
1991) have been detected in both the cells of the trigeminal ganglion and the CNS of 
individuals with AD (Riviere et al., 2002). Other spirochetes for example B. burgdorferi 
(Cadavid et al., 2000) and Treponema pallidum (Sell and Salman, 1992) have been 
identified within axons of peripheral nerves in experimental animals, and in the CNS 
(Miklossy et al., 2006). Further support for the dissemination of bacteria via the nerves 
comes from evidence that the herpes virus infected the brains of mice following intra-
pulpal inoculation (Barnett et al., 1995).  
 
ii) The lymphatic system route 
The lymphatic system is designed to filter out bacteria, amongst other material. 
However, it functions less efficiently when there is high lymph flow due to acute tissue 
inflammation or if there is an overwhelming burden of microbes. Bacteria such as the 
periodontal pathogen P. gingivalis have developed phagocytosis evasion mechanisms 
(Belstrøm et al., 2011) and they may spread by using this route (Amodini et al., 2012). 
The gingiva is supplied with the lymphatic system that is able to drain the interstitial 
fluid and transport immune cells to the lymph nodes for antigen presentation (Mkonyi et 
al., 2010). In addition to the lymphatic system providing a transport mechanism to 
systemic circulation there is also potential for bacteria and/or their products to invade 
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the brain, despite its immune privileged status. The subarachnoid space contains CSF 
which in turn communicates with the lateral and third ventricles, and re-absorption of 
CSF into the venous circulation provides a potential communication between the CNS 
and the cervical lymphatic system (Weller, 1998). Once organisms are present in the 
ventricular CSF, they can potentially invade the subarachnoid space. From the CSF, 
bacteria cross the ependymal epithelial cell layer lining the ventricle wall for entry into 
the brain parenchyma. This system provides pathogens with potential access to all areas 
of the CNS. It has been shown that ependymal cells are located strategically at the 
boundary between the CSF and the brain and express a variety of receptors of the innate 
immune system (phagocytic receptors, the mannose receptor and TLRs 2 and 4), hence, 
in healthy individuals they are equipped to detect and clear bacteria. 
 
iii) The vascular systemic route 
Murray and Moonsnic (1941) demonstrated positive cultures of oral bacteria in arterial 
blood in 55% of patients with severe periodontal disease. Sensitive polymerase chain 
reaction (PCR) and sequencing along with fluorescence in-situ hybridisation 
technologies have identified genetic footprints of two members of the ―red complex‖ 
pathogens namely P. gingivalis and T. denticola in the walls of human coronary arterial 
tissues (Chiu, 1999; Haraszthy et al., 2000) and atheromatous plaques (Cavrini et al., 
2005; Kozarov et al., 2005). Therefore, eliminating any doubts over finding oral 
periodontal pathogens in the human vascular system. This observation is further 
strengthened by experimental animal models which demonstrate bacteria placed in the 
oral cavity not only induce periodontal disease in their original niche but also infiltrate 
into the systemic system where they can cause tissue related pathology (Rivera et al., 
2013; Chukkapali et al., 2014; Velsko et al., in press).  
71 
 
 
In addition to the transmigration via the lymphatic system (Amodini et al., 
2012), another mode of dissemination to the systemic system is via transient 
bacteraemia. This appears to be the most convenient route for oral bacteria to spread, 
given that the organisms which have successfully exploited this route are able to resist 
the complex immune defence mechanisms of the vascular system. As mentioned 
previously it is apparent that all three of the main periodontal pathogens (P. gingivalis, 
T. denticola and T. forsythia) are equipped to evade the immune surveillance, with P. 
gingivalis demonstrating both survival within systemic circulation and the ability to 
exploit red blood cells for transport around the body (Belstrøm et al., 2011). Further 
mechanisms of cellular translocations are also suggested elsewhere (Takeuchi et al., 
2011). In individuals with good oral hygiene the number of oral pathogenic bacteria 
reaching the systemic circulation is small (Stein et al., 2006). However, this number 
increases twofold to tenfold in individual‘s with periodontal disease (Stein et al., 2006).  
Organisms within the systemic circulation can then gain access to the brain via 
the circumventricular organs (CVOs) and the choroid plexus regions (that contains a 
rich blood supply), as these are recognised areas of the CNS void of the blood-brain 
barrier. Microglial cells in the CVOs have been demonstrated to express the CD14 
receptor and TLR4 suggesting that they are capable of detecting the PAMPs on bacteria.  
 In addition, bacteria may potentially access the CNS by direct transport across 
the blood-brain barrier. As an individual ages these barriers and protective mechanisms 
in the brain can become worn or damaged thereby making it easier for foreign agents to 
invade the CNS. It is suggested that the deterioration of the blood-brain barrier is a 
result of advancing age and this coincides with the fact that ageing remains a key risk 
factor for neurodegenerative conditions.  
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1.3.Part III: Review of evidence: A link between Alzheimer’s disease and 
periodontal disease? 
Both systemically derived inflammatory mediators and direct invasion of the CNS 
demonstrate potential mechanisms for a link between periodontal disease and AD. 
Although the two diseases are unrelated, the commonality between them is the chronic 
inflammatory status (Watts et al., 2008; Kamer et al., 2008; Hajishengalis, 2010; 
Akiyama et al., 2000).  Longitudinal studies have shown that people who went on to 
develop AD had poorer oral health (Kondo et al., 1994; Gatz et al., 2006; Kim et al., 
2007; Stein et al., 2007; Arrivé et al., 2012; Paganini-Hill et al., 2012; Philip et al,. 
2012; Syrjälä et al., 2012, Yamamoto et al., 2012). These studies allowed the cause of 
the disease to be assessed and increased the confidence that poorer oral health may 
initiate the development/progression of AD. However, many studies used a cross-
sectional design which does not allow a temporal relationship to be established and so 
cannot demonstrate that periodontal disease caused AD. Due to the decline in oral 
health associated with individuals with dementia it is often difficult to determine if poor 
oral health contributes to the onset or merely the progression of AD. 
With regards to the view of periodontal disease as a source of systemic 
inflammation there is little specific evidence. A number of studies used non-specific 
measures of inflammation, hence they cannot link the pathogenesis directly with 
periodontal disease. Some studies have, however, used more specific measures 
including IgG levels to P. gingivalis and other specific periodontal pathogens (Okuda et 
al., 1986; Kamer et al., 2009; Noble et al., 2009). Of particular interest is a study by 
Sparks Stein et al., (2012), as they used the cohort methodology analysing levels of 
serum antibodies to periodontal pathogens. At the start of the study period, all 
participants were cognitively intact, but higher levels of serum antibodies to periodontal 
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pathogens at baseline led to some individuals developing AD (Sparks Stein et al. 2012). 
As baseline measures were taken years before diagnosis of AD, the elevation in serum 
antibodies cannot be attributed to secondary effects of AD (for example, poor oral 
hygiene). Although clinical measurements of oral health were not taken in the Sparks 
Stein et al. (2012) investigation, periodontal bacterial species are generally accepted as 
being specific to periodontal disease and assessing serum antibody levels to these 
pathogens may prove to be a true indicator of periodontal disease in AD patients.  
On the other hand, methodological studies have emerged demonstrating the 
presence of bacteria within the cerebral tissues, suggesting that the association between 
poor oral health and AD may result from the direct invasion of the CNS by oral bacteria 
and/or their virulence factors. One seminal study using molecular and immunological 
methodologies demonstrated the presence of seven oral Treponema species in 14 of 16 
AD cases, reaching statistical significance (Riviere, 2002). In addition, the same authors 
demonstrated that the trigeminal nerve ganglia, hippocampus and the pons taken from 
embalmed cadavers (2 out of 4) also confirmed the presence of Treponema species. 
Furthermore, Miklossy (1993, 2008) reported that various types of spirochetes can 
invade the brain and play a role in the pathogenesis of AD suggesting that between 
others, oral spirochetes may be candidate spirochetes. 
It remains to be determined whether the potential link between the two diseases 
is direct (via the bacteria itself invading the organ) or indirect (via the systemic 
inflammation caused by the presence of periodontal bacteria). 
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1.4.Rationale for the project 
Currently AD affects an estimated 24 million people worldwide representing a major 
public health concern accounting for 68-80% of all dementia cases (Thies and Bleiler, 
2011). Susceptible individuals can take decades before clinically presenting with the 
disease, implying that the aetiology of AD is heterogeneous. Hence, the importance of 
finding new risk factors for development of late-onset AD remains a priority. This will 
aid the identification of diagnostic markers as well as effective treatment; therefore, 
research in this area is much desired. 
Literature suggests a link between periodontal disease and AD, yet further 
evidence is required to support a causative association between periodontal pathogens 
and AD. Understanding the factors and mechanisms involved in the aetiology of AD is 
of paramount importance as AD and other neurodegenerative disorders are becoming 
increasingly common amongst ageing populations and yet the diagnostic markers and 
therapy are still awaited. This is also the case for adverse oral health conditions. 
However, unlike AD, poor oral health – including caries, tooth loss, and periodontitis – 
is potentially treatable and preventable. A number of risk factors have been identified 
for AD, some of which are immutable, whereas others can be modified by simple 
changes to an individual‘s lifestyle. Periodontal disease is an easily modified risk factor 
and, hence, the need to prioritize further research into the link between these two 
conditions.  
 
1.5.Aims of the project 
To identify if chronic periodontal disease is a risk factor for the development of AD. 
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1.6.Objectives 
1. Establish an aetiological link between chronic periodontal disease and AD. This 
was performed by investigating an intra-cerebral presence of oral bacteria and/or 
their products in post-mortem tissue from AD (N=10) and non-AD controls (N = 
10).  
2. Provide proof of concept for the link using animal models of experimentally 
induced periodontal disease. Initially by identifying if periodontal pathogens 
and/or their virulence factors access in the brains of ApoE
null
 mice induced with 
periodontal disease. 
3. Perform a thorough investigation to identify the pathological lesion caused by 
the presence of periodontal pathogens. 
i) Evaluate specific effect of PD pathogens on brain cells in vivo 
animal models (inflammation). 
ii) Detect any alterations in AD makers in periodontal disease mouse 
brain 
1.7.Research Approach 
Ageing is a risk factor for both AD and periodontal disease, and the proven effect of 
periodontal disease on systemic inflammation as a potential link between the two 
conditions warrants this investigation. Due to the complexity and originality of this 
study a wide range of methodologies were employed, that complement each other and 
facilitate a thorough investigation. The main methodologies used were PCR, cloning 
and genetic sequencing, as well as immunolabelling and immunoblotting techniques for 
the detection of specific periodontal pathogens (P. gingivalis, T. denticola and T. 
forsythia) and/or their virulence factors in the brain tissue, as guided by the brains for 
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Dementia Research. Further, immunolabelling (using an array of antibodies), with the 
addition of histology/light microscopy stains were employed to assess morphology and 
any potential lesions within the brain. How these techniques will be employed to meet 
each of the objectives is outlined below. 
 
Objective 1 (To establish an intra-cerebral presence of oral bacteria and/or their 
products in post-mortem tissue from AD (N=10) and non-AD controls (N=10)) was 
achieved using a number of different approaches to analyse the tissue samples provided. 
The initial stages involved characterising the gift antibodies to the three periodontal 
pathogens (P. gingivalis, T. denticola and T. forsythia). These antibodies were then used 
to analyse all human brain tissue samples (AD and non-AD controls) and additional 
immunostaining was performed in order to identify specific lesions of AD. Following 
this genomic DNA was isolated from all cases and subjected to PCR, Topo cloning, 
sequencing and specification. All techniques were thoroughly optimised for use with the 
human brain samples. Results were then be analysed and experiments repeated where 
necessary. 
Objective 2 (To establish an intra-cerebral presence of the oral bacteria and/or their 
products in tissue from Periodontal disease ApoE
null 
mice models (N=12/group) and 
controls (N=12)) was achieved in the same way as objective 1 providing evidence of the 
presence of specific oral bacteria (P. gingivalis, T. denticola and T. forsythia) using 
molecular techniques, histology and immunohistochemistry the methods for which were 
optimised during the human AD phase of the investigation. 
Objective 3i (To determine the effect of periodontal disease related pathogens on CNS 
cells) was achieved using the ApoE
null
 mouse model of periodontal disease. The cells 
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were assessed to determine if periodontal disease has any impact on them using both 
histology and immunochemistry. 
Objective 3ii (To detect any alterations in AD makers in periodontal disease mouse 
brain) was achieved using antibodies specific to AD makers, Aβ and Tau, by both 
immunoblotting and immunofluorescent labelling techniques. Also specific changes 
related to AD lesion formation were assessed by interpreting histological data with 
respect to neurobiology and related changes reflected by the changing pathology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
 
 
 
 
 
 
Chapter 2: 
Investigating a link between Alzheimer’s and 
periodontal disease using human post-mortem brain 
tissue. 
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2.1. INTRODUCTION 
Neurodegenerative disease conditions are notoriously complex and the exact aetiology 
of the common form of dementia, AD, remains under investigation. In contrast, 
periodontal disease has a known bacterial aetiology.  Some scientists believe that the 
same bacterial species involved in periodontal disease aetiology may be responsible for 
the deposition of Aβ plagues in AD brains (McDonald, 2006; Miklossy et al., 2006). 
When searching for clues towards bacterial infections having an aetiological role in late-
onset AD researchers are faced with a number of challenges as post-mortem brain tissue 
is all that may be available due to ethical issues surrounding availability of human brain 
tissue. Post-mortem brain tissue is subjected to a post-mortem delay (often 24-48 
hours), hence, autolysis will begin and this can give rise to undesirable artefacts and 
potentially falsify results. Autolysis can be avoided if post-mortem delay can be 
minimised and tissue preserved by lowering temperature (snap freezing) or performing 
chemical fixation immediately after collecting specimens. The role of tissue banks is to 
aid researchers by collecting and appropriately storing valuable human tissue without 
the added wait for arranging ethical clearance and consent, and prevent any delay in 
post-mortem examination. In addition to investigating the presence of periodontal 
pathogens in the brain of AD individuals, this study also aims to validify the use of 
post-mortem tissue for future investigations. Some of the results in this chapter are 
published in the journal of Alzheimer‘s disease (Poole et al., 2013). 
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2.2. MATERIALS AND METHODS 
2.2.1. Human brain specimens and source 
A formal request for post-mortem brain tissue was placed to the brain tissue bank 
(request number 2010-41). Subsequently, previously diagnosed AD (N = 10) and age-
matched non-AD control (N = 10) specimens were obtained from ―Brains for Dementia 
Research‖ following a material transfer agreement (MTA) between the University of 
Central Lancashire (UCLan) and the University of Newcastle, UK. The specimens were 
received on dry ice and were of 1 cm
3
 core taken from the peri-lateral ventricular region 
of the brain. The hippocampus region of the brain was not included. The post-mortem 
interval for all AD cases ranged from 4 - 12 hours from death, and the non-AD age 
matched control brains were taken from a 16-24 hour range (see table 2.1 for full 
details). On receipt all cases were assigned an UCLan code using a simple numbering 
system: AD cases 1-10 and control cases; non-AD 1-10 (Table 2.1). All specimens were 
held in a freezer according to the rules and regulations for storage of human tissue Act.   
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Table 2.1: The age and post-mortem interval of all human cases analysed. 
Case Age Post-mortem interval (hours) 
AD 1 78 12 
AD 2 77 8 
AD 3 84 8 
AD 4 84 8 
AD 5 85 9 
AD 6 83 9 
AD 7 80 4 
AD 8 83 10 
AD 9 63 11 
AD 10 83 12 
Non-AD 1 69 16 
Non-AD 2 72 17 
Non-AD 3 103 21 
Non-AD 4 78 23 
Non-AD 5 89 24 
Non-AD 6 81 43 
Non-AD 7 78 34 
Non-AD 8 89 34 
Non-AD 9 67 22 
Non-AD 10 22 22 
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The human brain tissue was allocated for molecular identification of selected 
periodontal pathogens (P. gingivalis, T. denticola and T. forsythia) as per MTA 
agreement. In addition, the tissue was also used for on-section immunolabelling and for 
immunoblotting where appropriate. 
2.2.2. Sources of antibodies/antisera against bacterial and human proteins 
Primary antibodies: rat anti-T. denticola (factor H-binding protein B (FhbB) protein), 
Prof. Thomas T. Marconi, USA; rabbit anti-T. forsythia (s-layer protein), Dr G. 
Stafford, University of Sheffield, UK; rabbit anti-T. forsythia (rBspA), Dr A. Sharma, 
State University of New York at Buffalo, NY, USA; mouse anti-P. gingivalis (Clone 
61BG1.3), Prof. R. Gmür, University of Zurich, Switzerland; mouse anti-P. gingivalis 
(Clone 1B5), Prof. M. A. Curtis, London, UK; mouse anti-CD14 (clone HCD14), 
Thermo-Fisher; rabbit anti-human IgG (H8765), Sigma Aldrich, UK; mouse anti-GFAP 
(clone GA-5), Thermo-Fisher; mouse anti HLA-DP, DQ, DR clone CR3/43, 
DaoCytomation, goat anti-GFAP, Professor P. Morgan, Cardiff University. Secondary 
detection antibodies: goat anti-mouse - FITC (Fluorescein isothiocyanate)(107K6058), 
Sigma Aldrich, UK; goat anti-rabbit – FITC (01K60571), Sigma Aldrich, UK; rabbit 
anti-goat – FITC (019K4796), Sigma Aldrich, UK; rabbit anti-rat Alexa Fluor 488 (A-
21210), Invitrogen; rabbit anti-goat Alexa Fluor 555 (A21431), Invitrogen; goat anti-
rabbit TRITC (Tetramethylrhodamine), Hycult Biotech. 
2.2.3. Source of whole formalin fixed bacteria and bacterial DNA 
P. gingivalis FDC 381, T. denticola ATCC 35404, and T. forsythia ATCC 43037 fixed 
in formalin and genomic DNA from the same bacteria was a gift from Prof. L. Kesavalu 
(University of Florida).  
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2.2.4. Gift culture supernatant and source 
Sterile bacterial growth medium (medium control) and the culture supernatant was a gift 
from Prof. M A. Curtis (Blizard Institute of cell & Molecular Science, London). The 
medium control refers to the sterile liquid medium containing brain heart infusion broth 
supplemented with haemin (5 mg/l) and menadione (1 mg/l). The culture supernatant 
refers to the same medium except P. gingivalis ATCC 33277 or ATCC 53978 (W50) 
was inoculated and optimally cultured for 48 hours. Following growth, the bacterial 
culture was centrifuged at 15,000 rpm (revolutions per minute) at 4 °C for 30 mins to 
pellet cells, the supernatant containing secreted ―virulence factors‖ was then collected 
for in vitro investigations. On receipt, these supernatants were aliquoted as 1 and 0.5 ml 
in pre-labelled screw top sterile polypropylene vials and stored at -80 °C for subsequent 
use. 
2.2.5. Sources of all other reagents 
A glial cell line (SVGp12) and control cell line, Rahul Previn, MSc student c/o Dr. Sim 
Singhrao, UCLan; Eagle‘s minimal essential medium (EMEM), Sigma; foetal calf 
serum (FBS), Sigma; Analar grade acetone, Fisher Scientific; glutamine, life 
technologies; sodium pyruvate, Sigma; non-essential amino acids, Invitrogen; QIAamp 
DNA Mini Kit, Qiagen; ATL buffer, Qiagen; proteinase K, Qiagen; 
Phenol:Chloroform:Isoamyl Alcohol 25:24:1 Saturated with 10 mM Tris, pH 8.0, 1 mM 
Ethylenediaminetetraacetic acid (EDTA), Sigma; Glycogen, Sigma; sodium acetate, 
Sigma; ethanol, Fisher Scientific; AE buffer, Qiagen; Taq polymerase, Fisher Scientific; 
Phusion High-Fidelity Hot start II DNA Taq Polymerase, ThermoScientific; Taq Buffer 
A, Qiagen; dNTPs (deoxynucleotide triphosphates) mix, Fisher;  agarose, Fisher 
Scientific; ethidium bromide, Sigma; 1 Kb marker, ExactGene, Fisher; TOPO TA 
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cloning kit, Life Technologies; Tris Acetate, Sigma; EDTA, Sigma; microCLEAN, 
Microzome ltd; Luria Broth (LB) agar, Fisher Scientific; Methanol, Fisher Scientific; 
LB broth, Fisher Scientific; KOAc, Sigma; KCl, Sigma; CaCl2, Sigma; glycerol, Fisher 
Scientific; MOPs, Fisher Scientific; TA cloning kit PCR® 2.1 vector 45-0046, 
Invitrogen; Kanamycin, Fisher Scientific; X-Gal, Fisher Scientific; M13 forward primer 
(10 μM), Invitrogen; M13 reverse primer (10 μM), Invitrogen; Qiaquick kit, Qiagen; 
BigDye® Terminator v3.1 Cycle sequencing kit, Applied Biosystems; OCT® adhesive, 
Fisher scientific; phosphate buffered saline (PBS), in house; Normal goat serum, 
DakoCytomation; normal rabbit serum, DakoCytomation; tween 20, Fisher Scientific; 
10% neutral buffered formalin, Sigma; bovine serum albumin (BSA), Sigma; 
Vectashield® propidium iodide (PI) mounting medium, Vector laboratories; 
Vectashield® DAPI (4',6-Diamidino-2-Phenylindole, Dihydrochloride) mounting 
medium, Vector laboratories; NP40, Sigma; NaCl, Sigma; protease inhibitors 
(cOmplete ULTRA Tablets), Roche; E. coli LPS, Sigma; Coomassie blue reagent, 
Sigma; polyvinylidene difluoride (PVDF) membrane Immobilon-P, Millipore, UK; Tris 
base, Sigma; Sodium Dodecyl Sulfate (SDS), Fisher Scientific; ammonium persulphate 
(APS), Sigma; 30% acrylamide/0.8% N, N –methylene bisacrylamide stock solution, 
GE Healthcare; N,N,N′,N′-Tetramethylethylenediamine, Sigma; methanol, Fisher 
Scientific; Laemmli reducing sample buffer (non-reducing Laemmli sample buffer 
BioRad 161-0737 with the addition of 5% β-mecaptoethanol Sigma); gel loading, tips, 
Elkay; pre-stained protein markers, Lonza; chemiluminescence detection reagent, Bio-
Rad.  
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2.2.6. In vitro culture of SVGp12 cells  
To generate relevant controls the SV40 immortalised human glial cell line SVGp12 and 
in another experiment the IMR32 neuroblastoma cell line were used. A culture of the 
SVGp12 or IMR32 cells were exposed to a ¼ dilution of medium control or P. 
gingivalis (33277 or W50) culture supernatant diluted in antibiotic free EMEM 
supplemented with heat inactivated 10 % FBS, 4 mM glutamine, 2 mM sodium 
pyruvate and  0.1 mM non-essential amino acids for 24 hours. The cells were either 
fixed for immunofluorescent labelling or used for preparing lysates for immunoblot 
analysis (Section 2.2.9). 
2.2.7. Molecular Biology 
i) Genomic DNA isolation 
Isolation of DNA was initially performed using two different protocols to identify the 
best method to maximise yield without compromising the purity of the DNA: 
Genomic DNA Isolation method 1: Qiagen kit 
DNA was isolated from 25 mg of human brain tissue using the QIAamp DNA Mini Kit 
according to manufacturer‘s instructions. The column eluted DNA was quantified using 
the Nanodrop 1000 spectrophotometer (ThermoScientific) and stored at -20 °C until 
required for further use. 
Genomic DNA Isolation method 2: phenol chloroform extraction and ethanol 
precipitation 
Equivalent amount of tissue (25 mg), as used for the Qiagen kit method, was taken from 
each sample (AD and non-AD controls) and digested overnight at 56 °C in 180 μl ATL 
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buffer and 20 μl proteinase K from a 10 mM stock solution. Following complete 
enzymatic digestion DNA was extracted using phenol/chloroform/isoamylalcohol; 
avoiding the column elution. This method involved addition of 
phenol/chloroform/isoamylalcohol (200 μl) to each sample, followed by vortex mixing 
and centrifugation for 5 mins at 13,000 rpm. The upper aqueous layer (containing the 
DNA) was transferred to a fresh, sterile 1.5 ml Eppendorf® tube, followed by ethanol 
precipitation; 1 μl Glycogen (20 μg/μl), 0.5x volume of sample sodium acetate (7.5 M) 
and 2.5x volume of sample 100 % ethanol (ice cold) was added to each sample mixed 
by vortexing and then placed at -80 °C for a minimum of 1 hour. Each sample was then 
centrifuged at 4 °C for 30 mins at 13,000 rpm in order to pellet the DNA. Once the 
supernatant was removed the pellet was washed by adding 150 μl 70% ethanol, 
followed by centrifugation at 4 °C for 2 mins at 13,000 rpm. The wash step was 
repeated twice then the tube was left at room temperature for 15 mins to dry the pellet, 
followed by re-suspension in 100 μl AE buffer. Finally the DNA was quantified using 
the Nanodrop 1000 spectrophotometer (ThermoScientific) and stored at -20 °C until 
required for further use. 
ii) PCR optimisation 
For each primer set the PCR required optimisation, this was carried out using a series of 
reactions under different conditions to determine the optimum working protocol. The 
stages involving PCR optimisation are described in detail below.  
DNA template 
A maximum of 1 µg (0.5 µg when using Phusion HS Taq) of DNA template is 
recommended by manufacturers. For each primer set, reactions were initially performed 
out using 0.25 µg, 0.5 µg, 0.75 µg and 1 µg DNA concentrations. For use with universal 
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bacterial primers using Taq polymerase an optimal concentration of 1 µg was 
determined. Whereas when using specific bacterial primers (T. denticola, T. forsythia 
and P. gingivalis) coupled with Phusion High-Fidelity Hot start II DNA Taq 
Polymerase the optimal DNA template concentration was 0.25 µg. The requirement for 
a relatively high concentration of DNA template may be explained by the fact that the 
target DNA is only likely to be present in small quantities within the complex mixture 
of genomic DNA making up each sample. 
Primer concentration 
The optimal primer concentration for each primer set was determined by performing a 
series of PCR reactions with different primer concentrations (final concentration of 
0.05-1 µM). For all primer sets the recommended final primer concentration of 0.2 µM 
was considered to be optimal, this was achieved by adding 0.5 µl of 10 µM 
concentration of each primer (forward and reverse) to a 25 µl reaction.   
Magnesium concentration 
The recommended magnesium concentration for both Taq polymerases (Fisher and 
Phusion HS) did not require further optimisation as the commercial buffers supplied in 
the kit were fully optimised for the required concentration of MgCl2 (15 mM for Fisher 
Taq polymerase and 7.5 mM for Phusion).  
Taq concentration 
The optimum concentration of Fisher Taq polymerase (0.1 U/µl) was achieved by 
adding 0.5 µl of 5 U/µl Taq polymerase per 25 µl reaction. Whereas for Phusion High-
Fidelity Hot start II DNA Taq, the optimal final concentration in the PCR reaction was 
0.02 U/µl (0.2 µl of 2 U/µl Taq per 20 µl reaction). 
88 
 
 
Annealing temperature 
For each primer set the annealing temperature was determined by running a gradient 
PCR using the Verity step on the Veriti™ Thermal Cycler (Applied Biosystems). 
Temperatures of 2 °C intervals were performed (generally ranging from 54 °C – 64 °C), 
if a clear band was visible at all temperatures (and the negative controls were clear) then 
the highest temperature which produced the most compact, single band was selected to 
achieve the highest specificity. 
Extension time 
The rule of thumb was applied for use with the Fisher Taq polymerase which is: 1 
minute extension time per 1 Kb product size, hence a 1 minute 30 second extension was 
employed for universal primer sets (product size: 1.5 Kb). This was increased to 1 
minute 40 seconds during cloning as the product size was larger (~1600 bp) when using 
M13 primers. When using Phusion High-Fidelity Hot start II DNA Taq Polymerase the 
process was much quicker, the manufacturers recommended that when using this taq for 
high complexity genomic DNA to use as little as 30 seconds for 1 Kb length of DNA. A 
number of PCR reactions were performed using a range of extension times for each 
primer set (20, 25, 30, 35 and 40 seconds). Those parameters which produced the 
clearest results, for each primer set, were then selected for routine use here onwards. 
iii) PCR- universal 16s bacterial gene primer sets 
Following DNA extraction the 16S rRNA genes were amplified under standard 
conditions using universal bacterial primer sets (Forward primer: D88, 
GAGAGTTTGATYMTGGCTCAG; Reverse primers: C90 for Spirochetes 
GTTACGACTTCACCCTCCT, F01 for Bacteroidetes CCTTGTTACGACTTAGCCC) 
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as published by Paster et al., (2001) fully optimised as above. The PCR reactions were 
performed in 0.2 ml PCR tubes, vortex mixed and centrifuged briefly before 
amplification using a Veriti™ Thermal Cycler (Applied Biosystems). Each reaction had 
a total volume of 25 μl; consisting of 2.5 μl Buffer A, 0.5 μl dNTPs, 0.5 μl each primer 
(forward and reverse 10 µM), 0.2 μl Taq, 1 μg sample DNA and sterile RNA/DNA free 
water to make the volume up to 25 μl. The negative control samples contained all PCR 
reagents except for the sample DNA. The positive control samples contained all PCR 
reagents together with P. gingivalis, T. denticola or T. forsythia DNA (dependant on the 
primer set being used). The PCR parameters used for all 16s analysis were: 95 °C for 8 
mins, 35 cycles of; 94 °C for 1 min, 55 °C for 30 seconds, 72 °C for 1 min 45 seconds, 
followed by 72 °C for 10 mins.  
iv) Electrophoresis 
PCR product (5 µl of PCR product in 2 µl of loading dye) was examined for expected 
bands around 1500 bp using 1.5 % agarose gel electrophoresis performed at 100 V in 1x 
TAE (0.04 M Tris Acetate, 0.001 M EDTA) buffer. The gel was post stained with 
ethidium bromide (0.5 µg/ml) and the bands were visualised using a GENE GENIUS 
Bio imaging system and Gene snap software (Syngene, UK). 
v) Purification of PCR product 
The PCR product of interest was purified using microCLEAN as per manufacturer‘s 
instructions. Briefly, an equal volume of microCLEAN was added to the PCR product 
and mixed by pipetting then left at room temperature for 5 mins. Followed by 
centrifugation at 13,000 rpm for 7 mins, then the supernatant was removed. Finally the 
pellet was re-suspended in AE buffer (20 µl) and quantified using the Nanodrop 1000 
spectrophotometer (ThermoScientific) for Topo cloning. Any remaining sample was 
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stored at – 20 °C.   
vi) Topo Cloning  
Chemically prepared competent cells  
A discrete colony of Escherichia coli strain DH5-α bacteria maintained previously on 
an LB agar plate (stored at 4 °C) was inoculated into 5ml of LB for an initial overnight 
miniculture at 37 °C in a shaker set at 200 rpm. The following day, 1ml of the fresh 
mini culture was used to inoculate a larger culture in sterile LB (100ml) which was 
incubated at 37 °C in a shaker set at 200 rpm and monitored for growth until an OD600 
of approximately 0.5 was obtained. Then cells were incubated on ice for 10-15 mins 
before transferring the culture, in equal volumes, into two sterile 50 ml centrifuge 
(Falcon
TM
) tubes and centrifuged at 4,000 rpm for 5 min at 4 °C. The supernatant was 
discarded and the remaining cells were re-suspended in 30 ml sterilized TBF1 buffer 
(30 mM KOAc, 50 MnCl2, 100 mM KCl, 10 mM CaCl2 in 15 % glycerol, pH 7.3) per 
50 ml original culture. Following further incubation on ice for 15 min, the cells were 
pelleted by centrifugation (4,000 rpm for 5 min at 4 °C), and re-suspended in sterilised 
TBF2 buffer (10 mM MOPs, 75 mM CaCl2, 10 mM KCl in15 % glycerol, pH 7.3). The 
chemically competent cells (on dry ice) were aliquoted (100 µl) into sterile Eppendorf 
TM 
tubes and stored at -80 °C until needed.  
Ligation 
A ligation reaction was set up using an Invitrogen cloning kit (TA cloning kit PCR® 2.1 
vector) according to manufacturer‘s instructions. In brief a 10 µl ligation reaction was 
prepared consisting of 20 ng fresh PCR product, 1 µl 10X ligation buffer, 2 µl pCR®2.1 
vector (25 ng/µl) and sterile (RNA/DNA free) water to a total volume of 9 µl followed 
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by 1 µl T4 DNA ligase (4.0 Weiss units). The reaction was incubated at 14 °C 
overnight. 
Transforming chemically competent cells 
The ligation product was centrifuged briefly and stored on ice, a 100 μl vial of the 
chemically treated E. coli DH5-α strain (prepared as above) was thawed on ice then 2 μl 
of ligation product was added directly to the vial of competent cells and mixed gently. 
The vials were incubated on ice for 30 mins then heat shocked for 30 seconds at 42 °C, 
without shaking, and immediately returned to ice. S.O.C. medium (200 μl) was added to 
each vial of cells and incubated for 1 hour at 37 °C shaking at 225 rpm. LB agar plates 
were prepared (containing 50 μg kanamycin) and spread with 40 μl X-Gal (40 mg/ml) 
which was left to soak into the agar at 37 °C for approximately 30 mins. Two different 
volumes (50 μl and 100 μl) of each transformation vial was spread onto separate LB 
agar plates containing kanamycin (previously coated with X-Gal) and incubated 
overnight at 37 °C. All plates were then moved to 4 °C for 2-3 hours to allow for 
complete colour development. 
Analysing transformants 
On average 20 % of all colonies (white only) were selected and each mixed with 20 μl 
sterile distilled water, 5 μl of each colony suspension was re-plated onto another pre-
labelled LB agar plate containing kanamycin and incubated overnight at 37 °C. The 
remaining 15 μl was heat killed at 65 °C for 15 mins. 5 μl of the heat killed colony was 
then applied to a PCR mix along with 2.5 μl Buffer A, 0.5 μl dNTPs, 0.5 μl M13 
forward primer (GTAAAACGACGGCCAG, 10 μM), 0.5μl M13 reverse primer 
(CAGGAAACAGCTATGAC, 10 μM), 0.2 μl Taq and 10.8 μl sterile RNA/DNA free 
water. PCR parameters were as follows; 95 °C for 5 mins, 25 cycles of; 94 °C for 1 min, 
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55 °C for 30 seconds, 72 °C for 1 min 45 seconds, followed by 72 °C for 10 mins. 
Results were visualised using agarose (1.5 %) gel electrophoresis post staining with 
ethidium bromide. When a positive clone was identified by PCR (colony screen) that 
specific colony was selected from the LB agar/kanamycin plate and cultured overnight 
in 20 ml LB broth containing 50 μg/ml kanamycin at 37 °C whilst shaking at 200 rpm. 
vii) Plasmid Isolation 
Following a 24 hour liquid culture, the tubes were centrifuged at 4,500 rpm for 20 mins 
to pellet cells. The plasmid DNA was isolated using a plasmid isolation kit (Qiaquick) 
according to the supplier‘s instructions. The elution volume used was 50 μl, and the 
yield was measured on the Nanodrop 1000 spectrophotometer (ThermoScientific). Here 
a PCR reaction using the same parameters as the colony screen (but replacing the 10μl 
of colony with 1μg plasmid DNA) was used to check if the correct plasmid had been 
isolated. 
viii) Sequencing PCR 
Sequencing was carried out using the BigDye® Terminator v3.1 Cycle sequencing kit 
according to the manufacturer‘s instructions. Reactions were performed in volumes of 
10 μl as follows: 0.8 μl reaction premix, 3.6 μl reaction buffer, 1.6 μl (1 μM) primer 
(either the M13 forward or the M13 reverse primers as described above), 10-40 ng DNA 
(Table 2.2) and RNA/DNA free water added up to the required volume. 
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Table 2.2 – The concentration of template needed for DNA sequencing using the 
BigDye® terminator v3.1 cycle sequencing kit. 
Size of PCR product (sequencing 
template) 
Concentration for sequencing reaction 
100-200 bp 1-3 ng 
200-500 bp 3-10 ng 
500-1000 bp 5-20 ng 
1000-2000 bp 10-40 ng 
 
All reactions were performed in 0.2 ml PCR tubes, vortex mixed and centrifuged prior 
to amplification in a Veriti™ Thermal Cycler (Applied Biosystems, UK). The PCR 
parameters were as follows: 96 °C for 1 minute, 25 cycles of; 96 °C for 10 seconds, 50 
°C for 5 seconds, 60 °C for 4 mins. 
ix) Purification of the sequenced reaction 
Purification of the sequencing reactions was carried out using the sodium 
acetate/EDTA/glycogen and ethanol precipitation method recommended by Applied 
Biosystems. For this 1 μl of 3 M sodium acetate pH 5.2, 1 μl of 100 mM EDTA pH 8.0, 
1 μl of 20 mg/ml glycogen and 30 μl ice cold 95% ethanol was added to each reaction. 
The solutions were mixed by pipetting and left at room temperature for a minimum of 1 
hour to allow for DNA precipitation. DNA was pelleted by centrifugation at 13,000 rpm 
at 4 °C for 30 mins. The pellet was washed with 100 μl of 70% ethanol; vortex mixed 
and centrifuged at 13,000 rpm at 4 °C for 15 mins, then the supernatant was removed. 
The wash step was repeated and finally the pellet was dried for 10 mins at 60 °C. 
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x) Capillary electrophoresis of sequencing products 
Analysis of the sequencing product was performed by the Institute for Translation, 
Innovation, Methodology and Engagement, Central Biotechnology services, Cardiff 
University. Following analysis the results were converted into a FASTA sequence and 
submitted to the BLAST (Basic Local Alignment Search Tool) nucleotide search engine 
(http://blast.ncbi.nlm.nih.gov/) to identify the organism(s) with 99-100% match. 
2.2.8. Immunofluorescence labelling 
i) Cryo-sectioning  
A 3 mm
2
 thick section of brain tissue from each case was separated from the original 
snap frozen unfixed cores and mounted onto a specimen holder using the OCT® 
adhesive. Sections (10 µm thickness) were cut using the Leica CM1850 cryostat (Leica 
UK) and collected onto superfrost+® glass slides (Leica UK). Spare sections on slides 
were stored at -80 °C. 
ii) Controls for immunofluorescence labelling 
Negative controls 
Alongside the non-AD control brain sections (whereby both primary and secondary 
antibodies were added) and additional negative control was always included in which 
the primary antibody was omitted. For SVGp12 cells on coverslips, as well as the 
omission of the primary antibody, an additional negative control involved the inclusion 
of the primary antibody (anti-P. gingivalis clone 1B5) on medium control challenged 
cells.  
Positive controls - Bacterial smears 
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Formalin fixed P. gingivalis FDC 381, T. denticola ATCC 35404, and T. forsythia 
ATCC 43037 were smeared on appropriately labelled glass slides using a disposable, 
microbiology loop. Once the smear had dried, the bacteria were heat fixed to firmly 
adhere them to the glass slide. These were used as positive controls for 
immunolabelling alongside the cryo-sections.     
iii) Optimisation of antibodies for immunofluorescent labelling 
No pre-treatments were required on cryo-sections and/or bacterial smears. For every 
antibody used a dilution profile was determined for each application and then adhered to 
for the same application throughout the experimental phase of the study, unless a new 
batch was purchased. Secondary antibody dilution was previously optimised for routine 
use by immunofluorescence in our laboratory (FITC labelled secondary detection 
antibodies used at 1/200 and Alexa Fluor at 1/1000).  
Each of the selected dilutions was tested on a positive control section where possible. 
The optimal dilutions, which produced clear results with no background/non-specific 
labelling, for each antibody are: rat anti-T. denticola (FhbB protein) 1/5000; rabbit anti-
T. forsythia (s-layer protein) 1/20,000; mouse anti-P. gingivalis (Clone 1B5) 1/10; 
mouse anti-CD14 (clone HCD14) 1/200; rabbit anti-human IgG (for detection of Aβ 
plaques) 1/200. 
iv) Immunolabelling snap frozen, cryostat tissue sections 
All unfixed sections were allowed to air dry at room temperature before tissue 
stabilisation for 5 min in cold Analar grade acetone. Unless otherwise stated, no 
quenching of autofluorescence or any other antigen retrieval step was employed. 
Sections were equilibrated in 0.01 M PBS (pH 7.3) once for 5 mins and blocked in the 
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blocking solution (0.01 M PBS pH 7.3 containing 0.01% normal goat/rabbit serum and 
2% tween 20). The sections were incubated overnight at 4 °C in the primary antibody 
(rat anti-T. denticola (FhbB protein); 1/5,000; rabbit anti-T. forsythia (s-layer protein) 
1/20,000; mouse anti-P. gingivalis (Clone 1B5) 1/10; mouse anti-CD14 (clone 
HCD14) 4 μg/ml; rabbit anti-human IgG (for detection of Aβ plaques) 1/200; mouse 
anti-GFAP (clone GA-5) 4 μg/ml; mouse anti HLA-DP, DQ, DR clone CR3/43 (for 
detection of microglia) 1/100) diluted in the blocking solution. The secondary detection 
was carried out using the appropriate secondary antibody (rabbit anti-rat Alexa Fluor 
488 1/1000; goat anti-mouse FITC 1/100; goat anti-rabbit FITC 1/100) diluted in the 
blocking solution as above. Following further washes in PBS (3x 5 mins) sections were 
mounted under a glass coverslip using PI Vectashield mounting medium. Labelling was 
observed and images were captured using the 510 series Zeiss confocal microscope 
(Carl Zeiss Ltd). 
v) Immunofluorescence labeling of in vitro culture of SVGp12 cells 
The cells (on coverslips) were fixed in 10 % neutral buffered formalin for a minimum of 
1 hour at 4 °C. Following a thorough wash in 0.01 M PBS (pH 7.3), the cells were 
either used immediately or held in PBS for up to 1 week at 4 °C before 
immunolabelling.  
Immunolabelling was performed with appropriate primary antibodies as described 
for cryostat brain tissue sections (see above section iv). Briefly; following fixation and 
incubation of cells in the blocking solution (0.01 M PBS pH 7.3 containing 0.01 % 
normal goat/rabbit serum and 2% tween 20), the coverslips were incubated in the 
following primary antibodies: mouse anti-CD14 (1/200), mouse anti-P. gingivalis 
(clones 1B5 and 1A1; diluted 1/10 and 1/50 respectively) and mouse anti-GFAP (1/200) 
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overnight at 4 ºC. Secondary detection was performed using the goat anti-mouse FITC 
(1/100). The results were visualised and imaged using the 510 Zeiss confocal 
microscope. 
vi) Double immunolabelling of in vitro culture of SVGp12 cells 
Formalin fixed SVGp12 cells on coverslips were dual labelled with goat-anti GFAP 
(1/1000) and mouse anti-P. gingivalis (clone 1B5) (1/10) as above except the blocking 
solution used was 0.01 M PBS pH 7.3 containing 1% BSA. Secondary detection 
antibodies were goat anti-mouse FITC (1/200) and rabbit anti-goat Alexa Fluor 555 
(1/1000) diluted in blocking solution (0.01 M PBS/1% BSA). Sections were mounted 
under a glass coverslip using the Vectashield® DAPI mounting medium and imaged as 
described above (Section iv). 
 
2.2.9. Biochemistry  
i) Tissue lysates  
A 3 mm
2
 section of all brain specimens were taken from the original snap frozen 
unfixed tissue core and minced in lysis buffer containing 50 mM Tris pH 8.0, 1% NP40, 
150 mM NaCl, 5 mM EDTA and protease inhibitors. Protease inhibitors are added in 
order to prevent the degradation of the proteins by the protease enzymes released during 
cell lysis within the sample. Following incubation on ice for 30 mins and frequent 
vortex mixing, the tissue homogenate was then centrifuged at 12,000 rpm for 20 mins at 
4 °C using a micro-centrifuge. Finally the supernatant was collected in pre-labelled, 
sterile, 1.5 ml Eppendorf® tubes and stored at -20 °C until needed. 
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ii) Cell lysate  
Following exposure to either to P. gingivalis (33277 or W50) secreted virulence factors 
(culture supernatant) or the medium control for 48 hours (as described in section 2.2.6), 
SVGp12 cells were pelleted free of culture medium and washed three times in cold, 
sterile PBS with centrifugation (5 mins at 2,500 rpm) between each wash. The cells 
were lysed in buffer containing protease inhibitors (as above) and incubated on ice for 
30 mins with frequent vortex mixing. Finally, the cell homogenate was centrifuged and 
collected as before, in pre-labelled Eppendorf® tubes and stored at -20 °C. 
iii) Controls  
Along with the lysates prepared from both human brain tissue and SVGp12 cells a 
number of positive and negative controls were also generated: 
Negative control  
Sterile bacterial growth medium was used as the medium control. Once thawed protease 
inhibitors were added to a 1 ml aliquot and it was then freeze dried for at least 12 hours 
and re-suspended in a 200 μl volume of lysis buffer containing 50 mM Tris pH 8.0, 1% 
NP40, 150 mM NaCl, 5 mM EDTA. The aliquots were stored at -20 °C for subsequent 
needs. 
Positive control 
An aliquot (0.5 ml) of each P. gingivalis culture (ATCC 33277 and W50)  was freeze 
dried  inclusive of protease inhibitors overnight and re-suspended in 200 µl volume of 
lysis buffer and stored at -20 °C until needed (as described above).  
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Control lipopolysaccharide (LPS) lysate  
As a check for cross reactivity of the primary antibody with LPS from other bacteria 
commercially prepared (phenol extracted) lyophilized powder from E. coli LPS was 
used. The LPS (1 µg) was re-suspended in 250 μl lysis buffer containing protease 
inhibitors used above and stored at -20 °C until required. 
iv) Protein assay 
The total protein concentrations of all lysates (cells, human brain tissue and cultures) 
were determined using the Bradford colorimetric assay (Bradford, 1976). Briefly, 
protein concentration was obtained from a standard curve prepared using 100-400 
mg/ml BSA diluted in lysis buffer. Following addition of the Coomassie blue reagent to 
all standards and test samples, absorbance was measured at 595 nm wavelength using a 
Jenway 7315 spectrophotometer. The unknown concentration of the samples was 
calculated by comparing the absorbance values with the standard curve. 
v) Optimisation of western blotting 
SDS PAGE conditions: 
Percentage gel 
Selecting the correct percentage gel is important as this will determine the rate of 
migration and degree of separation between proteins. Initially the percentage gel had to 
be considered for each protein of interest; lower percentage gels (7.5%) were used when 
trying to resolve proteins of a larger size, whereas higher percentage gels (12.5-15%) 
were required for resolution of smaller proteins.  
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Amount of protein to load per well  
All samples were loaded at the same concentration (30 µg total protein). For the 
negative controls a consistent amount of total protein was added (30 µg).  However, 
when using the same amount of protein (30 µg) for the positive controls a rapid, high 
signal, was produced saturating before a 1 second exposure, hence the original stock 
was diluted to ensure the emergence of the signal in line with tests. This meant that the 
positive controls were not always loaded at equivalent protein concentration to the test 
samples.  
Transfer conditions 
Following the electrotransfer, the gels were stained with Coomassie blue reagent in 
order to determine if all proteins had been successfully transferred to the PVDF 
membrane, as indicated by an almost clear gel following the protein stain.  
Immunoblotting conditions 
Blocking solution 
Initially two different blocking solutions were tested; the Invitrogen blocking solution 
and 5% w/v skimmed milk/PBS. Following a number of tests it was determined that 5% 
w/v skimmed milk/PBS produced cleaner blots with no background, whereas the 
Invitrogen blocking solution was associated with a high background with some 
antibodies. Hence, 5 % w/v skimmed milk/PBS was used as the blocking solution 
thereafter.  
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Optimal primary antibody concentration 
The concentration of both primary antibodies (mouse anti-P. gingivalis clones 1B5 and 
1A1) were tested on positive and negative controls, along with human brain specimens, 
at a variety of different concentrations (similar to those previously published; 1/5, 1/10, 
1/20, 1/40). The optimal concentrations for each antibody were: mouse anti-P. 
gingivalis (clone 1B5) 1/20 and mouse anti-P. gingivalis (clone 1A1) 1/50.  
Secondary antibody concentration  
The same assay dependant concentration was used for the secondary antibody, using the 
range suggested by the manufacturer (1/5,000-1/100,000) again testing on both positive 
and negative controls along with human brain specimens. The concentration of the 
secondary which produced the best results, with no background or non-specific binding 
was 1/20,000. 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) was used to 
separate the proteins within each sample by their size (kDa). The detection of specific 
proteins within the complex mixture (cell/tissue lysate) was performed by transferring 
the proteins from the gel matrix onto a PVDF membrane for immunoblotting using 
antibodies specific to target the desired protein. 
vi) Casting gels 
Bio-Rad mini gel electrophoresis system was used to prepare gels for SDS-PAGE. 
Glass plates (both short and spacer plates) were cleaned using 70% ethanol and 
assembled in the apparatus as per manufacturer‘s instructions. At this stage distilled 
water was added to ensure it was sealed tightly. Following removal of the water, the 
required percentage gels were cast as per table 2.3 using the following reagents: Upper 
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buffer (Stacking gel buffer) 0.5 M Tris base and 0.4 % SDS, pH 6.8; Lower buffer 
(resolving gel buffer) 1.5 M Tris base and 0.4 % SDS, pH 8.8; freshly prepared 10 % 
aqueous APS; 30 % acrylamide/0.8 % N, N –methylene bisacrylamide stock solution 
and N,N,N′,N′-tetramethylethylenediamine (TEMED). The lower (resolving) gel was 
added first, overlaid with a layer of 70% methanol until set, to insure a smooth divide 
between gels with no air bubbles. Once the gel was set the methanol was removed using 
a series of washes in distilled water, then the upper (stacking) gel was poured on top of 
the resolving gel, putting the comb in place to create 10 sample loading wells. Once the 
gel had set the combs were removed and the gels were arranged in the electrophoresis 
unit (Bio-Rad) as per manufacturer‘s instructions. 1x electrophoresis buffer was added 
following dilution from 10x stock (10 x electrophoresis (running) buffer stock: 144 g 
glycine, 30 g Tris base, 1 l distilled water and 0.1 % SDS, pH 8.3). 
Table 2.3: Quantity of reagents required for preparation of resolving and stacking gels 
for SDS-PAGE. 
Reagents Resolving Gel Stacking Gel 
 7.5% 10% 12.5% 15% 4% 
40% 
bisacrylamide 
2.72 ml 3.83 ml 4.53 ml 5.51 ml 575 µl 
1M Tris HCl, pH 
8.8 
3.63 ml 3.63 ml 3.63 ml 3.63 ml  - 
1M Tris HCl, pH 
6.8 
- - - - 1.3 ml 
10% APS 75 µl 75 µl 75 µl 75 µl 37.5 µl 
dH20 8.16 ml 7.05 ml 6.35 ml 5.37 ml 4.075 ml 
TEMED 15 µl 15 µl 15 µl 15 µl 7.5 µl 
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vii) Sample preparation 
Samples were prepared for SDS-PAGE to the correct dilutions (30 µg total protein, as 
per protein assay results) using distilled water. A total volume of 15 µl was prepared for 
each sample. Then an equal volume of Laemmli reducing sample buffer (15 µl) (non-
reducing Laemmli sample buffer with the addition of 5% β-mecaptoethanol) was added 
and the sample was heated at 95 °C for 5 min using a heat block. Following this 
samples (30 µl) were loaded into the appropriate wells using gel loading tips with the 
first lane on each gel containing pre-stained protein markers. 
viii) SDS-PAGE 
A current of 80 V was applied until the dye front (0.01 % bromophenol blue present in 
the Laemmli buffer) was visible approximately 1 cm from the bottom of the gel. 
ix) Electrotransfer  
Following SDS-PAGE, the separated proteins were transferred from the gel matrix to a 
PVDF membrane using the Bio-Rad trans-blot transfer cell (Bio-Rad) as per 
manufacturer‘s instructions. In brief, the PVDF membrane was prepared, washed in 
methanol for 30 seconds and left to equilibrate in 1x transfer buffer prior to the transfer 
process. Transfer buffer was diluted from 10x stock (10 x transfer buffer: 144 g glycine, 
30 g Tris base, 1 l distilled water pH 8.3) in distilled water containing 10 % methanol 
and used to fill the tank to the appropriate level. The required components were layered 
in a specific order inside the plastic cassette – sponge, filter paper, PVDF membrane, 
gel, filter paper then sponge (all made moist using 1x transfer buffer without methanol). 
The cassette was placed within the transfer tank and temperature was controlled by 
placing ice packs in the tank. The electrodes were connected, then 180 mA was applied 
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for a total of 2 hours allowing transfer of the proteins from the gel (+) to the membrane 
(-). 
x) Immunoblotting 
Following the electrotransfer of proteins to a PVDF membrane the membranes were 
blocked for 30 mins at room temperature in 5% w/v skimmed milk/PBS prior to 
incubation overnight at 4 C in anti-P. gingivalis clone 1B5 or 1A1 diluted 1/20 or 1/50 
respectively using 5% w/v skimmed milk/PBS. Following 3x 15 min washes in PBS 
containing 0.2 % tween 20, the membranes were incubated in the horse radish 
peroxidase (HRP)-conjugated IgG secondary antibody, goat anti-mouse, diluted 
1/20,000 in 5% w/v skimmed milk/PBS for 2 hours at room temperature. Membranes 
were washed in PBS/tween 20, (3x 15 mins) followed by the detection of any positive 
bands using the enhanced chemiluminescence detection reagent in a chemi-doc imaging 
station (Bio-Rad) using the Molecular Analyst software. India ink was used to stain the 
membrane as a loading control.  
2.2.10. Statistical analysis  
The non-parametric Mann Whitney-U test was performed comparing the AD specimens 
to the non-AD ages matched controls. Differences were considered significant at P 
<0.05. 
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2.3. RESULTS 
2.3.1. Molecular Biology  
Optimisation of genomic DNA isolation on sample AD-1 (note the same amount of 
tissue was used for each method) demonstrated the kit method gave a poor yield 
compared with the manual method. The results are presented in table 2.4.  
Table 2.4: Results from DNA quantification following two different protocols, as stated 
in materials and methods section 2.2.7. 
Genomic DNA isolation Method DNA Concentration 
(ng/µl) 
purity Total yield 
(µg) 
1. Qiagen kit 28.4 1.98 0.284 
2. Phenol chloroform/ ethanol 
precipitation 
110 1.95 1.1 
 
Hence, from here onwards all genomic DNA isolation was carried out using phenol 
chloroform extraction coupled with ethanol precipitation as this method produced  the 
greatest DNA yield without compromising its purity. 
PCR analysis using primers specific for Spirochetes produced negative results in all AD 
and non-AD human brain specimens (Fig. 2.1a and b) despite the positive control 
showing a clear band (lane 3 Fig. 2.1a and b) and the negative control remaining clear 
(lane 2 Fig. 2.1a and b). When using the same genomic DNA samples (from all AD and 
non-AD cases) with primers specific for Bacteroidetes the controls remained consistent; 
negative control clear and the positive control showing a single bright band, (Fig. 2.2, 
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lanes 2 and 3). However, 4 cases presented with clear positive bands (Case ID: AD 1, 
AD 7, AD 9 and Non-AD 2) with another 4 cases presenting with faint bands of the 
correct size ~1500 bp (Case ID: AD 2, AD 8, AD 10 and Non AD 1) (Fig. 2.2).  
 
Figure 2.1: PCR results from all human cases using primers specific for Spirochetes.  a) 
shows the 1 Kb marker (lane 1) followed by a negative control (lane 2), positive control 
(lane 3), then human AD cases 1-10 (lanes 4-13)  b) shows the 1Kb marker (lane 1) 
followed by a negative control (lane 2), positive control (lane 3), then human non-AD 
control cases 1-5 (lanes 4-8). 
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Figure 2.2: PCR results from all human cases using primers specific for Bacteroidetes. 
a) shows the 1 Kb marker (lane 1) followed by a negative control (lane 2), positive 
control (lane 3), then human AD cases 1-10  (lanes 4-13). b) Shows the 1 Kb marker 
(lane 1) followed by a negative control (lane 2), positive control (lane 3), then human 
non-AD control cases 1-5 (lanes 4-8).  
 
Following cloning, colony screening demonstrated some bands with the correct size 
insert (~1600 bp) to be isolated for sequencing (Fig. 2.3).  
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Figure 2.3: Results of colony screen to check for success of cloning; positive colony 
shown by a bright band at ~1600 bp (indicated by arrow). Gels show 1 Kb marker (lane 
1- on all gels A-E), and a number of colony screens, here a total of 68 colonies were 
screened across all cases (lanes 2-15 on gels A-E). Arrow adjacent to each gel indicates 
expected position of positive band (~1600 bp). 
Sequencing identified that the DNA was from bacterial phylotypes outside the scope of 
this study (Table 2.5). Oral bacteria Prevotella oulorum strain WPH 179 and 
Propinobacterium acnes were commonly identified, however, they were both present in 
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the AD and non-AD control brain tissue therefore proving insignificant when tested 
using the non-parametric Mann-Whitney U test. 
Table 2.5: Sequencing results from human brain tissue (AD and Non-AD controls).  
Case Sequence 
length (bp)                               
Identification E 
value 
% nucleotide 
match 
AD 1 1286 Massilia aurea (strain 
AP13)   
0.0 99 
AD 2 1310 Pseudomonas 
psychrotolerans (strain 
C36) 
0.0 99 
AD 7 505  Prevotella oulorum (strain 
WPH 179) 
0.0 98 
AD 8 1203 Propinobacterium acnes 0.0 99 
AD 9 1098 Sphingomonas spp. 0.0 99 
AD10 1219 P. acnes 0.0 100 
Non AD 1 1280 P. oulorum (strain WPH 
179) 
0.0 99 
Non AD 2 1186 P. acnes 0.0 99 
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2.3.2. Immunofluorescence labelling 
i) Controls  
All control human brain tissue sections were semi-serial to those shown under test 
conditions and were exposed to identical conditions. The sections whereby the primary 
antibody was omitted remained negative with FITC labelled secondary detection system 
(Fig. 2.4a). There was some generalised auto fluorescence associated with erythrocytes, 
but this remained below the threshold of noise to signal ratio except for the elastin in 
arteries. There was also strong auto fluorescence associated with brain pigment but this 
was of a different wavelength and colour (yellow) to that of FITC (green). Non-AD 
control brain tissue sections also remained negative (Fig. 2.4b) despite labelling with 
both the primary and secondary antibodies. SVGp12 cells challenged with medium-
control remained negative when incubated with the anti-P. gingivalis (clone 1B5) 
antibody (Fig. 2.4c) and when the primary antibody was omitted.  
For all bacterial antibodies positive controls were generated using smears of 
each bacterium (T. denticola, T. forsythia and P. gingivalis) dried onto microscope 
slides. In all cases the antibodies were tested using identical conditions to those used on 
the human brain sections. The results show that the antibodies correctly labelled their 
respective epitopes (Fig. 2.4 d-f), although only weak labelling of the whole cell was 
detected by both T. denticola and T. forsythia antibodies (Fig. 2.4 d and e). 
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Figure 2.4: Control images for immunofluorescent labelling of human brain tissue. a) 
Human brain tissue section whereby the primary antibody was omitted, the secondary 
antibody being goat anti-mouse FITC (green). b) Human non-AD control brain tissue 
section where both primary (mouse anti P. gingivalis clone 1B5) and secondary (goat 
anti-mouse FITC) antibodies were applied. c) SVGp12 cells treated with medium 
control for 48 hours, labelled with both primary (mouse anti-P. gingivalis clone 1B5) 
and secondary (goat anti-mouse FITC) antibodies. Red (PI) indicates the nuclear label. 
d) T. denticola positive bacterial smear labelled with rat anti-T. denticola (FhbB 
protein). e) T. forsythia bacterial smear positively labelled with rabbit anti-T. forsythia 
(s-layer protein). f) P. gingivalis bacterial smear positively labelled with mouse anti-P. 
gingivalis clone 1B5. 
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ii) Immunofluorescence labelling of human brain tissue 
Tests using both T. denticola and T. forsythia antibodies on human brain sections (both 
AD and non-AD controls) remained negative throughout. The human brain tissue 
sections labelled with the mouse anti-P. gingivalis (clone 1B5) revealed strong cellular 
surface membrane labelling on glial cells in 4 out of 10 AD cases (Case ID: AD 3, AD 
5,  AD 8 and AD 10; p = 0.029; Fig. 2.5 b-d) and not in the non-AD age matched 
controls. Surface membrane labelling was confirmed by labelling adjacent brain tissue 
sections with a monoclonal anti-CD14 antibody (Fig. 2.5e).  
 
Figure 2.5: A-D) Human brain tissue sections labelled with anti-P. gingivalis clone 1B5 
(FITC-green) and PI nuclear label (Red). A) negative control image whereby the 
primary antibody was omitted. B) labelling of human AD brain tissue with anti-P. 
gingivalis (clone 1B5) antibody; Red is the nuclear label (PI), green demonstrates P. 
gingivalis positive labelling (FITC). Cell surface labelling was observed in AD cases 3, 
5, 8 and 10. C-D) Further examples of P. gingivalis positive labelled cells at higher 
magnification. E) Human AD brain tissue sections labelled with CD14 to demonstrate 
cell surface labelling on adjacent section to that shown in B, green shows CD14 positive 
labelling (FITC). 
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In addition to the cell surface labelling particulate extracellular aggregates were also 
present within the human AD brain specimens (Case ID: AD 3, AD 5,  AD 8 and AD 
10), labelling positive with the anti-P. gingivalis antibody (Fig. 2.6). These aggregates, 
with pebbly appearance, were frequently observed within the brain parenchyma and in 
association with arterio-venus shunts, and smaller blood vessels as clearly shown by a 
phase image overlaid on the dark field image shown in figure 2.7a , alongside H/E stain 
carried out on the same sections where possible (Fig. 2.7 b and c). 
 
 
Figure 2.6: Human AD brain tissue sections demonstrating extracellular 
immunolabelling for P. gingivalis (clone 1B5). Red is the nuclear label (PI) and green 
demonstrates P. gingivalis positive labelling (FITC). Extracellular, granular particles 
(pebbly in appearance) shown at different magnifications (AD Cases 3, 5, 8 and 10). 
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Figure 2.7: Human AD brain tissue sections demonstrating immunolabelling for P. 
gingivalis (clone 1B5) associated with blood vessels. Red is the nuclear label (PI) and 
green shows P. gingivalis positive labelling (FITC). A) P. gingivalis positive 
extracellular particles associated with a blood vessel, particles shown at higher 
magnification and blood vessel further demonstrated by the phase image overlaid on the 
dark filed image. B and C) again show P. gingivalis positive extracellular aggregates 
associated with blood vessels, further demonstrated by the phase image overlaid on the 
dark field image; blood vessel confirmed by H/E stain on the same section. 
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Alongside labelling for the specific bacteria, the number of Aβ plaques labelled with the 
anti-human IgG antibody (Fig. 2.8) were counted on three serial sections for each case 
and the average number of plaques was recorded (table 2.6). Results revealed that the 
same 4 out of 10 AD cases which were positive for P. gingivalis also presented with the 
highest number of Aβ plaques (average 58.625). No plaques were observed with the 
same antibody when applied to age matched non-AD cases and the average for the other 
6 out of 10 cases was 4.25 Aβ plaques (Table 2.6).  
 
Figure 2.8: Human brain tissue sections immunolabelled with anti-IgG for detection of 
Aβ plaques. The secondary antibody was conjugated with FITC, hence the green is the 
positive labelling. Red (PI) is the nuclear label. A) Human non-AD control tissue 
section labelled with both the primary and secondary antibodies. B and C) human AD 
brain tissue labelled with anti-IgG antibody; showing IgG positive plaques. 
 
In addition the levels of inflammation, as demonstrated by immunolabelling of both 
microglial and astroglial cell populations, were estimated and scored in accordance with 
that from the control specimens (Fig. 2.9, Table 2.6). The 4 out of 10 AD cases positive 
for P. gingivalis  scored higher than the non-AD control cases, however, no significant 
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difference in inflammation was noted between the 4 cases positive for P. gingivalis and 
the remaining 6 AD cases.  
 
Figure 2.9: Scoring system for immunolabelling of both microglial and astroglial cell 
populations. A) The scoring system used for the level of GFAP labelling Red is the 
nuclear label (PI), green is GFAP positive labelling (FITC). B) The scoring system for 
measuring the level of microglial cell labelling Red is the nuclear label (PI) Green is 
microglia positive labelling (FITC). 
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Table 2.6- Summary of all immunofluorescent labelling data collected on the human 
AD and non-AD control specimens (ND refers to samples which were not done). 
Case ID P. gingivalis 
antibody labelling 
Average No. of 
plaques labelled 
with IgG 
GFAP score 
(1=min, 3=max) 
Microglial 
score (1=min 
4=max) 
AD 1 Negative 0 2 3 
AD 2 Negative 0 3 3 
AD 3 Positive 60.5 3 2 
AD 4 Negative 0 2 4 
AD 5 Positive 18 2 3 
AD 6 Negative 25.5 2 1 
AD 7 Negative 0 2 1 
AD 8 Positive 76.5 2 3 
AD 9 Negative 2 (diffused) 3 3 
AD 10 Positive 79.5 3 3 
Non AD 1 Negative 0 1 1 
Non AD 2 Negative 0 2 2 
Non AD 3 Negative 0 3 2 
Non AD 4 Negative 0 1 2 
Non AD 5 Negative 0 1 2 
Non AD 6 Negative ND ND ND 
Non AD 7 Negative  ND ND ND 
Non AD 8 Negative ND ND ND 
Non AD 9 Negative ND ND ND 
Non AD 10 Negative ND ND ND 
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iii) Immunofluorescencelabeling of SVGp12 cells 
As stated in the materials and methods (section 2.2.6) SVGp12 cells were treated with 
either a medium control or the secreted virulence factors (culture supernatant) of P. 
gingivalis  ATCC 33277 or ATCC 53978 (W50) for up to 48 hours, washed, fixed and 
then immunolabelled for the detection of P. gingivalis virulence factors. The SVGp12 
cells (Fig. 2.10a), including both media control treated cells and those challenged with 
P. gingivalis (33277) culture supernatant, showed no non-specific labelling with the 
secondary antibody (Fig. 2.10b), and presented with GFAP (Fig. 2.10c) labelling as 
expected.  
 
Figure 2.10: Immunofluorescent labelling of SVGp12 cell line a) light microscopy 
image of SVGp12 cells in culture b) negative control image using FITC conjugated 
secondary (green), Red (PI) indicates the nuclear label c) GFAP labelling of SVGp12 
cells Red is the nuclear label (PI) Green indicates GFAP positive labelling (FITC).  
The media control treated SVGp12 cells remained negative when immunolabelled with 
both the primary (mouse anti-P. gingivalis clone 1B5) and secondary antibodies (goat 
anti-mouse FITC) as shown in figure 2.11. Whereas, immunolabelling of SVGp12 cells 
treated with culture supernatant (33277) using the anti-P. gingivalis (clone 1B5) 
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antibody demonstrated surface membrane labelling (Fig. 2.12). The cell membrane was 
intensely labelled and appeared highly vesiculated (Fig. 2.12). 
 
Figure 2.11: Media control treated SVGp12 cells immunolabelled with mouse anti-P. 
gingivalis (clone 1B5) and detected using the secondary antibody goat anti-mouse 
conjugated with FITC (green), Red represents PI, nuclear label. 
 
Figure 2.12: SVGp12 cells treated with P. gingivalis culture supernatant for 48 hours, 
and immunolabelled using the mouse anti-P. gingivalis (clone 1B5) antibody. Nuclei 
are red (PI), green demonstrates P. gingivalis positive labelling (FITC). 
Further, cells from all treatment groups (media control, and P. gingivalis culture 
supernatant from both ATCC 33277 and W50) were dual labelled for both P. gingivalis 
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virulence factors and GFAP (Fig. 2.13). Again the media control treated cells were 
negative for P. gingivalis virulence factors but expressed GFAP as expected (Fig. 
2.13a). Whereas the SVGp12 cells treated with P. gingivalis culture supernatants (from 
both strains 33277 and W50) demonstrated P. gingivalis positive cell surface labelling 
on the GFAP positive cells (Fig. 2.13 b and c). 
 
 
Figure 2.13: Double immunofluorescent labelling of SVGp12 cells with mouse anti-P. 
gingivalis (clone 1B5) and goat anti-GFAP. Blue is the nuclear label (DAPI), Red 
demonstrates GFAP positive labelling (Alexa Fluor 555), whereas green represents P. 
gingivalis positive labelling (FITC). A) SVGp12 cells treated with medium control for 
48 hours, immunolabelled with both primary and secondary antibodies. B) SVGp12 
cells treated with P. gingivalis (strain 33277) culture supernatant for 48 hours, then 
immunolabelled for P. gingivalis (clone 1B5) and GFAP. C) SVGp12 cells treated with 
P. gingivalis (strain W50) culture supernatant for 48 hours, then immunolabelled using 
the mouse anti P. gingivalis (clone 1B5) and anti-GFAP antibodies. 
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2.3.3. Biochemistry 
i) Immunoblot analysis of controls 
All control samples were analysed under reducing conditions using immunoblotting 
with the anti-P. gingivalis (clone 1B5) antibody (Fig. 2.14) for the detection of P. 
gingivalis LPS and/or gingipains. The results show no bands in lanes loaded with the 
medium control, E. coli LPS and SVGp12 cells treated with sterile medium control. The 
lanes with culture supernatants from P. gingivalis ATCC 33277 and SVGp12 cells 
challenged with the P. gingivalis culture supernatant (48 hours) both showed a dark, 
high molecular weight band for gingipains (Fig. 2.14a) and a ladder of bands around 45-
12 kDa corresponding to LPS (Fig. 2.14a). This data agrees with the previously 
published literature for P. gingivalis (W50) LPS using the same antibody (Curtis et al., 
1999, Paramonov et al., 2005) and is further supported by the immunofluorescent 
labelling of SVGp12 cells treated with P. gingivalis culture supernatant labelled using 
the same antibody (Fig. 2.14b). Alongside this an identical blot was probed using the 
anti-P. gingivalis (clone 1A1) antibody (Fig. 2.15), here only high molecular weight 
bands for gingipains were observed in both the culture supernatant and SVGp12 cells 
challenged with the same supernatant (Fig. 2.15). The medium control, medium control 
treated SVGp12 cells and E. coli LPS remained negative as before. 
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Figure 2.14: Immunoblot analysis and immunofluorescent labelling of SVGp12 cells 
(treated and untreated) using anti-P. gingivalis (clone 1B5). A) Immunoblot of lysates 
prepared from in vitro investigation using anti-P. gingivalis (clone 1B5) antibody to 
further support cellular staining. Labels clearly state samples present in each lane. Both 
P. gingivalis culture supernatant and SVGp12 cells treated with the same supernatant 
demonstrated both gingipains and LPS. Whereas the medium control, medium control 
treated SVGp12 cells and E. coli LPS remained negative. B) SVGp12 cells treated with 
P. gingivalis (strain 33277) culture supernatant for 48 hours, then  immunolabelled 
using the mouse anti P. gingivalis (clone 1B5) antibody; Red is the nuclear label (PI), 
whereas green represents P. gingivalis positive labelling (FITC), showing presence of 
both LPS and gingipains, supporting the immunoblot data in A. 
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Figure 2.15: Immunoblot of lysates prepared from in vitro investigation using anti-P. 
gingivalis (clone 1A1). Labels clearly state samples present in each lane. Both P. 
gingivalis culture supernatant and SVGp12 cells treated with the same supernatant 
demonstrated the presence of gingipains. Again the medium control, medium control 
treated SVGp12 cells and E. coli LPS remained negative. 
ii) Immunoblot analysis of non-AD age matched control brain  
The negative and the positive controls from the P. gingivalis bacterial media and the 
SVGp12 cells treated with culture supernatant (48 hours) were loaded alongside 5 non-
AD age matched brain samples (Cases non-AD 1-5) (Fig. 2.16). The controls remained 
consistent in that no bands were present in lanes corresponding to the medium control 
and SVGp12 cells treated with medium control (Fig. 2.16). A laddering pattern of bands 
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corresponding to LPS was observed in the culture supernatant (33277) and SVGp12 
cells treated with culture supernatant between 45-12 kDa molecular weights (Fig. 2.16). 
No bands were detected in any of the 5 control brains (Fig. 2.16). 
 
Figure 2.16: Immunoblot using anti-P. gingivalis (clone 1B5) antibody on control 
human brain tissue lysates (case ID: non-AD 1-5), using cell lysates as appropriate 
controls, labels clearly state samples loaded to each well. The controls were consistent, 
whereas the non-AD cases 1-5 were negative for P. gingivalis LPS/gingipains. 
The same process was carried out on the remaining non-AD control cases (6-10) (Fig. 
2.17). Again no bands were detected in the medium control or the cells treated with the 
same medium, and the positive controls (culture supernatant and SVGp12 treated with 
the culture supernatant) remained consistent producing bands corresponding to LPS and 
gingipains of P. gingivalis (45-12 kDa). No bands were detected in the remaining 5 
human non-AD control brains (case ID non-AD 6-10) (Fig. 2.17).  
125 
 
 
 
 
Figure 2.17:  Immunoblot using anti-P. gingivalis (clone 1B5) antibody on control 
human brain tissue lysates (case ID: non-AD 6-10), using cell lysates as appropriate 
controls, labels clearly state samples loaded to each well. The controls were consistent, 
whereas the non-AD cases 6-10 were negative for P. gingivalis LPS/gingipains. 
 
iii) Immunoblot analysis of AD brain  
Initially the immunoblotting for P. gingivalis virulence factors was performed on the 
AD cases which were positive when screened using immunofluorescent labelling with 
the same antibody (anti-P. gingivalis clone 1B5), these cases were identified as AD 3, 
AD 5, AD 8 and AD 10 (Fig. 2.18). Consistently, no bands were detected in the lanes 
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corresponding to the sterile control medium, E. coli LPS and SVGp12 cells treated with 
sterile control medium when blotting was performed with the anti-P. gingivalis (clone 
1B5) antibody. Bands in a laddering pattern characteristic for LPS were observed in 
both the culture supernatant (33277) (38 kDa-12 kDa) and SVGp12 cells treated with 
the culture supernatant (48 hours) between 38-31 kDa molecular weight positions (Fig. 
2.18). A weak band for LPS was observed in AD brain case 3; along with more intense 
bands for LPS in AD cases designated 5, 8 and 10 (Fig. 2.18). 
 
Figure 2.18: Immunoblot using anti-P. gingivalis (clone 1B5) antibody on human AD 
samples (case ID: AD 3, 5, 8 and 10), using cell lysates as appropriate controls, labels 
clearly state samples loaded to each well. The anti-P. gingivalis antibody (clone 1B5) 
detected bands characteristic of the LPS at the expected molecular weight in AD cases 
3, 5, 8, and 10. 
127 
 
 
 
Finally, tissue lysates from the remaining human AD cases (case ID: AD 1, AD 2, AD 
4, AD 6, AD 7 and AD 9) were immunoblotted using the same conditions, probing for 
P. gingivalis virulence factors with the anti-P. gingivalis (clone 1B5) antibody (Fig. 
2.19). Again, the controls remained consistent (Fig. 2.19) and the AD cases designated 
1, 2, 4, 6, 7, and 9, which were negative by immunofluorescence, consistently failed to 
detect any bands (Fig. 2.19). 
 
Figure 2.19: Immunoblot using anti-P. gingivalis (clone 1B5) antibody on the remaining 
human AD samples (case ID: AD 1, 2, 4, 6, 7 and 9). Again, cell lysates along with 
control and culture supernatant (33277) were used as appropriate controls, labels clearly 
state samples loaded to each well. The anti-P. gingivalis antibody (clone 1B5) 
consistently failed to detect and bands characteristic of LPS in AD cases numbers 1, 2, 
4, 6, 7 and 9. 
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2.4. DISCUSSION  
The initial investigation of the aetiological hypothesis was dependent upon sampling 
tissues from post-mortem specimens obtained from both AD and non-AD individuals, 
taken from areas of the brain that are not directly involved in the pathology of the 
disease. The main reason for using the chosen area of brain tissue was that the 
hippocampus region of the brain is vital for the neuropathological confirmation of the 
disease at post-mortem. A pre-requisite for diagnostic neuropathology is that the 
appropriate areas of the brain are formalin fixed and embedded in paraffin wax for 
subsequent staining techniques. Formalin fixed, paraffin wax embedded tissue is not 
ideal for extracting genomic DNA, as was required in this study. Thus the human post-
mortem brain tissue samples were isolated from an area adjacent to the lateral ventricle 
of the parietal lobe and received in an unfixed, snap frozen state from the ―Brains for 
Dementia Research‖ network via the Newcastle Brain Tissue Resource. The use of 
brain tissue from this region was of significant interest as it is from the brain site close 
to the CVOs, which act as a port of entry for LPS into brain (Lacroix et al., 1998). 
Therefore, improving the chances of finding a molecular footprint and/or endotoxins 
(LPS) of periodontal bacterial. The cases examined did not accompany the patients‘ 
dental records, making it difficult to establish if the human donors had suffered from 
chronic periodontal disease during their lifetime.  
In order to eliminate the potential autopsy contamination of tissues from 
anaerobic periodontal pathogens in the oral cavity and in CNS post-mortem specimens 
AD cases were selected with a short post-mortem interval, whereas controls were from 
cases with a greater post-mortem interval. In addition, as mentioned previously, the 
investigation was limited to the identification of the red complex pathogens. This was 
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vital to avoid any ambiguities occurring between all other bacteria that are likely to be 
on the cadaver during post-mortem examination if the specimens become contaminated 
at any stage during handling. This study is only the second investigation to be 
performed on human post-mortem tissues in relation to periodontal pathogens and hence 
remains original.   
Analysis of genomic DNA from all AD and control cases using PCR with 
universal bacterial primer sets (Paster et al., 2001) (as stated in materials and methods 
section 2.2.7) failed to identify the pathogens of interest.  There could be several 
reasons for this finding, for example the bacterial DNA may have degraded hence could 
not be amplified. Despite the absence of the periodontal pathogens of interest, bacterial 
DNA of irrelevant species including M. aurea (strain AP13), P. oulorum and P. acnes 
was identified, demonstrating that the technique was working.  
M. aurea was detected in one case (AD case 1) and was concluded to be the 
result of a common water contaminant. On the other hand, P. oulorum is an example of 
a true oral bacterium which was detected in the brain. P. oulorum was identified in two 
cases (1 AD case and 1 non-AD control) and is an oral bacterium originally isolated 
from the subgingival biofilm of an individual with moderate periodontitis (Shah et al., 
1985). P. oulorum is commonly implicated in bacterial ―plaque‖ above the gingivae that 
leads to gingivitis. It is not surprising to find this bacterium in the brain as it has 
previously been reported in association with abscess formation in the CNS (Mylonas et 
al., 2007), although, it has not to date been associated with dementia. 
In addition, P. acnes was identified in three cases (2 AD cases and 1 non-AD 
control). P. acnes is a Gram positive, slow-growing bacterium which primarily forms 
part of the normal skin flora (Grice and Segre, 2011). P. acnes is also linked to the oral 
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cavity, large intestine, conjunctiva and the external ear canal (Funke et al., 1997; Grice 
and Segre, 2011; Portillo et al., 2013). Its presence within the brain, though surprising, 
is biologically plausible as P. acnes is an opportunistic pathogen and has been 
implicated as a cause of a number of CNS infections such as brain abscess (Maniatis 
and Vassilouthis, 1980; Cohle et al., 1981; Brenson and Bia, 1989), subdural and 
epidural empyema (Yoshikawa et al., 1975), and meningitis (Beeler et al., 1976; 
Schlesinger and Ross, 1977; Everett et al., 1976). Ramos et al., (1995) demonstrated 
that the pathogenicy of P. acnes may be the cause of severe CNS infections, reporting 
such events in a number of cases over a five year period. In addition, Kranick et al., 
(2009) presented a case whereby P. acnes complicated neurosurgical procedures 
resulting in abscess formation 10 years post-surgery.  
Although the identification of both P. orulum and P. acnes was an interesting 
result and potentially related to periodontal disease, it was of no statistical significance 
as they were detected in both AD and non-AD brain specimens. Therefore, it would be 
incorrect to speculate any link to the development or pathology of AD. Also, as 
mentioned previously, this study was focused solely on the three ‗red complex‘ bacteria 
(T. denticola, T. forsythia and P. gingivalis) hence, these findings were beyond the 
initial scope of the research.  
Further assessment for the presence of the major periodontal bacteria was 
performed using immunofluorescence labelling with a number of antibodies specific for 
P. gingivalis, T. denticola and T. forsythia. All antibodies were tested on cryo-sections 
taken from all AD and non-AD cases using indirect immunofluorescence see materials 
and methods section 2.2.8. The T. forsythia  and T. denticola  antibodies poorly detected 
the native antigen on whole cells and subsequently all results from brain tissue sections 
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were negative, hence, further assessment of these organisms was not pursued during this 
stage of the project as these were the only antibodies accessible.  
On the other hand the anti-P. gingivalis antibodies intensely labelled P. 
gingivalis antigen both on whole cells and within brain tissue sections. Immunolabelling 
was performed using the monoclonal anti-P. gingivalis (clone 1B5) antibody (Curtis et 
al., 1999). This antibody is well characterized (Curtis et al., 1999) and is specific for P. 
gingivalis LPS and gingipain epitopes (Paramonov et al., 2005). Positive 
immunolabelling for P. gingivalis (clone 1B5) was observed in 4 out of 10 AD cases on 
the surface of glial cells and as extracellular aggregates within the human AD brain 
tissue. As this monoclonal antibody (Curtis et al., 1999) detects both P. gingivalis LPS 
and gingipains further labelling with two additional monoclonal antibodies specific for 
gingipains was performed (Curtis et al., 1996; Marcotte et al., 2006). The subsequent 
immunofluorescent labelling for gingipains was negative on all tissue sections thereby 
suggesting that it was LPS of P. gingivalis labelling positive in the human tissue 
sections.  
In addition to the cellular labelling, extracellular aggregates of ―LPS‖ were 
frequently observed within the brain tissue as well as in association with a number of 
blood vessels and intra-venous sinuses, potentially supporting the vascular systemic 
route of entry to the CNS. Although, further investigation would be required to confirm 
this route of entry supporting data comes from studies which have confirmed that 
periodontal pathogens P. gingivalis and T. denticola can be found in the human vascular 
system. Both P. gingivalis and T. denticola have been identified in the walls of human 
coronary arterial tissues (Chiu, 1999; Haraszthy et al., 2000) and in atheromatous 
plaques (Cavrini et al., 2005; Kozarov et al., 2005). The more virulent forms of P. 
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gingivalis (FDC 318) have the ability to adhere to erythrocytes for innate immune 
evasion (Chiu, 1999; Haraszthy et al., 2000; Cavrini et al., 2005; Belstrøm et al., 2011) 
as well as gaining advantage for transportation to remote body organs (Belstrøm et al., 
2011) further supporting a vascular route of entry. Also the human brain tissue used for 
this study was isolated from close proximity to the CVOs, this area being void of the 
blood-brain barrier hence, it is biologically plausible that the LPS of P. gingivalis may 
have exploited this route to enter the CNS (Lacroix et al., 1998). 
In order to clarify the findings in human tissue an in vitro investigation was 
performed whereby the human glial cell line (SVGp12) was treated with P. gingivalis 
culture supernatant containing a battery of molecular determinants, including endotoxin 
(LPS) and extracellular cysteine proteases (gingipains) (Holt et al., 1999) as well as 
metabolites such as butyric and propionic acids. Immunolabelling, using the same 
monoclonal antibodies for P. gingivalis, demonstrated that LPS was adsorbed on the 
surface membrane of the astroglial cell line whereas gingipains demonstrated an 
intracellular localisation (Scragg et al., 2002). This observation supports the results 
from the human brain tissue which demonstrated that LPS was adsorbed on the surface 
membrane of glial cells, as was validated by the anti-CD14 receptor antibody labelling 
of tissue sections.  
These findings were confirmed by performing complementary immunoblot 
analysis using the same (anti-P. gingivalis clone 1B5) antibody (Curtis et al., 1999; 
Paramonov et al., 2005). Immunoblotting demonstrated that the culture supernatant 
from P. gingivalis ATCC 33277 contained LPS, thus supporting the previously 
published literature from P. gingivalis W50 (Curtis et al., 1999; Paramonov et al., 
2005). Further immunoblotting performed on the cell cultures treated with P. gingivalis 
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culture supernatant demonstrated a characteristic LPS laddering pattern, thereby 
supporting the immunofluorescent labelling results. An additional immunoblot analysis 
(using the same conditions) conclusively revealed that it was LPS, and not gingipains, 
from P. gingivalis that was detected in 4 out of 10 AD brain specimens. LPS was absent 
from the control brain tissues and the remaining six AD cases when analysed by 
immunoblotting (using identical conditions) despite the post-mortem interval extending 
to 43 hours. Therefore, all immunoblotting results were consistent with the 
immunofluorescent labelling data performed on the same tissue. With 4 out of 10 AD 
cases labelling positive for P. gingivalis LPS the non-parametric Mann-Whitney U test 
demonstrated that, even from this small series, the data reached statistical significance 
(p = 0.029) when compared with the non-AD controls.  
In addition to the detection of the red complex bacteria and their products the 
number of Aβ plaques present in the brain specimens was assessed. Interestingly the 
highest number of plaques were detected in the four brains which were positive for P. 
gingivalis LPS. A number of researchers have found bacteria (Hammond et al., 2010) 
and viruses associated with Aβ deposits and tau positive NFTs (Itzhaki and Wozniak, 
2008; Balin et al., 2008; Miklossy et al., 2011) in late-onset AD brains. However, in 
this study P. gingivalis LPS was only detected on glial cells and not in association with 
Aβ plaques or NFTs. Glial cells participate in the innate immune responses in relation to 
infection in the brain. It has been suggested that inflammatory processes may lead to 
increased production of Aβ protein and its deposition in the form of senile plaques seen 
in AD brain (Eikelenboom et al., 1991; Miklossy, 2006), however, the mechanisms 
involved remain elusive.  
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LPS is a potent activator of the innate immune response via the CD14/TLR 
receptors on the surface of a number of cells within the CNS, resulting in the production 
of inflammatory mediators. When challenged with systemic LPS microglia demonstrate 
an activated phenotype capable of mounting an innate immune response to combat the 
destructive effects of the extrinsically derived endotoxins. Continued exposure of 
microglia to both circulating systemic LPS due to concurrent infections (for example 
bronchopneumonia, urinary tract and oral infections) together with pathogens entering 
the brain results in the continual activation of microglia and the adoption of a 
hypersensitive ‗activated‘ phenotype. The LPS hyper-sensitised microglia increase 
synthesis of TNF-α, IL-1β, IL-6, complement factors, TLRs 2 and 4 and nitric oxide 
that release free radicals and ROS (Boje and Arora, 1992; Lodge and Sriram, 1996; 
Floyd, 1999;  Laflamme and Rivest, 2001; Ye and Johnson, 2001; Gasque, 2004;  
Godbout et al., 2005) and increase tissue damage.Therefore, the results from this 
investigation still has relevance to neurodegeneration, and potentially AD, on the basis 
that LPS is a powerful stimulator of the innate immune system, suggesting that bacteria 
and/or their degradation products may enhance a cascade of events leading to amyloid 
deposition in AD (Miklossy et al., 2006). In addition, the inflammatory signals that 
initiate phagocytosis by microglia are also driven by Aβ and involve the CD14 and 
TLR2 and TLR4 signalling (Kopec and Carroll 1998; Fassbender et al., 2004; Walter et 
al., 2007; Reed-Geaghan et al., 2009). Also, bacterial products such as LPS and 
peptidoglycan not only elicit a variety of proinflammatory responses they have also 
been shown to induce amyloidosis (AD pathology) in vitro and in vivo (Picken, 2000; 
Hauss-Wegrzyniak and Wenk, 2002). The mechanism by which LPS and bacterial 
toxins induced amyloidoisis remains unclear although it has been proposed that the 
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changes may be influenced by changes in secretase activity, specifically the inhibition 
of α-secretase activity (Lee et al., 2008). 
  Another hypothesis potentially linking LPS to Aβ plaque formation is that Aβ is 
acting as an AMP to counteract infections (Soscia et al., 2010). Here, Aβ functions as 
part of the early innate immune defence mechanisms that mediate the innate and 
adaptive immune responses (Zaiou, 2007). The main target for AMPs is the pathogen 
cell membrane, as most AMPs are cationic (Yeaman and Yount, 2003). AMPs undergo 
electrostatic interactions with negatively charged molecules to penetrate bacterial cell 
walls, including anionic lipids and LPS (Yeaman and Yount, 2003). They then invade 
the lipid bilayer creating trans-membrane pores through which leakage of ions, 
metabolites and cytoplasmic components, dissipation of electrical potentials, and 
microbial cell death takes place (Kawahara et al., 2011). This hypothesis suggests the 
involvement of a pathogenic precursor in the initiation of Aβ release before 
inflammation becomes detectable. Although, further investigations would be required to 
confirm any relationship between the presence of P. gingivalis LPS and Aβ plaques, 
preferably in tissue sections from the primary regions bearing neuropathology (i.e. the 
hippocampus). 
 These results indicate that the brain of AD patients may be at a greater risk of 
secondary chronic infection from the periodontal pathogen P. gingivalis which has long 
been implicated in chronic and severe adult periodontitis (Slots and Genco, 1984; Slots 
and Lostgarten, 1988). If the dental records of individuals, whose brain specimens 
examined here, were available, it would have been possible to delineate all those with 
periodontal disease, hence, harbouring P. gingivalis infection. Alternatively, if all of the 
AD cases examined had suffered from periodontal disease but only a small proportion 
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indicated the presence of LPS (4 out of 10), it would have been possible to conclude 
whether it is only the highly virulent pathogens that translocate to the brain. Although 
due to the absence of these records no comment on any direct relationship of 
periodontal disease with AD during life can be made. However, due to the poor memory 
exhibited by AD patients, these individuals may forget to maintain optimal oral hygiene 
which during advanced stages of AD would be expected to deteriorate even further 
(Arai et al., 2003; Henry and Wekstein, 1997; Shimazaki et al., 2001; Philip et al., 
2012). Therefore, without a full dental history this study is unable to determine if the 
periodontal infection leading to P. gingivalis LPS in the brain of AD individuals is due 
to the increased rates of periodontal infection associated with the elderly or the ongoing 
inflammatory burden present in individuals with periodontal disease throughout life. 
The fact that there was no contamination with the red complex pathogens in the 
non-AD controls (despite the extended post-mortem interval) aids the validation of the 
use of post-mortem brain tissue for such investigations. The use of post-mortem brain 
tissue was previously considered to be potentially flawed due to the possibility of the 
spread of bacteria following death. Hence the autopsy contamination of tissues from 
anaerobic periodontal pathogens in the oral cavity and the CNS in post-mortem 
specimens can be excluded.  
Despite the importance of the study using human post-mortem brain tissue to 
establish a potential link between periodontal disease and AD, there are a number of 
limitations associated with using human tissue. For example, the inability to control for 
confounding factors such as smoking status and lifestyle choices, also the brain tissue 
available for research into AD is limited. Therefore, to further the investigation there is 
need for research using animal models. This study was performed as a collaboration 
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with the University of Florida, where researchers have developed a number of animal 
models of established periodontal disease (Kesavalu et al., 2007; Verma et al., 2010; 
Rivera et al., 2013; Chukkapalli et al., 2014) providing an opportunity to not only 
investigate if periodontal pathogens can access the CNS, but also the lesion caused by 
periodontal disease infections, either via a direct or systemic route while controlling for 
any confounding factors. 
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Chapter 3:  
Identification of periodontal pathogens and/or their 
virulence factors in the brains of ApoE
null
 mice induced 
with periodontal disease. 
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3.1. INTRODUCTION 
As is apparent from the introducing chapter, a link between periodontal disease and AD 
is proposed and is thought to be via the major periodontal pathogens such as T. 
denticola, P. gingivalis, and T. forsythia. Several studies suggest that periodontal 
disease-associated bacteria can penetrate gingival JE, enter the blood stream, and induce 
a transient bacteremia to affect the pathology of distant organs including the brain. In 
the previous chapter, LPS from the oral pathogen P. gingivalis, was shown to access the 
brain. In this chapter, proof of concept is explored by taking the rare opportunity to 
enhance the initial study (using human AD brain tissue specimens) by utilising an 
experimental periodontal disease animal model. This eliminates the autolytic artifacts 
associated with human post-mortem delay allowing the preservation of the brain tissue 
for both DNA isolation and histological investigations. The results from this chapter are 
published in the journal of Alzheimer‘s disease (Poole et al., 2014).  
 
3.2. MATERIALS AND METHODS 
3.2.1. In vivo animal model c/o the University of Florida  
Eight-week old male ApoE
null 
male mice (strain B6.129P2-Apoe
tm1Unc/J
) were obtained 
from Jackson Laboratories, Bar Harbor, ME, USA and acclimated as described by 
Rivera et al., (2013). The animal model was established using the methods described by 
Chukkapalli et al., (2014). The strains of bacteria used were P. gingivalis (strain 
FDC381), T. denticola (ATCC 35404), T. forsythia (ATCC 43037) and F. nucleatum 
(ATCC 49256). Briefly, at 11 weeks of age mice were randomly assigned to sham 
infected, mono infected (P. gingivalis, T. denticola, T. forsythia) or polymicrobial 
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infected groups (n = 24 for each group). Note, in the polymicrobial infection F. 
nucleatum was added in addition to the red complex pathogens (P. gingivalis, T. 
denticola, T. forsythia) due to its function as a bridging bacteria in biofilm formation. In 
keeping with the human study the presence of only the three red complex pathogens 
was investigated. Antibiotic pre-treatment was used to reduce the amount of indigenous 
murine oral flora to facilitate colonization by the human periodontal pathogens being 
given for infection.  Human periodontal pathogens do not readily colonize the mouse 
oral cavity, and reducing the mouse normal flora load is thought to reduce the 
competition for the human bacteria, and so facilitate colonization. There was a 3 day 
period following antibiotic administration in which the mice were provided antibiotic-
free water to remove all traces of the antibiotic from their systems. For polymicrobial 
infection, P. gingivalis was mixed with an equal quantity of T. denticola for 5 min; 
subsequently, T. forsythia was added to the culture tubes containing P. gingivalis and T. 
denticola, and cells were mixed thoroughly and allowed to interact for an additional 5 
min. P. gingivalis, T. denticola, and T. forsythia were then mixed with F. nucleatum 
followed by mixing with an equal volume of 4% (w/v) sterile carboxymethylcellulose 
(CMC) in PBS, this mixture was then used for oral infection (5×10
9
 bacteria/ mL) in 
ApoE
null
 mice. For mono infections 10
9
 P. gingivalis/T. denticola/T.forsythia cells in 
RTF-4% CMC were used to infect the appropriate mice. Mice were orally inoculated by 
gavage for four consecutive days per week every third week for four (12 week) or eight 
(24 week) weeks of infection.  
Following infections, animals were sacrificed (n = 12/group at 12 weeks and n= 
12/group at 24 weeks post infection) and several tissues (aorta, heart, brain, pancreas, 
lymph nodes, serum, jaw bones) were collected for analysis to evaluate periodontal 
disease and atherosclerosis in the University of Florida, USA. From these the brains of 
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the mice were intended for use in this study. The brain was removed from its skull and 
separated into two. One cerebral hemisphere was snap frozen immediately for molecular 
analyses and stored in RNA-later and the other hemisphere was immerse fixed in 10% 
neutral buffered formalin for histological analysis.  
This investigation is a collaboration with the University of Florida and UCLan 
(MTA ref no. A10415). Ethical approval was obtained from the animal projects 
committee at UCLan (UK) for research on animal tissues as secondary users (ref no 
RE/11/01/SS), as well as in accordance with the approved protocol guidelines (Protocol 
# 201004367) set forth by the Institutional Animal Care and Use Committee (IACUC) 
of the University of Florida. The University of Florida has an Assurance with OLAW 
(Office of Laboratory Animal Welfare) and follows PHS (Public Health Service) policy, 
the Animal Welfare Act and Animal Welfare Regulations, and the Guide for the Care 
and Use of Laboratory Animals. The University of Florida is also AAALAC 
(association for the assessment and accreditation of laboratory animal care international) 
accredited. 
Evaluation of selected oral pathogens (excluding F. nucleatum), accessing the brain and 
the subsequent innate immune responses of CNS cells following mono and 
polymicrobial infections were examined at UCLan, UK. The specimens were sent to 
UCLan in compliance with rules and regulations for their import into the UK (certified 
by Defra ref nos: IMP/GEN/2010/12 (unfixed tissues); IMP/GEN/2011/03 (formalin 
fixed); IMP/GEN/2008/03 (DNA, protein, antibodies etc.). The specimens were sent 
within 48 hours of collection via International FedEx courier service to UCLan, UK 
either on dry ice (Frozen specimens) or at room temperature (suspended in 10 % 
formalin). All specimens, on receipt were labelled with the University of Florida‘s code 
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denoting the group number (1, 2, 3 or 5), tissue (brain), duration of infection (12 and 24 
weeks) and number of the animal (1-12). As per agreed rules and regulations of the 
MTA, following receipt, UCLan codes were allocated to each specimen. Thereafter, all 
data recorded about those specimens was identified by the UCLan code. The 
experimenter was completely unaware of the group number corresponding to each 
infected and control group (P. gingivalis, T. forsythia, T. denticola, mono and 
polymicrobial sham infected and polymicrobial infected). They are identified here for 
the purposes of reporting. From here onwards the time points will be referred to as 12 
and 24 weeks, this is the time period from the initial infection; 12 and 24 weeks i.e. a 
total of four infections and eight infections respectively. 
All tests described in this chapter were performed on the frozen brain specimens. 
 
3.2.2. Source of antibodies  
Primary antibodies: As per chapter 2 (section 2.2.2). 
3.2.3. Source of all other reagents 
In addition to those in chapter 2 section 2.2.5; 5x HF buffer ThermoScientific; dNTPs 
Fisher Scientific; Phusion High-Fidelity Hot start II DNA Taq Polymerase 
ThermoScientific; Glycine Fisher Scientific; T. denticola (Dr Daniel Miller, USA); and 
T. forsythia (Dr. Graham Stafford, University of Sheffield) positive controls for 
immunoblotting. 
 
 
 
143 
 
 
3.2.4. Molecular Biology 
i) Genomic DNA Isolation 
Genomic DNA was isolated for all groups (both mono and polymicrobial infected) at 
both time points as per human tissue (see section 2.2.7). Approximately 25 mg of mouse 
brain, taken from the periventricular regions, was digested overnight in proteinase K, 
followed by phenol/chloroform extraction and ethanol precipitation. The exact DNA 
yield of each sample was quantified using the Nanodrop 1000 spectrophotometer 
(ThermoScientific) and all DNA was stored in sterile PCR grade Eppendorf® tubes at -
20 °C until use. 
ii) PCR 
Specific bacterial genes for periodontal (red complex) pathogens 
For amplification of specific bacterial genes (T. denticola, T. forsythia and P. 
gingivalis) the primer sets from Figuero et al., (2011; P. gingivalis forward: 
AGGCAGCTTGCCATACTGCG; P. gingivalis reverse: 
ACTGTTAGCAACTACCGATGT; T. forsythia forward; 
GCGTATGTAACCTGCCCGCA; T. forsythia reverse: 
TGCTTCAGTGTCAGTTATACCT) and Rivera et al., (2013; T. denticola forward: 
TAATACCGAATGTGCTCATTTACAT; T. denticola reverse; 
CTGCCATATCTCTATGTCATTGCTCTT) were used. The PCR reaction consisted of 
4 μl 5x HF buffer, 0.5 μl dNTPs, 0.5 μl each primer (10 µM forward and reverse), 0.2 μl 
Phusion High-Fidelity Hot start II DNA Taq Polymerase, 250 ng sample DNA and 
sterile RNA/DNA free water to a final 20 μl volume. The negative controls contained 
all PCR reagents except for the sample DNA. The positive controls contained all PCR 
reagents together with DNA from P. gingivalis, T. denticola, or T. forsythia dependent 
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on the primer sets being used. The expected product sizes for each primer set are as 
follows: P. gingivalis – 404 bp, T. denticola – 860 bp and T. forsythia - 641 bp. 
The PCR parameters used were as follows: 
T. denticola  
98 °C for 3 mins, 28 cycles of; 98 °C for 10 seconds, 60 °C for 30 seconds, 72 °C for 35 
seconds, followed by 72 °C for 10 mins.  
T. forsythia 
98 °C for 3 mins, 28 cycles of; 98 °C for 10 seconds, 56 °C for 30 seconds, 72 °C for 30 
seconds, followed by 72 °C for 10 mins.  
P. gingivalis 
98 °C for 3 mins, 28 cycles of; 98 °C for 10 seconds, 58 °C for 30 seconds, 72 °C for 25 
seconds, followed by 72 °C for 10 mins.  
Following visualisation of the PCR products by electrophoresis (1.5 % agarose gel post 
stained using ethidium bromide) any amplified product was purified using 
MicroCLEAN according to supplier‘s instructions (Eluted in 20 μl volume of AE 
buffer). 
iii) Cloning and sequencing 
In the event of a positive amplification cloning of the PCR product (ligation, 
transformation, analysis, plasmid isolation) followed by sequencing, purification and 
capillary electrophoresis of sequencing products were performed as for the human 
specimens (section 2.2.7). 
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3.2.5. Immunofluorescent labelling with specific bacterial antibodies 
i) Cryo-sectioning  
Cryo-sectioning was performed on all mouse brains from all groups at both time points 
Where possible using the temporal lobe region (to include the hippocampus). 
ii) Bacterial cell smears 
 In addition, bacterial cell smears (P. gingivalis, T. denticola and T. forsythia) on 
microscope slides were also prepared to characterise the specific antibodies for each 
bacterial species by immunofluorescent labelling (chapter 2, section 2.2.8). 
iii) All controls  
All mouse brain tissue sections included omission of the primary antibody (to check 
specificity of the secondary antibody) alongside the inclusion of the primary antibody 
on the sham infected groups for both polymicrobial and mono infections (12 and 24 
weeks); hence, all groups were treated identically. The bacterial cell smears acted as 
positive controls. 
iv) Immunofluorescent labelling 
Immunolabelling was performed using an overnight, indirect method as described for 
the human brain tissue (section 2.2.8) for the immunodetection of bacterial virulence 
factors. In brief sections were fixed in cold Analar grade acetone for 5 mins and any 
tissue associated endogenous fluorescence was quenched for 10 mins in 50 mM 
glycine/PBS, followed by 3x 5 min washes in distilled water. Sections were equilibrated 
in 0.01 M PBS for 5 min and then blocked in PBS containing 0.01 % normal serum 
(goat or rabbit depending on the nature of the secondary antibody) and 2 % tween 20. 
The sections were incubated overnight at 4 °C in the primary antibody (rat anti-T. 
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denticola (FhbB protein) (1/5000), rabbit anti-T. forsythia (s-layer protein) (1/20,000), 
mouse anti-P. gingivalis (Clone 1B5) (1/10).  The secondary detection was then 
performed using the appropriate secondary antibody (goat anti-mouse FITC (1/200), 
Alexa Fluor® 488 goat anti-mouse IgG1 (γ1) (1/1000), Alexa Fluor® 488 goat anti-rat 
IgG (H+L) (1/1000), goat anti-rabbit FITC (1/200) diluted in the blocking solution as 
before. Following further washes in PBS for 3x 5 min, sections were mounted under a 
glass coverslip using PI Vectashield® Mounting Media. Labelling was observed and 
images were captured using the 510 series Zeiss confocal microscope (Carl Zeiss Ltd). 
3.2.6. Biochemistry 
i) Tissue lysates  
Tissue lysates were prepared from all mice brains (polymicrobial and mono infected at 
both time points) as for the human tissue (see section 2.2.9) from a section 
(approximately 25 mg) of unfixed tissue stored in RNA-later. The final lysates were 
collected in pre-labelled tubes and stored at -20 °C until required. 
ii) Controls 
The controls used when immunoblotting for P. gingivalis virulence factors were 
identical to those used in the human study (see section 2.2.9). In addition, the sham 
infected group of mice were tested using identical conditions to all infected mice. When 
immunoblotting for T. denticola and T. forsythia the positive controls used were obtain 
via gift (see sources of all reagents section 3.2.3). 
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iii) Protein assay 
Total protein concentrations of all lysates (cells, tissue and controls) were determined 
using the Bradford colorimetric assay (Bradford 1976) as described for the human tissue 
(see section 2.2.9).  
iv) Immunoblot 
Immunoblotting using anti- P. gingivalis (1B5) was carried out as described for the 
human study (see section 2.2.9). However, for the in vivo work 40 µg of protein was 
loaded per lane. The same protocol was used for the other antibodies except 7.5 % gels 
were used for rabbit anti-T. forsythia, (against the s-layer) and 15% gels used for the rat 
anti-T. denticola ATCC 35405 antibody (against FhbB protein). The protocol was 
identical to that used for anti-P. gingivalis 1B5 (see section 2.2.9) except the primary 
antibodies were rabbit anti-T. forsythia (s-layer protein) (1/20,000) and rat anti-T. 
denticola ATCC 35405 antibody (against FhbB protein) (1/10,000) diluted in blocking 
solution (5 % w/v skimmed milk/PBS). HRP - conjugated secondary antibodies were 
used (goat anti-mouse HRP; 1/20,000), goat anti-mouse IgG1 HRP (1/2,000), goat anti-
rat HRP (1/5,000), goat anti-rabbit HRP (1/80,000)) with all antibodies being diluted in 
blocking solution (5 % w/v skimmed milk/PBS) as before.  
3.2.7. Statistical analysis 
As per human specimens (see section 2.2.10) 
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3.3. RESULTS 
3.3.1. Molecular biology 
i) Mono bacterial infections of ApoEnull mice  
T. denticola 
Molecular profiling using primers specific for T. denticola was negative when 
performed on DNA isolated from the sham infected group of mice, at both 12 (Fig. 
3.1a) and 24 weeks (Fig. 3.1b). The positive control in both cases (lane 3, Fig. 3.1a and 
b) produced a band with the expected fragment size (860 bp) and the negative control 
remained clear (lane 2, Fig. 3.1a and b). The same technique was employed on the DNA 
isolated from the brains of ApoE
null 
mice infected with T. denticola (Fig. 3.2) this also 
failed to demonstrate the presence of T. denticola within the specimens at both time 
point (Fig. 3.2a and b). Although the T. denticola positive control was detected clearly 
as shown by a bright positive band of the correct size (860 bp) (lane 3, Fig. 3.2a and b). 
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Figure 3.1: T. denticola PCR on mono sham infected ApoE
null 
mice A) PCR on DNA 
isolated from sham infected mice at 12 weeks; lane 1 is the 100 bp marker, lane 2 is the 
negative control, lane 3 is the positive control containing T. denticola DNA, lanes 4-15 
contain DNA isolated from 12 week sham infected ApoE
null
 mice brains (cases 1-12). 
B) PCR performed on DNA isolated from sham infected mice at 24 weeks; lanes 1-3 are 
as described for A, lane 4 was left empty, lanes 5-12 correspond to 24 week sham 
infected mice brains 1-8, and lanes 13-15 correspond to 24 week sham infected mice 
brains 10-12 (note case 9 is missing). 
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Figure 3.2: T. denticola PCR on mono T. denticola infected ApoE
null
 mice A) PCR on 
DNA isolated from T. denticola infected mice at 12 weeks; lane 1 contains the 100 bp 
marker, lane 2 is the negative control, lane 3 is the positive control containing T. 
denticola DNA, lanes 4-15 contain DNA isolated from 12 week T. denticola infected 
ApoE
null
 mice brains (cases 1-12). B) PCR performed on DNA isolated from T. 
denticola infected mice at 24 weeks; lanes 1-3 are as described for A, lanes 4-14 
correspond to DNA isolated from 24 week T. denticola infected ApoE
null
 mice brains 2-
12 (note case 1 is missing). 
T. forsythia 
The sham infected mouse brains were negative when tested (using molecular 
techniques) for the presence of T. forsythia DNA at both 12 (Fig. 3.3a) and 24 (Fig. 
3.3b) week time points. The negative control remained negative and the positive control 
produced the correct band at 641 bp as expected (Fig. 3.3, lanes 2 and 3 respectively). 
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Identical molecular techniques also provided consistently negative results when tested 
on the DNA isolated from the brains of ApoE
null
 mice orally infected with T. forsythia 
(Fig. 3.4) and both 12 and 24 week time points (Fig. 3.4a and b respectively), despite 
the positive control showing a clear band of the correct size.   
 
Figure 3.3: T. forsythia PCR on mono sham infected ApoE
null
 mice A) PCR on DNA 
isolated from sham infected mice at 12 weeks; lane 1 represents the 100 bp marker, lane 
2 contains the negative control, lane 3 is the positive control containing T. forsythia 
DNA, lanes 4-15 contain DNA isolated from 12 week  sham infected mice brains (cases 
1-12). B) PCR performed on DNA isolated from mono sham infected mice at 24 weeks; 
lanes 1-3 are as described for A, lanes 4-15 contain DNA isolated from 24 week sham 
infected ApoE
null
 mice brains 1-12. 
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Figure 3.4: T. forsythia PCR on mono T. forsythia infected ApoE
null 
mice A) PCR on 
DNA isolated from T. forsythia infected mice at 12 weeks; lane 1 is the 100 bp marker, 
lane 2 contains the negative control, lane 3 is the positive control (containing T. 
forsythia DNA), lanes 4-15 contain DNA isolated from 12 week T. forsythia mono 
infected ApoE
null
 mice brains (cases 1-12). B) PCR performed on DNA isolated from T. 
forsythia mono infected mice at 24 weeks; lanes 1-3 are as described for A, lanes 4-15 
contain to DNA isolated from 24 week T. forsythia infected ApoE
null
 mice brains 1-12. 
P. gingivalis 
The molecular profiling failed to demonstrate the presence of genomic DNA from P. 
gingivalis when analysing the  DNA isolated from sham infected ApoE
null
 mice at both 
12 and 24 week time points; figure 3.5 a and b respectively. However using identical 
molecular methodologies the PCR with P. gingivalis specific bacterial gene primers 
demonstrated 6 out of 12 ApoE
null
 mice brain specimens contained P. gingivalis 
genomic DNA at 12 week time point (Fig. 3.6a), which further increased to 9 out of 12 
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at 24 weeks  (Fig. 3.6b). These results are highly significant when analysed by the non-
parametric Mann Whitney-U test, P values are 0.006 at 12 weeks and 0.0001 at the 24 
week time point.  
 
 
Figure 3.5: P. gingivalis PCR on mono sham infected ApoE
null
 mice. A) PCR on DNA 
isolated from mono sham infected mice sacrificed at 12 weeks; lane 1 represents the 100 
bp marker, lane 2 was left empty, lane 3 contains the negative control, lane 4 is the 
positive control containing P. gingivalis DNA, lane 5 was left empty, and lanes 6-17 
contain DNA isolated from 12 week sham infected mice brains (cases 1-12). B) PCR 
performed on DNA isolated from mono sham infected mice at 24 weeks; lane 1 
represents the 100 bp marker, lane 2 was left empty, lane 3 contains the negative 
control, lane 4 was left empty, lane 5 is the positive control containing P. gingivalis 
154 
 
 
DNA, lane 6 was left empty, and lanes 7-17 contain DNA isolated from 24 week sham 
infected mice brains (cases 1-8 and 10-12). 
 
 
Figure 3.6: P. gingivalis PCR mono P. gingivalis infected ApoE
null 
mice A) PCR on 
DNA isolated from P. gingivalis infected mice at 12 weeks; lane 1 is the 100 bp marker, 
lane 2 was left empty, lane 3 contains the negative control, lane 4 is the positive control 
(containing P. gingivalis DNA), lane 5 was left empty, and lanes 6-17 contain DNA 
isolated from 12 week P. gingivalis mono infected ApoE
null
 mice brains (cases 1-12). 
Positive results are seen in lanes 6, 7, 10, 13, 14 and 16; corresponding to animals 1, 2, 
5, 8, 9 and 11 from 12 week ApoE
null
 mice orally infected with P. gingivalis. B) PCR 
performed on DNA isolated from P. gingivalis mono infected mice at 24 weeks; lanes 
1-3 are as described for A, lane 4 was left empty, lane 5 is the positive control (P. 
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gingivalis DNA), lanes 6-17 contain to DNA isolated from 24 week P. gingivalis 
infected ApoE
null
 mice brains 1-12. Positive results are seen in lanes 7, 8, 9, 10, 11, 14, 
15, 16 and 17; corresponding to animals 2-6 and 9-12 from ApoE
null 
mice orally infected 
with P. gingivalis, sacrificed after 24 weeks. 
ii) Polymicrobial infections of ApoEnull mice  
T. denticola 
As for the mono infections, molecular techniques failed to detect the presence of DNA 
from T. denticola from the polymicrobial sham infected ApoE
null
 mice at either time 
points (12 and 24 weeks; Fig. 3.7a and b respectively). The positive control consistently 
produced the expected band (lane 3, Fig.  3.7a and b) and the negative control lane 
remained clear (lane 2, Fig. 3.7a and b). The DNA isolated from the brain of ApoE
null
 
mice given a polymicrobial oral infection were also negative when tested for T. 
denticola DNA (Fig. 3.8) at both 12 (Fig. 3.8a) and 24 (Fig. 3.8b) week time points. 
Again the controls remained consistent (lanes 3 and 4 Fig. 3.8 a and b)  
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Figure 3.7: T. denticola PCR on polymicrobial sham infected ApoE
null 
mice A) PCR on 
DNA isolated from polymicrobial sham infected mice at 12 weeks; lane 1 is the 100 bp 
marker, lane 2 is the negative control, lane 3 is the positive control containing T. 
denticola DNA, lanes 4-15 contain DNA isolated from 12 week sham infected 
(polymicrobial) ApoE
null
 mice brains (cases 1-12). B) PCR performed on DNA isolated 
from sham infected (polymicrobial) mice at 24 weeks; lanes 1-3 are as described for A, 
lanes 4-15 correspond to 24 week polymicrobial sham infected mice brains 1-12. 
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Figure 3.8: T. denticola PCR on polymicrobial infected ApoE
null
 mice A) PCR on DNA 
isolated from polymicrobial infected mice sacrificed at 12 weeks; lane 1 contains the 
100 bp marker, lane 2 was left empty, lane 3 is the negative control, lane 4 is the 
positive control containing T. denticola DNA, lane 5 was left empty, lanes 6-16 contain 
DNA isolated from 12 week polymicrobial infected ApoE
null
 mice brains (cases 1-11). 
B) PCR performed on DNA isolated from polymicrobial infected mice at 24 weeks; 
lanes 1-5 are as described for A, lanes 6-16 correspond to DNA isolated from 24 week 
polymicrobial infected ApoE
null
 mice brains. 
 
T. forsythia 
Again, no bands were detected for the presence of T. forsythia DNA in the brain 
specimens collected from polymicrobial sham infected ApoE
null
 mice at either 12 or 24 
week time points (Fig. 3.9 a and b respectively). Also, DNA isolated from the 
polymicrobial infected animals failed to demonstrate the presence of T. forsythia DNA 
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at both 12 (Fig. 3.10a) and 24 (Fig. 3.10b) week infections. In all cases the positive 
controls produced the expected band at 641 bp and the negative control lanes remained 
clear. 
 
 
 
Figure 3.9: T. forsythia PCR on polymicrobial sham infected ApoE
null 
mice. A) PCR on 
DNA isolated from polymicrobial sham infected mice at 12 weeks using T. forsythia 
specific primers; lane 1 is the 100 bp marker, lane 2 is the negative control, lane 3 is the 
positive control containing T. forsythia DNA, lanes 4-15 contain DNA isolated from 12 
week sham infected (polymicrobial) ApoE
null
 mice brains (cases 1-12). B) PCR 
performed on DNA isolated from sham infected (polymicrobial) mice at 24 weeks; 
lanes 1-3 are as described for A, lanes 4-15 correspond to 24 week polymicrobial sham 
infected mice brains 1-12. 
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Figure 3.10: T. forsythia PCR on polymicrobial infected ApoE
null 
mice. A) PCR on 
DNA isolated from polymicrobial infected ApoE
null 
mice at 12 weeks using T. forsythia 
specific primers; lane 1 is the 100 bp marker, lane 2 was left empty, lane 3 is the 
negative control, lane 4 is the positive control containing T. forsythia DNA, lane 5 was 
left empty, lanes 6-16 contain DNA isolated from 12 week polymicrobial infected 
ApoE
null
 mice brains. B) PCR performed on DNA isolated from polymicrobial infected 
mice at 24 weeks; lanes 1-5 are as described for A, lanes 6-16 correspond to 24 week 
polymicrobial infected mice brains. 
 
P. gingivalis  
As for the other periodontal bacteria, there were no positive bands for P. gingivalis 
DNA in the brains samples from sham infected group of polymicrobial infected animals 
at both time points (Fig. 3.11a and b) despite the positive controls showing a clear band 
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(lane 4, Fig. 3.11a and b). In all cases the negative control lane remained clear (lane 3, 
Fig. 3.11a and b). Specific bacterial primers failed to detect P. gingivalis DNA in the 
polymicrobial infected mice at 12 week time point (Fig. 3.12a), however by 24 weeks, 2 
out of 12 polymicrobial infected ApoE
null
 mice brain specimens demonstrated the 
presence of P. gingivalis DNA (Fig. 3.12b). The differences between the sham infected 
and the poly infected groups were not statistically significant (P > 0.05). All molecular 
biology data are summarised in table 13. 
 
 
Figure 3.11: P. gingivalis PCR on polymicrobial sham infected ApoE
null 
mice A) PCR 
on DNA isolated from polymicrobial sham infected mice at 12 weeks using P. 
gingivalis specific primers; lane 1 is the 100 bp marker, lane 2 is the negative control, 
lane 3 was left empty, lane 4 is the positive control containing P. gingivalis DNA, lane 
5 was left empty, lanes 6-16 contain DNA isolated from 12 week sham infected 
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(polymicrobial) ApoE
null
 mice brains. B) PCR performed on DNA isolated from sham 
infected (polymicrobial) mice at 24 weeks; lanes 1-5 are as described for A, lanes 6-16 
correspond to 24 week polymicrobial sham infected mice brains. 
 
Figure 3.12: P. gingivalis PCR on polymicrobial infected ApoE
null 
mice. A) PCR on 
DNA isolated from polymicrobial infected ApoE
null 
mice at 12 weeks using P. 
gingivalis specific primers; lane 1 is the 100 bp marker, lane 2 was left empty, lane 3 is 
the negative control, lane 4 is the positive control containing P. gingivalis DNA, lane 5 
was left empty, lanes 6-16 contain DNA isolated from 12 week polymicrobial infected 
ApoE
null
 mice brains. B) PCR performed on DNA isolated from polymicrobial infected 
mice at 24 weeks; lanes 1-5 are as described for A, lanes 6-16 correspond to 24 week 
polymicrobial infected mice brains. Positive results are seen in lanes 12 and 14, 
corresponding to polymicrobial infected 24 week ApoE
null
 mice 7 and 9. 
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Table 3.1: Summary of molecular results for the identification of P. gingivalis, T. 
denticola or T. forsythia in the brains of sham, mono and polymicrobial infected 
ApoE
null 
mice at both 12 and 24 weeks. 
Group  Mono infected mice Polymicrobial infected mice 
Bacterial DNA 
present 12 week 
Bacterial DNA 
present 24 week 
Bacterial DNA 
present 12 week 
Bacterial DNA 
present 24 week 
1 (P. gingivalis)  6 out of 12 
P = 0.006 
9 out of 11 
P = 0.000 
0 out of 11 2 out of 11 
2 (T. denticola)  0 out of 12 0 out of 12 0 out of 11 0 out of 11 
3 (T. forsythia)  0 out of 12 0 out of 12 0 out of 11 0 out of 11 
5 (control)  0 out of 12 0 out of 11 0 out of 11 0 out of 11 
 
Following detection by PCR the positive results for P. gingivalis DNA in the brain 
tissue specimens of ApoE
null
 mice were isolated and cloned. Positive clones were 
determined using a colony screen (Fig. 3.13) and then purified and sequenced in order 
to confirm the specificity of the primers and to determine the exact strain of P. 
gingivalis being detected. The molecular sequencing data confirmed it to be P. 
gingivalis strain FDC381 having 99-100% match with >200 bases (see table 14). 
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Figure 3.13: Colony screen following cloning of PCR product from P. gingivalis 
infected ApoE
null
 mice. Expected size for a positive colony is approximately 500 bp. 
Lane 1 contains the 100 bp marker, lanes 2-17 contain single colonies isolated 
following cloning. Positive results are seen in lanes 2, 7, 8 and 11-16.  
Table 3.2: Sequencing results of PCR product detected by P. gingivalis specific primers 
on brain tissue from mono P. gingivalis infected ApoE
null
 mice 
Case sequenced Sequence length Identification E value Nucleotide match 
(%) 
G1 Br1 24Wk 400 bp P. gingivalis gene from 
16s strain FDC 381 
0.0 100 
G1 Br2 24Wk 400 bp P. gingivalis gene from 
16s strain FDC 381 
0.0 100 
G1 Br5 24Wk 402 bp P. gingivalis gene from 
16s strain FDC 381 
0.0 99 
G1 Br11 24Wk 403 bp P. gingivalis gene from 
16s strain FDC 381 
0.0 100 
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3.3.2. Immunofluorescent labelling 
The anti-T. denticola ATCC 35405 antibody raised against FhbB protein generated in 
rats remained negative when tested on all tissue sections, despite correctly labelling the 
positive control bacterial smear (Fig. 3.14a). All tissue sections also remained negative 
when immunolabelled with rabbit antiserum raised against T. forsythia (whole cell and 
s-layer). Although both antibodies correctly labelled the whole cell; figure 3.14b shows 
labelling of T. forsythia bacterial cells with rabbit anti-T. forsythia (s-layer) whereas 
figure 3.14c demonstrates immunolabelling with the antibody against T-forsythia 
(whole cell). Figure 3.14d demonstrates positive labelling of the P. gingivalis bacterial 
smear using the anti-P. gingivalis (clone 1B5) antibody, again all mouse brain sections 
were negative when tested using this antibody. 
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Figure 3.14: Positive control images for immunofluorescent labelling with specific 
bacterial antibodies. A) T. denticola bacterial smear labelled with anti-T. denticola 
ATCC 35405 antibody raised against FhbB protein generated in rats, the secondary 
antibody was goat anti-rat Alexa fluor 488 so the positive result is indicated by green 
labelling. B) T. forsythia bacterial smear immunolabelled with rabbit antisera raised 
against T. forsythia (against the s-layer). The secondary antibody was goat anti-rabbit 
conjugated to FITC; therefore, positive result is green. C) T. forsythia bacterial smear 
labelled using rabbit anti-T. forsythia (against the whole cell) and an FITC conjugated 
secondary (goat and rabbit-FITC); hence, the positive result is indicated by green 
labelling. D) demonstrates positive labelling (green) of the P. gingivalis bacterial smear 
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using the anti-P. gingivalis (clone 1B5) antibody, coupled with a goat anti-mouse FITC 
secondary antibody.  
 
3.3.3. Biochemistry  
Immunoblotting was performed on all brain specimens with anti-T. denticola ATCC 
35405 antibody against FhbB protein, anti-T. forsythia antibody against the whole cell 
and s-layer and anti-P. gingivalis (clone 1B5) antibody for LPS and gingipains. Figures 
3.15-3.17 show the results of immunolabelling with each antibody carried out on the 24 
week ApoE
null
 mice which were mono infected with their respective bacteria. In all 
cases the positive controls demonstrated appropriate bands at the expected molecular 
weights. The anti-T. denticola antibody against FhbB protein showed a positive band at 
around 11.4 kDa (Fig. 3.15) as reported by Miller et al., (2013), although, all test brains 
remained negative (Fig. 3.15). The T. forsythia antibody against the s-layer 
demonstrated multiple bands with two prominent bands at 230 and 270 kDa (Fig. 3.16) 
as previously reported by Settem et al., (2013), however, the specimens from the T. 
forsythia mono infected group (24 weeks) failed to detect any bands (Fig. 3.16). The 
anti-P. gingivalis (clone 1B5) antibody demonstrated a ladder of bands in the range of 
45-12 kDa in the lane corresponding to the positive control (culture supernatant) as 
reported previously by Poole et al., (2013) (Fig. 3.17). The test tissue lysates failed to 
detect LPS or gingipains. These results were the same in all cases, both mono and 
polymicrobial infected animals, at both time points (data not shown). A possible 
explanation for the absence of LPS and gingipains despite the presence of DNA is that 
the animals, due to their young age and already primed microglia (ApoE
null
), readily 
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removed the ‗harmful‘ products from the CNS. In addition, the detection limits of the 
antibodies used will not be as sensitive as that of molecular techniques. 
 
 
 
Figure 3.15: Immunoblotting of T. denticola infected ApoE
null
 mice (24 weeks) using 
the anti-T. denticola antibody against FhbB protein.  A) Immunoblotting of lysates 
prepared from brains 1-7 of T. denticola infected ApoE
null
 mice. B) Immunoblotting of 
lysates prepared from brains 8-12 of T. denticola infected ApoE
null
 mice. For both A and 
B the medium control remained negative as expected, the positive control demonstrated 
a positive band at around 11.4 kDa, all test brains remained negative. 
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Figure 3.16: Immunoblotting of T. forsythia infected ApoE
null
 mice (24 weeks) using the 
T. forsythia antibody against the s-layer. A) Immunoblotting of lysates prepared from 
brains 1-7 of T. forsythia infected ApoE
null
 mice sacrificed at 24 weeks. B) 
Immunoblotting of lysates prepared from brains 8-12 of T. forsythia infected ApoE
null
 
mice sacrificed at 24 weeks. For both A and B the medium control remained negative, 
whereas the positive control demonstrated multiple bands (a smear) with two prominent 
bands at 230 and 270 kDa, however, all specimens from the T. forsythia mono infected 
group were negative. 
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Figure 3.17: Immunoblotting of P. gingivalis infected ApoE
null
 mice (24 weeks) using 
the anti-P. gingivalis (clone 1B5) antibody. A) Immunoblotting of lysates prepared from 
brains 1-7 of P. gingivalis infected ApoE
null
 mice sacrificed at 24 weeks. B) 
Immunoblotting of lysates prepared from brains 8-12 of P. gingivalis infected ApoE
null
 
mice sacrificed at 24 weeks. For both A and B the medium control remained negative, 
whereas the positive control (spent medium) demonstrated a ladder of bands in the 
range of 45-12 kDa, although, none of the test tissue lysates demonstrated P. gingivalis 
LPS or gingipains. 
 
3.4. Discussion 
The results from the first phase of the investigation using AD brain tissue specimens 
(C/o ―Brains for Dementia Research‖) provided novel experimental evidence towards 
establishing an aetiological link between periodontal disease and AD.  Proof of concept 
was explored using experimental animals induced with periodontal disease (Kesavalu et 
al., 2007; Chukkapalli et al., 2014). Therefore, any autolytic artifacts associated with 
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human post-mortem delay could be eliminated and both the DNA and general brain 
tissue could be preserved according to experimental needs.  
 The initial investigation of the in vivo model explored the possibility of oral 
pathogens P. gingivalis, T. denticola and T. forsythia or their associated virulence 
factors accessing the brain of ApoE
null
 mice following experimental induction of 
periodontitis as mono and polymicrobial infections. As mentioned previously Foschi et 
al., (2006) used an endodontic infection and, despite the absence of any reported 
neuropathological findings, they did identify the presence of T. denticola in distant 
organs including the brain, heart and spleen.  
The present study identified P. gingivalis as the dominant organism that 
accessed the brain and both T. denticola and T. forsythia went undetected. The 
identification of P. gingivalis DNA and the absence of T. denticola in the present study 
did not support the previous findings reported by Foschi et al., (2006). Although this 
may be attributed to the specific strains of bacteria used in each study in addition to the 
method used to infect the animals and their genetic composition. Firstly, different 
diseases were induced in each study, Foschi et al., (2006) used an endodontic infection 
whereas the present study induced periodontal disease in the mice. Secondly, different 
strains of bacteria were used in each study. The only common strain between this study 
and that of Foschi et al., (2006) is T. forsythia (ATCC 43037) and based on this result 
alone it is likely that T. forsythia, being a non-motile bacterium and lacking fimbriae, 
are unable to transmigrate to the brain (Settem et al., 2012). The present study identified 
P. gingivalis strain FDC381 DNA within the brains of ApoE
null
 mice, this strain has 
fimbriae for adherence and is a more virulent form compared with the avirulent strain P. 
gingivalis ATCC 33277 (Mayrand and Holt, 1988) used by Foschi et al., (2006), 
therefore, providing a possible reason for the difference in findings. The strains of T. 
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denticola used in both studies (ATCC 35404 and ATCC 35405) are motile. However, in 
the study by Foschi et al., (2006) T. denticola (ATCC 35405) was detected in the brain 
despite being applied at a lower dose (10
8
) than in the present study (10
9
). Thus, the 
outer membrane with abundant pore-forming adhesion protein that may be lacking in 
our T. denticola (ATCC 35404) strain may have contributed to its accessibility to the 
brain, rather than being a dose dependent effect which could account for the 
polymicrobial infection model.  
The results show that P. gingivalis strain FDC 381 used to infect the oral cavity 
of the ApoE
null
 mice was able to access the brain. This result alone provides definitive 
evidence for transmigration of P. gingivalis, a common bacteria implicated in chronic 
periodontal disease, from the oral cavity to the brain. The mode of entry to the CNS, in 
this case, was not investigated although a systemic route is favoured due to its 
association with atherosclerotic lesions and its ability to adhere to erythrocytes for 
innate immune evasion (Chiu, 1999; Haraszthy et al., 2000; Cavrini et al., 2005; 
Belstrøm et al., 2011; Chukkapalli et al., 2014) as well as gaining advantage for 
transportation to remote body organs (Belstrøm et al., 2011). Finding molecular 
evidence of P. gingivalis in the ApoE
null
 mice brains supports the previous findings 
(chapter 2) in which P. gingivalis specific LPS was detected in 4 out of 10 AD brains 
using anti-P. gingivalis specific monoclonal antibodies (Poole et al., 2013).  
However, in the in vivo mouse study it was specifically the DNA of the 
periodontal pathogen P. gingivalis that was found in the brains of the appropriate 
infected groups with high significance. Bacterial virulence factors were not detected in 
any of the brains by immunoblotting or immunolabelling for P. gingivalis, T. denticola 
and T. forsythia using the aforementioned antibodies. Initially, the absence of any 
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virulence factors appeared surprising in light of the findings in the human brain tissue. 
However, the lack of detection may be attributed to the younger age of these animals 
(compared with AD individuals) allowing them to rapidly clear the virulence factors 
(LPS) from the systemic circulation, therefore, preventing them from accessing the 
brain. Also it is possible that the virulence factors may have been neutralised upon entry 
by the already enhanced microglial inflammatory phenotype in this animal model 
(Roselaar and Daugherty, 1998; de Bont et al., 1999), whereas, the DNA of the bacteria 
appears to have remained intact.  
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Chapter 4: 
In vivo investigation to find neutral bacterial virulence 
factors and to determine dementia like pathological 
lesion(s) following an oral infection in the ApoE
null
 
mouse model of periodontal disease 
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4.1. INTRODUCTION 
Conventional identification of bacteria using specific molecular tools (primers) 
provided evidence in favour of a link between oral pathogens and AD using an in vivo 
model of periodontal disease. However, immunolabelling with antibodies to common 
bacterial epitopes can also be used for an exhaustive search and visualisation of such 
proteins in disease specific lesions and cells. In addition, this approach can be used to 
assess chemically fixed tissue specimens which present with better morphological 
preservation and allow the application of conventional light microscopy stains for 
preliminary understanding of the disease process. Hence, the investigation of brain 
tissue from ApoE
null
 mice with induced periodontal disease continues using such 
methodologies.  
 
4.2. MATERIALS AND METHODS 
4.2.1. In vivo animal model c/o the University of Florida 
As per chapter 3 section 3.2.1. 
4.2.2. Source of antibodies  
Mouse anti-bacterial peptidoglycan (MAB995), Millipore; rabbit anti-PGP9.5 (protein 
gene product 9.5) (ab27053), Abcam; Secondary detection antibodies: goat anti-mouse 
FITC, Sigma; Alexa Fluor® 488 goat anti-mouse IgG1 (γ1) (A-21121), Life 
Technologies; goat anti-rabbit FITC, Sigma; goat anti-rabbit TRITC, Hycult biotech; 
goat anti-mouse HRP (A4416), Sigma; goat anti-mouse IgG1 HRP (ab98693), Abcam. 
4.2.3. Source of all other reagents 
Mayers Haematoxylin, RA Lamb;  Eosin, RA Lamb; Schiff‘s reagent, Sigma 395-2; 
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Wrights stain, Sigma; DPX mounting medium, Sigma; Thioflavin T, Fisher Scientific; 
glycerol, Fisher Scientific; Silver nitrate, Fisher Scientific; hexamine, Fisher Scientific; 
borax (disodium tetraborate), Sigma; periodic acid, Fisher Scientific; sodium 
thiosulphate, Sigma; FragEL
TM 
DNA Fragmentation Detection Kit, Calbiochem; 
glutaraldehyde, Sigma; aqueous osmium tetroxide solution, Agar Scientific; propylene 
oxide, Sigma; Araldite CY212, Agar Scientific; plastic capsules, Agar Scientific; 300 
mesh naked nickel grids, Agar Scientific, UK; uranyl acetate, Sigma; lead citrate, 
Sigma; Glycine, Fisher Scientific; paraffin wax pellets, Tissue prep 2; tissue processing 
cassettes and embedding moulds, Fisher Scientific; hydrogen peroxide, Sigma;  3,3‘-
Diaminobenzidine tetrahydrochloride hydrate, Sigma; Gold chloride solution, gift, 
University of Cardiff; Na2S, Fisher Scientific; silver solution, gift, University of 
Cardiff; zymosan, Sigma. 
 
Unless otherwise stated, all histology and immunolabelling described in this chapter 
was performed on Paraffin embedded tissue sections 
 
4.2.4. Formalin fixed tissue processing 
All specimens were thoroughly washed in PBS pH 7.3 (at least 3 changes over 24 
hours). The intact hemisphere was divided into the frontal cortex and temporal lobe 
inclusive of the hippocampus. Also, the brain stem and cerebellum were kept together 
where possible. The specimens were processed in cassettes through a series of alcohol 
and xylene washes using an automated tissue processor (Shandon Citadel 2000, Thermo 
Scientific) and infiltrated in molten paraffin wax. The protocol employed by the tissue 
processor was; 70% ethanol for 1 hour, 80% ethanol for 3 hours, 90% ethanol for 3 
hours, 3 x 100% ethanol for 4 hours, 2 x 100% xylene for 4 hours, 100% xylene for 5 
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hours, 2x paraffin wax for 7 hours, then held in paraffin wax for a minimum of 1 hour. 
The tissue was then embedded in paraffin wax in appropriately labelled embedding 
moulds using an embedding station (RA Lamb).  
4.2.5. Tissue Sectioning 
The paraffin wax embedded tissue blocks with temporal lobe inclusive of the 
hippocampus were trimmed to expose the tissue specimen then pre-cooled on ice for 1 
hour prior to sectioning using the Leica RM2235 microtome. A temperature regulated 
water bath was switched on and maintained at 50 °C to float sections and to collect 
them onto Superfrost+® glass microscope slides (Leica, UK). The pre-cooled block was 
held in the chuck such that the tissue faced the vertical plane of a microtome blade. 
Following setting of the section thickness to 5 µm, ribbons of the sections were picked 
with the aid of forceps and a paint brush and floated onto the surface of the water in the 
bath. At least 3 consecutive sections/slide and multiple slides/block were collected. All 
sections on slides were allowed to dry at 37 °C in an incubator overnight. Further 
bonding of the tissue sections to the glass slides was achieved by placing the slides at 65 
°C for 2 hours. The slides were removed and allowed to cool at room temperature prior 
to further use. 
4.2.6. Bacterial smears 
 See chapter 2, section 2.2.8. 
4.2.7. Histology 
i) Haematoxylin and Eosin 
Haematoxylin and Eosin staining was performed in order to assess the general histology 
of the brain sections. Paraffin wax sections (all brains from each group, at both time 
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points) were deparaffinised (2x 15 mins xylene) and rehydrated (5 mins absolute 
ethanol, 5 mins 80% ethanol, 5 mins 70% ethanol, 2x 5 mins distilled water). Sections 
were then placed in running water for 5 mins, followed by incubation in Mayers 
Haematoxylin for 5 mins. Following this the sections were washed in cold running 
water for 5 mins then subjected to hot running water for 30 seconds followed by a 30 
second incubation in Eosin. Finally sections were washed briefly in water then blotted 
dry and mounted using DPX mounting medium. Sections were examined using the 
Nikon Eclipse E200 microscope and imaged using the Nikon DS-L2 v.441 software. 
ii) FragELTM DNA Fragmentation Detection Kit. 
To assess the hippocampus for any apoptotic cell bodies paraffin wax sections were 
bought to water then analysed using the FragELTM DNA Fragmentation Detection Kit 
according to manufacturer‘s instructions. This assay is a non-isotopic system for 
labelling of DNA breaks in apoptotic nuclei. Results were visualised and imaged using 
the 510 Zeiss confocal microscope (Carl Zeiss). 
iii) Wrights stain  
The Wrights stain was carried out in order to detect any haematopoietic cells in the 
brain tissue. Again sections were deparaffinised and rehydrated as above (section i) and 
stained in Wright‘s stain as per suppliers‘ protocol. Finally, sections were rinsed with 
deionized water and blot dried before mounting with DPX mountant. 
 
 
 
178 
 
 
4.2.8. Searching for characteristic AD hallmark lesions in ApoE
null
 mouse brains 
using neutral dyes and silver impregnation methods 
i) Thioflavin T 
Thioflavin T is a stain used which positively labels amyloid. Paraffin wax mouse brain 
tissue sections were deparaffinised and rehydrated as above (section 4.2.7.i) then treated 
in Haematoxylin solution for 2 mins to quench nuclear fluorescence. The sections were 
washed in water and incubated in 1% aqueous Thioflavin T for 5 min. This was 
followed by rinsing sections in water and differentiating in 1% acetic acid for 20 mins 
to reduce background fluorescence. Finally, sections were washed in water and mounted 
in glycerol/PBS (9:1 ratio) and imaged using the 510 series Zeiss confocal microscope 
(Carl Zeiss Ltd). 
ii) Methenamine silver solution and impregnation 
Methenamine silver staining methods positively label argyrophillic components of a 
tissue section, historically this staining methodology has been used to positively label 
the pathological hallmarks associated with AD alongside other particles (Pick bodies 
associated with Picks disease). Methenamine silver solution was prepared by mixing 
three solutions; Silver nitrate 0.0625 g (in 5 ml distilled water), 3 % hexamine solution 
(in 25 ml distilled water) and 3 % borax (disodium tetraborate) (in 5 ml distilled water). 
Rehydrated paraffin wax sections, were initially oxidised in 0.5 % periodic acid for 10 
mins. Following washings in water, the sections were transferred into pre-heated 
methenamine silver solution at 60 °C for 40 – 60 mins and monitored until the desired 
degree of silver impregnation was achieved. All sections were then rinsed in deionized 
water and fixed in 2.5 % aqueous sodium thiosulphate for 2 mins. Followed by a further 
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wash in water, the sections were counterstained in haematoxylin (3 mins), blotted dry, , 
cleared using a series of xylene washes (2 x 5 mins) and mounted with DPX mountant. 
iii) Periodic Acid Schiff’s stain 
PAS stain is used to detect polysaccharides such as glycogen, and mucosubstances such 
as glycoproteins, glycolipids and mucins in tissues. PAS histochemitry was carried out 
using Schiff‘s reagent and the sigma protocol (No. 395) for tissue sections (standard 
procedure). Briefly, sections were deparaffinised and rehydrated, immersed in periodic 
acid solution (1 g/dL) for 5 mins at room temperature then rinsed in several changes of 
distilled water. Following this, sections were immersed Schiff‘s Reagent for 15 mins at 
room temperature then washed with running tap water (5 mins). Finally, sections were 
counterstained using Mayers Hematoxylin solution for 90 seconds, rinsed in distilled 
water, dehydrated, cleared and mounted in DPX mountant. 
4.2.9. Immunofluorescence labelling  
i) All controls  
All mouse brain tissue sections included omission of the primary antibody (to check 
specificity of the secondary antibody) alongside the inclusion of the primary antibody 
on the sham infected groups for both mono and polymicrobial infections (12 and 24 
weeks). 
ii) Antigen retrieval 
Rabbit anti-PGP9.5 antibody required pre-treatment in order to expose the relevant 
antigen which is specifically expressed following microwave heating of tissue sections 
for 35 mins in 0.2 % citric acid buffer at pH 6.0 using 750W power.  
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Mouse anti-bacterial peptidoglycan antibody (MAB995) required sections to be 
permebilised in 10 % SDS for 15 mins, followed by thorough washes in PBS (3x 
5mins), then 10 mins in 50 mM glycine/PBS to quench autofluorescence. 
iii)  Universal bacterial peptidoglycan 
Immunofluorescence labelling was carried on rehydrated paraffin sections employing 
the same methodology as for human brain tissue (section 2.2.8). Antigen retrieval and 
other pre-treatments were incorporated where necessary (see above section ii). All 
sections were blocked (PBS 2 % tween 20, containing 0.01 % normal goat serum) and 
incubated overnight at 4 °C in mouse anti-bacterial peptidoglycan (MAB995) (1/200). 
Followed by detection using goat anti-mouse IgG1 (Alexa fluor 488, 1/1000) or goat 
anti mouse FITC (1/200). Slides were mounted using the Vectashield PI mounting 
medium and imaged on the Zeiss confocal microscope as before. 
iv) Cell marker antibodies  
Immunofluorescent labelling was performed on rehydrated paraffin wax sections as 
previously (section 2.2.8); pre-treatments were applied where necessary (above section 
ii). The primary antibodies (rabbit anti-PGP9.5 (1/100), rabbit anti-GFAP (1/1000)) 
were diluted in block solution and applied overnight at 4 °C, followed by labelling with 
the appropriate secondary (goat anti- rabbit FITC; 1/200) and then mounted under a 
glass coverslip using PI and imaged as before (see section 2.2.8).  
v) Double labelling  
Rehydrated paraffin wax ApoE
null
 mouse brain sections were double labelled with rabbit 
anti-PGP9.5 (for neuronal labelling; 1/100) and the bacterial peptidoglycan (1/200) 
antibody, as well as with rabbit anti-GFAP (1/1000) and mouse anti- peptidoglycan 
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(1/200). The same protocol was used for dual labelling as was for the single 
immunofluorescent labelling (see section 2.2.8), except the blocking solution used was 
1% BSA in PBS. As there was no non-specific reactivity between any of the antibodies 
they were diluted in the same solution and applied to the section overnight at 4 °C. 
Secondary detection antibodies (goat anti-rabbit TRITC (1/50) and goat anti-mouse 
IgG1 (γ1) Alexa Fluor® 488 (1/1000)) were diluted together in blocking solution and 
applied to the sections for 1 hour at room temperature. goat anti-rabbit TRITC 
conjugated secondary antibody was used to allow differentiation between the labelling 
from each antibody. Finally sections were mounted under a glass coverslip using the 
Vectashield® DAPI mounting medium and imaged as described above. 
4.2.10. Biochemistry 
i) Tissue lysates  
Tissue lysates were prepared from all mice brains (polymicrobial and mono infected at 
both time points) as described in chapter 3 (see section 2.2.9) and were used for dot 
blots with the anti-bacterial peptidoglycan antibody (MAB995). 
ii) Dot blot 
To confirm the presence of peptidoglycan, dot blots were performed by transferring 30 
µg of total protein onto a PVDF membrane which had been previously permeabilized 
with methanol and hydrated in transfer buffer. The membrane was subsequently blocked 
for 30 min at room temperature in 5% w/v skimmed milk/PBS then incubated overnight 
at 4 °C with the anti-bacterial peptidoglycan antibody (MAB995) diluted 1/400 in 5% 
w/v skimmed milk/PBS. Following 3x 15 min washings in PBS containing 0.2 % tween 
20, the membrane was incubated in HRP-conjugated goat anti-mouse Ig secondary 
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antibody diluted 1/10,000 in 5 % w/v skimmed milk/PBS for 2 hours at room 
temperature. Following further washes in PBS/tween 20, (3x 15 min each) bands were 
detected using the enhanced chemiluminescence detection reagent as before.  
4.2.11. Electron microscopy of bacterial cell pellets and IMR32 cellular debris 
The cellular debris was collected from a flask of IMR32 cells treated with culture 
supernatant and from a flask treated with control medium (Chapter 2, section 2.2.6) 
following centrifugation for 5 mins at 2,500 rpm to form a pellet. All pellets were then 
fixed for up to 1 hour at 4 °C in 2.5 % glutaraldehyde and subsequently post-fixed in 2 
% aqueous osmium tetroxide solution (Agar Scientific) for 2 hours at room temperature 
in a fume hood. The pellets were fully dehydrated in a series of graded alcohols (70 %, 
80 % and 100 %) then placed in propylene oxide, with 3 changes lasting 10 mins each. 
The specimens were then infiltrated in a mixture of propylene oxide and Araldite 
CY212 using a 1:1 ratio for initial infiltration of the resin into the specimen, followed 
by at least 3 changes in fresh resin over 24 hours. Following this the specimen blocks 
were embedded and polymerised in plastic capsules (Agar Scientific) at 65 °C for 48 
hours. Thin sections were cut with a glass knife at 80-100 nm thickness using the Leica 
Ultracut E microtome (Leica, UK). The sections were collected onto 300 mesh naked 
nickel grids (Agar Scientific, UK) and stained in heavy metal salts (saturated uranyl 
acetate, 20 mins, and lead citrate, 5 min). All sections were examined and images were 
captured using the Philips CM 120 BioTwin TEM. The same process was used for 
bacterial cells provided by Prof. Kesavalu (University of Florida), initially cells were 
pelleted by centrifugation at 2,500 rpm for 5 mins. 
4.2.12. IMR32 cellular debris 
Cell debris from IMR32 treated cells was also smeared onto glass microscope slides for 
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assessment of autofluorescence. 
4.2.13. Statistical analysis 
As per human specimens (see section 2.2.10). 
 
4.3. RESULTS 
4.3.1. Mouse brain morphology 
Overall morphological observations of the temporal lobe including the hippocampus by 
H/E analysis of the brains of all animals (sham, mono, and polymicrobial infected at 
both time points) appeared well preserved. There were no abscesses in the brain and 
there were no signs of the classical blood borne inflammatory cells (neutrophils, 
lymphocytes) or sites of focal haemorrhage. The pyramidal neurons CA1-CA4 regions 
and the dentate gyrus neurons of the hippocampus in sham and infected brains generally 
appeared well preserved (Fig. 4.1). However, on a number of occasions shrunken and 
darker neurons were noted, to varying extent, in CA1-CA4 regions and the dentate hilus 
with a random distribution (Fig. 4.2). The extent of the ‗darker‘ neuronal staining within 
the hippocampus of all ApoE
null
 mice (sham, mono, and polymicrobial infected animals 
at both time points) was scored on a scale of one to three (denoting minor, medium and 
extensively shrunken and darker staining) by myself and an additional investigator (Dr. 
Sim Singhrao) on separate occasions. Fig. 4.3 represents the averages scores for each 
group.  
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Figure 4.1 H/E stain of mouse hippocampus from sham infected ApoE
null
 mice (24 
weeks). Labels denote the various regions visible; the cortex, lateral ventricle (LV), 
choroid plexus (Cpx), dentate gyrus molecular layer (DG: Mo layer), dentate gyrus 
granular layer (DG: Gr layer) and the CA1, CA2, CA3 and CA4 regions of the 
pyramidal neurons. 
 
Figure 4.2: A) H/E stain of mouse hippocampus from mono P. gingivalis infected 
ApoE
null
 mice (24 weeks). B) higher magnification image of dentate gyrus region in A. 
C) a higher magnification of the pyramidal neurons shown by the blue box in A. D) a 
higher magnification image of the dentate gyrus neurons shown by the red box in A.  
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Figure 4.3: Graph showing the average score of the extent the neurons of the 
hippocampus appeared ‗shrunken and darker‘. Scored on a scale of 0-3 for all brains in 
all groups (sham, mono and polymicrobial infected animals sacrificed following 12 and 
24 weeks) and averaged depending on the number of cases in each group – note if the 
hippocampus was not located then the case was denoted as missing. 
Initial tests were performed in an attempt to outline the difference between the 
darker stained neurons and those which appeared healthy. The first test was using 
FragELTM DNA Fragmentation Detection Kit to see if the cells were undergoing 
necrotic death. The results show that despite the test working (as seen by the positive 
control; Fig. 4.4a and b) no DNA fragmentation was detected in the tested brains (Fig. 
4.4 c and d). At this point, as no evidence of cell death or damage was detected in the 
cases scoring the highest for ‗darker‘ neurons, the investigation into these neurons was 
terminated. 
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Figure 4.4: FragELTM DNA Fragmentation Detection Kit test on hippocampus of 
ApoE
null
 mouse brain sections (which had previously scored high for ‗darker‘ neurons). 
A) Positive control generated for the purpose of the test, red is the nuclear label (PI), 
green indicates DNA fragmentation. B) a higher magnification of A. C) Fragmentation 
Detection Kit test performed on hippocampus of ApoE
null
 mouse brain, identical 
conditions to that in A and B; red is the nuclear label (PI), green indicates DNA 
fragmentation. D) A higher magnification image of C. Note, the test brain is negative 
for DNA fragmentation. 
4.3.2. Searching for characteristic AD hallmark lesions in ApoE
null
 mouse brains 
using neutral dyes and silver impregnation methods 
A number of stains were used in attempt to identify the presence of the pathological 
hallmarks of AD. Both thioflavin T (for labelling amyloid) and methanamine silver 
neutral staining methods (to detect both NFTs and Aβ plaques amongst other 
argyrophillic components) failed to demonstrate any evidence, in all of the brains, for 
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the presence of either Aβ plaques or NFT‘s in the hippocampus or in the fronto-
temporal cortex regions. However, the methenamine silver stain presented with positive 
argyrophillic clusters of granules within the hippocampus of a number of brains as 
shown in figure 4.5.  
 
Figure 4.5: Silver methenamine staining of brain sections from mono P. gingivalis 
infected ApoE
null
   mice (24 weeks). Red circles and arrows highlighting the clusters 
labelling positive. A) Region of the hippocampus demonstrating extracellular 
argyrophillic granules. B-C) higher magnification images of the extracellular 
argyrophillic granules. D) Argyrophillic labelled neuronal cell from the CA neurons of 
the hippocampus. 
4.3.3. Periodic acid Schiff’s 
The results from the silver methenamine staining appeared similar in appearance to 
those reported by Akiyama et al., (1986) which were reported as being PAS positive, 
therefore, the brain tissues from all groups were tested using PAS stain. Following 
histochemical staining with PAS reagent the rehydrated paraffin wax sections 
demonstrated numerous clusters of PAS positive granules (Fig 4.6), as shown at a range 
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of magnifications. The granules within the hippocampus of ApoE
null
 mice brain were 
always present in clusters of variable size supporting the findings of Akiyama et al., 
(1986).  
 
Figure 4.6: PAS staining of the hippocampus of ApoE
null 
mice – using cases previously 
positive for extracellular argyrophillic granules. Images of varying magnification 
demonstrating that the same granules are also weakly labelled with PAS – Red circles 
highlighting areas of positive labelling.  
 
4.3.4. Immunofluorescence labelling for bacterial peptidoglycan 
Immunofluorescent labelling for bacterial peptidoglycan was performed to identify if 
there was any presence of the bacterial cell wall component in the ApoE
null
 mouse brain 
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sections to indicate any bacterial presence which may have been beyond the detection 
limit of the species specific antibodies used in chapter 3. 
i) Controls 
All negative controls whereby the primary antibody was omitted remained consistently 
negative (Fig. 4.7a), whereas the positive control bacterial smears (T. denticola, T. 
forsythia and P. gingivalis) labelled with the peptidoglycan antibody (MAB995) as 
expected (Fig. 4.7b-d).  
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Figure 4.7: Control images for peptidoglycan immunofluorescent labelling on ApoE
null
 
mouse brain tissue sections. A) Negative control, here the primary antibody was omitted 
and brains were subsequently labelled with the secondary antibody against mouse IgG1 
conjugated to Alexa Fluor® 488 (green), red indicates PI, the nuclear label. B-D) 
Positive controls, in all cases the primary antibody used was mouse anti- peptidoglycan 
(MAB995) and the secondary antibody was Alexa Fluor® 488, hence green indicates 
positive labelling. B) T. denticola bacterial smear immunolabelled for peptidoglycan C) 
T. forsythia bacterial smear immunolabelled for peptidoglycan D) P. gingivalis bacterial 
smear immunolabelled for peptidoglycan. 
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i) ApoEnull mouse brain immunolabelled for peptidoglycan 
Rehydrated paraffin wax sections from all infected groups were immunolabelled with 
the anti-peptidoglycan antibody, the results are shown in Figure 4.8. 
Sham infected  
Immunolabelling of the mono sham infected mice sacrificed at 12 weeks presented with 
only one case showing positive labelling in clusters of granules (Fig. 4.8a). The 
granules were observed at the same location and looked similar in appearance to those 
seen labelling positive with silver methenamine and PAS. An abundance of inclusions 
were also observed in 2 out of 11 brains analysed from the mono sham infected animals 
sacrificed at 24 weeks (Fig. 4.8b). 
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Figure 4.8: Immunofluorescent labelling results for peptidoglycan on all groups (sham, 
P. gingivalis, T. denticola, T. forsythia and polymicrobial infected). Positive labelling 
for peptidoglycan (MAB995) is shown in green, whereas red represents PI, nuclear 
label. A) Sham infected mice at 12 weeks demonstrating positive clusters of granules in 
the hippocampal region. B) Sham infected mice at 24 weeks also demonstrating positive 
clusters of granules in the hippocampal region, insert shows higher magnification of 
peptidoglycan positive granules. C) P. gingivalis infected mice at 12 weeks, showing 
granules as in A, insert shows granules at higher magnification. D) P. gingivalis 
infected mice at 24 weeks demonstrated peptidoglycan positive cellular labelling in 
addition to the granules in the hippocampal region of the brain. E) T. denticola infected 
mice at 12 weeks showing positive granules as in A. F) T. denticola infected mice at 24 
weeks, again showing positive granules as in A. G) T. forsythia infected mice at 12 
weeks, showing peptidoglycan positive granules as in A. H) T. forsythia infected mice 
at 24 weeks, showing peptidoglycan positive granules, insert displays granules at higher 
magnification. I) Polymicrobial infected mice also displayed peptidoglycan positive 
granules in selected cases at 12 weeks. J) Polymicrobial infected mice at 24 weeks 
showing positive granules as in the sham infected A. 
 
P. gingivalis  
ApoE
null
 mice which were orally infected with P. gingivalis presented with clear 
positive extracellular labelling (granular) in 4 out of 12 cases at the 12 week time point 
(Fig. 4.8c). Whereas, only 2 positive cases were observed at the 24 week time point 
(Fig. 4.8d). In addition, cellular localisation of peptidoglycan was observed in 
abundance in both cases which were positive at 24 weeks (Fig. 4.8d).  
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T. denticola 
Results from the ApoE
null
 mice orally infected with T. denticola immunolabelled for 
peptidoglycan showed a greater number of cases were positive with these granules at 
both 12 and 24 week time points (Fig. 4.8e and f; total number of cases being 5 and 6 
respectively). When compared with the sham infected groups the difference between the 
number of positive cases were close to reaching statistical significance (P = 0.065) with 
the labelling appearing clearer in the T. denticola infected group than that detected in 
the sham infected mice at both time points (Fig. 4.8). 
T. forsythia 
The number of brains displaying the peptidoglycan positive granules in the 
hippocampus was also higher in the T. forsythia infected group than the sham infected 
group at the 12 week time point (Fig. 4.8g), having 4 cases positive for peptidoglycan 
granules in the hippocampus (P = 0.140). However, by the 24 week time point (Fig. 
4.8h) this had dropped to 2 out of 12 cases, the same as that in the sham infected group. 
Again the granules were intensely labelled within the hippocampus and remained 
variable in size (Fig. 4.8g and h). 
Polymicrobial infected  
The polymicrobial sham infected animals also presented with the same granular 
labelling in the hippocampus of a number of cases at both 12 and 24 week time points. 
This was also the case when analysing the hippocampus of polymicrobial infected 
ApoE
null
 mice at 12 and 24 weeks post infection (Fig. 4.8i and j respectively). There was 
no statistical difference in the number of brains demonstrating the extracellular granules 
in the sham and the polymicrobial infected animal brains at either of the two time 
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points. See table 4.1 for a full summary of the number peptidoglycan positive cases for 
each group of animals, the data for which is consistent for those producing positive 
granules in the hippocampus using light microscopy tests (silver methanamine and 
PAS). No groups of animals presented with statistically significant differences when 
compared with the sham-infected group of animals, although, the T. denticola infected 
group came closest to reaching significance. However, it was only the P. gingivalis 
infected animals at the 24 week time point which displayed cellular labelling for 
peptidoglycan.  
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Table 4.1: Summary of peptidoglycan labelling data for all groups of ApoE
null
 mice at 
both 12 and 24 week time points. P values given were generated using the Mann 
Whitney U test comparing all test groups with the relevant sham infected group. 
Group  peptidoglycan 
positive  
12 week 
p value when 
compared with 
control group 
peptidoglycan 
positive  
24 week 
p value when compared 
with control group 
Mono sham 
infected   
1 out of 12 . 2 out of 11  . 
P. gingivalis 
infected  
4 out of 12  2 out of 9  0.827 
T. denticola 
infected  
5 out of 12 0.065 6 out of 12  0.118 
T. forsythia 
infected   
4 out of 12 0.140 2 out of 12  0.925 
Poly sham 
infected 
5 out of 12 . 6 out of 12 . 
Polymicrobial 
infected 
6 out of 12 0.688 6 out of 12 1 
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In order to investigate the origin of the peptidoglycan positive granules double 
immunolabelling with neuronal marker (PGP9.5) and the bacterial peptidoglycan 
antibody was performed to identify if the peptidoglycan labelling was localising with 
neurons or neuronal components. The results showed that cellular labelling was not 
associated with neurons (Fig. 4.9), although, demonstrated further examples of both 
extracellular and cellular peptidoglycan labelling. Additional dual labelling was 
performed using GFAP and the bacterial peptidoglycan (clone MAB995) antibody to 
see if peptidoglycan was labelling astrocytes/astrocytic components. Results 
demonstrated it was astrocytes that were immunolabelling positive for bacterial 
peptidoglycan (Fig. 4.10).  
 
 
Figure 4.9: Peptidoglycan (MAB995) and PGP9.5 (neuronal cell marker) dual 
immunofluorescent labelling of paraffin wax brain tissue sections from mono P. 
gingivalis infected ApoE
null
 mice (24 weeks). Blue is the DAPI nuclear label, green 
demonstrates peptidoglycan positive labelling and red demonstrates PGP9.5 positive 
neuronal labelling. A) Negative control image, primary antibodies were omitted. B) 
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Peptidoglycan positive labelling in the hippocampus, both cellular and extracellular 
labelling is present. Note, the labelling is not neuronal. 
 
Figure 4.10: Peptidoglycan (MAB995) and GFAP dual immunofluorescent labelling of 
paraffin wax sections from mono P. gingivalis infected ApoE
null
 mice (24 weeks). Blue 
is the DAPI nuclear label, green demonstrates peptidoglycan positive labelling and red 
demonstrates GFAP positive labelling. Note, cells are clearly astrocytes. 
Further tests were performed in order to exclude any cross-reactivity with the 
mouse primary antibody on mouse tissue sections. This was carried out using a positive 
control from human AD brain 6 was tested under the same conditions used on the 
mouse brain tissue sections. The results also demonstrated an abundance of reactive 
cells labelled with the bacterial peptidoglycan (MAB995) antibody (Fig. 4.11) as well 
as a corpus amylaceum (Fig. 4.11 f insert), the human alternative to the PAS positive 
granules. Double immunolabelling with an anti-human GFAP antibody and the bacterial 
peptidoglycan antibody (MAB995) confirmed that the cells immunolabelled with the 
peptidoglycan antibody were astrocytes (Fig. 4.12). 
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Figure 4.11: Human Alzheimer‘s disease post-mortem brain tissue immunolabelled for 
bacterial peptidoglycan (MAB995). Red is PI nuclear label, green represents 
peptidoglycan positive labelling. A) Negative control image whereby the primary 
antibody was omitted. B) Intense cellular labelling for peptidoglycan was observed 
throughout the brain parenchyma. C) Higher magnification images of cells in B. Insert 
in C shows the presence of corpora amylaceum, also labelling positive for bacterial 
peptidoglycan.  
 
Figure 4.12: Dual immunofluorescent labelling of human Alzheimer‘s disease post-
mortem brain tissue using both the anti-bacterial peptidoglycan antibody (MAB995) 
and anti-human GFAP. Blue is the DAPI nuclear label, green demonstrates 
peptidoglycan positive labelling and red demonstrates GFAP positive labelling. Note, 
the cells are clearly astrocytes. 
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4.3.5. Analysis of cell debris from IMR32 cells treated with spent medium. 
Alongside this cell debris from IMR32 neurons treated with spent medium from all 
three bacteria (separately) and a control group treated with sterile control medium was 
analysed by electron microscopy in order to see the effect of PD bacterial virulence 
factors on healthy neurons. The results demonstrated intact IMR32 neurons from the 
control treated culture (Fig. 4.13a). Whereas, the cells treated with the culture 
supernatant from all three periodontal bacteria (P. gingivalis, T. denticola and T. 
forsythia at 24 h) appeared to have burst expelling their subcellular content including 
debris resembling nuclear remnants (Fig. 4.13b and c) in between other intact cells (Fig. 
4.13b). At a higher magnification, the subcellular components appeared to be membrane 
bound organelles including mitochondria, but their ultrastructure was poorly preserved 
(Fig. 4.13c).The cellular debris also demonstrated clear autofluorescence (Fig. 4.14). 
 
Figure 4.13: Electron microscopy analysis of debris from IMR32 cells treated with 
spent media. A) Cells treated with sterile control medium demonstrated intact IMR32 
neurons. B) Cells treated with spent medium show subcellular content in between other 
intact cells. C) Higher magnification of subcellular content from B appears to 
demonstrate membrane bound organelles such as mitochondria; however, their 
ultrastructure is poorly preserved. 
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Figure 4.14: Fluorescent analysis of cell debris from IMR32 neuronal cells treated with 
spent media. In all cases the debris was clearly autofluorescent (A and B).  
 
4.4. DISCUSSION 
The identification of DNA belonging to the periodontal pathogen P. gingivalis in the 
brains of ApoE
null
 mice orally infected with the pathogen encouraged further 
investigation into the neuropathological changes occurring in the brain, an element not 
reported by previous studies (Foschi et al., 2006). Due to the greater preservation of 
formalin fixed tissue specimens, for the initial stages of this investigation, conventional 
light microscopy stains were employed to explore clues for potential lesions. Later to be 
confirmed by an alternative approach, as used by Miklossy (2006), to localise common 
(neutral) bacterial antigens in the same mice brains following the negative result when 
using species specific bacterial antibodies. 
Rehydrated paraffin wax sections were examined following staining with H/E 
for general morphological preservation of the fronto-temporal lobe including the 
hippocampus. These areas appeared well preserved however, shrunken and darker 
stained neurons were occasionally noted in CA1-CA4 regions of the dentate gyrus and 
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dentate hilus in both the sham and the infected animals. The reasons for this observation 
are unclear. Tests for any DNA fragmentation in these neurons as an indication of 
apoptotic cell death returned negative results; therefore, further investigation into these 
neurons was halted. 
 The fact that there were no signs of any abscess formation or whole bacterial 
cells in the brain suggests that P. gingivalis (FDC 381) was unlikely to have been 
metabolically active upon accessing the brain. In addition, there were no myeloid 
lineage cells (neutrophils, lymphocytes) infiltrating into the brain and no sites of focal 
brain haemorrhage. 
Following analysis of the H/E data the investigation was focused on the 
detection of any early cellular changes occurring in the ApoE
null
 mice brains. According 
to Braak and Braak (1995), neurodegeneration begins in the entorhinal cortex and 
spreads to the hippocampus followed by other regions; hence, the hippocampus was the 
main area of interest in this study. Screening for the AD hallmark associated structures 
by thioflavin T and methenamine silver methods did not provide any evidence for the 
fibrillar Aβ and NFT‘s in the entorhinal cortex or the hippocampus regions. Since ApoE 
is an essential protein for amyloid to form insoluble fibrils this was not an unexpected 
finding (Wisniewski and Frangione, 1992). Thus, the intra-cerebral inflammatory 
precursors (fibrillar Aβ and NFT‘s) in this model can be excluded from any endogenous 
inflammation in all groups of infected animal brains, including sham infected.  
Despite silver impregnation methods failing to demonstrate any evidence of Aβ 
or NFTs, the results did demonstrate the presence of argyrophilic granules in the 
hippocampus of ApoE
null
 mice, which were later determined to be PAS-positive and 
their distribution closely resembled those described previously (Akiyama et al., 1986; 
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Jucker et al., 1992; 1994; Kuo et al., 1996). These inclusions displayed a low level of 
quenchable autofluorescence, suggesting the presence of advanced glycation end (AGE) 
products as another possible constituent. This may be a unique property of the granules 
in the ApoE
null
 mice as this has not been reported previously (Akiyama et al., 1986; 
Jucker et al., 1994).  
Subsequently, immunofluorescence labelling was employed to detect common 
bacterial cell wall constituents (bacterial peptidoglycan) in the ApoE
null
 mouse brains. 
Results demonstrated that the age-related granules were specifically and intensely 
immunolabelled with this bacterial virulence factor (peptidoglycan) in some of the sham 
infected and the mono and polymicrobial infected brains. Alongside the presence of the 
granules labelling positive within the hippocampal regions, astrocytic cellular labelling 
was also observed, however, this was only observed in abundance in selected cases of 
the P. gingivalis infected groups. The cell type was identified using dual labelling and 
confirmed by the observation of identical astrocytic labelling, using the same antibody 
for peptidoglycan, within human AD brain sections (taken from the first phase of the 
study). In the human brain a number of positively labelled corpora amylacia were also 
detected using the anti-peptidoglycan antibody thereby supporting the findings from the 
mouse model.  
Positive immunolabelling for bacterial peptidoglycan in the sham infected 
control brains at 12 week time point was surprising as these animals were still under 7 
months of age, although this could possibly be related to the peroxisomal mediated 
degradation of lipids and proteins (Monastyrska and Klionsky, 2006) in the ApoE
null
 
mice. Under various physiological conditions, cytoplasmic components and organelles 
are randomly isolated into membrane-bound vesicles leading to autophagy 
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(Monastyrska et al., 2006). This method involves the non-enzymatic breakdown of 
lipids by catalase and hydrogen peroxide content of the peroxisome. SAMP8 
(Senescence Accelerated Mouse-Prone 8) mice demonstrate autophagic processes 
(Caballero et al., 2009; Ma et al., 2011) at around 7 months of age, when PAS-positive, 
argyrophilic granules form, which appears to correlate with cognitive decline (Ma et al., 
2011). The peroxisomal process imparts endogenous peroxidase activity to PAS-
positive, argyrophilic granules leading to their non-specific immunostaining. Thus 
immunolabelling of the age-related granules, whether from human or murine origins, 
has to be interpreted with caution. As described earlier, the presence of positive 
labelling in the sham infected brain is attributed to this peroxisomal process. 
In view of the inflammatory component of the ApoE
null
 mice and their 
predisposition to infections (Roselaar and Daugherty, 1998; de Bont et al., 1999), 
induction of chronic periodontal disease in these mice may provide the necessary 
catalyst to trigger the occurrence of these PAS-positive inclusions in the hippocampus 
where the greatest intensity of their deposition takes place (Akiyama et al., 1986; Jucker 
et al., 1994; Kuo et al., 1996). The bacterial cell walls of all eubacteria, irrespective of 
their Gram stain characteristics, consist of variable amounts of peptidoglycan. 
Peptidoglycan is a mixture of proteins and complex polysaccharide carbohydrates (short 
peptides and N-acetyl glucosamine and N- acetyl muramic acid) and has been found in 
brains of patients with dementia along with argyrophilic disease hallmarks (Miklossy et 
al., 1996). The same hallmarks are known to be associated with heparan sulphate 
proteoglycans (Su et al., 1992; Snow et al., 1994) as well as the PAS-positive granules 
in SAMP8 mice (Kuo et al., 1996). The presence of subcellular organelles such as 
―abnormal mitochondria and membrane-like structures‖ within the ultrastructure of 
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ageing SAMP8 mice (Kuo et al., 1996) implies that these granules might be 
components of degraded organelles resulting from on-going cell death. 
This view was supported by electron microscopy analysis of IMR32 neurons 
treated with spent media from each of the three red complex pathogens. The results 
demonstrated that the IMR32 neurons released their intracellular content following 
exposure to bacterial virulence factors, possibly due to an episode of oxidative stress 
causing free radicals to be generated as a result of infection with periodontal bacterial 
components and endotoxins (Shapira et al., 2002). Therefore, it is possible that there 
exists an alternative pathway of formation of the age-related granules in the mouse brain 
where they originate from initial interaction with ―bacterial factors‖. This causes cells to 
release their sub-cellular components into the molecular layer of the dentate gyrus 
within the hippocampal region.  
In a complementary study (c/o Dr. Sim Singhrao) SVGp12 cells upon in vitro 
treatment of periodontal bacteria (T. denticola) from culture supernatants demonstrated 
an up-regulation of IL-6 cytokine secretion by 72 fold compared with controls. 
Similarly, the interaction of another periodontal bacterium (T. forsythia) also showed an 
increase (3 fold) in IL-6 secretion levels. The higher IL-6 secretion appeared to be 
responsible for INF-γ which can modulate proinflammatory conditions in the host. This 
is supported by data concerning the levels of systemic inflammatory markers present in 
the serum of the animals used in this model, as published by our collaborators 
(Chukkapalli et al., 2014). They demonstrated that periodontal pathogens induced an 
increase in systemic antibody (IgG) levels along with the production of serum 
inflammatory mediators (Chukkapalli et al., 2014; Velsko et al., in press). The current 
study found no direct evidence for the presence of T. denticola and T. forsythia in the 
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brain, however, the ApoE
null
 mice orally infected with these bacteria presented with age-
related PAS-positive granules, hence there may also be a systemic contribution from 
periodontal disease (Kamer et al., 2008; Watts et al., 2008).  Multiple systemic 
infections can exacerbate premorbid cognitive status in AD patients and the current 
view indicates that this is the result of proinflammatory mediators crossing the BBB 
(Kamer et al., 2009; Holmes et al., 2003; 2009). 
The observations in the current study are in agreement with previous reports 
showing a higher presence of PAS-positive argyrophilic granules in the B6 mice strains 
and the potential contribution of these granules towards the development of 
neurodegenerative diseases (Akiyama et al., 1986; Jucker et al., 1994). Results support 
the view that these granules are processed by astrocytes, since they were also 
immunopositive with the bacterial peptidoglycan antibody, in both ApoE
null
 mice and 
humans. These granules may significantly serve as an alternative source of potentially 
neurotoxic subcellular proteins which could ultimately provide a nidus for the 
development of neurodegenerative disease pathology in the appropriate host.  
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Chapter 5: 
In vivo Assessment of glial cell activation and 
complement activation fragments in ApoE
null
 mouse 
model of periodontal disease using immunolabelling 
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5.1. INTRODUCTION 
Having established the identity of the PAS-positive argyrophillic granules using 
immunolabelling, it was possible to investigate the contribution made by the 
complement system in the brains of an ApoE
null
 mouse model of periodontal disease. In 
this chapter the extent to which glia are involved in the inflammatory neuropathology 
will be examined. In vitro studies suggest that activated glial cells (astrocytes and 
microglia) can generate a full and functional complement system involved in an innate 
immune defence mechanism against pathogens (Barnum, 1995; Gasque et al., 2000).  
 
5.2. MATERIALS AND METHODS  
5.2.1. In vivo animal model c/o the University of Florida 
As per chapter 3 section 3.2.1. 
5.2.2. Source of antibodies  
Rabbit anti-mouse CD14 (ab106285), Abcam; goat anti-Iba1 (Ionized calcium binding 
adaptor molecule 1)(ab5076), Abcam; rat anti-mouse C3b/iC3b/C3d, Hycult Biotech, 
UK; rabbit anti-rat C9 neoepitope, Professor P. Morgan, Cardiff University. Secondary 
detection antibodies: goat anti-rat IgG (H+L) Alexa Fluor® 488 (A-11006), Life 
Technologies; goat anti-rabbit FITC, Sigma; goat anti-rabbit TRITC, Hycult Biotech; 
rabbit anti-goat Alexa Fluor® 488, Life Technologies. 
5.2.3. Source of all other reagents  
As for Chapters 2-4 (see sections 2.2.5; 3.2.3; 4.2.3)   
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5.2.4. Tissue preparation 
Cryo-sections were prepared for all mouse brains (all groups at both time points) using 
the same method as for human tissue (section 2.2.8). In addition, brain tissue from 
ApoE
null
 mice (all groups) was also prepared in the form of paraffin wax sections as 
described in chapter 4 sections 4.2.4 and 4.2.5. 
 
5.2.5. Immunofluorescent labelling 
i) Paraffin embedded tissue sections immunolabelled using cell marker 
antibodies 
Antigen retrieval 
Rabbit anti-PGP9.5 and goat anti-Iba 1 antibodies required pre-treatment in order to 
expose the relevant antigen by microwave heating (750 W) tissue sections for 35 mins 
in 0.2 % citric acid buffer at pH 6.0.  
All controls  
As for previous chapters all mouse brain tissue sections included omission of the 
primary antibody (to check specificity of the secondary antibody) alongside the 
inclusion of the primary antibody on the sham infected groups for both polymicrobial 
and mono infections (12 and 24 weeks). 
 
Immunolabelling - Cell marker antibodies  
Immunolabelling for cell markers was performed as for human tissue (section 2.2.8). 
The primary antibodies used were rabbit anti-PGP9.5 (1/100), rabbit anti-GFAP 
(1/1000), goat anti-Iba 1 (1/500) diluted in block solution and applied to tissue sections 
210 
 
 
overnight. After a series of washes (3x 5 mins in PBS) sections were labelled with the 
appropriate secondary (goat anti-rabbit FITC (1/200) rabbit anti-goat Alexa Fluor® 488 
(1/1000), washed again (3x 5 mins in PBS) and then mounted under a glass coverslip 
using PI as before (see section 2.2.8). Labelling was observed using the 510 series Zeiss 
confocal microscope (Carl Zeiss Ltd) and images were captured using the Zeiss LSM 
510 software. 
 
ii) Immunofluorescent labelling of cryostat tissue sections for CD14 
Immunofluorescent labelling of mouse brain cryo-sections was performed as for the 
human brain tissue (section 2.2.8). The primary antibody used was rabbit anti-mouse 
CD14 (1/50), followed by detection using goat-anti rabbit FITC (1/200). 
 
iii) Immunofluorescent labelling of cryostat tissue sections for complement 
activation proteins 
Immunolabelling was performed using an overnight, indirect method as described for 
the human brain tissue (section 2.2.8) for the detection of complement activation 
proteins. Acetone stabilised tissue sections were treated in 50 mM glycine/PBS for 10 
mins to quench any tissue associated endogenous fluorescence. Following an overnight 
incubation at 4 °C in primary antibodies (rat anti-mouse C3b/iC3b/C3d (1/50), rabbit 
anti-rat C9neoepitope (1/100)) diluted in the appropriate blocking solution, the 
secondary detection was carried out using the appropriate secondary antibody (goat 
anti-rat IgG (H+L), 1/1000; goat anti-rabbit FITC, 1/200) in the blocking solution as 
before. Following further washes in PBS (3x 5 min) sections were mounted under a 
glass coverslip using PI (Vectashield®). Labelling was observed using the 510 series 
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Zeiss confocal microscope (Carl Zeiss Ltd.) and images were captured using the Zeiss 
LSM 510 software. 
 
iv) Double immunolabelling 
Cryo-sections were dual labelled using with rat anti-C3 (1/50) and rabbit anti-C9 
(1/100), using the same method as for human tissue (section 2.2.8). The secondary 
detection antibodies used were goat anti-rat IgG (H+L) Alexa Fluor 488 (1/1000) and 
goat anti-rabbit TRITC (1/50). Following labelling all sections were mounted in 
Vectashield DAPI mounting medium and imaged using the Zeiss confocal microscope 
as previously (section 2.2.8). 
 
5.3. RESULTS 
5.3.1. Immunolabelling to determine glial cell activation (GFAP) 
 
ApoE
null
 mouse brain tissue sections from all groups were immunolabelled with an anti-
GFAP antibody in order to determine glial cell activation as a marker of inflammation. 
i) Controls  
Negative control sections, whereby the primary antibody was omitted remained 
negative throughout (Fig. 5.1). No non-specific binding of the secondary antibody was 
detected. 
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Figure 5.1: Negative control for GFAP immunofluorescent labelling on ApoE
null
 mouse 
brain tissue sections. Here the primary antibody was omitted and brains were 
subsequently labelled with a secondary antibody conjugated to FITC (green), red 
indicates PI, the nuclear label.  
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ii) ApoEnull mice brain sections immunolabelled for GFAP 
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Figure 5.2: ApoE
null
 mice brains (sham, P. gingivalis, T. denticola, T. forsythia and 
polymicrobial infected) immunolabelled for GFAP, showing results from both 12 and 
24 weeks. Positive labelling for GFAP is shown in green, whereas red represents PI, 
nuclear label. A) Sham infected mice at 12 weeks showing positive labelling 
specifically in the hippocampal region. B) Sham infected mice at 24 weeks showing 
lateral ventricle surrounded by GFAP positive astrocytes. C) P. gingivalis infected mice 
at 12 weeks also showing lateral ventricle surrounded by astrocytes with activated 
phenotype. D) P. gingivalis infected mice at 24 weeks again showing positive labelling 
surrounding a lateral ventricle. E) T. denticola infected mice at 12 weeks showing 
positive labelling in the hippocampus. F) T. denticola infected mice at 24 weeks 
demonstrating GFAP positive astrocytes surrounding the lateral ventricle. G) T. 
forsythia infected mice at 12 weeks showing positive cellular labelling in the 
hippocampus. H) T. forsythia infected mice at 24 weeks, again high levels of positive 
cellular labelling in the hippocampus. I) Polymicrobial infected mice at 12 weeks 
showing an abundance of GFAP positive astrocytes in the hippocampal region. J) 
Polymicrobial infected at 24 weeks demonstrating high levels of reactive astrocytes 
around a ventricle. 
 
A selection of results for the immunolabelling of mouse brain tissue from all groups 
(sham, P. gingivalis, T. denticola, T. forsythia and polymicrobial infected) is shown in 
figure 5.2. Immunolabelling of the sham infected control brain sections for GFAP 
demonstrated numerous astrocytes with activated phenotype scattered within the 
hippocampus CA1-CA4 regions and surrounding the lateral ventricles at both 12 and 24 
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weeks (Fig. 5.2a and b respectively). The immunolabelling using the anti-GFAP 
antibody on all of the mono-infected groups (P. gingivais, T. denticola and T. forsythia) 
clearly demonstrated an abundance of astrocytes around the periphery of the lateral 
ventricles and within the hippocampus (Figs. 5.2 c-h). Although there was no statistical 
difference when cells/area were counted and compared with the sham infected group of 
animals at each time point. The only difference noted was in tissue sections from T. 
forsythia mono infected ApoE
null 
mice at 12 weeks, they demonstrated a lower density 
of astrocytes scattered around the periphery of the lateral ventricles and within the 
hippocampus, in the majority of cases, when compared with the P. gingivalis and T. 
denticola group as well as the sham group. Although a few cases at the 12 week time 
point presented with similar labelling to that demonstrated by the sham infected mice 
within the hippocampal region and by 24 weeks GFAP positive astrocytes were seen in 
abundance within the hippocampus (Fig. 5.2).  
In addition, rehydrated paraffin wax sections from all polymicrobial infected 
ApoE
null 
mice (sham and poly infected) at both time points were immunolabelled for 
GFAP. As for the mono infected group, the sham infected polymicrobial brains at 12 
and 24 weeks (Fig. 5.2i and j) presented with positively labelled astrocytes around the 
periphery of the lateral ventricles and scattered throughout the hippocampus region (Fig 
5.2j).  Again, there was no significant difference in the polymicrobial infected group of 
animals when compared with the sham infected group at both 12 (Fig. 5.2a) and 24 
(Fig. 5.2b) weeks.  
Overall there was no significant difference between the level of glial cell 
activation when comparing all test groups with the relevant controls, as is shown by the 
average score (Fig. 5.3) for each group (mono and poly microbial infections) at both 12 
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and 24 weeks. The only low scoring group was T. forsythia 12 week mono infection, 
however, by the 24 week time point this had returned to the same level as the other 
groups. 
 
Figure 5.3: Graph showing the average score of GFAP labelling in the ApoE
null
 mouse 
brain sections. Scored on a scale of 0-3 for all brains in all groups (sham, mono and 
polymicrobial infected animals sacrificed following 12 and 24 weeks) and averaged 
depending on the number of cases in each group. 
 
5.3.2. Immunolabelling to determine microglial cell activation (Iba1) 
The sham infected mouse brain sections whereby the primary antibody was omitted 
remained negative for microglial cell distribution (Fig. 5.4a and d). Only a few 
microglial cells were observed following immunolabelling of sections with the Iba 1 
antibody around the lateral ventricles at 12 and 24 weeks in the sham infected brain 
sections (Fig. 5.4b) and even fewer cells (mainly processes, Fig. 5.4c) were noted in the 
hippocampus. Similar, microglial cell distribution was observed in the P. gingivalis 
infected brains around the lateral ventricles (Fig. 5.4e). Again, few microglial cell 
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bodies with branched processes were observed in the hippocampus (Fig. 5.4f). The 
brain tissue sections from T. denticola mono infected groups at 12 and 24 weeks 
demonstrated no differences in the density of microglia scattered around the periphery 
of the lateral ventricles and within the hippocampus (not shown) as was observed in the 
sham infected and the P. gingivalis infected animals. Similarly there were no 
differences between sham and T. forsythia infected brain sections.  
Figure 5.4: Rehydrated paraffin wax embedded tissue sections immunolabelled with 
goat anti-mouse Iba1 antibody to assess microgliosis. A-C) are images taken from the 
mono sham infected group of animals, and D-F) are images taken from the mono P. 
gingivalis infected animals, both at the 24 week time point. A and D) negative control 
images whereby primary antibody is omitted. B) demonstrated an abundance of 
immunopositivity especially around the periphery of the lateral ventricles C) Few Iba1 
positive cells were noted in the hippocampus region of the Sham infected mice (24 
weeks). E) Mono P. gingivalis infected brains at 24 weeks demonstrated a more 
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widespread distribution of fibrillary astrocytes around ventricles. F) The distribution 
within the hippocampus region was similar to that observed in the sham infected brains, 
few cells were positively labelled.  
 
5.3.3. Immunolabelling to determine complement activation.  
ApoE
null
 mouse brain tissue (cryo-sections) were immunolabelled for the presence of 
complement activation products including C3 components (iC3b, C3b and C3d) and the 
C9 neoepitope to determine if the complement system was activated in the brain of mice 
both infected with periodontal disease and sham infected. 
i) Controls 
All negative control sections whereby the primary antibody was omitted remained 
negative (Fig. 5.5). 
 
Figure 5.5:  Negative control for complement products (C3 and C9) labelling on 
ApoE
null
 mouse brain tissue sections. Here the primary antibody was omitted and brains 
were subsequently labelled with the secondary antibody conjugated to FITC (green), red 
indicates PI, the nuclear label. Note, no non-specific binding of the secondary antibody 
was detected. B and C showing areas of the hippocampus – CA neurons. 
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ii) ApoEnull mice brain sections immunolabelled for complement activation 
at 12 weeks 
Cryo-sections taken from sham infected ApoE
null 
mice at 12 weeks demonstrated 
complement activation products for the common C3 component activation fragments 
(iC3b, C3b and C3d) and C9 neoepitope specifically on microglia and not on astrocytes 
and/or neurons (5.6a and b). This was also the case for all of the infected groups of mice 
(P. gingivalis, T. denticola, T. forsythia and polymicrobial infected; Figs 5.6c-j) at 12 
weeks, all groups demonstrated strong labelling for both C3 and C9. Positive labelling 
was intracellular and on microglia alone (Fig. 5.6c-j), as seen in the sham infected group 
of mice (Fig. 5.6a and b). 
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Figure 5.6: ApoE
null
 mice brains (sham, P. gingivalis, T. denticola, T. forsythia and 
polymicrobial infected) immunolabelled for complement activation products C3 and 
C9, showing results from 12 weeks Positive labelling for complement activation 
products (C3 and C9) is shown in green, whereas red represents PI, nuclear label, all 
cases show positive labelling on microglia alone for C3 and C9. A) Sham infected mice 
immunolabelled for C3. B) Sham infected mice at 24 weeks immunolabelled for C9. C) 
C3 labelling of P. gingivalis infected mice. D) C9 labelling of P. gingivalis infected 
mice. E) C3 labelling of T. denticola infected mice. F) C9 labelling of T. denticola 
infected mice. G) C3 labelling of T. forsythia infected mice at 12 weeks. H) C9 
labelling of T. forsythia infected mice. I) C3 labelling of polymicrobial infected mice. J) 
C9 labelling of polymicrobial infected mice. 
 
iii) ApoEnull mice brain sections immunolabelled for complement activation 
24 weeks 
Sham infected 
Cryo-sections taken from sham infected ApoE
null 
mice at 24 weeks also demonstrated 
complement activation products for the common C3 component activation fragments 
(iC3b, C3b and C3d) and C9 neoepitope specifically on microglia and not on astrocytes 
and/or neurons (Fig. 5.7a and b), as was observed at the 12 week time point.  
P. gingivalis  
The complement activation products for the common C3 components (iC3b, C3b and 
C3d) and C9 were detected in P. gingivalis infected mouse brains at 24 weeks, the glial 
cell labelling was still high as seen at 12 weeks (Fig. 5.7d) plus C3 activation fragments 
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appeared to be opsonised onto pyramidal neurons particularly in the CA2 area of the 
hippocampus in 4 out of 12 infected brains (P =  0.032) (Fig. 5.7c). The C9 neoepitope 
was also observed in association with the pyramidal neurons, but only in 2 out of 12 
specimens (P > 0.05). 
T. denticola  
In addition to the high glial cell labelling (Fig. 5.7e) observed at 12 weeks, in the brain 
sections from mono T. denticola infected ApoE
null
 mice at 24 weeks 1 out of the 12 
cases demonstrated both C3 (iC3b, C3b and C3d) and C9 neoepitope localised to CA 
neurons (P > 0.05) (Fig. 5.5.7f). The complement activation fragments appeared to be 
opsonised onto pyramidal neurons particularly in the CA2 area of the hippocampus as 
shown in Fig. 5.7f. 
T. forsythia 
Again, at the 24 week time point, 1 out of 12 cases from the T. forsythia mono infected 
group of mice demonstrated complement activation products (C3 (iC3b, C3b and C3d) 
and C9) localised to CA neurons (P > 0.05) (Fig. 5.7h). In this case the glial cell 
labelling observed was still high (fig. 5.7g) and the complement activation fragments 
appeared to be opsonised onto the CA2 area of the hippocampus (Fig.5.7h). 
Poly microbial infected  
By the 24 week time point, glial cell labelling remained high (as seen at 12 weeks, Fig. 
5.7i) in the polymicrobial infected mice, and 2 out of the 12 cases presented with 
additional labelling present on the surface membrane of neurons (P > 0.05) (Fig. 5.5.7j). 
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Figure 5.7: ApoE
null
 mice brains (sham, P. gingivalis, T. denticola, T. forsythia and 
polymicrobial infected) immunolabelled complement activation products C3 and C9, 
showing results from 24 weeks. Positive labelling for complement activation products is 
shown in green, whereas red represents PI, nuclear label. A) Sham infected mice 
immunolabelled for C3 showing high microglial labelling. B) Sham infected mice at 24 
weeks immunolabelled for C9 showing high levels of microglial labelling. C) C3 
labelling of P. gingivalis infected mice, here labelling is observed on the surface of the 
CA neurons. D) C9 labelling of P. gingivalis infected mice showing intracellular 
microglial labelling. E) C3 labelling of T. denticola infected mice showing high 
labelling on microglia alone. F) C9 labelling of T. denticola infected mice showing cell 
surface labelling on hippocampal neurons. G) C3 labelling of T. forsythia infected mice, 
again showing high levels of microglial labelling. H) C9 labelling of T. forsythia 
infected mice, in one case presented with cell surface labelling of hippocampal neurons. 
I) C3 labelling of polymicrobial infected mice shows further microglial labelling. J) C9 
labelling of polymicrobial infected mice, again in limited cases demonstrating cell 
surface labelling on the neurons of the hippocampus. 
 
iii) Double labelling for complement products 
Dual labelling for both C3 components (iC3b, C3b and C3d) and C9 was performed to 
demonstrate the presence of both complement activation products within the same 
section (Fig. 5.8). Fig. 5.8 A-C clearly demonstrates both glial and neuronal localisation 
of C3 and C9 respectively.  
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Figure 5.8: Dual immunolabelling of brain tissue from ApoE
null
 mice infected with P. 
gingivalis (24 weeks) for complement products C3 and C9. Blue is the DAPI nuclear 
label, Green demonstrates C3 positive labelling and Red demonstrates C9 positive 
labelling. A-C) positive labelling for complement in the hippocampus, both glial cell 
and neuronal labelling is present.  
iv) Immunolabelling to detect CD14 
To determine if the CD14 cell surface receptor had been lost from these neurons 
immunolabelling was performed to detect CD14 (Figure 5.9). The negative control 
(where the primary antibody was omitted) showed no non-specific labelling (Fig. 5.9 a) 
and the test brains presented with normal C14 cell surface labelling on all pyramidal 
neurons including the dentate gyrus (Fig. 5.9 b).  
226 
 
 
 
 
Figure 5.9: CD14 labelling on brain sections from P. gingivalis infected ApoE
null 
mice 
(24 weeks). A) A negative control whereby the primary antibody was omitted. B and C) 
Images from the hippocampus of 24 week mono infected (P. gingivalis) mouse, which 
had previously scored high when assessing extent of ‗darker‘ neurons. Red is the 
nuclear label (PI) and green (FITC) indicates a positive CD14 result. 
 
5.4. DISCUSSION 
Having established the identity of the PAS-positive argyrophillic granules and in 
the absence of Aβ plaques or NFTs, it was then possible to investigate the innate 
immune responses of glial cells for an inflammatory contribution in the brain following 
peripheral oral infections, focusing on the contribution made by the complement 
system. In vitro studies have demonstrated that activated glial cells (astrocytes and 
microglia) can generate a full and functional complement system involved in an innate 
immune defence mechanism against pathogens (Barnum, 1995).   
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The results demonstrated the presence of responsive fibrillary astrocytes 
particularly at the peri-circumventricular organ sites following initial microglial cell 
activation. Studies on ApoE
null
 mice have identified glial cell activation in which 
microglia demonstrate evidence in favour of an increased secretion of cytokines, 
especially of TNF-α (Roselaar and Daugherty, 1998; de Bont et al., 1999) a cytokine of 
macrophage origin. This observation has been suggested as an impaired 
immunomodulatory function of macrophages in controlling the innate immune 
responses in this animal model (Ophir et al., 2005; Tsoi et al., 2007; Vitek et al., 2009). 
Microglia are the tissue bound macrophages of the brain capable of expressing a range 
of proinflammatory cytokines and phagocytosing cellular debris to reduce the 
inflammatory response to pathogens. However, the finding that the ApoE
null
 mice have 
higher levels of endogenous proinflammatory cytokines especially TNF-α implies that it 
is likely that microglia were already in their activated phenotype. Hence, explaining the 
presence of activated microglia across all groups of animals, including the sham 
infected mice.  
Complement is a pivotal pathway in the CNS innate immune responses 
following infections, as described in the introduction (Chapter 1 section 1.1.2) (Gasque, 
2004; Morgan and Gasque, 1996; Markiewski and Lambris, 2007). In brief, the 
complement system comprises of three different activation pathways (classical, 
alternative and the MBL), all of which converge upon the central component C3 which 
then leads to activation of the terminal pathway. Through this activation process 
numerous enzymatic activation fragments are generated many of which have 
immunomodulatory functions, examples of these include the anaphylotoxins C3a, C5a 
and cytolytic MAC. In the CNS the dominant mode of complement activation is the 
classical pathway (Singhrao et al., 2000). Therefore, this study assessed if there was any 
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evidence for the activation of the common C3 and the terminal pathways leading to 
formation of the MAC in the brains of ApoE
null
 mice both with and without the presence 
of periodontal infections (including both mono and polymicrobial infections). 
Immunofluorescent labelling using both C3 and the C9neoepitope antibodies 
was employed to detect their respective complement components (C3 and C9 
respectively) as well as the C3 activation fragments and the MAC on the surface 
membrane of complement activated cells. The results demonstrated an intracellular 
localisation of C3 and C9 exclusively in microglia in all brains suggesting these cells 
were actively synthesizing complement components, again supporting the view that in 
ApoE
null
 mice microglia are already in their activated state (Roselaar and Daugherty, 
1998; de Bont et al., 1999; Ramaglia et al., 2012). However, the demonstration of the 
cell surface membrane staining of C3 activation fragments (iC3b, C3b and C3d) and the 
MAC (anti-C9neoepitope) exclusively on CA pyramidal neurons of the mono and 
polymicrobial infected groups at 24 weeks, but not at 12 weeks, suggested the high 
chronic inflammatory burden of periodontal disease may have tipped the balance from 
protection to bystander injury on complement activated neurons. The C3 activation 
fragments opsonised to neurons in the P. gingivalis mono infected group were 
statistically significant (P = 0.032) whereas the observed MAC detected on neurons in 
the same group did not reach significance (P > 0.05). In all cases the CD14 receptor on 
the CA neurons remained intact.  
In view of detecting C3 activation fragments being opsonised on the pyramidal 
neurons, it appears likely that bacterial (P. gingivalis) DNA itself may have been the 
trigger for complement activation as it was detected in the same brains. Due to the 
activated glial cells throughout all groups (attributed to the ApoE
null
 genotype), it is 
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possible that a slight insult from the presence of PAMPs within the CNS or a peripheral 
infection such as periodontal disease has initiated activation of the complement cascade 
where fragments of C3 and C9 resulted in opsonising pyramidal neurons thereby 
indicating that they are under attack by complement mediated lysis leading to their 
eventual demise. However, due to the presence of complement opsonised neurons in 
animals from the T. forsythia and T. denticola infected groups (although not statistically 
significant), in the absence of any detectable bacterial DNA, a contribution from 
systemic inflammation cannot be ruled out. 
The opsonisation of hippocampal neurons reported in the present study may 
indicate a potential link with AD as human brain tissue specimens from post-mortem 
AD patients have been shown to demonstrate evidence of neuroinflammation via the 
activated complement system, plus C1q, C3b, and ROS have all been implicated in the 
formation of amyloid fibrils (Eikelenboom et al., 1991; 2011; Akiyama et al., 2000). 
These observations are strengthened by genome-wide studies supporting the role of 
innate immune components such as CR1 (Lambert et al., 2009; Harold et al., 2009) in 
AD, plus the CR1 gene has been linked to defective clearance of the Aβ in AD. 
Thereby, suggesting the potential for a link between oral pathogens and AD hallmarks 
(Aβ) via the complement system. 
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6. DISCUSSION 
6.1 General discussion  
The theory of the human mouth as a focus of infection states that oral microbial 
infections contribute to the developing pathologies of remote body organs by infiltrating 
into the systemic system (Miller, 1891; Hunter, 1900). This concept prompted us to 
explore the hypothesis in relation to finding an aetiological link between periodontal 
disease and AD. Studies to understand the relationship between environmental factors 
such as pathogens and their role in dementia, including the deposition of Aβ, are crucial 
to understanding the contribution made by microbial agents to disease pathogenesis and 
progression.  
Numerous population-based, observational studies suggest a strong association 
between tooth loss due to periodontal disease and the development of AD (Gatz et al., 
2006; Stein et al., 2007). One study demonstrated that monozygotic twins had a strong 
association between tooth loss and the presence of AD with an odds ratio of 5.5 (Gatz et 
al., 2006). Also Stein et al., (2007) reported a statistically significant association 
between tooth loss due to periodontal disease and the development of AD in catholic 
nuns. However, the only established experimental link to date between true periodontal 
infections and direct effect on the brain is by Riviere et al., (2002). In this study, the 
robust technique of PCR coupled with immunolabelling detected Treponema species of 
oral bacteria in 14 out of 16 AD cases. Furthermore, the AD brains were more 
susceptible to infection by Treponema genus of bacteria than the age matched control 
brains (Riviere et al., 2002). In addition, the same authors also demonstrated that the 
trigeminal nerve ganglia, hippocampus and the pons taken from embalmed cadavers (2 
out of 4) also contained evidence of the same species of bacteria.  
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Subsequent studies have demonstrated that AD patients express high circulatory 
antibody titres to periodontal pathogens and higher levels of the pro-inflammatory 
cytokine TNF-α in their blood than the age matched controls (Kamer et al., 2009). High 
levels of TNF-α cytokine in the blood plasma is considered a risk factor for cognitive 
deficit (Holmes et al., 2009). The possible role of periodontitis in AD is an interesting 
concept and has obvious parallels with the emerging role of periodontitis in other 
inflammatory based disorders such as Rheumatoid arthritis and CVD.  
Recurrent bacteraemia from dental procedures including dental extractions, 
periodontal surgery, tooth scaling, brushing and flossing can seed oral bacteria into 
systemic circulation (Forner et al., 2006). The aim of this study was to determine the 
plausibility of oral pathogens P. gingivalis, T. forsythia and T. denticola accessing the 
brain in both humans and in animal models (ApoE
null
 mice) with established periodontal 
disease, in addition to describing any organ specific pathology related to hallmark 
features of dementia in the latter.  
This study was performed in two phases, with the results from each stage being 
discussed in full at the end of each chapter (see sections: 2.4, 3.4, 4.4 and 5.4). The first 
phase used human post-mortem brain tissue to assess the presence of periodontal 
bacteria in AD and non-AD age matched control brains. This formed a vital part of the 
investigation, not only in terms of assessing if periodontal pathogens or their products 
are present in the brain of AD individuals but also to validate the use of post-mortem 
brain tissue for such investigations. The original request for obtaining human post-
mortem tissue from control individuals and those diagnosed AD cases was approved on 
the basis that the investigation was restricted specifically to finding P. gingivalis, T. 
forsythia and T. denticola (the red complex; Holt and Ebersole, 2005) bacteria.  
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The key findings from the initial phase of the study using human pm brain tissue 
show that there was no presence of bacterial DNA belonging to the three red complex 
pathogens (P. gingivalis, T. denticola and T. forsythia) within the brains of human AD 
or non-AD individuals. However, the immunofluorescent labelling investigation using 
species specific antibodies for the red complex pathogens identified positive labelling 
for P. gingivalis in 4 out of 10 AD cases and none of the non-AD control brains. This 
labelling was observed associated with glia as well as extracellulary and was later 
confirmed to be P. gingivalis LPS via immunoblotting with the same antibody. 
 The identification of P. gingivalis LPS in the brain of AD individuals 
was not only a novel finding but significant in that LPS is a potent activator or the 
hosts‘ immune response in most cases inducing organ specific inflammation (Boje and 
Arora, 1992; Lodge and Sriram, 1996; Floyd, 1999; Laflamme and Rivest, 2001; Ye 
and Johnson, 2001; Gasque, 2004; Godbout et al., 2005). These findings provide 
experimental evidence in favour of a link between periodontal disease and AD, 
however, due to the absence of the dental records of the individuals the present study is 
unable to comment on if PD was present in the individuals before or after the onset of 
AD. The findings contribute significantly to the growing area of research into a link 
between periodontal disease and AD, and prompt further investigation as well as 
successfully validating the use of pm brain tissue for such studies.  
The second phase of the study involved the analysis of an animal model 
(ApoE
null
 mice) induced with periodontal disease (see materials and methods section 
3.2.1) to confirm or refute the results from the human brains by investigating if the red 
complex bacteria could access the brain following chronic oral infection.  
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The use of ApoE
null
 mice in this study introduced the potential to assess the 
neuronal damage caused by the periodontal infections which has not been performed to 
date.  In addition, ApoE is essential for neuronal repair following infection therefore in 
the absence of ApoE repair of damaged tissue will be inhibited to expose the related 
lesion. Also, ApoE has been demonstrated to play a vital role in the formation of 
insoluble Aβ fibrils (Wisniewski and Frangione, 1992). Therefore, it was possible to 
assess changes occurring in the CNS in the absence of the classical hallmarks of AD 
(Aβ plaques).  
The time course for this experimental model was 12 weeks (n=12/group) and 24 
weeks (n=12/group) post infection, although this would seem inadequate for the 
detection of the pathological hallmarks of AD I was privileged to have access to the 
brain tissue from an established periodontal disease animal model. This gave me the 
opportunity to assess any early signs of tissue damage in addition to exploring the 
possibility of the bacteria entering the brain following periodontal infection. Prior 
studies (Foschi et al., 2006) have used an endodontic infection, hence making this study 
a vital, original investigation into the potential link between periodontal disease and 
AD. 
The aim of the initial investigation using the animal model was to identify if 
there was any evidence of periodontal pathogens used to orally infect the animals and/or 
their virulence factors present in the brain. The results found evidence of DNA from P. 
gingivalis in a number of cases which were orally infected with the pathogen with this 
number of cases increasing from the 12 to 24 week time points (number of cases being 
6 and 9 respectively), although there were only 2 positive cases from the polymicrobial 
infected group. Although the findings didn‘t support a pervious study using an 
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endodontic infection (Foschi et al., 2006) this can be explained by the difference in 
strains used as well as the primer sets and antibodies employed by each study. The only 
common strain between the two studies (Foschi et al., 2006) is T. forsythia which 
represents the only consistent result. Thereby, suggesting that the virulence factors of 
each strain can play a key role in the translocation or the bacteria to distant organs. 
In addition the difference in the result from the mono and polymicrobial 
infections can potentially be explained due to the does exhibited in each group – 
although the polymicrobial group were given the same total bacterial dose ultimately 
the dose of each of the bacteria was much lower. Despite finding DNA belonging to P. 
gingivalis in the brain of the infected mice there was no presence of LPS or gingipains 
detected when immunolabelling and/or immunoblotting with species specific 
antibodies. However, this may be simply due to the difference in sensitivity and 
detection limit or the antibodies when compared with molecular methodology. 
Following on from investigating for the presence of the pathogens in the brain 
tissue, the study then turned to assess the histological aspects of the brain to determine 
if the oral infection had an effect on the brain itself. The first step involved an overall 
histological analysis which demonstrated that the brain tissue was well preserved and no 
significant differences were noted between the sham and the infected groups. In 
addition, an investigation into the histological hallmarks of AD showed no positive 
results for Aβ plaques or NFTs. However, PAS positive, peptidoglycan positive, 
argyrophillic granules were noted in a number of cases including some from the sham 
infected group. The granules observed were similar in appearance to those reported 
previously (Akiyama et al., 1986; Jucker et al., 1994). The number of cases showing 
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these granules only came close to reaching statistical significance in the T. denticola 
infected group when compared with the sham infected group. 
As mentioned previously, these granules may be a unique property in ApoE
null
 
mice, not reported to date. The labelling may be attributed to the perioximal process or 
alternatively the increased levels on systemic inflammation in periodontal disease may 
have triggered the occurrence of these granules which could contain components of 
degraded organelles as a result of cell death via interaction with ‗bacterial factors‘ – 
which would explain the peptidoglycan positive labelling. These components are the 
packaged into granules by astrocytes – again explaining why astrocytes were also 
labelling positive for peptidoglycan. It‘s important to note that at this stage no 
statistically significant difference was noted between the infected and sham infected 
group and at present these granules cannot be linked to neurodegenerative disease. 
Hence, further investigation is required in order to suggest any link between the 
presence of the granules and periodontal disease or AD and also to prove any 
association with the ApoE
null
 model. 
The final stage of the investigation into the mouse model of periodontal disease 
was to identify any differences in levels of inflammation between the sham and infected 
groups of animals. The model being used (ApoE
null
) is known for its high levels of 
inflammation (Roselaar and Daugherty, 1998; de Bont et al., 1999; Ophir et al., 2005; 
Tsoi et al., 2007; Vitek et al., 2009), therefore the finding that there was no difference 
in glial cell activation (measured by GFAP labelling) between the groups was expected. 
In addition all groups (including the sham infected group) displayed high levels of 
complement synthesis, as shown by C3 and C9 intracellular labelling observed in 
microglia alone. However, by the 24 week time point complement components (C3 and 
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C9) were observed opsonised on the CA pyramidal neurons of the hippocampus in a 
number of cases from the infected animals but not the controls (sham infected). 
Although, potentially due to the small sample size, the number of cases showing 
complement opsonisation on hippocampal neurons only reached statistical significance 
in the P. gingivalis mono-infected group at 24 weeks. Although this result coincides 
with the positive results for P. gingivalis DNA therefore the presence of the PAMP 
within the brain may have been the trigger to change the complement activation from 
synthesis to bystander damage. Together both the work on human pm tissue and the 
novel investigation using the periodontal disease animal model provides further 
experimental evidence in favour of a link between periodontal disease and AD in 
addition to paving the way for future studies. 
6.2. Conclusions  
In summary, this study has demonstrated the presence of LPS specifically from P. 
gingivalis in the post-mortem brain tissue of human AD individuals. DNA from the 
same bacteria was also detected in ApoE
null
 mouse brain tissue following its 
administration in the oral cavity. Both of the PAMP‘s (LPS and bacterial DNA) have 
the capacity to stimulate an inflammatory response in the host (Beutler, 2003) resulting 
in the local release of potentially neurotoxic substances such as cytokines, complement 
factors, and ROS, exacerbating the pre-existing disease-related inflammatory pathology. 
This study provides preliminary evidence for the complement factors and complement 
mediated damage in pyramidal neurons in the CA region of the hippocampus in the 
brains which demonstrated DNA from P. gingivalis. In addition, the PAS-positive age-
related granules within the hippocampus were observed in the ApoE
null
 mice, these 
granules accumulate during advancing age in human brain. Their appearance in the 
238 
 
 
mice as well as the human brain are said to serve as a source of potentially neurotoxic 
subcellular proteins.  
The infected ApoE
null
 mice also demonstrated systemic inflammation in the form of 
abundant up regulation of serum amyloid A, serum antibodies (IgM and IgG) as well as 
some cytokines (Chukkapali et al., 2014 and Velsko et al., in press), presenting a further 
potential link with AD via the systemic inflammatory mediator hypothesis of Kamer et 
al., (2008), Watts et al., (2008) and Holmes et al., (2009). 
This study set out to find aetiological associations between two inflammatory 
diseases, periodontal disease and AD. The results support the growing body of evidence 
for inflammatory cytokines and complement mediated neurodegeneration and 
microgliosis in AD (Hanisch, 2002; Akiyama et al., 2000), and provides experimental 
evidence in favour of a link between periodontal disease and AD. Periodontal disease is 
potentially a modifiable risk factor for the common form of dementia, AD. The 
evidence in favour of a link between these two conditions is increasing rapidly and, 
following proof of concept, treatment of periodontal disease (in both the young and the 
elderly) coupled with a greater awareness of the importance of maintaining good oral 
health may potentially help to decrease the prevalence of dementia along with other 
systemic diseases. 
6.3. Future prospective 
This study has demonstrated a clear potential association between periodontal disease 
and AD via systematic investigation of human post-mortem brain tissue followed by 
proof of concept that periodontal pathogens placed in the mouth can translocate to the 
CNS using animal models. This work now paves the way for finding a cause and effect 
relationship between periodontal pathogens and dementia inclusive of symptoms and 
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neuropathology. A number of future projects are under consideration which have 
stemmed from this research, these are listed below. 
 
6.3.1. Human post mortem-brain tissue  
Expansion of the initial study leads to an investigation of the putative association of 
periodontal pathogens with advanced stages of AD and their role in cognitive 
impairment in a larger number and/variety of individuals. The immune system of AD 
patients is inefficient to deal with infections in general; hence, they are at a greater risk 
of harbouring microorganisms from existing chronic infections in the oral cavity. The 
current view on the oral status of AD patients who have become debilitated by the 
disease process suggests that there is a lack of quality of oral care; this not only makes 
them more susceptible to systemic infections but also the invasion of the brain by the 
bacteria or their components. Following invasion of the CNS bacteria and/or their 
components can contribute towards priming of microglia and subsequently maintaining 
―hyperinflammatory status‖ resulting in bystander damage to functional cells and 
deteriorate memory. The present study aims to test this theory by analysing brain tissues 
from non-demented and demented cases in comparison with brains from other 
neurodegenerative disease in which memory remains intact e.g. amyotrophic lateral 
sclerosis and a demyelinating disease e.g. multiple sclerosis together with their dental 
records. If the investigation supports the current theory of a lack of provision for oral 
care, then recommendations can be made to the policy makers for periodontal therapy 
and prevention strategies to be made accessible to the at risk group of the population. 
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6.3.2. Animal models  
Currently P. gingivalis and spirochetes (T. denticola) appear to be the two main types of 
oral bacteria that show associations with the CNS. They are also found in the walls of 
arteries suggesting their systemic involvement and subsequent generation of 
inflammation. One interesting study would be to examine their effect on the two 
hallmarks of AD pathology (Aβ and NFT‘s in relation to tau protein) in the CNS of AD 
mouse models following chronic infection with multiple periodontal bacteria (mono  
and/or polymicrobial infection) over a longer period of time. This will determine if 
increased levels of immune mediators (cytokines, chemokines and immune receptors) in 
systemic circulation following periodontal bacterial infection affects Aβ plaque 
formation or tau pathogenesis in vivo.  
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ADI 2012 Abstract Submission 
Fact or Fiction 
Risk Factors and Prevention 
ADI12-1411 
PRELIMINARY EVIDENCE FOR A LINK BETWEEN PERIODONTAL DISEASE AND 
ALZHEIMER’S DISEASE 
S. Poole 1,*, S. K. Singhrao 2, S. Crean 1 
1School of Postgraduate Medical and Dental Education, 2University of Central Lancashire, Preston, 
United Kingdom 
Presentation Method - Preference: Oral or Poster 
Do you give permission for your accepted abstract to be published on the ADI website?: 
Yes 
If your abstract is accepted for oral presentation at the conference, would you allow your 
PowerPoint presentation to be on the ADI website after the conference?: Yes 
Are you submitting a scientific or non scientific abstract?: Scientific 
Objectives: Alzheimer‘s disease (AD) is associated with impaired memory and a number of classical 
features such as Aβ4 deposits, hyperphosphorylated neurofibrillary tangles and synapse loss that are 
implicated for loss of function. Some research suggests that exogenous sources of inflammatory 
mediators may access brain tissue and exacerbate the disease process. This concept links periodontal 
disease (PD) with AD as antibodies to PD pathogens and cytokines have been identified in blood serum 
from AD patients. PD is a complex inflammatory disease encompassing Porphyromonas gingivalis, 
Treponema denticola and Tannerella forsythia as aetiological agent. This aims of this study was to 
identify an intra-cerebral presence of P. gingivalis and/or its virulence factors in AD brains.  
Methods: Brain tissues from 10 AD cases and 5 age-related controls (Brains for Dementia Research 
tissue bank) were examined. Genomic DNA was isolated and amplified using primers from the 16s RNA 
gene of the bacterial domain using polymerase chain reaction (PCR). To demonstrate virulence factors, 
immunofluorescence labelling and immunoblotting was performed on brain tissue sections and tissue 
lysate respictively, using a specific antibody raised to P. gingivalis. Histology was used to confirm the 
likely mode of entry of the microorganisms and/or the virulence factors into the brain tissue. 
Results: At the gene level, PCR data from all human brain specimens remained negative for 
P.ginigivalis DNA. At the protein level, immunofluorescence labelling was detected intracellulary in 
only a few cells but demonstrated significant extracellular aggregates that were also observed in blood 
vessel lumens. Immunoblotting demonstrated bands corresponding to lipopolysaccharide (LPS) from 
P.ginigivalis used as a positive control.  
Conclusion: This study provides some evidence of the presence of LPS from P. gingivalis in AD brain 
tissue suggesting a preliminary link between PD and AD. The fact that the staining was associated with 
extracellular aggregates that were also associated with the blood vessels suggests LPS may gain entry to 
the brain via the vascular channels. Research assessing potential relationships between PD pathogens and 
their impact on early pathological signs contributing to cognitive dysfunction is important for uncovering 
unique pathogenic mechanisms for cognitive impairment and ultimately AD. 
Disclosure of Interest: None Declared 
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 Title: Evidence that Porphyromonas gingivalis accesses the brain from the oral cavity of 
ApoEnull mice induced with periodontal disease.  
Authors: Sophie Poole, Sim K. Singhrao, Mercedes Rivera1, Sasanka Chukkapalli1, Irina 
Velsko1, Lakshmyya Kesavalu1,2, StJohn Crean  
Affiliation: Oral & Dental Sciences Research Group (ODSRG), School of Postgraduate Medical & 
Dental Education, University of Central Lancashire, Preston, PR1 2HE, UK.  
Department of Periodontology1 and Oral Biology2, College of Dentistry, University of Florida, 
FL, USA.  
Introduction: Numerous population-based observational studies suggest a strong association 
between tooth loss due to periodontal disease and the development of Alzheimer’s disease. 
Prior study reported oral treponemes in human brains including cortex, trigeminal ganglia and 
pons. This study was aimed to investigate the possibility of oral pathogen Porphyromonas 
gingivalis accessing the brain of ApoEnull mice during experimental periodontitis.  
Methods: ApoEnull mice were orally infected (N=12) with 109 P. gingivalis FDC 381 cells four 
days/week every third week for eight infections. Molecular methods were employed to 
examine brain tissue from mice infected with P. gingivalis along with the control sham infected 
mice (N=11) sacrificed after 24 weeks of chronic infection. Genomic DNA was isolated and 
amplified using specific primers for the 16s rDNA gene of P. gingivalis. Nucleotide sequencing 
was performed to confirm the identity of the amplified product. Immunofluorescence labelling 
of brain tissue sections was performed using an anti-bacterial peptidoglycan monoclonal 
antibody.  
Results: Molecular methods demonstrated 9 out of 12 ApoEnull mice brain specimens 
contained the P. gingivalis genomic DNA whilst all control sham-infected mice brains remained 
negative. This result was highly significant (p = 0.003) when tested by the non-parametric 
Kolmogorov-Smirnov test for two independent samples. Of these twelve infected ApoEnull 
mice brains, one demonstrated peptidoglycan deposition within the molecular layer of the 
dentate gyrus of the hippocampus.  
Conclusion: These results show P. gingivalis strain FDC 381 used to infect the oral cavity of the 
ApoEnull mice was able to access the brain. This supports the concept of the focal infection 
theory which states that oral pathogens can access remote body organs including the brain. 
This work is significant as it provides preliminary evidence for transmigration of P. gingivalis 
from the oral cavity to the brain.  
Funding support: The project is supported by 1R01 DE020820-01A1, NIH/NIDCR, USA. 
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Abstract. The aim of this study was to establish a link between periodontal disease and Alzheimer’s disease (AD) with a
view to identifying the major periodontal disease bacteria (Treponema denticola, Tannerella forsythia, and Porphyromonas
gingivalis) and/or bacterial components in brain tissue from 12 h postmortem delay. Our request matched 10 AD cases for tissue
from Brains for Dementia Research alongside 10 non-AD age-related controls with similar or greater postmortem interval. We
exposed SVGp12, an astrocyte cell line, to culture supernatant containing lipopolysaccharide (LPS) from the putative periodontal
bacteria P. gingivalis. The challenged SVGp12 cells and cryosections from AD and control brains were immunolabeled and
immunoblotted using a battery of antibodies including the anti-P. gingivalis-specific monoclonal antibody. Immunofluorescence
labeling demonstrated the SVGp12 cell line was able to adsorb LPS from culture supernatant on its surface membrane; similar
labeling was observed in four out of 10 AD cases. Immunoblotting demonstrated bands corresponding to LPS from P. gingivalis
in the SVGp12 cell lysate and in the same four AD brain specimens which were positive when screened by immunofluorescence.
All controls remained negative throughout while the same four cases were consistently positive for P. gingivalis LPS (p = 0.029).
This study confirms that LPS from periodontal bacteria can access the AD brain during life as labeling in the corresponding
controls, with equivalent/longer postmortem interval, was absent. Demonstration of a known chronic oral-pathogen-related
virulence factor reaching the human brains suggests an inflammatory role in the existing AD pathology.
Keywords: Alzheimer’s disease, lipopolysaccharide, periodontal disease, Porphyromonas gingivalis, postmortem
INTRODUCTION
Periodontal disease (PD) is a chronic immuno-
inflammatory disease initiated by complex polymi-
crobial subgingival biofilm. This results in the
∗Correspondence to: Dr. Sim K. Singhrao, Oral & Dental Sci-
ences Research Group, School of Postgraduate Medical and Dental
Education, University of Central Lancashire, Preston, PR1 2HE,
UK. Tel.: +44 1772 895137; Fax: +44 1772 892965; E-mail:
SKSinghrao@uclan.ac.uk.
inflammatory destruction of tooth supporting tissues,
including the gingivae, periodontal ligament, and alve-
olar bone [1]. Analysis of the human oral microbiota
has revealed more than 700 bacterial species in the oral
cavity and over 400 species in the subgingival plaque
of healthy and PD oral biofilms [2]. These pathogens
interact with the host and result in significant systemic
inflammation characterized by the induction of proin-
flammatory cytokines, chemokines, and exaggerated
host immune responses [3, 4].
ISSN 1387-2877/13/$27.50 © 2013 – IOS Press and the authors. All rights reserved
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Periodontal pathogens adhere to and colonize the
subgingival pocket in the form of a biofilm and the
net effect of this bacterial biofilm community is to
maintain a persistent chronic infection within the host.
Several studies suggest that PD-associated bacteria can
penetrate gingival tissues and enter the bloodstream
during chewing, tooth brushing, or dental procedures
and may induce a recurrent transient bacteremia [5,
6]. Thus, periodontal lesions are recognized as con-
tinually renewing reservoirs for the systemic spread
of bacteria, antigens, and cytokines along with other
proinflammatory mediators. Once the bacteria, viru-
lence factors, and/or indirectly released inflammatory
mediators reach remote body organs, it has been pos-
tulated that they may induce similar inflammatory
responses, resulting in the tissue-specific pathology.
Chronic PD has been linked to several systemic dis-
eases such as atherosclerotic vascular disease [7],
adverse pregnancy outcome [8, 9], diabetes [10, 11],
respiratory diseases [12], renal disease [13], rheuma-
toid arthritis [14, 15], and Alzheimer’s disease (AD)
[16].
Thus, a link between periodontitis and AD has been
proposed [16] although the strength and relevance
of the association remains to be fully investigated.
Besides oral pathogens being found in the aged human
brains, viruses such as Herpes Simplex Virus Type
1 [17] and diverse bacterial infections, including
Chlamydia pneumoniae [18] and Borrelia burgdorferi
[19], have also been implicated in the pathogen-
associated etiology of the late onset AD, as recently
reviewed by Miklossy [19, 20]. The pathological
characteristics of AD are the extracellular fibrillar
amyloid- (A) deposits and the neurofibrillary tan-
gles [21]. However, elderly cognitively unimpaired
individuals also show these lesions in the brain but
to a lesser degree than that expected to cause dementia
[22].
Brain inflammation behind the blood-brain barrier
(BBB) differs from inflammation in the periphery
by the relative absence of leukocytes (including
neutrophils, monocytes, B cells, and T cells) and anti-
bodies; however, the presence of activated microglial
cells is the key contributor of inflammation in the
brain [23]. Activated microglial cells express a range of
proinflammatory cytokines [23, 24] and are capable of
recognizing the non-self-pathogen-associated molec-
ular patterns (PAMPs) on bacteria and their cellular
debris. However, the current view regarding the inflam-
matory response in the AD brain is viewed as being
a downstream consequence of the A accumulation
resulting in the activation of microglia; this initi-
ates a pro-inflammatory cascade and brings about the
local release of potentially neurotoxic substances such
as cytokines, complement factors, and reactive oxy-
gen species [24]. Interestingly, experimentally induced
microbial infections and/or their virulence factors also
appear to contribute to CNS inflammation and in some
cases to lead to A deposition [25–28].
Inflammation also plays a key part in the oral cav-
ity; the immediate response to periodontal pathogens
and their endotoxins is to activate the local and sys-
temic innate immune responses [29] leading to the
recruitment of inflammatory cells (macrophages, T
and B cells) that secrete cytokines [(interleukin (IL)-
1, IL-6, tumour necrosis factor-alpha (TNF-), and
interferon-gamma (INF-) [29–31]. The inability of
the innate immune system to remove pathogens such as
P. gingivalis [32–35] results in progressive local tissue
destruction together with a chronic systemic inflam-
matory response with potential for damaging distant
organs such as the brain.
The brain was originally considered an immunopriv-
ileged microenvironment due to the existence of the
BBB; however, it is now recognized that the BBB is
incomplete in both the circumventricular organs and
the choroid plexus regions [36–38]. The incomplete
BBB provides an opportunity for systemic proteins and
cells to gain access to the CNS. Microglial cells in the
circumventricular organs have been demonstrated to
express the CD14 receptor and the toll-like receptor
4 (TLR-4), suggesting that these cells are capable of
detecting bacterial PAMPs [37, 39, 40].
This initial concept received additional support from
clinical studies that demonstrated a significant corre-
lation between tooth loss due to PD and memory loss
in AD [16]. The same researchers reported that indi-
viduals with deteriorating memory also have increased
incidence of the apolipoprotein E (ApoE) allele 4 [41].
ApoE is a cholesterol-transporting protein and, in the
brain (with a few exceptions), is synthesized largely by
astrocytes for repair of and protection of neurons [42].
AD individuals are known to have antibodies to oral
bacteria in their plasma along with an increased pres-
ence of TNF- [43, 44]. It was also reported that a high
titer of circulating IgG from a range of PD pathogens,
during advancing age, statistically correlates with
a possible onset of mild cognitive impairment and
AD [33]. Methodological studies demonstrating the
presence of bacteria within the cerebral tissues are
sparse. The limiting factor may be availability of suit-
able postmortem (PM) tissue and corresponding data
regarding cognitive impairment and PD in relation to
pathogens such as Treponema denticola, Tannerella
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forsythia, and Porphyromonas gingivalis indigenous
to the oral cavity. One seminal study using molecu-
lar and immunological methodologies demonstrated
the presence of seven oral Treponema species in 14
of 16 AD cases, reaching statistical significance [45].
Moreover, immune-suppressed rodents demonstrated
an increased risk from endodontic infections with the
fastidious oral spirochete T. denticola [46]. Thus it is
plausible that bacteria and/or their virulence factors
have a greater chance of accessing the brain of indi-
viduals with AD due to their immuno-compromised
status. The aim of this study was to determine if the
major PD bacteria (T. denticola, T. forsythia, and P.
gingivalis) and/or bacterial components are present in
brain tissue of individuals with and without dementia.
MATERIALS AND METHODS
Human brain specimens and tissue sectioning
All research procedures met approval of our
academic institute (Ref No. 071) and the ethical guide-
lines, including adherence to the legal requirements of
study in the UK. PM human brain tissue was obtained
from the Brains for Dementia Research network and
was provided by the Newcastle Brain Tissue Resource.
These specimens included previously diagnosed AD
(n = 10) and, where possible, age-matched non-AD
control (n = 10) brains. Samples of frozen human brain
tissue from an area adjacent to the lateral ventricle of
the parietal lobe were dissected using aseptic methods.
Precautions were taken to prevent cross contamina-
tion during sample preparation. The brain specimens
(1 cm3 core) were in sterile polystyrene tubes in dry ice
when received via next-day-delivery courier service.
The PM interval for all AD cases ranged from 4 to 12 h
and the non-AD age-matched control brains from 16
to 43 h (Table 1). On receipt, all specimens were allo-
cated a code number and thereafter all data recorded
about those cases were identified by that code. The
experimenter was completely unaware of which cases
corresponded to AD and control brains. The cases are
identified here as being AD and non-AD controls for
clarity of reporting. A 3-mm2 section of the brain tissue
was separated from the original snap-frozen unfixed
cores and mounted onto a specimen holder using the
OCT® adhesive (Fisher Scientific). Sections (10m
thickness) were cut using the Leica CM1850 cryo-
stat (Leica, UK) and were collected onto Superfrost +®
glass slides (Leica, UK). The sections were used imme-
diately or stored at –80◦C until needed.
Table 1
The age and postmortem interval of the cases analyzed
Case Age Postmortem interval (h) LPS detected
AD 1 78 12 No
AD 2 77 8 No
AD 3 84 8 Yes
AD 4 84 8 No
AD 5 85 9 Yes
AD 6 83 9 No
AD 7 80 4 No
AD 8 83 10 Yes
AD 9 63 11 No
AD 10 83 12 Yes
Non-AD 1 69 16 No
Non-AD 2 72 17 No
Non-AD 3 103 21 No
Non-AD 4 78 23 No
Non-AD 5 89 24 No
Non-AD 6 81 43 No
Non-AD 7 78 34 No
Non-AD 8 89 34 No
Non-AD 9 67 22 No
Non-AD 10 22 22 No
In vitro culture of SVGp12 cells
The SV40 immortalized normal human glial cell
line SVGp12 was obtained from the American Type
Culture Collection ATCC Ref No. CRL-8621 (Man-
assas, VA, USA) and cultured in Eagle’s minimal
essential medium supplemented with heat-inactivated
10% fetal calf serum, 4 mM glutamine, 2 mM sodium
pyruvate, and 0.1 mM non-essential amino acids (Invit-
rogen) without the addition of penicillin/streptomycin.
Cells were cultured in flasks (T25, T75) or on sterile
uncoated glass coverslips placed in six well plates in
the presence of appropriate culture medium and incu-
bated at 37◦C in a humidified atmosphere of 5% CO2,
95% air with regular media changes every two to three
days where applicable.
In vitro responses of the SVGp12 cell line to P. gin-
givalis ATCC 33277 was examined following initial
confirmation of LPS in culture supernatant (Table 2).
SVGp12 cells were exposed for 24–48 h to diluted
P. gingivalis culture supernatant.
Immunoﬂuorescence labeling of brain tissue
sections
Tissue sections from snap-frozen brain were allowed
to air dry at room temperature and stabilized for
5 min in cold analar-grade acetone (Fisher Scien-
tific, UK). Unless otherwise stated, no quenching of
autofluorescence or any other antigen retrieval step
was employed. Sections were equilibrated in 0.01 M
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Table 2
Source of antibodies and their working concentration and/or dilutions applied
Antibody Source Final concentration and/or dilution
Mouse anti-CD14 (clone HCD14) Thermo-Fisher 4g/ml
Mouse anti-P. gingivalis (Clones 1B5 and
1A1) tissue culture supernatant
Prof. M. A. Curtis (co-author) 1B5 1/10, 1A1 1/50
Mouse anti-P. gingivalis (Clone 61BG1.3)
tissue culture supernatant
Prof. R. Gmur, University of Zurich, Switzerland Neat and 1/5
Rabbit anti-T. forsythia (rBspA) Dr A Sharma, State University of New York at Buffalo, NY,
USA
1/50
Mouse anti-T. denticola Tissue culture supernatant raised in-house from hybridoma
cell lines TDII (HB-9966) and TDIII (HB-9967)
purchased from ATCC
Neat and 1/5
Blocking solution In-house: 0.01 M phosphate buffered saline (PBS) pH 7.3
containing 0.01% normal goat serum and 2.5% tween 20
-
Normal goat serum (X0907) and normal
rabbit serum (X0902)
DakoCytomation, Germany, 0.01%
E. coli LPS Sigma Aldrich, UK 4g/l
phosphate buffered saline (PBS) once for 5 min and
blocked in PBS containing 0.01% normal goat or rabbit
serum and 2.5% tween 20. The sections were incubated
overnight at 4◦C in the following monoclonal antibod-
ies raised to different epitopes of P. ginigvalis: where
clone 1B5 of anti-P. gingivalis detects both LPS and
gingipains [47] and clone 1A1 [48] and 61BG1.3 [49]
recognize gingipains specifically from this bacterium
(Table 2). Anti-T. forsythia antibodies (recombinant
bacterial surface protein A (rBspA), gift from Dr.
Ashu Sharma, USA), were raised against the rBspA
protein which was heat/SDS denatured before immu-
nization in rabbits [50]. Anti-T. denticola antibodies
were raised in-house from hybridoma cell lines (TDII
(HB-9966) and TDIII (HB-9967) from ATCC) accord-
ing to the manufacturer’s instructions. In addition,
anti-CD14 (Fisher Scientific, UK) was also applied
to tissue sections following dilution in the blocking
solution (Table 2). The secondary detection was car-
ried out using either the goat anti-mouse or the goat
anti-rabbit IgG conjugated to FITC (Sigma-Aldrich,
UK) at 5g/ml. Following further washes in PBS for
three times 5 min, sections were mounted under a glass
coverslip using propidium iodide (Vector Laborato-
ries, Peterborough, UK). Labeling was observed and
images were captured using the 510 series Zeiss con-
focal microscope (Carl Zeiss Ltd).
Immunoﬂuorescence labeling of SVGp12 cells
SVGp12 cells were immunolabeled following fix-
ation of cells (on coverslips) in 10% neutral buffered
formalin ranging from 1 h to overnight at 4◦C and sub-
sequently washed in 0.01 M PBS, pH 7.3. Primary
antibodies [mouse anti-CD14 and anti-P. gingivalis
(clones 1B5 and 1A1) (Table 2)] were applied to cells
in the blocking solution (Table 2) and the conditions
for incubation and secondary detection was performed
as described for labeling of brain tissue sections above.
Controls
The primary antibody was either omitted from all
control brain tissue sections and from cells on cov-
erslips or included anti-P. ginigvalis (clones 1B5 and
1A1) antibodies on medium-control-challenged cells.
Bacteria and LPS
P. gingivalis (ATCC 33277 and W50) was grown
for 48 h, in a brain/heart-infusion broth supplemented
with haemin (5 mg/l), and menadione (1 mg/l), pur-
chased from Sigma-Aldrich, (UK). Following growth,
each culture was centrifuged at 15,000 rpm at 4◦C
for 30 min to pellet bacterial cells and the culture
supernatant was collected. Aliquots (1 ml or 0.5 ml)
were prepared in pre-labeled sterile Eppendorf® tubes
and stored at −80◦C until needed. Protease inhibitors
(cOmplete ULTRA®, Roche Applied Science, USA)
were added to one of the aliquots, from the culture
supernatants and the growth medium (control) and
freeze dried for at least 12 h. The lyophilized powder
was re-suspended in a 200l volume of lysis buffer
containing 50 mM Tris pH 8.0, 1% NP40, 150 mM
NaCl, and 5 mM EDTA before the total protein con-
centration was determined. These aliquots were stored
at −20°C until needed. Commercially prepared (phe-
nol extracted) lyophilized powder from Escherichia
coli LPS was obtained from Sigma-Aldrich (UK) and
re-suspended (1 mg) in 250l lysis buffer containing
protease inhibitors (used above) and stored at −20◦C.
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Positive and negative control cell lysates
Following exposure to either the sterile bacterial
growth medium (medium control) or to the P. gingi-
valis culture supernatant, SVGp12 cells were pelleted
and washed twice in cold sterile PBS with centrifuga-
tion (5 min at 2,500 rpm). The cells were lysed in buffer
containing protease inhibitors (used above). Following
incubation on ice for 30 min and frequent vortex mix-
ing, the cell homogenate was centrifuged at 12,000 rpm
for 20 min at 4◦C in a microcentrifuge. The super-
natant was collected in pre-labeled tubes and stored at
−20◦C.
Human brain tissue lysates
To prevent secondary cross contamination of the
human brain during the experimental procedures,
the specimens were handled only in the bench-top
microflow cabinet (Astec Microflow Ltd., UK), which
is regularly serviced and was always disinfected with
2% sodium hypochlorite solution (Fisher Scientific)
and sprayed with 70% ethanol before use and at the
end of the experiment. The experimenter wore dis-
posable face masks and gloves when handling tissue
and preparing the tissue lysate. A 3-mm2-thick sec-
tion of all brain specimens was taken from the original
snap-frozen unfixed tissue core and minced in the lysis
buffer containing protease inhibitors as above. Follow-
ing incubation on ice for 30 min and vortex mixing, the
tissue homogenate was centrifuged and collected in
pre-labeled tubes and stored at −20◦C. The total pro-
tein concentration of all lysates was determined using a
colorimetric assay. Protein concentration was obtained
from a standard curve prepared using 100–400g/ml
bovine serum albumin diluted in lysis buffer con-
taining protease inhibitors. After Coomassie® protein
assay reagent (Sigma-Aldrich, UK) was added to all
standards and test samples, absorbance was measured
at 595 nm wavelength using the Jenway 7315 spec-
trophotometer. The concentration of the unknowns was
calculated by comparing absorbance values with the
standard curve.
Immunoblot analysis
To confirm the presence of LPS and gingipains in
P. gingivalis culture supernatant and medium control
(initially at 60g, later adjusted to 30g per lane),
electrophoresis was performed under reducing condi-
tions using 12.5% (w/v) SDS-PAGE gels. The proteins
were electro-transferred to a polyvinylidene difluo-
ride membrane (PVDF, Immobile-P; Millipore, UK)
and blocked for 30 min at room temperature in 5%
(w/v) skimmed milk/PBS prior to incubation overnight
at 4◦C with the primary anti-P. gingivalis antibodies
(clones 1B5 and 1A1) diluted 1/20 and 1/50 respec-
tively, in 5% (w/v) skimmed milk/PBS. Following
three 15-min washes in PBS containing 0.2% tween
20, the membrane was incubated in horseradish perox-
idase (HRP)-conjugated goat anti-mouse Ig secondary
antibody (Chemicon) diluted 1/10,000 in 5% (w/v)
skimmed milk/PBS for 2 h at room temperature. Fol-
lowing further washes in PBS/tween 20, (3x15 min
each) the bands were detected using the enhanced
chemiluminescence detection reagent (Bio-Rad, UK)
under transmitted ultra violet light in a gel-doc imaging
station using the Molecular Analyst software (Bio-
Rad, UK). India ink was used to stain the membrane
to determine the amount of protein transferred onto
the membrane(s) as a loading control. Electrophore-
sis of brain tissue and SVGp12cell samples was also
carried out under reducing conditions as described
above, except the extracts loaded were 30g per lane.
Electrophoresis and immunoblotting were performed
at least six times and cross checked by at least two
experimenters.
Statistical analysis
The significance of the difference between AD and
non-AD controls was analyzed by a non-parametric
Mann-Whitney U test for two independent samples
(IBM SPSS statistics 20). The differences were con-
sidered significant at p≤ 0.05.
RESULTS
Immunoﬂuorescence labeling
Controls
All control tissue sections from the human brain
were exposed to the same conditions as the test sec-
tions. The sections in which the primary antibody
was omitted remained negative with the FITC-labeled
secondary detection system (Figs. 1a, 2a (phase over-
lay), 3a). Some generalized autofluorescence was
associated with erythrocytes, but remained below
the threshold of the noise-to-signal ratio except for
the elastin in arteries. Strong autofluorescence was
associated with brain pigment, but this was of a
different wavelength and color to that of the FITC
signal. SVGp12 cells challenged with medium con-
trol remained negative when incubated with the anti-P.
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a b c
10 µm 10 µm 10 µm
Fig. 1. Human AD brain. Confocal microscope images captured from snap-frozen brain tissue sections from Alzheimer’s disease (AD) showing
nuclei due to propidium iodide (PI) uptake. The images are overlaid with PI and the FITC signals. a) Negative control, primary antibody omitted.
b) Immunolabeled using the anti-P. gingivalis (clone 1B5) antibody overnight at 4◦C followed by detection using goat anti mouse FITC. Insert
shows extracellular aggregates with granular (pebbly) appearance embedded within a smoother matrix. c) An adjacent section from the same
brain labeled with mouse anti-CD14 for surface membrane labeling.
a b c
10 µm10 µm 10 µm
Fig. 2. An arterio-venous sinus. Immunolabeling as described for Fig. 1. a) Phase contrast image with the extracellular aggregate within the
lumen of the arterio-venous sinus. b) The extracellular aggregate is labeled with the anti-P. gingivalis antibody (clone 1B5). c) The phase contrast
image from (a) is overlaid on the immunofluorescent image from (b).
gingivalis antibody clones 1B5 (Fig. 4a) and 1A1 (not
shown) and when the primary antibody was omitted.
a b
20 µm 20 µm
Fig. 3. SVGp12 cells challenged with P. gingivalis culture super-
natant. SVGp12 cells exposed to medium control and P. gingivalis
culture supernatant for 24 h. Immunolabeling (anti-P. gingivalis,
1B5) and nuclear stain are as for Fig. 1. a) The cells exposed
to medium control remained negative despite the application of
the antibody. b) Cells exposed to the P. gingivalis culture super-
natant demonstrated intense labeling localized to membrane-bound
vesicles.
Human brain tissue sections
Post labeling the human brain tissue sections with
the mouse anti-P. gingivalis (clone 1B5), revealed
strong cellular surface membrane labeling in four out
of 10 AD cases (Fig. 1b) and not in the non-AD age-
matched controls. Extracellular aggregates “pebbly” or
“granular” in appearance were also present and were
intensely labeled in the same four AD cases (Fig. 1b
insert). Surface membrane labeling was validated with
a monoclonal anti-CD14 antibody in adjacent brain
test sections (Fig. 1c). The extracellular aggregates
were frequently observed within the brain parenchyma
and in association with arterio-venus sinuses (Fig. 2b)
as clearly shown by a phase image overlaid on the
immunofluorescence image (Fig. 2c). No labeling
associated with anti-P. gingivalis antibodies (clones
1A1 and 61BG1.3) was observed in any of the tissue
sections from control and/or AD brains. No immuno-
labeling was observed with the anti-T. forsythia
antibodies raised to rBspA protein nor with the anti-T.
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Fig. 4. Immunoblots to demonstrate gingipains and LPS are components of the culture supernatant from P. gingivalis ATCC 33277 and W50.
Total protein/lane (60g) was loaded on a 12.5% SDS-PAGE gel followed by a successful transfer to a PVDF membrane. Immunoblotting using
the primary antibody (anti-P. gingivalis clone 1B5) and secondary detection using goat anti-mouse conjugated to HRP (see text). a) Medium
control (lane 1) failed to produce any bands whereas the positive control culture supernatants from P. gingivalis ATCC 33277 (lane 2) and W50
(lane 3) demonstrated an abundance of gingipains (dark long band above and below 52 kDa) and a number of bands (45–12 kDa) corresponding
to LPS in P. gingivalis culture supernatants from ATCC 33277 and W50. b) Total protein/lane (30g) was loaded on the gel as in Fig. 4a. The
same medium control (lane 1) failed to produce any bands, whereas the positive control culture supernatant (lane 2) demonstrated bands for
gingipains at the higher molecular weight and at 45–12 kDa corresponding to LPS in P. gingivalis culture supernatant from ATCC 33277. E. coli
LPS (lane 3), and cells treated with medium control (lane 4) showed no bands. The result in lane 5 confirmed the de-novo antigen detected by
the anti-P. gingivalis (clone 1B5) antibody was LPS on SVGp12 cells. The loading control represented by India ink failed to stain the medium
control (lane 1), culture supernatants (lanes 2 and 3), and E. coli LPS (lane 3). c) A duplicate blot to that shown in (b) was exposed to the anti-P.
gingivalis clone 1A1 antibody. The same medium control (lane 1) produced no bands, whereas the positive control culture supernatant from
ATCC 33277 (lane 2) demonstrated bands for gingipains at the higher molecular weight size. E. coli LPS (lane 3) and the cells treated with
medium control (lane 4) failed to produce any bands. The presence of gingipains in SVGp12 cells was confirmed (lane 5).
denticola antibodies, although they weakly labeled the
whole bacterial cells (not shown). Experiments using
these antibodies were terminated at this stage.
In vitro culture of SVGp12 cells challenged with
P. gingivalis culture supernatant
Immunolabeling using the anti-P. gingivalis (clone
1B5) antibody demonstrated that the surface mem-
brane of SVGp12 glial cell line was intensely
labeled and appeared highly vesiculated (Fig. 3b).
The anti-P. gingivalis antibody (clone 1A1) which
is specific for gingipains was applied to SVGp12
treated cells with P. gingivalis ATCC 33277 for
over 24 h and demonstrated that the labeling was
restricted to perinuclear sites and in lysosomes (not
shown).
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Fig. 5. Human non-AD control brain tissue immunoblotted with anti P. gingivalis (clone 1B5). Electrophoresis and protein transfer was as for
Fig. 4. Total protein was 30g per lane and, unless otherwise stated, conditions for immunoblotting and loading control were as described in
Fig. 4b. While the negative controls (lanes 1 and 3) and positive controls (lanes 2 and 4) remained as expected, there were no bands in the
specimens from all five non-AD control brains (lanes 5–9).
Immunoblot analysis
LPS and gingipains were components of
P. gingivalis culture supernatant
The medium control (sterile liquid medium) ana-
lyzed under reducing conditions using immunoblotting
with the anti-P. gingivalis (clone 1B5) antibody
(Fig. 4a) failed to show any bands (lane 1). The lanes
with culture supernatants from P. gingivalis ATCC
33277 (lane 2) and W50 (lane 3) both showed a dark,
high molecular weight band for gingipains (Fig. 4a)
and a ladder of bands around 45–12 kDa corresponding
to LPS (Fig. 4a). These data agree with the previously
published literature for W50 LPS using the same anti-
body [47, 51].
Positive and negative controls
All control samples were analyzed using
immunoblotting with the anti-P. gingivalis (clones
1B5 and 1A1) antibodies (Fig. 4a-c); no bands were
visible in lanes loaded with the medium control (lane
1), E. coli LPS (lane 3, Fig. 4b-c), and SVGp12 cells
treated with sterile medium control (lane 4, Fig. 4b-c).
A ladder of bands in the range of 45–12 kDa, corre-
sponding to LPS, was detected in the P. gingivalis
culture supernatant (lane 2, Fig. 4a-b) and SVGp12
cells challenged with the same supernatant for 48 h
(lane 5, Fig. 4b). Only high molecular weight bands
were observed with anti-P. gingivalis (clone 1A1)
in both the culture supernatant (lane 2, Fig. 4c) and
SVGp12 cells challenged with the same supernatant
(lane 5, Fig. 4c). Medium control (lane 1), P. gingivalis
culture supernatant (lane 2-Fig. 4a-b, 5–7), and E. coli
LPS (lane 3-Fig. 4b-c and 5–6) consistently failed to
stain with India ink.
Human control brain
Immunoblotting with anti-P. gingivalis (clone 1B5)
(Fig. 5) detected no bands in lanes corresponding to
the sterile medium control (lane 1) and SVGp12 cells
treated with sterile control medium (lane 3). A lad-
dering pattern of bands (45–12 kDa) corresponding
to LPS was observed in both the P. gingivalis culture
supernatant (lane 2) and in SVGp12 cells treated with
the same culture supernatant (lane 4). However, no
bands were detected in the lanes loaded with the age-
matched non-AD control brains labeled 1–5 (Fig. 5,
lanes 5–9). Further control brains (Non-AD 6–10) were
also analyzed on a separate blot under identical con-
ditions and again all of the test lysates (from non-AD
brains 6–10) remained negative (data not shown).
AD brain
Consistently, no bands (Fig. 6) corresponding to the
sterile medium control (lane 1), E. coli LPS (lane 3),
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Fig. 6. Human AD brain tissue immunoblotted with anti-P. gingivalis (clone 1B5). Electrophoresis and protein transfer was as for Fig. 4. Total
protein/lane, immunoblotting reagents, and loading control conditions were the same as for Fig. 4b. The orders of negative and positive controls
(lanes 1–5) are as for Fig. 4b. Anti-P. gingivalis antibody (1B5) detected bands characteristic of the LPS at the expected molecular weight in
AD case numbers 3, 5, 8, and 10.
Fig. 7. Statistical analysis. The non-parametric Mann-Whitney U
test for two independent samples (IBM SPSS statistics 20) confirmed
there was statistical difference in AD compared with non-AD cases
(p = 0.029).
and SVGp12 cells treated with sterile medium con-
trol (lane 4) were detected following incubation in
the anti-P. gingivalis (clone 1B5) antibody. Bands in a
characteristic P. gingivalis LPS laddering pattern were
observed in lanes loaded with P. gingivalis culture
supernatant (lane 2), SVGp12 cells treated with the cul-
ture supernatant (lane 5) and in AD cases designated 3,
5, 8, and 10 (lanes 6–9) between 45–12 kDa molecular
weight positions (Fig. 6). The AD cases designated 1, 2,
4, 6, 7, and 9 were negative by immunofluorescence but
when tested by immunoblotting under identical condi-
tions to those described for Fig. 6, they (AD cases 1, 2,
4, 6, 7, and 9) consistently failed to detect any bands
(data not shown).
Statistical analysis
Immunolabeling and immunoblotting using the anti-
P. gingivalis (clone 1B5) antibody identified four out of
10 of the AD brain specimens as being positive while
10 out of 10 non-AD age-matched controls were neg-
ative for LPS. The non-parametric Mann-Whitney U
test demonstrated that the four positive AD cases were
statistically significant (p = 0.029) compared with the
non-AD controls (Fig. 7).
DISCUSSION
The theory of the human mouth as a focus of infec-
tion states that oral microbial infections contribute to
the developing pathologies of remote body organs by
infiltrating into the systemic system [52, 53]. This con-
cept prompted us to explore the hypothesis in relation
to finding a causal link between PD and AD. Studies
to understand the relationship between environmental
factors such as pathogens and their role in dementia
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including the deposition of A are crucial to under-
standing the contribution made by microbial agents to
disease pathogenesis and progression. An investiga-
tion of the etiological hypothesis will therefore rely on
sampling tissues from PM specimens obtained from
AD and non-AD individuals, with and without evi-
dence of oral infection, and from older subjects with
longer interval between onset of dementia and death.
All these variables can be investigated once autopsy
contamination of tissues from anaerobic periodontal
pathogens in the oral cavity and the CNS in PM speci-
mens has been excluded. Potentially important bacteria
include P. gingivalis, T. denticola, and T. forsythia,
one of which (T. denticola) has already been linked
to neurodegeneration and dementia [20, 45].
We assessed the presence of the major periodon-
topathogenic bacteria P. gingivalis, T. denticola, and T.
forsythia, in a small series of 10 AD brains with a 12 to
24 h PM delay and 10 non-AD cases with an extended
(16 to 43 h) PM delay. As stated (in the Materials and
Methods section), a number of antibodies were tested
on the AD and non-AD age-related control sections
using indirect immunofluorescence. The T. forsythia
[50] and T. denticola antibodies poorly detected the
native antigen on whole cells and in the brain tissue
sections. Hence, further assessment of these organisms
was not pursued. Anti-P. gingivalis antibodies, on the
contrary, intensely labeledP. gingivaliswhole cells and
their antigen within tissue sections. This prompted fur-
ther investigation of this organism in the brain tissue
of individuals with dementia with a validated neu-
ropathological diagnosis of the sporadic form of AD
(c/o Brains for Dementia Research).
The monoclonal antibody used in this investiga-
tion is well characterized [47] and is specific for P.
gingivalis LPS and gingipain epitopes [51]. To delin-
eate if it was the LPS and/or gingipains that were
being detected on the surface of cells by the anti-
P. gingivalis (clone 1B5); two additional and specific
monoclonal antibodies to gingipains [48, 49] were also
used. Immunofluorescence labeling of cells and the
immunoblot analysis conclusively revealed that it was
LPS and not gingipains from P. gingivalis that was
detected in AD brain specimens. The same antibody
confirmed that the culture supernatant from P. gin-
givalis ATCC 33277 contained LPS, thus supporting
the previously published literature from P. gingivalis
W50 [47, 51]. The non-parametric Mann-Whitney U
test demonstrated that, even from this small series,
AD cases provided a statistically significant result
(p = 0.029) compared with the non-AD controls. A
number of researchers have found bacteria [54] and
viruses associated with A deposits and tau positive
neurofibrillary tangles [17–20] in the late-onset AD
brains. However, we only detected the P. gingivalis
LPS epitope on glial cells which participate in the
innate immune responses in relation to infection in the
brain.
These results indicate that the brain of AD patients is
at a greater risk of secondary chronic infection from the
periodontal pathogen P. gingivalis which has long been
implicated in chronic and severe adult periodontitis
[55, 56]. Dental records of the individuals whose brain
specimens we examined were not available; hence, it
is difficult to comment on any direct relationship of
PD with AD during life. However, due to the poor
memory exhibited by AD patients, these individuals
may forget to maintain optimal oral hygiene which
during advanced stages of AD would be expected to
deteriorate even further [57–60].
Bacteremia in AD patients is inevitable because of
impaired swallowing reflexes during the late stages
of the disease process. The impaired functionality of
the muscles associated with swallowing is likely to
increase oral pathogens gaining entry into the systemic
circulation. Direct access of pathogens and/or their
endotoxins into the CNS from the circumventricular
organs can take place because these regions of the brain
have an incomplete BBB [36, 38] and are the primary
port for bacterial and LPS entry into the brain following
systemic infections [37]. An alternative route of direct
access of bacteria and/or their products into the CNS is
from the perivascular space using systemic circulation.
Multiple systemic infections are reported to exac-
erbate premorbid cognitive status in AD patients and
the current view indicates that this is the result of
proinflammatory mediators crossing the BBB [43,
61, 62]. We frequently observed aggregates of “LPS”
within the brain tissue as well as in some intravenous
sinuses. Detecting systemic LPS is relevant because it
is a powerful stimulator of the innate immune system.
Once in the brain it will activate local glia to mount an
innate immune response. The LPS hyper-sensitized
microglia increase synthesis of inflammatory medi-
ators, such as TNF-, IL-1, and IL-6, complement
factors, TLRs 2 and 4 and nitric oxide that release free
radicals and reactive oxygen species [24] and increase
tissue damage.
In this study, the in vitro data has demonstrated that
SVGp12 cells adsorbed LPS from P. gingivalis cul-
ture supernatant that contained a battery of molecular
determinants, including endotoxin (LPS) and extracel-
lular cysteine proteases (gingipains) [63, 64] as well
as metabolites such as butyric and propionic acids.
S. Poole et al. / P. gingivalis LPS in Alzheimer’s disease brains 675
Of these, LPS was adsorbed on the surface mem-
brane by the astroglial cell line whereas gingipains
demonstrated an intracellular localization [65]. This
observation supports the results from the human brain
which demonstrated that LPS was adsorbed by CNS
glia as detected by the surface membrane immunola-
beling using the anti-P. gingivalismonoclonal antibody
[47, 51], and validated by the anti-CD14 receptor
antibody. In addition, the immunoblot detecting char-
acteristic LPS laddering pattern using the same (anti-P.
gingivalis) antibody [47, 51] on the same AD cases
unequivocally demonstrates that it was LPS adsorbed
by CNS glia in the human brain. LPS was absent from
the control brain tissues with PM interval extending to
43 h.
In summary, immunolabeling and immunoblotting
of brain tissue from individuals with and without
dementia has provided statistically significant evi-
dence to implicate the presence of LPS from P.
gingivalis in AD cases with 12 h maximum PM delay.
No evidence of LPS from P. gingivalis was detected in
the non-AD control tissues with longer PM delay (up
to 43 h). Once in the brain, microglia will respond to
the LPS and activate the CNS innate immune system.
This will result in the initiation of a pro-inflammatory
cascade to bring about the local release of potentially
neurotoxic substances such as cytokines, complement
factors, and reactive oxygen species and exacerbate the
preexisting disease-related inflammatory pathology.
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PD is an easily modified 
risk factor; hence the 
need to prioritise 
further research into 
the link between these 
two conditions
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Emerging evidence for associations between periodontitis 
and the development of Alzheimer’s disease 
by Sophie Poole, Sim K Singhrao and St John Crean
Periodontal disease (PD) is an inflammatory disease 
affecting tooth-supporting tissues in which interaction of 
specific bacteria and the host’s immune responses play a 
pivotal role. The pathogenic bacteria associated with PD are 
a source of systemic inflammation as they have the ability 
to enter systemic circulation during everyday tasks such as 
brushing teeth and chewing food. Alzheimer’s disease (AD) 
is a form of dementia whereby inflammation is thought to 
play a key role in its pathogenesis and the risk of developing 
the disease increasing with age. The exact aetiology of the 
late-onset AD is unknown but peripheral infections are 
being considered as a potential risk factor.
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PD begins as a peripheral infection, inducing inflam-
mation that leads to cellular destruction. It contributes 
to systemic inflammation and is highly prevalent in the 
elderly population, hence the potential link with AD. 
Although a clear causative relationship between PD and 
AD has not yet been established, there is a basis for local 
inflammatory responses being initiated within the cen-
tral nervous system (CNS) following the direct invasion 
of PD pathogens and/or their virulence factors, or the 
migration of systemic inflammatory mediators (cyto-
kines) into the brain. If chronic inflammation becomes 
established, it will compromise the health of neurons 
and lead to poor memory. This review will briefly look at 
the theory behind the potential of PD to cause or exacer-
bate AD pathology and the existing evidence in favour of 
a link between the two conditions.
Periodontal disease
Periodontal disease is a disease of the tooth-supporting 
tissues in which interaction of specific bacteria and the 
host’s immune system play a pivotal role.1 In the early 
stages of PD (gingivitis), the host’s innate and adaptive 
immune responses are able to control bacterial infection. 
However, once the amount of bacteria and its products 
increase beyond the host’s immune threshold level then 
the balance shifts from a healthy to diseased status. 
This results in an uncontrolled inflammatory response, 
leading to the destruction of tooth-supporting tissues, 
including the gingivae, periodontal ligament, and alveo-
lar bone. The rate at which the disease progresses varies 
among individuals and is influenced by oral hygiene, 
dietary composition, salivary flow rates and the host’s 
immune defenses.
The ‘red complex’ pathogenic bacteria are strongly asso-
ciated with chronic PD and comprise Treponema denticola, 
Tannerella forsythia and Porphyromonas gingivalis.2,3 These 
are armed with multiple virulence factors to maximise tis-
sue destruction and invasion outside of the oral cavity via 
bacteriemic episodes that occur during the performance 
of essential daily chores such as chewing food and brush-
ing teeth.4–6 Therefore PD is a chronic infectious disease 
that, if left untreated, results in years of significant bacte-
rial infection and inflammation, both locally and within 
the systemic system. The presence of oral pathogens 
within the systemic system and the inflammation caused 
by them form the basis for the proposed link between 
periodontal disease and systemic diseases including car-
diovascular diseases,7,8 diabetes,9 rheumatoid arthritis,10–12 
and Alzheimer’s disease.13–16
Alzheimer’s disease
Dementia is a common disorder among the elderly that 
becomes more prevalent with advancing age. Given 
that there has been a rapid rise in the world popula-
tion, with the most elderly being the fastest growing 
segment, dementia has become an increasing public 
health concern. Dementia comprises a group of neuro-
degenerative diseases in which the symptoms include a 
decline in cognitive and intellectual function, together 
oral pathogens within 
the systemic system 
and the inflammation 
caused by them form 
the basis for the 
proposed link between 
periodontal disease 
and systemic diseases 
including cardiovascular 
diseases, diabetes, 
rheumatoid arthritis 
and Alzheimer’s disease
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with loss of memory, attention and problem-solving skills. 
Alzheimer’s is considered to be the most common cause 
of dementia, representing 68–80% of all cases. The exact 
cause of the development and progression of sporadic 
AD remains under investigation – however, inflammation 
is thought to play a vital role. 
The pathological characteristics of AD are an accumula-
tion of intracellular neurofibrillary tangles (NFT) and 
extracellular deposits of fibrillary beta amyloid (Aβ). 
These hallmark proteins have traditionally been given 
the full credence for intracerebral inflammation in AD 
owing to the belief that brain is an ‘immunoprivileged 
organ’ and as such is protected from plasma proteins 
and extracerebral toxins entering the brain and causing 
an immune response by local CNS glial cells. It is now 
understood that the circumventricular organs (CVO) 
are not protected by the blood-brain barrier17 and that 
peripheral infections and inflammatory mediators can 
access the brain.18–20 This implies microbial infections 
and the innate immune system may play a role in the de-
velopment of inflammation within the brain, contribut-
ing to the pathogenesis of cognitive deficit in subclinical 
and the clinical AD individuals. 
Indeed, the aetiological hypothesis suggests that viruses 
and bacteria and/or their virulence factors can access 
the brain and thereby contribute to AD pathogenesis. 
A review by Holmes and Cotterell21 outlines a range of 
infective agents consistently being linked to AD. These 
include herpes simplex virus type I,22 Chlamydophilia pneu-
monia,23 Treponema spp.,13 Borrelia burgdorferi,24 and more 
recently lipopolysaccharide (LPS) from P. gingivalis,16 
one of the key bacteria linked to PD. As with the other 
infections implicated in AD, PD begins as a peripheral 
infection that can induce inflammation leading to cel-
lular destruction, contribute to systemic inflammation 
and most importantly is highly prevalent in the elderly 
population.
Evidence in favour of a link between periodontal disease 
and Alzheimer’s
In support of the aetiological hypothesis from the 
periodontopathogens aspect, longitudinal studies sug-
gest that individuals who develop AD have poor oral 
health.14,25–28 This may be due to the longstanding inflam-
matory burden of PD pathogens on the systemic system 
and potentially the CNS. Although another explanation 
is subsequent poorer quality of oral health care when se-
verity of dementia prevents the individual from maintain-
ing their personal hygiene.27,29 Subsequent studies have 
tried to identify biomarkers to find a more specific link 
between periodontal disease and AD. Researchers have 
demonstrated that AD patients express high-circulatory 
antibody titers to periodontal pathogens alongside 
higher levels of the proinflammatory cytokine tumour 
necrosis factor-α (TNF-α) cytokine in their blood than 
the age-matched controls.15,30 It was also reported that a 
high titer of circulating IgG from a range of periodontal 
pathogens, during advancing age, significantly corre-
lates with onset of mild cognitive impairment and AD.31 
Although these markers allow general immune function 
to be monitored, they may not necessarily be specific to 
periodontal disease. It remains to be determined wheth-
er the potential link between the two diseases is direct 
(via the bacteria itself invading the organ) or indirect 
(via the systemic inflammation caused by the presence 
of periodontal bacteria). Evidence is accumulating in 
favour of peripheral inflammatory mechanisms that can 
alter brain inflammation, with the current view indicat-
ing that this is the result of proinflammatory mediators.32 
The same researchers have demonstrated that multiple 
systemic infections can exacerbate premorbid cognitive 
status in AD patients.32,33 
On the contrary, methodological studies have emerged 
demonstrating the presence of bacteria within the cere-
bral tissues, suggesting that the association between poor 
oral health and AD may result from the direct invasion 
of the CNS by oral bacteria or their virulence factors. 
One seminal study using molecular and immunological 
methodologies demonstrated the presence of seven oral 
Treponema species in 14 of 16 AD cases, reaching statisti-
cal significance.13 In addition, the same authors demon-
strated that the trigeminal nerve ganglia, hippocampus 
and the pons taken from embalmed cadavers (2 out of 
4) also confirmed the presence of Treponema species. Fur-
thermore, Miklossy34 identified Treponema species of bac-
teria in 14/16 AD cases and only 4/18 non-AD controls; 
some of which were from oral origin. Studies performed 
on immunosuppressed mice have also demonstrated 
an increased risk from endodontic infections, with the 
fastidious oral spirochete T. denticola35 supporting the 
findings of Riviere et al,13 and Miklossy.34 
Recent findings using immunolabelling and immunob-
lotting of brain tissue from individuals with and without 
dementia provide statistically significant evidence to 
implicate the presence of LPS from P. gingivalis in AD 
cases with short postmortem (PM) delay. No evidence of 
LPS from P. gingivalis was detected in the non-AD con-
trol brain tissues with longer PM delay (up to 43h).16 The 
demonstration of systemic LPS (of oral origin) is relevant 
because it is a powerful stimulator of the innate immune 
system. Once in the brain it will activate local glia to 
mount an innate immune response. The LPS hyper-
sensitised microglia increase synthesis of inflammatory 
mediators, such as TNF-α, IL-1β and IL-6, complement 
factors, TLRs 2 and 4 and nitric oxide, which release 
free radicals and reactive oxygen species and increase 
bystander tissue damage. Animal studies have shown 
that chronic infusion of LPS into rat brains may result 
in long-lasting inflammatory reaction, with pathological 
changes such as increased number of activated glia and 
increase in cytokine burden leading to the degeneration 
of hippocampal pyramidal neurons and impairment in 
spatial working memory. PD provides a significant bacte-
rial and inflammatory burden within the systemic system 
and, with the addition of a direct invasion of the CNS 
by PD-associated bacteria or their virulence factors, it is 
becoming increasingly evident that PD has the ability to 
enhance inflammation within the brain and contribute 
to the initiation and/or pathogenesis of AD.
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Conclusions
Literature suggests a link between PD and AD. Further 
evidence is needed to support a causative link between 
periodontal pathogenic bacteria and AD. Understand-
ing the factors and mechanisms involved in the aetiology 
of AD is of paramount importance as, in common with 
adverse oral health conditions, AD and other neurode-
generative disorders are becoming increasingly common 
among aging populations. However, unlike AD poor oral 
health – including caries, tooth loss, and periodontitis 
– is potentially treatable and preventable. A number of 
risk factors have been identified for AD, some of which 
are immutable; whereas others can be modified by 
simple changes to an individual’s lifestyle. PD is an easily 
modified risk factor; hence the need to prioritise further 
research into the link between these two conditions. 
References 
1. Haffajee AD, Socransky SS, Dzink JL et al. Clinical, microbiological 
and immunological features of subjects with destructive  periodontal 
diseases. J Clin Periodontol 1998;15: 240–246.
2. Socransky SS, Haffajee AD, Cugini MA et al. Microbial complexes in 
subgingival plaque . J Clin Periodontol 1998; 25: 134–144.
3. Holt SC, Ebersole JL. Porphyromonas gingivalis, Treponema denticola 
and Tannerella forsythia: the “red complex”, a prototype polybacterial 
pathogenic consortium in periodontitis. Periodontol 2000 2005; 38: 
72–122.
4. Forner L, Larsen T, Kilian M, Holmstrup P. Incidence of bacteremia 
after chewing, tooth brushing and scaling in individuals with 
periodontal inflammation. J Clin Periodontol 2006; 33: 401–407.
5. Lockhart PB, Brennan MT, Sasser HC et al. Bacteremia associated 
with toothbrushing and dental extraction. Circulation 2008; 117: 
3,118–3,125.
6. Bahrani-Mougeot FK, Paster BJ, Coleman S et al. Diverse and novel 
oral bacterial species in blood following dental procedures. J Clin 
Microbiol 2008; 46: 2,129–2,132.
7. DeStefano F, Anda RF, Kahn HS et al. Russell Dental disease and risk 
of coronary heart disease and mortality. BMJ 1993; 13;306: 688–691. 
8. Wu T, Trevisan M, Genco RJ et al. Periodontal disease and risk of 
cerebrovascular disease: the first national health and nutrition 
examination survey and its follow-up study. Arch Intern Med 2000; 160: 
2,749–2,755.
9. Scannapieco FA, Grossi SG, Genco RJ. Periodontal disease and 
diabetes mellitus: a two-way relationship. Ann Periodontol 1998; 3: 
51–61.
10. Gleissner C, Willershausen B, Kaesser U, Bolten WW. The role of risk 
factors for periodontal disease in patients with rheumatoid arthritis. 
Eur J Med Res 1998; 3: 387–392.
11. Bartold PM, Marshall RI, Haynes DR. Periodontitis and rheumatoid 
arthritis: a review. J Periodontol 2005; 76: 2,066–2,074.
12. Pischon N, Pischon T, Kroger J et al. Association among rheumatoid 
arthritis, oral hygiene, and periodontitis. J Periodontol 2008; 79: 
979–986.
13. Riviere GR, Riviere KH, Smith KS. Molecular and immunological 
evidence of oral Treponema in the human brain and their association 
with Alzheimer’s disease. Oral Microbiol Immunol 2002; 17: 113–118.
14. Stein PS, Desrosiers M, Donegan SJ et al. Tooth loss, dementia 
and neuropathology in the Nun Study. J Am Dent Assoc 2007; 138: 
1,314–1,322.
15. Kamer AR, Craig RG, Pirraglia E et al. TNF-alpha and antibodies 
to periodontal bacteria discriminate between Alzheimer's disease 
patients and normal subjects. J Neuroimmunol 2009; 30: 216: 92–97. 
16. Poole S, Singhrao SK, Kesavalu L et al. Determining the presence 
of periodontopathic virulence factors in short-term postmortem 
Alzheimer's disease brain tissue. J Alzheimers Dis 2013; 1: 36: 665–677.
17. Oldfield BJ, Mckinley MJ. Circumventricular organs. In: Paxinos G ed. 
The Rat Nervous System. San Diego: Academic Press; 1995.
18. Lacroix S, Feinstein D, Rivest S. The bacterial endotoxin 
lipopolysaccharide has the ability to target the brain in upregulating 
its membrane CD14 receptor within specific cellular populations. 
Brain Pathol 1998; 8: 625–640.
19. Ross CA, Poirier MA. Protein aggregation and neurodegenerative 
disease. Nat Med 2004; 10: S10–17.
20. Rivest S. Regulation of innate immune responses in the brain. Nat Rev 
Immunol 2009; 9: 429–39.
21. Holmes C, Cotterell D. Role of infection in the pathogenesis of 
Alzheimer’s disease. CNS Drugs. 2009; 23: 993–1002.
22. Itzhaki RF, Wozniak MA. Herpes simplex virus type 1 in Alzheimer's 
disease: the enemy within. J Alzheimers Dis 2008; 13: 393–405.
23. Balin BJ, Little CS, Hammond CJ et al. Chlamydophila pneumoniae 
and the etiology of late-onset Alzheimer's disease. J Alzheimers Dis 2008; 
13: 371–380.
24. Miklossy J. Alzheimer’s disease – a neurospirochetosis. Analysis of the 
evidence following Koch’s and Hill’s criteria. J Neuroinflammation 2011; 8: 
90.
25. Arrivé E, Letenneur L, Matharan F et al. Oral health condition of 
French elderly and risk of dementia: a longitudinal cohort study. 
Community Dent Oral Epidemiol 2012; 40: 230–238.
26. Paganini-Hill A, White SC, Atchison KA. Dentition, dental health 
habits, and dementia: the Leisure World cohort study. J Am Geriatr Soc 
2012; 60: 1,556–1,563.
27. Philip P, Rogers C, Kruger E, Tennant M. Oral hygiene care status 
of elderly with dementia and in residential aged care facilities. 
Gerodontology 2012; 29: 306–311.
28. Syrjälä AM, Ylöstalo P, Ruoppi P, Komulainen K, Hartikainen S, 
Sulkava R et al. Dementia and oral health among subjects aged 75 
years or older. Gerodontology 2012; 29: 36–42.
29. Arai K, Sumi Y, Uematsu H, Miura H. Association between dental 
health behaviours, mental/physical function and self-feeding ability 
among the elderly: a cross-sectional survey. Gerodontology 2003; 20: 
78–83.
30. Sparks Stein P, Steffen MJ, Smith C et al. Serum antibodies to 
periodontal pathogens are a risk factor for Alzheimer’s disease. 
Alzheimers Dement 2012; 8: 196–203.
31. Okuda K, Kato T, Naito Y et al. Susceptibility of Bacteroides gingivalis 
to bactericidal activity of human serum. J Dent Res 1986; 65: 1,024–
1,027.
32. Holmes C, El-Okl M, Williams AL et al. Systemic infection, interleukin 
1beta, and cognitive decline in Alzheimer’s disease. J Neurol Neurosurg 
Psychiatry 2003; 74: 788–789.
33. Holmes C, Cunningham C, Zotova E et al. Systemic inflammation 
and disease progression in Alzheimer’s disease. Neurology 2009; 73: 
768–774.
34. Miklossy J, Kis A, Radenovic A et al. Beta-amyloid deposition and 
Alzheimer's type changes induced by Borrelia spirochetes. Neurobiol 
Aging 2006; 27: 228–236.
35. Foschi F, Izard J, Sasaki H et al. Treponema denticola in disseminating 
endodontic infections. J Dent Res 2006; 85: 761–765.
RESEARCH
Sophie Poole, Sim K Singhrao and  St John Crean
42
FACULTY DENTAL JOURNAL January 2014 • Volume 5 • Issue 1
Un
co
rre
cte
d A
uth
or
 P
ro
of
Journal of Alzheimer’s Disease xx (20xx) x–xx
DOI 10.3233/JAD-140315
IOS Press
1
Active Invasion of Porphyromonas gingivalis
and Infection-Induced Complement
Activation in ApoE−/− Mice Brains
1
2
3
Sophie Poolea,1, Sim K. Singhraoa,∗, Sasanka Chukkapallib,1, Mercedes Riverab, Irina Velskob,
Lakshmyya Kesavalub,c,2 and StJohn Creana,2
4
5
aOral & Dental Sciences Research Group, School of Medicine and Dentistry, University of Central Lancashire,
Preston, UK
6
7
bDepartment of Periodontology, College of Dentistry, University of Florida, Gainesville, Florida, USA8
cDepartment of Oral Biology, College of Dentistry, University of Florida, Gainesville, Florida, USA9
Accepted 26 May 2014
Abstract. Periodontal disease is a polymicrobial inflammatory disease that leads to chronic systemic inflammation and direct
infiltration of bacteria/bacterial components, which may contribute to the development of Alzheimer’s disease. ApoE−/− mice
were orally infected (n = 12) with Porphyromonas gingivalis, Treponema denticola, Tannerella forsythia, and Fusobacterium
nucleatum as mono- and polymicrobial infections. ApoE−/− mice were sacrificed following 12 and 24 weeks of chronic infection.
Bacterial genomic DNA was isolated from all brain tissues except for the F. nucleatum mono-infected group. Polymerase chain
reaction was performed using universal 16 s rDNA primers and species-specific primer sets for each organism to determine
whether the infecting pathogens accessed the brain. Sequencing amplification products confirmed the invasion of bacteria into
the brain during infection. The innate immune responses were detected using antibodies against complement activation products
of C3 convertase stage and the membrane attack complex. Molecular methods demonstrated that 6 out of 12 ApoE−/− mice brains
contained P. gingivalis genomic DNA at 12 weeks (p = 0.006), and 9 out of 12 at 24 weeks of infection (p = 0.0001). Microglia
in both infected and control groups demonstrated strong intracellular labeling with C3 and C9, due to on-going biosynthesis.
The pyramidal neurons of the hippocampus in 4 out of 12 infected mice brains demonstrated characteristic opsonization with C3
activation fragments (p = 0.032). These results show that the oral pathogen P. gingivalis was able to access the ApoE−/− mice
brain and thereby contributed to complement activation with bystander neuronal injury.
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INTRODUCTION25
Alzheimer’s disease (AD) is a form of demen-26
tia associated with cognitive decline and irreversible27
memory loss. The pathological hallmarks of AD28
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brains are an accumulation of intracellular hyper- 29
phosphorylated tau-positive neurofibrillary tangles 30
(NFT) together with insoluble, fibrillary amyloid- 31
(A) plaques, which are traditionally recognized as 32
being triggers that stimulate glial cell activation and 33
initiate local innate immune responses [1]. AD has a 34
complex etiology in which the genetic makeup of the 35
individual and environmental factors play a role. The 36
late-onset form of AD is particularly interesting as its 37
etiology remains unknown despite the known genetic 38
risk factors, including apolipoprotein E (ApoE) gene 39
and its E4 allele inheritance [2, 3]. This risk factor is 40
ISSN 1387-2877/14/$27.50 © 2014 – IOS Press and the authors. All rights reserved
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associated with severe AD pathology and an enhanced41
inflammatory response by microglia [4].42
Peripheral infections also serve as a significant43
risk factor affecting mental health as demonstrated in44
clinical studies in which cognitive decline and deterio-45
rating memory are reported [5–7]. A range of infective46
agents is consistently being linked to AD [8], including47
viruses such as the Herpes simplex virus type 1 (HSV-48
1) [9]; bacteria such as Chlamydophila pneumoniae49
(C. pneumoniae) [10]; and various types of spiro-50
chetes, including Borrelia burgdorferi (B. burgdorferi)51
[11–13] and periodontal Treponema spp., [14] and52
more recently Porphyromonas gingivalis (P. gingi-53
valis) [15]. P. gingivalis and some oral Treponema54
species are invasive and virulent within their origi-55
nal niche where they induce gingival inflammation56
that leads to connective tissue degradation and alve-57
olar bone resorption around teeth [16, 17]. Once58
the junctional epithelium that links the gingiva to59
the tooth enamel transforms to pocket epithelium,60
pathogenic bacteria induce bacteremia and initiate61
systemic inflammation by infiltrating the local blood62
vessels [18–20]. These factors may lead to various63
chronic inflammatory disorders such as cardiovascular64
disease(s) [21, 22], diabetes [23], rheumatoid arthritis65
[24–26], premature births [27], and AD [14, 15 28, 29].66
Clinical studies by Stein et al. [28] support a strong67
association between tooth loss due to periodontal dis-68
ease and the development of AD. They noted a greater69
rate of cognitive decline occurring in carriers of the70
ApoE 4 allele variant with fewer teeth [30]. Although71
chronic infection by Treponema pallidum is widely72
accepted for the atrophic form of general paresis, it and73
B. burgdorferi infections (etiological bacteria for Lyme74
disease) are also reported to result in dementia [11–13].75
These spirochete infections give rise to the similar76
pathological hallmark features such as A4 plaques77
and NFTs seen in AD [11–13]. This is regarded as a78
direct link between spirochete infections and the devel-79
opment of AD. C. pneumoniae and HSV-1 infections80
of the brain also appear to be associated with the A81
deposition observed in AD [9, 10, 12]; however, their82
role as infection by individual pathogen or occurring83
as co-infections with the invading spirochetes remains84
under investigation [12]. T. denticola and P. gingivalis85
oral infections of the brain are also reported [14, 15],86
but their direct involvement with the deposition of A487
and NFTs is not clear.88
Inflammation in the brain is characterized by89
the presence of reactive microgliosis and astrocy-90
tosis (inflammatory phenotype) and is an accepted91
component of AD pathology [1]. Traditionally, the92
inflammatory component of the pathology in AD is 93
believed to be the result of cytokines, oxidative stress, 94
and complement activation, including the membrane 95
attack complex due to the hallmark proteins of AD 96
[1]. However, the fact that pathogens are implicated 97
in some forms of central nervous system (CNS) dis- 98
eases that result in the eventual development of AD 99
(11–13), suggests that the existing hypothesis cannot 100
exclude a possible role of chronic infections gener- 101
ating an inflammatory pathology in AD. Concerning 102
chronic infections in AD brains, in 2008 two inde- 103
pendent research groups implicated the indirect role 104
of periodontal pathogens and/or their virulence factors 105
in the development of AD [31, 32] involving acute- 106
phase proteins, including cytokines, as a plausible 107
link between periodontal bacteria and inflammatory 108
AD pathology. Miklossy (2008) proposed a direct link 109
between oral spirochetes and AD via bacterial infection 110
of the brain in which either the spirochetes or their vir- 111
ulence factors activate the classical and the alternative 112
pathways of complement, resulting in vital cell loss via 113
the membrane attack complex [33]. Thus, the presence 114
of cytokines and/or an activated complement cascade 115
can be used as a marker to measure CNS inflammation 116
in this context. 117
Further demonstration of a high titer of antibodies 118
against periodontal pathogens in the serum of elderly 119
who progressed to AD also suggests the possible asso- 120
ciation between periodontal disease and AD [34]. 121
Poor oral hygiene [35] is strongly linked to the devel- 122
opment of dementia; however to date there are very 123
few reports establishing an experimental link between 124
periodontal disease and AD. Two studies using human 125
brain tissue explored the impact of periodontal infec- 126
tions on AD [14, 15]. These studies examined AD brain 127
tissue specimens using molecular profiling methodolo- 128
gies to identify seven Treponema species [14] and the 129
immunogenic endotoxin, lipopolysaccharide (LPS), 130
from P. gingivalis [15]. 131
Focal dissemination of periodontal pathogens from 132
the oral cavity to distant organ sites has long been 133
hypothesized, but few studies have explored this the- 134
ory. Previous studies using wild-type mice (C57BL/6J) 135
explored the dissemination of periodontal pathogens 136
in an endodontic infection model [36]. However, the 137
study detailed here was unable to trace the dissemi- 138
nation of periodontal pathogens to distant organ sites 139
due to the disadvantages associated with using a wild- 140
type mouse model [36]. The ApoE−/− mouse model, 141
which is a proatherogenic model for co-morbidity stud- 142
ies, is unable to deposit A in the brain as the essential 143
ApoE isoforms are lacking [37]. This mouse serves 144
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as a suitable model with which to study the associa-145
tion between periodontal disease and AD as it avoids146
confounding factors that may result from an overlap147
of signaling in response to AD hallmark proteins and148
pathogen-associated molecular patterns. Thus, keep-149
ing in view the lack of in vivo experimental evidence150
for a link between periodontal pathogens/disease and151
AD, the present study aimed to explore such an asso-152
ciation using the ApoE−/− mouse as a model. This153
study also tested the hypothesis that infectious agents154
and/or their components from oral diseases such as155
periodontitis can access the brain and modulate local156
CNS inflammation. To this end, we investigated the157
role of the oral pathogens P. gingivalis, T. denticola,158
and T. forsythia in accessing the brain of ApoE−/−159
mice following chronic experimental periodontitis and160
in contributing to the development of local inflam-161
mation as an early pathological lesion in relation to162
AD.163
The present study explored the possibility of specific164
oral pathogens altering normal functioning of the brain165
in experimental animals with established periodonti-166
tis. In this infection model F. nucleatum was used as a167
bridging organism that co-aggregates with major peri-168
odontal bacteria in both supra- and subgingival biofilm169
development and for the subsequent progression of170
periodontitis [38–40].171
MATERIALS AND METHODS172
Mice, oral infection, and brain173
The study involved oral infection of ApoE−/− mice174
with periodontal pathogens either as mono- or poly-175
bacterial for a chronic infection period of 24 weeks.176
Following the infection period the mice were eutha-177
nized and the brain tissue was collected and preserved.178
Later, using molecular, immunological, and patholog-179
ical detection techniques we evaluated the invasion of180
periodontal bacteria into the mice brains.181
Microbial strains182
P. gingivalis FDC 381, T. denticola ATCC 35404, T.183
forsythia ATCC 43037, and F. nucleatum ATCC 49256184
were used in the study and were routinely cultured185
anaerobically at 37◦C as described previously [41].186
ApoE−/− mice oral infection187
Eight-week-old male ApoE−/− mice strain188
B6.129P2-Apoetm1Unc/J, Jackson Laboratories, Bar189
Harbor, ME, USA) were randomly assigned to sham- 190
infected, mono-infected (P. gingivalis, T. denticola, 191
T. forsythia,F. nucleatum) and polymicrobial-infected 192
groups, n = 12 in each group). This mouse study 193
was carried out in strict accordance with the rec- 194
ommendations in the Guide for the Care and Use 195
of Laboratory Animals of the National Institutes 196
of Health, USA. All procedures were performed in 197
accordance with the approved protocol guidelines 198
(Protocol # 201004367) set forth by the Institutional 199
Animal Care and Use Committee of the University of 200
Florida. The University of Florida has an Assurance 201
with the Office of Laboratory Animal Welfare and fol- 202
lows Public Health Service policy, the Animal Welfare 203
Act and Animal Welfare Regulations, and the Guide 204
for the Care and Use of Laboratory Animals, USA. 205
ApoE−/− mice were administered with 500g/mL 206
kanamycin in drinking water for 3 days followed by 207
a mouth rinse with 0.12% chlorhexidine gluconate 208
[42] before the first oral lavage with the periodontal 209
bacteria [42] to suppress the murine indigenous 210
oral microflora. While mono-infections involved a 211
bacterial inoculum of 109 cells/mL of respective 212
bacteria, the polymicrobial-infection constituted 213
an inoculum of 5 × 109 combined bacteria/mL, as 214
described previously [41, 42]. This investigation is 215
part of an on-going collaboration with the University 216
of Florida and the University of Central Lancashire 217
(UCLan) (MTA Ref. No. A10415). Ethical approval 218
was obtained from the Animal Projects Committee 219
of UClan for research on animal tissues as secondary 220
users (Ref. No. RE/11/01/SS). 221
Collection and storage of brain tissue specimens 222
The mouse brains were removed following 12 and 24 223
weeks of oral infection as well as sham-infection and 224
separated into two halves. One cerebral hemisphere 225
was immediately stored at −80◦C in RNAlater® buffer 226
for subsequent molecular biology analysis and the 227
other half fixed in 10% neutral buffered formalin for 228
histopathological analysis. 229
Genomic DNA Isolation 230
To confirm the spread of periodontal pathogens from 231
the mouth to the brain of ApoE−/− male mice, genomic 232
DNA was isolated from the brains of all the infected 233
and sham-infected groups. Briefly, frozen brain tissue 234
(25 mg) was removed, close to the circumventricu- 235
lar organs in a bench top microflow cabinet (Astec 236
Microflow Ltd., UK), using the aseptic technique [15]. 237
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Table 1a
PCR primers from Paster et al. [43]
Primer Function Orientation Sequence
D88 PCR Forward GAGAGTTTGATYMTGGCTCAG
E94 PCR Reverse GAAGGAGGTGWTCCARCCGCA
Table 1b
Specific primer sets used for analysis of bacterial DNA from ApoE−/− mice brains by PCR
Primer [Ref] Amplicon size Primer Sequence
P. gingivalis [44] PCR Forward AGGCAGCTTGCCATACTGCG
P. gingivalis [44] PCR Reverse ACTGTTAGCAACTACCGATGT
T. denticola [41] PCR Forward TAATACCGAATGTGCTCATTTACAT
T. denticola [41] PCR Reverse CTGCCATATCTCTATGTCATTGCTCTT
T. forsythia [44] PCR Forward GCGTATGTAACCTGCCCGCA
T. forsythia [44] PCR Reverse TGCTTCAGTGTCAGTTATACCT
M13 (Invitrogen) Sequencing Reverse CAGGAAACAGCTATGAC
Following the manufacturer’s protocol (Qiagen DNA238
easy blood & tissue kit 69504), brain tissue was239
lysed and genomic DNA was isolated manually using240
ethanol precipitation.241
DNA ampliﬁcation and sequencing242
Polymerase chain reaction (PCR) was performed243
using a thermocycler (Veriti, Applied Biosystems,244
UK), initially using the universal bacterial primers245
(Table 1a) from the 16 s rDNA bacterial genes [43]. For246
the bacterial-specific gene amplification, the primer247
sets from Figuero et al. [44] and Rivera et al. [41]248
(Table 1b) were employed, adhering to the published249
PCR protocols [41, 44]. PCR products were analyzed250
using agarose gel electrophoresis (1.5%) and visu-251
alized in the Gene Genius bio-imaging system, and252
images were captured using the Gene snap software253
(Syngene, UK). The PCR product was cleaned in254
MicroCLEAN DNA Cleanup® reagent (Web Scientific255
Ltd.) and cloned using the TA TOPO cloning kit (Invit-256
rogen) according to the manufacturer’s instructions.257
Following successful colony screening, a mini culture258
(10 ml) of each of the selected colonies was set up259
overnight and plasmid DNA isolated using a Qiaquick260
kit (Qiagen). This was followed by sequencing (40 ng)261
with the M13 forward or reverse primers (TA TOPO262
cloning kit, Invitrogen) and using the BigDye™263
Terminator v3.1 cycle sequencing kit (Applied Biosys-264
tems) according to the manufacturer’s instructions.265
The sequencing parameters were an initial denatura-266
tion step at 96◦C for 1 min and 25 cycles involving267
(96◦C for 10 s), annealing (50◦C for 5 s), and elonga-268
tion (60◦C for 4 min) according to Paster et al. [43].269
Following sequencing the results were submitted to270
BLAST nucleotide search engine for 16 s DNA genes 271
(http://blast.ncbi.nlm.nih.gov/) to identify the organ- 272
ism(s) with 99–100% match with at least 200 bases. 273
Immunodetection of periodontal pathogens in 274
mouse brain tissue 275
Isolation of total protein from mouse brain tissue 276
In each case a 3-mm-thick section of the cortical 277
brain was minced in the lysis buffer containing pro- 278
tease inhibitors [15]. The total protein concentration 279
of all cell lysates was determined as described previ- 280
ously [15]. A number of positive and negative controls 281
were kindly provided as gift reagents and their sources 282
are identified in Table 2. These were sterile bacterial 283
growth medium (medium control) and P. gingivalis 284
culture supernatant as described in Poole et al. [15], 285
purified recombinant T. denticola protein (FhbB) [45], 286
and ready-to-use T. forsythia whole-cell lysate [46]. 287
Immunoblot analysis 288
Immunoblotting was performed under reducing con- 289
ditions in which up to 60g per lane of total protein 290
from all brain specimens was loaded [15] on SDS- 291
PAGE gels of variable percentages (7.5% gels were 292
used for high-molecular-weight proteins such as the 293
S-layer of T. forsythia, 12.5% for gingipains and LPS 294
from P. gingivalis and 15% w/v gels were used for the 295
low-molecular-weight proteins detected by anti-T. den- 296
ticola antibodies). Following electrophoresis, proteins 297
were electro-transferred to a polyvinylidene difluoride 298
membrane (PVDF, Immobilon-P; Millipore, UK). The 299
membranes were blotted with mouse anti-P. gingivalis 300
(clone 1B5), rabbit anti-T. forsythia against the S-layer, 301
and anti-T. denticola ATCC 35405 antibody against 302
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Table 2
Source of antibodies and their working concentration and/or dilutions used
Antibody Supplier Final conc/ dilution
Rabbit anti-GFAP (gift) Dr Jia Newcombe (The Multiple Sclerosis Society
Laboratory, UK)
1/1000
Goat anti-Iba 1 (ab5076) Abcam 1/250
Mouse anti-P. gingivalis (Clones 1B5) tissue culture
supernatant (gift)
Prof. Michael A. Curtis (London, UK) 1B5 1/10
Rabbit anti-T. forsythia (S-layer protein) Dr Graham Stafford (University of Sheffield, UK) 1/20,000
Rat anti-T. denticola (FhbB protein) Prof. Thomas T. Marconi (USA) 1/5,000
Blocking solution 0.01 M phosphate buffered saline, pH 7.3,
containing 0.01% normal goat or rabbit serum and
0.25% tween 20
–
Normal serum: goat (X0907), rabbit (X0902). DakoCytomation (Germany) 0.01%
Rat anti-mouse C3b/iC3b/C3d Hycult Biotechnology (UK) 1/50
Rabbit anti-rat C9 neoepitope Professor B. Paul Morgan, and Dr Timothy R.
Hughes (Cardiff University)
1/100
FhbB protein generated in rats (sources of antibodies303
and their dilutions used are listed in Table 2).304
Histopathological staining of brain tissue305
The formalin-fixed brain tissue was thoroughly306
washed in PBS and the intact hemisphere was divided307
into the frontal cortex, temporal lobe inclusive of the308
hippocampus, and the brain stem and cerebellum. The309
specimens were then processed and embedded in paraf-310
fin wax. The tissue blocks with temporal lobe inclusive311
of the hippocampus were sectioned (5m in thickness)312
using the Leica RM2235 microtome.313
Cryo-sections (10m thickness) from frozen314
unfixed brain tissue (hippocampus) were cut using the315
Leica CM1850 cryostat (Leica UK). Both paraffin wax316
and cryo-sections were collected onto superfrost+®317
glass slides (Leica UK). The cryo-sections were either318
used immediately or stored at −80◦C until required319
for further use. Rehydrated paraffin wax sections were320
examined for morphology following staining with321
Hematoxylin and Eosin (H&E). In addition, a modified322
methenamine silver (silver impregnation) technique323
adapted from resin-embedded-tissue specimens as pre-324
viously described by Singhrao et al. [47] was used to325
demonstrate the A plaques and the NFTs. All sec-326
tions were also stained with 1% aqueous thioflavin T327
as a standard neuropathology technique for detecting328
fibrillar amyloid deposition.329
Immunoﬂuorescence labeling of periodontal330
pathogens in brain tissue331
Antigen retrieval was carried out on rehydrated332
paraffin wax sections for labeling with goat anti-Iba1333
(Abcam) by microwave heating of tissue sections at334
750 W power for 35 min in 10-mM citric acid buffer335
(pH 6.0). The infected as well as sham-infected control 336
brain sections were incubated in primary antibodies 337
and subsequently in secondary detection antibodies. 338
Rehydrated paraffin wax sections were immunola- 339
beled with rabbit anti-glial fibrillary acidic protein 340
(GFAP) (Table 2) and the calcium binding protein 341
marker Iba 1 (AbCam). For formalin fixative sensi- 342
tive antibodies, tissue sections from frozen brains were 343
stabilized by fixation in cold acetone for 10 min fol- 344
lowed by a 5-min wash in PBS. Tissue-associated 345
endogenous fluorescence was quenched for 10 min 346
in 50-mM glycine/PBS. All brain tissue specimens 347
were immunolabeled using the mouse anti-P. gingi- 348
valis (1B5), anti-T. denticola against FhbB protein, 349
and anti-T. forsythia (against S-layer) and for com- 350
plement C3 activation products rat anti-C3b/iC3b/C3d 351
(Hycult Biotech), and a rabbit anti-C9 neoepitope to 352
detect the membrane attack complex. The dilutions 353
for incubation of sections in primary antibodies are 354
given in Table 2. Where appropriate, the antibodies 355
were diluted in block solution containing 0.01% nor- 356
mal serum (goat serum for GFAP,P. gingivalis (1B5),T. 357
denticola (FhbB),T. forsythia (S-layer), C3b/iC3b/C3d 358
and C9 neoepitope; rabbit serum for Iba 1) in PBS pH 359
7.3 and 0.25% tween 20. FITC-conjugated secondary 360
detection antibodies were goat anti-rabbit (Sigma- 361
Aldrich Ltd., UK) diluted 1/200 and rabbit anti-goat 362
Alexa Fluor 488® and goat anti-rat Alexa Fluor® 488 363
(Molecular Probes, UK) diluted 1/1000, in block solu- 364
tion. Sections were mounted under a glass coverslip 365
using the Vectashield® PI (propidium iodide) mount- 366
ing medium (Vector laboratories, Perterborough, UK). 367
Labeling was observed and images were captured 368
using a 510 series Zeiss confocal microscope (Carl 369
Zeiss Ltd). A semi-quantitative approach was taken 370
by manually counting the number of cells/area for all 371
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Table 3
DNA detected from periodontal pathogens in the ApoE−/− mice brains
Mono DNA detected DNA detected Polymicrobial infections Polymicrobial infections
infections at 12 weeks at 24 weeks 12 weeks 24 weeks
Sham-infected 0 out of 12 0 out of 11 0 out of 11 0 out of 11
P. gingivalis 6 out of 12, 9 out of 11 0 out of 11 2 out of 11
p = 0.006 p = 0.0001
T. denticola 0 out of 12 0 out of 12 0 out of 11 0 out of 11
T. forsythia 0 out of 12 0 out of 12 0 out of 11 0 out of 11
brains in each infected group and compared with the372
sham group to assess glial cell activation.373
Statistical analysis374
Data are presented as mean ± standard deviation375
(n≥ 3 replicates per treatment) and tested for normality376
and equal variance prior to analysis. Where treatment377
groups did not meet the assumptions for parametric378
analysis, the non-parametric Mann Whitney-U test was379
performed comparing the number of positive cases380
in each group of infected mice with those in the381
sham-infected group. Differences were considered sig-382
nificant at p≤ 0.05.383
RESULTS384
Molecular identiﬁcation of pathogens in brain385
specimens386
Molecular analysis using universal primers failed387
to detect T. denticola or T. forsythia in the brain tis-388
sues from sham-, mono-, and polymicrobial-infected389
groups at both time intervals (Fig. 1a-c). The species-390
specific bacterial gene primers revealed 6 out of 12391
ApoE−/− mice brain specimens containing P. gin-392
givalis genomic DNA at 12 weeks (Fig. 1d), which393
further increased to 9 out of 12 at 24 weeks (Fig. 1e).394
These results are highly significant when analyzed by395
the non-parametric Mann Whitney-U test; p = 0.006 at396
12 weeks and p = 0.0001 at 24 weeks. The molecular397
identity of the organism was further confirmed follow-398
ing purification of the amplification product and direct399
sequencing. A nucleotide basic local alignment search400
tool (BLAST) identified a 99-100% match with >200401
bases of the submitted sequence for P. gingivalis. Fol-402
lowing molecular identification using specific bacterial403
gene primers, the group of brains from the polymicro-404
bial infections failed to detect P. gingivalis genomic405
DNA at 12 weeks. However, by 24 weeks 2 out of406
12 ApoE−/− mice brain specimens demonstrated the407
presence of P. gingivalis genomic DNA (Fig. 1f).408
The brain tissue sections from polymicrobial-infected409
Fig. 1. Molecular identification of P. gingivalis in brain tissue sec-
tions using specific primers. Panels a and b) mono sham-infected
group 12 and 24 weeks, c) polymicrobial sham-infected group 24
weeks, d) Mono- infection with P. gingivalis at 12 weeks, e) Mono-
infection with P. gingivalis at 24 weeks, f) Polymicrobial infection
with P. gingivalis at 24 weeks. d) Lanes corresponding to Brain 1,
2, 5, 8, 9, 11 demonstrated a band at 400 bp. p = 0.006. e) Lanes
corresponding to Brain 1, 2, 3, 4, 5, 6, 8, 9, 10, 11 demonstrated a
band at 400bp. p = 0.0001. f) Lanes corresponding to Brain 8 and 10
demonstrated a band at 400 bp.
mice did not show the presence of T. denticola and T. 410
forsythia at either 12 weeks or 24 weeks (Table 3). 411
Immunoblot analysis of infected mouse brain 412
tissue 413
None of the test tissue lysates demonstrated 414
LPS, FhbB protein, and the S-layer protein from 415
their respective bacterial species in the mono- and 416
polymicrobial-infected groups (data not shown). 417
Histology of the infected mouse brain 418
Overall morphological observations of the temporal 419
lobe, including the hippocampus, appeared well pre- 420
served in H&E preparations obtained from all brains 421
(Fig. 2). The pyramidal neurons in all sub-regions of 422
the hippocampus (CA1-CA4) and the dentate gyrus 423
in sham-infected and infected brains generally also 424
appeared to be well preserved (Fig. 2a-d). Occasion- 425
ally, shrunken and darker neurons were noted to a 426
varying extent in CA1-CA4 regions and the dentate 427
hilus with a random distribution (not shown). There 428
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Fig. 2. Hematoxylin and Eosin stained tissue section from the temporal lobe of Apo E−/− mice demonstrating the overall preservation of a)
CA1-CA4 regions of the hippocampus, b) Higher magnification of the dentate gyrus neurons, c) the cortical and hippocampal fissure by the
lateral ventricle in relation to CA2 and 3 neurons, d) higher magnification of the CA2 neurons. DG: Gr layer, dentate gyrus granule cell layer.
The red arrows depict fused hippocampal fissure. LV, lateral ventricle containing the choroid plexus.
were no abscesses in the brain and there were no signs429
of the classical blood-borne inflammatory cells (neu-430
trophils, lymphocytes) or sites of focal hemorrhage.431
Thioflavin T and methenamine silver neutral staining432
methods failed to demonstrate any evidence for the433
presence of either A plaques or NFTs in the hip-434
pocampus or in the frontotemporal cortex regions in435
all of the brains examined.436
Immunoﬂuorescence detection of periodontal437
pathogens in infected mouse brain tissue438
Cell markers associated with glial cell activation439
Astrocytes (GFAP): All the sections from the sham-440
infected brains and mono- and polymicrobial-infected441
groups in which the primary antibody was omitted442
remained negative (Fig. 3a, d).443
Immunolabeling of sections for GFAP in the444
sham-infected control brains demonstrated numerous445
astrocytes with activated phenotypes around the lat-446
eral ventricles (Fig. 3b) as well as scattered astrocytes447
within the hippocampus CA1-CA4 regions at both448
time points (Fig. 3c). The brain tissue sections from449
P. gingivalis mono-bacterial-infected groups at 12450
and 24 weeks showed astrocytes at the periphery of 451
the lateral ventricles (Fig. 3e) and within the hip- 452
pocampus (Fig. 3f). There was no statistical difference 453
when cells/area were counted and compared with the 454
sham-infected mice. The brain tissue sections from T. 455
denticola mono-infected groups at 12 and 24 weeks 456
demonstrated a similar density of astrocytes scattered 457
at the periphery of the lateral ventricles and within 458
the hippocampus (not shown) as observed in the P. 459
gingivalis-infected and sham-infected mice. The brain 460
tissue sections from T. forsythia mono-infected groups 461
at 12 and 24 weeks demonstrated a lower density 462
of astrocytes scattered at the periphery of the lat- 463
eral ventricles and within the hippocampus compared 464
with the P. gingivalis and T. denticola groups as well 465
as the sham-infected mice (not shown). Equally, the 466
polymicrobial-infections demonstrated no significant 467
difference compared with the control group. GFAP 468
labeling was observed in the circumventricular regions 469
as well as in the hippocampus (not shown). 470
Microglia (Iba 1): All mouse brain sections in which 471
the primary antibody was omitted remained negative 472
for microglial cell distribution (Fig. 4a,d). Only a few 473
microglial cells were observed following immunola- 474
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Fig. 3. Immunolabeling of the temporal lobe of ApoE−/− mice with rabbit anti-human GFAP to assess astrogliosis. a and d) negative control
images whereby primary antibody is omitted. Sham-infected (b, c) in which (b) demonstrated abundance of immunopositivity especially around
the periphery of the lateral ventricles and the inset in (c) shows the morphology of cells labeled with anti-GFAP. These appeared as fibrillary
astrocytes with reactive phenotype. The mono P. gingivalis infected (e, f) brains at 24 weeks demonstrated a more widespread distribution of
fibrillary astrocytes around ventricles but their distribution within the hippocampus region was similar to that observed in the sham-infected
brains.
beling of sections with the Iba 1 antibody around the475
lateral ventricles at 12 and 24 weeks in the sham-476
infected brain sections (Fig. 4b), with even fewer cells477
(mainly processes, Fig. 4c) in the hippocampus. Sim-478
ilar microglial cell distribution was observed in the P.479
gingivalis-infected brains around the lateral ventricles480
(Fig. 4e), and few microglial cell bodies with branched481
processes were observed in the hippocampus (Fig. 4f).482
The brain tissue sections from T. denticola mono-483
infected groups at 12 and 24 weeks demonstrated no484
differences in the density of microglia scattered around485
the periphery of the lateral ventricles or within the hip-486
pocampus (not shown). Similarly, there were no differ-487
ences observed between sham-infected, T. forsythia-488
infected, and polymicrobial-infected brain sections.489
Detection of bacterial virulence factors in infected490
mouse brain tissue491
Immunolabeling of brain cryo-sections was unable492
to demonstrate the presence of any of the three bacteria493
used for infection when tested using anti-P. gingivalis 494
antibody, rabbit antisera againstT. forsythia, and anti-T. 495
denticola. 496
Detection of complement activation proteins in 497
mouse brain tissue 498
The sham-infected mouse brain sections, in which 499
the primary antibody was omitted, remained negative 500
for C3 complement activation products (Figs. 5a, 6a). 501
Intracellular labeling detected complement activation 502
products for the common C3 component activation 503
fragments (iC3b, C3b and C3d) (Figs. 5b, 6b) and the 504
membrane attack complex C9 neoepitope (Fig. 6c), 505
specifically on microglia rather than on astrocytes 506
and/or neurons from all brain tissues in sham-infected 507
mice. The complement activation products for the com- 508
mon C3 components (iC3b, C3b, and C3d) and C9 509
(C9 neoepitope) were detected in P. gingivalis-infected 510
mouse brains (12 weeks), but the labeling was intracel- 511
lular and exclusive to microglia. By 24 weeks, the glial 512
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Fig. 4. Immunolabellng of the temporal lobe of ApoE−/− mice with goat anti-mouse Iba1 antibody to assess microgliosis. a and d) negative
control images whereby primary antibody is omitted. Sham-infected (b, c) in which (b) demonstrated immunopositivity around the periphery of
the lateral ventricles. The mono- P. gingivalis 24 weeks infected (e, f) brains demonstrated similar labeling to that observed in the sham-infected
brains, in both the lateral ventricles and hippocampal regions.
cell labeling was still high (Fig. 5c), but C3 (Fig. 6d,e),513
and C9 (Fig. 6f) activation fragments appeared to be514
opsonized onto pyramidal neurons, particularly in the515
CA2 area of the hippocampus in 4 out of 12 infected516
brains (p = 0.032). Labeling of the C9 neoepitope was517
observed in 2 out of 12 specimens (p > 0.05, Fig. 6f).518
In contrast, both T. denticola and T. forsythia infec-519
tions (12 weeks) were similar to the control mice,520
demonstrating intracellular staining in microglial cells.521
However, at 24 weeks, 1 out of 12 from each group522
demonstrated both C3 (iC3b, C3b, and C3d) and523
C9 neoepitope localized to CA neurons (p > 0.05)524
(data not shown). Immunolabeling of polymicrobial-525
infected mouse brains (12 and 24 weeks) with the same526
antibodies also demonstrated the glial cells.527
DISCUSSION528
Infectious agents have previously been linked to529
cognitive decline [9–13], and more recently periodon-530
tal pathogens and/or their virulence factors have been531
implicated in the development of AD [14, 15]. This532
study explored the hypothesis that infectious agents533
and/or their components from oral diseases such as534
periodontitis can access the brain and contribute to535
local CNS inflammation that eventually leads to the 536
development of a chronic inflammatory component 537
of AD. In this study we investigated the possibil- 538
ity that oral pathogens P. gingivalis, T. denticola, 539
and T. forsythia can access the brains of ApoE−/− 540
mice following experimental induction of periodon- 541
titis as mono- as well as polymicrobial-infections. F. 542
nucleatum has the ability to co-aggregate with early 543
colonizers in the oral cavity as well as the late coloniz- 544
ers such as P. gingivalis, T. denticola, and T. forsythia 545
[36–38]. However, in the present study no attempt was 546
made to detect F. nucleatum in the brain specimens as 547
F. nucleatum is part of another ongoing study. The sig- 548
nificance of using a periodontal disease model to assess 549
AD lies in understanding the role of bacteria access- 550
ing the brain and thereby priming glial cells to mount 551
a subsequent local immune response and contribute 552
to neuronal lysis. One previous study, which was 553
performed with an endodontic infection model using 554
wild-type and the severe-combined-immunodeficiency 555
(SCID) mice, demonstrated that only the SCID mice 556
were conducive to T. denticola invasion following 557
mono- and polymicrobial-infections [36]. That study 558
showed that T. denticola can disseminate to distant 559
body organs, including the brain, heart, and spleen 560
while P. gingivalis and T. forsythia were undetected 561
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Fig. 5. Cryo-section from the temporal lobe of ApoE−/− mice immunolabeled for complement activation fragments in the hippocampus using
rat anti-mouse C3b/iC3b/C3d. (a) Control, where the primary antibody was omitted from the tissue section. In both sham-infected (b) and
infected (c) brains, the labeling appears intracellular within branched microglia demonstrating an activated phenotype. The inset (b-c) shows
the branched morphology of cells labeled with the same antibody.
Fig. 6. Immunodetection of complement fragments in brain tissue sections using rat anti-mouse C3b/iC3b/C3d. (a) Negative control (b–c)
sham-infected brains with rat anti-mouse C3b/iC3b/C3d (b) and rabbit anti-rat C9 neoepitope (c). (d–f) P. gingivalis infected brain with rat
anti-mouse C3b/iC3b/C3d (d and e) and rabbit anti-rat C9 neoepitope (f); showing labeling on the cell surface membranes of the CA neurons
in the infected brains (p = 0.032).
[36]. In our current study using a periodontal infec-562
tion model in ApoE−/− mice, we report a contrasting563
finding in which we observed the dominance of P.564
gingivalis in accessing the brain in comparison to T.565
denticola and T. forsythia. These differences in our566
study from those of Foschi et al. [36] maybe due to the567
bacterial strains used, the dosage of infection adminis- 568
tered, method of inoculating animals during infection, 569
differences in disease models (endodontic versus peri- 570
odontal disease), as well as the genetic makeup of 571
the mice used. For example, the only common strain 572
between this study and that of Foschi et al. [36] is T. 573
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forsythia (ATCC 43037) and the dose of bacteria used574
in each study was different (higher by a factor of 10 in575
this study). Based on the available data it is likely that576
T. forsythia, being a non-motile bacterium which lacks577
fimbriae, is unable to transmigrate to the brain [48]. We578
found that P. gingivalis FDC381 DNA predominated579
in the brains of ApoE−/− mice, and this strain is highly580
fimbriated compared to the P. gingivalis ATCC 33277581
[48] used by Foschi et al. [36]. Although both strains of582
T. denticola are motile, the T. denticola (ATCC 35405)583
used by Foschi et al. [36] at a lower dose disseminated584
to the brain. This difference may be attributed to the585
outer membrane, with abundant pore-forming adhe-586
sion protein that may be lacking in our T. denticola587
(ATCC 35404) strain [49]. Thus, the virulence of the588
bacteria may have contributed to its accessibility to the589
brain, rather than being a dose-dependent effect.590
Despite the differences in bacterial strains used and591
their dosage, as well as the genetics of the experimental592
animals, our results show that P. gingivalis strain FDC593
381 used to infect the oral cavity of the ApoE−/− mice594
was able to access the brain tissue, providing definitive595
evidence for transmigration of this bacterial species596
from the oral cavity to the brain. The fact that more597
brains demonstrated a greater P. gingivalis infection at598
24 weeks of infection suggests that the translocation of599
bacteria is likely to be time dependent. Inflammation600
occurring at 24 weeks of infection may be increasing601
the permeability of the blood-brain barrier and facili-602
tating easier access of bacteria into the brain.603
Detecting P. gingivalis in the ApoE−/− mice brains604
in this in vivo study supports the data presented in our605
recently published study of human brain specimens in606
which we detected P. gingivalis-specific LPS in 4 out607
of 10 AD human brains [15]. Together these studies608
provide evidence to support an association between609
periodontal disease and AD. When examined for gen-610
eral morphological preservation of the frontotemporal611
lobe, including the hippocampus, rehydrated paraffin612
wax sections showed no signs of abscess formation,613
no myeloid lineage cells (neutrophils, lymphocytes)614
infiltrating into the brain, and no sites of focal brain615
hemorrhage.616
Our immunoblotting and immunofluorescence tech-617
niques with specific antibodies did not show the618
presence of bacterial virulence factors in any of the619
brain tissues examined. If any of these are metaboli-620
cally active in the brain, it may take several years to621
form an abscess as seen in the case with non-oral bacte-622
ria such asPropionibacteriumacnes, which can take 10623
years to form an abscess following entry into the brain624
[50]. Although this appeared surprising at first, the lack625
of detection may be attributed to the inability of these 626
bacteria to access the brain due to their rapid clearance 627
from the systemic circulation and/or they were neu- 628
tralized upon entry by the already enhanced microglial 629
cell inflammatory phenotype in these mice [51, 52]. 630
Another possible reason may be that the antibodies 631
themselves failed to detect their epitope in tissue sec- 632
tions or the antigen itself was below the detection limit 633
of both immunoblotting and immunolabeling. 634
We focused on the hippocampus region of the brain 635
to detect any early cellular changes in the Apo E−/− 636
mice brains, as according to Braak and Braak [53] 637
neurodegeneration begins in the entorhinal cortex and 638
spreads to the hippocampus followed by other regions. 639
Screening for the AD hallmark associated structures by 640
thioflavin T and methenamine silver methods failed to 641
provide any evidence for the fibrillar A and NFTs in 642
the entorhinal cortex or the hippocampus regions. A 643
plausible reason for the inability to detect the AD hall- 644
mark proteins could be the relatively short time span of 645
chronic infection in our mouse model because, even in 646
the accelerated transgenic AD animal model and in the 647
APP and SS-1 transgenic mice, insoluble A depo- 648
sition and plaque formation usually takes between 6 649
to 12 months [54, 55]. Further, ApoE−/− mice used 650
in the current study are unlikely to demonstrate A 651
deposition as they lack the essential protein required 652
for amyloid to form insoluble fibrils [37]. Hence it will 653
be beneficial for a future study to be designed with a 654
longer duration of mono- and polymicrobial-infection 655
in a non-ApoE−/− rodent model so as to demonstrate 656
the direct link between periodontal disease and AD 657
hallmark proteins. 658
Previous studies with ApoE−/− mice have identified 659
glial cell activation in which microglia demonstrate 660
evidence of an increased secretion of cytokines, espe- 661
cially of tumor necrosis factor- (TNF-) [51, 52], a 662
cytokine of macrophage origin. This observation has 663
been suggested as an impaired immuno-modulatory 664
function of macrophages in controlling the innate 665
immune responses in this animal model [56–58]. 666
Microglial cells are the tissue-bound macrophages 667
of the brain capable of expressing a range of 668
proinflammatory cytokines and phagocytosing cellu- 669
lar debris to reduce the inflammatory response to 670
pathogens. However, the finding that the ApoE−/− 671
mice have higher levels of endogenous proinflamma- 672
tory cytokines, especially TNF- suggests that it is 673
likely that microglia were already in their primed phe- 674
notype. In this study we also found responsive fibrillary 675
astrocytes, particularly at the peri-circumventricular 676
organ sites following initial microglial cell activation. 677
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Complement is a pivotal pathway in the CNS innate678
immune response following infections. In the CNS,679
the dominant mode of complement activation is the680
classical pathway where neurons show vulnerability681
to complement mediated damage [59] and microglia682
synthesize complement proteins [60]. Hence, we set683
out to detect any evidence for the activation of the684
common C3 and the terminal pathway of complement685
leading to the formation of the membrane attack com-686
plex in our infected mice brain specimens. Our study687
demonstrated an intracellular localization of C3 and688
C9 exclusively in microglia in all brains, suggesting689
that these cells were actively synthesizing comple-690
ment components [60] rather than being opsonized691
with the complement activation fragments, again sup-692
porting the view that microglia were already in their693
primed/activated state [51, 52, 61].694
However, our observation of the cell surface mem-695
brane staining of C3 activation fragments (iC3b, C3b,696
and C3d) and the membrane attack complex (anti-697
C9 neoepitope) exclusively on CA pyramidal neurons698
of the mono- and polymicrobial-infected mice at 24699
weeks but not at 12 weeks suggests that the inflamma-700
tory burden was increasing from protection to causing701
bystander injury on complement activated neurons. In702
view of our detecting C3 activation fragments being703
opsonized on the pyramidal neurons, it appears likely704
that bacteria (P. gingivalis) and/or its DNA may have705
triggered the complement activation in these infected706
mice.707
Our study supports the observation from previous708
studies which hypothesized that bacterial infections709
would contribute to the development of AD pathol-710
ogy via mechanisms involving acute-phase proteins,711
including cytokines and the complement cascade in712
which neurons would be attacked [31–33]. The pres-713
ence of cytokines and activated complement cascade714
can be used as a marker to represent local CNS inflam-715
mation [1, 33]. Thus, the demonstration of activated716
complement cascade here in response to P. gingivalis717
directly infecting the brain supports the conclusion that718
chronic local inflammation constitutes a component of719
developing AD pathology.720
Finally, this study demonstrates that, in the absence721
of fibrillary A deposition the neurons remain vulnera-722
ble to complement mediated damage from P. gingivalis723
accessing the brain.724
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